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I have not failed, I’ve just found ten thousand ways that won’t work.
—Thomas Edison
CHAPTER 1
Mechanism of the Brønsted acid-catalyzed aza-Darzens reaction. Influence of
diazoalkane structure on the stereoselectivity of carbon–carbon bond
formation.
1.1 Introduction to diazoalkanes
1.1.1 Diazoalkanes in organic synthesis
Nearly 130 years since their discovery, diazo compounds continue to attract the attention
of organic chemists and new reactions utilizing diazoalkanes are still reported frequently.
What started with diazotization of ethyl glycinate to form ethyl diazoacetate,1 developed
into a branch of organic chemistry with an array of useful reagents and indispensable chemical
transformations. Probably one of the most widely recognized reactions of the simplest diazo-
alkane reagent, diazomethane, is a reaction with carboxylic acids to form esters (Scheme 1.1).
Because of its simplicity and high efficiency, this reaction was quickly adopted in the field of
natural product discovery and lipid chemistry where treatment of extracts with diazomethane
became a standard protocol for conversion of carboxylic acids to more soluble esters.
Scheme 1.1. Esterification of carboxylic acids with diazomethane.
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A very interesting aspect of the chemistry of diazoalkanes is the fact that their reactivity
can be considered in two separate contexts. On one hand the diazo group natively possesses
substantial reactivity both on carbon and nitrogen atoms. When left intact, diazoalka-
nes participate in 1,3-dipolar cycloaddition reactions with pi-bonds of alkenes and alkynes.
Maruoka and co-workers demonstrated that titanium(IV) catalyst 1 promotes a reaction be-
tween α-substituted acroleins and ethyl diazoacetate to give chiral 2-pyrazolines containing
a quaternary stereogenic center in good yield and high enantioselection (Scheme 1.2).2
1
Scheme 1.2. Maruoka’s enantioselective cycloaddition of diazoesters and enals.
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When a sufficiently activated electrophile such as aldehyde or imine (see also section
1.2) is used, one can take advantage of the nucleophilicity of the diazo carbon to perform
selective addition reactions. In 2010 Feng and co-workers reported the highly enantiose-
lective addition of α-alkyl-α-diazoesters to aromatic aldehydes (the Roskamp reaction) in
the presence of scandium(III)–N,N’-dioxide ligand 2. With just 0.05mol% of the catalyst
α-alkyl-β-ketoesters form in very high yield and enantioselectivity (Scheme 1.3).3
Scheme 1.3. Enantioselective Roskamp reaction of diazoesters.
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In addition to non-redox reactions, transition metal catalysts and diazoalkanes react read-
ily to give Fischer-type carbenes which are employed in a variety of stereoselective reactions.
Functionalization of X–H bonds (X = C, O, S, N) is now a mature field of organic synthesis
in which many efficient and selective transformations have been developed.4,5 Application
of donor–acceptor rhodium carbenes in stereoselective C–H functionalization reactions has
been extensively studied by Davies and co-workers.6 For example allylic silyl ethers will un-
dergo asymmetric C–H insertion reaction to give products in up to 92% ee (Scheme 1.4).7
Eletrophilic carbenes can also be attacked by nucleophilic amines to form azomethine ylides.
Hu and co-workers reported a three component reaction between ethyl diazoacetate, anilines
and azodicarboxylates catalyzed by Rh2(OAc)4 to give aminal products in good yield with
2
no N–H insertion products.8 Diazoalkanes are often utilized as methylene transfer agents to
alkenes. Highly enantioselective cyclopropanation reactions were developed over the last few
decades (Scheme 1.4).9,10
Scheme 1.4. Examples of utility of diazo compounds in metallocarbene mediated reac-
tions.
CH2O2tBu
N2
1:99 cis:trans
Ph
     1 mol %
0.5 mol% Cu(OTf)2 Ph CO2tBu
98% ee
B
N N
ArFArF
O
tBu
O
tBu
ArF = 3,5CF3C6H4
1,2-DCE, rt
(89%)
CO2Et
N2 1,2-DCE, rt(89%)
Ar NH2
Rh(OAc)4 NH2
H
EtO2C
Ar
DEAD
N
EtO2C
H
N
Ar
NHEtO2C
CO2Et
cyclopropanation
(Pfaltz 2005)
ylide formation
(Hu 2005)
MeO2C N2
Ar
R
OTBS
+
Rh2(S-DOSP)4
50 °C
R
OTBSMeO2C
Ar
up to 92% ee
C–H insertion
(Davies 2005)
3
3
More elaborate diazo compounds will undergo rearrangement reactions to form more
reactive intermediates such as ketenes. The Danheiser group demonstrated a new benzan-
nulation strategy based on the photochemical decomposition–rearrangement of diazo 4 to
3-(oxido)dienylketene 5. Compound 5 reacts with electron-rich alkynes in a 6 pi electrocy-
clization reaction to give highly substituted benzene rings 6 (Scheme 1.5).11
Scheme 1.5. Rearrangement–benzannulation reaction of α-diazo enones.
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1.1.2 Synthetic approaches to diazoalkanes
Due to more than a century of research exploring the reactivity of diazoalkanes, numerous
methods have been developed for their preparation. More general methods for the synthesis
of whole classes of diazo compounds exist next to more specific approaches towards individual
examples of diazoalkanes.12–15 The available synthetic routes can be divided into four groups:
• transfer of the dinitrogen functionality
• manipulations of functional groups containing one nitrogen atom
• manipulations of functional groups containing two nitrogen atoms
• substitution of an existing diazo compound
One of the best methods for preparing diazo compounds consists of the direct introduction
of both nitrogen atoms in a single reaction step. The entire azo group is transferred by a
donor, generally an azide, to an acceptor (C−H acidic compound), a process that is often
referred to as the Regitz diazo transfer (Scheme 1.6).16 Diazo transfer to 1,3-dicarbonyl
compounds usually works efficiently due to high proton activation by the carbonyl groups in
the presence of weak base, to give 2-diazo-1,3-dicarbonyl compounds in yields usually over
80%.17–19 The diazo transfer reaction produces a stoichiometric amount of a sulfonamide
which must be separated from the desired diazo compound, a challenging procedure in certain
cases.
Scheme 1.6. Regitz diazo-transfer reaction.
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4-Toluenesulfonyl azide is the standard reagent used, but because of safety problems
resulting from its potentially explosive nature, and because of the difficulty of product sepa-
ration, several alternative reagents have been developed. N -Dodecylbenzenesulfonyl azide20
has been reported to be very effective for the preparation of crystalline diazo compounds,
while p-acetamidobenzenesulfonyl azide21 offers the advantages of low cost, safety, and ease
of removal of the sulfonamide by-product through a simple trituration–filtration. The latter
significantly broadened the scope of the diazo transfer reaction. A different approach to
the problem of azide safety and removal of by-product was addressed by Kitamura and co-
workers.22 They developed a reagent based on imidazolinium salts that undergo an efficient
4
diazo-transfer reaction with diketones under mild conditions. The ionic character of the 2-
azido-1,3-dimethylimidazolinium salt 7 allows for easy and efficient removal of by-products
by a simple water wash. Additionally, differential scanning calorimetry (DSC) experiment
showed exothermic decomposition at around 200 ◦C which suggests that 7 could be used at
higher temperatures with a sufficiently large safety margin.
Scheme 1.7. Diazo-transfer reaction using imidazolium-based reagents.
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If the carbon acid is activated by only one electron-withdrawing group (e.g. methyl
ketones) diazo transfer can be problematic. This challenge can be addressed by introduction
of a second electron-withdrawing group, which can be easily removed after the diazo transfer
process. Early examples utilized formylation under Claisen conditions followed by treatment
with sulfonyl azide. It was used sporadically and only for simple ketones because of lack of
regioselectivity in thermodynamically controlled Claisen formylation.
Currently, diazo transfer to less reactive substrates is carried out with the assistance
of a trifluoroacetyl group. First reported by Doyle23 and popularized by Danheiser,24 it is
a powerful alternative to the use of a formyl group. This method has proved particularly
valuable in the preparation of diazo derivatives of enones. First, the substrate is converted
to an α-trifluoroacetyl derivative by reaction of the enolate with 2,2,2-trifluoroethyl trifluo-
roacetate. The intermediate is not isolated but subjected to a diazo transfer reaction with
an azide of choice and the trifluoroacetyl group is hydrolyzed during work-up to give the
diazo compound in good yield (Scheme 1.8).
Scheme 1.8. Detrifluoroacetylative diazo transfer reaction.
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A conceptually different diazo transfer from azides can be realized via rearrangement reac-
tions of 1,2,3-triazoles. This method is based on functionalization of ynamines or ynyl ethers.
Cycloaddition with azide bearing an electron-withdrawing group affords a 1,2,3-triazole
which is in equilibrium with the α-imino diazoalkane which can be isolated (Scheme 1.9).25
5
Scheme 1.9. Preparation of diazoalkanes by rearrangement of 1,2,3-triazoles.
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A second group of reactions producing diazo compounds are modifications of nitrogen-
containing functional groups such as oximes, hydrazones and ureas. Conversion of oximes
to diazoalkanes can be achieved through the Forster reaction in which oximes react with
chloramines with concomitant dehydration. This method was often practiced in the synthesis
of diazo analogs of steroids (Scheme 1.10).26
Scheme 1.10. Preparation of diazo analogs of steroids via Forster reaction.
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Hydrazones, mostly tosylhydrazones, are often utilized masked diazo groups. Under
strongly basic conditions, the sulfinate fragment is eliminated to give the diazo function-
ality. Using this approach, diazoesters can be prepared in a reaction of tosylhydrazone of
glyoxylic acid chloride with alcohols under basic conditions. Alcohol acylation is followed
by elimination to give the diazoester.27,28 More recently, Fukuyama and co-workers intro-
duced disulfonylhydrazine 8 as a precursor to the diazo group. Diazoacetates are prepared
from α-bromo esters after elimination of two molecules of sulfinate from the intermediate 9
(Scheme 1.11).29
Scheme 1.11. Formation of diazoesters from tosyl hydrazones.
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Electron rich diazoalkanes can be prepared by dehydrogenation of hydrazones, one of the
oldest methods for the synthesis of diazo compounds. Mercury(II) oxide has been used for a
long time as an oxidant for this transformation but since the mid-20th century numerous al-
ternatives, such as silver oxide or manganese(IV) oxide, have been developed (Scheme 1.12).30
Scheme 1.12. Preparation of diazoalkanes by dehydrogenation of hydrazones.
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The Bamford–Stevens reaction is an alternative to dehydrogenation of hydrazones. Al-
though this reaction is used mostly for the synthesis of alkenes, intermediate diazo com-
pounds can be isolated. In a typical procedure an N -sulfonylhydrazone of the carbonyl
compound is converted to the lithium salt followed by elimination (Scheme 1.13). Genera-
tion of diazo compounds under mild conditions is also possible. Elimination of the suspension
of a tosylhydrazone salt in the presence of a phase-transfer catalyst was utilized by Aggarwal
for the in situ generation of the desired diazoalkanes.31–35
Scheme 1.13. Synthesis of diazoalkanes via the Bamford–Stevens reaction.
R1
R2
N
H
N
nBuLi
SO2R R1
R2
N N SO2R
Li
–RSO2
R1
R2
N2
heat
Diazomethane (11) is a gas at room temperature and is usually generated from pre-
cursors such as N -methyl-N -nitrosourea (10). Treatment with base in a biphasic system
(aq KOH–diethyl ether) at room temperature affords an ethereal solution of diazomethane
(Scheme 1.14).36 The potentially explosive nature of diazomethane didn’t prevent it from
use in large industrial processes, such as the synthesis of the key intermediate to prepare the
HIV protease inhibitor nelfinavir.37 In a continuous process, diazomethane is generated from
N -methyl-N -nitroso-p-toluenesulfonamide with a production rate of 50–60 tons per year but
less than 80 g of diazomethane is present in the production unit.
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Scheme 1.14. Arndt’s synthesis of diazomethane from N -methyl-N -nitrosourea.
N
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NH2
KOH
H2O/Et2O H2C
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10 11
More elaborate diazo compounds are prepared by substitution at the diazo carbon. Prob-
ably the most common reaction of this type is acylation of diazomethane with acid chlorides.
Recently, Wang and co-workers demonstrated a transition metal-catalyzed C–C coupling us-
ing diazo compounds. Palladium catalyzed cross-coupling of ethyl diazo acetate with various
aryl or vinyl iodides gives coupled product 12 in good yield. When carbon monoxide is added,
2-diazo-3-oxocarboxylates 13 are the major products in good yield (Scheme 1.15).8
Scheme 1.15. Cross-coupling of diazoesters.
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1.2 Stereoselective reactions involving α-aminodiazonium intermediates
1.2.1 Metal catalyzed reactions
α-Aminodiazonium intermediates are commonly suggested in aziridination reactions. Cy-
clization of the amine onto neighboring diazonium carbon with concomitant removal of N2,
yields the heterocycle. Aziridines, the smallest heterocycles with one nitrogen atom have
been a subject of intensive research38,39 since 1888, when Gabrel synthesized the aziridine
(14, R1, R2, R3 = H).40 From the synthetic standpoint, aziridine can be prepared in one of
four ways (Figure 1.1):
• functionalization of the C–C pi bond with a nitrene
• functionalization of the C–N pi bond with a carbene
• addition–cyclization sequence
• substitution
8
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Figure 1.1. Approaches to aziridines by addition to double bonds.
Delivery of the nitrogen as a nitrene equivalent to a carbon–carbon double bond is a well
developed branch of stereoselective synthesis that has been reviewed recently.41,42 Approach
to aziridines that use carbene equivalents in addition to azomethines, are more relevant to
this chapter and will be discussed in detail.
Early studies in a carbene delivery to imines met with limited success43–45 until 1995 when
Rasmussen and Jørgensen reported aziridination of N -Ph imines, such as 15 with ethyl
diazoacetate in the presence of 10mol% of Cu(OTf)2 (95% yield, 6:1 cis:trans).46 When
copper(II)–bis(oxazoline) complexes were used, a fair enantioselection for 16 was observed
but the yield suffered significantly. Simultanously, Jacobsen and co-workers reported that
in the presence of CuPF6–bis(oxazoline) complex 17 such aziridination can also be achieved
with modest enantioselectivity, up to 44% ee, but still in poor yield (Scheme 1.16).47
Scheme 1.16. Aziridination of N -Ph benzaldimines with ethyl diazoacetate.
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Small amounts of pyrrolidine 18 were observed which suggested the presence of azome-
thine ylide 20. Metal carbenoid 19 reacts with benzaldimine 15 to give 20. Cycloaddition
to diethyl fumarate 21, the diazo homocoupling product, yields pyrrolidine 18. Low enan-
tioselection was attributed to a low degree of association between the chiral catalyst and
the ylide. Dissociation of the ylide from the catalyst allows for the formation of racemic
aziridine 22 and pyrrolidine 18 (Figure 1.2).
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Figure 1.2. Proposed mechanism of metallocarbene addition to azomethine
Later reports of metal catalyzed additions of ethyl diazoacetate to imines started to sug-
gest an alternative available pathway that takes advantage of diazo nucleophilicity. First
Bartnik and Mloston,44,45 then Brookhart and Templeton,48 and later Jørgensen49 showed
that various Lewis acids are able to promote the reaction to deliver predominantly cis-
aziridine 23 in good to excellent yield (Figure 1.3). In contrast to Cu and Rh catalyzed re-
actions characteristic by-products—fumarate, maleate and pyrrolidine—were not observed.
This time enamines of type 25 and 26 were present as side products and became the evi-
dence to support addition–cyclization mechanism. According to this mechanism, the Lewis
acid binds to the imine nitrogen and activates it towards diazo nucleophile. The putative
intermediate 24 that forms upon addition can close in SNi fashion to form aziridine or un-
dergo rearrangement to arrive at vinylogous amides 25 and 26 (Figure 1.3, path a and b).
Control experiments that attempt to trap a possible azomethine ylide intermediate didn’t
show any evidence of pyrrolidine 18.
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Figure 1.3. Lewis acid-catalyzed aziridination with diazo compounds.
Despite extensive studies of the active catalyst,50,51 chiral complexes of Lewis acids with
various ligands didn’t deliver products in highly enantioenriched form,52 until the break-
through contribution by Antilla and Wulff53,54 who developed a chiral boron–VAPOL com-
plexes that were able to activate benzhydryl imines 28 towards the nucleophilic addition
to provide cis-aziridines 29 almost exclusively with enantioselectivities in 90–98% ee range
(Scheme 1.17). Small amounts of secondary products of type 25 and 26 were also observed.
Over the years this methodology became a standard protocol for asymmetric aziridine synthe-
sis and its utility has been demonstrated in the synthesis of biologically active molecules.55–57
Scheme 1.17. Wulff’s asymmetric aziridination.
R H
N CHPh2 CO2Et
N2
N
CHPh2
R OEt
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>20:1 cis:trans
up to 98% ee
CH2Cl2, rt, 24 h
(90–98%)
5 mol % (S)-VAPOL
15 mol % B(OPh)3
R = aryl
28 29
Over course of several years, the active catalyst preparation protocol has been empiri-
cally optimized but the nature of the actual catalyst species was not well understood. In
the initially proposed model, catalyst activity was attributed to a single boron atom in a
chiral environment. However, investigation of the active catalyst by boron nuclear mag-
netic resonance suggested that the active catalyst is the pyroborate 30.56 Further NMR and
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X-ray studies revealed that the catalytic system acts as a chiral Brønsted acid where a proto-
nated imine is surrounded by a singular boroxinate counterion 31 (Figure 1.4).58 This result
provided an additional explanation for the empirically established optimal ratio of VAPOL
ligand to B(OPh)3 (1:3).
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O B
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OPh
Ph
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O B O B
OPh
OPh
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Ph
Ph OH
OH
(S)-VANOL
Ph
Ph OH
OH
30 31
Figure 1.4. Boron catalysts for asymmetric aziridination
1.2.2 Brønsted acid catalyzed reactions
Historically, diazoalkanes were considered incompatible with Brønsted acid catalysis be-
cause protonation of the diazo carbon would be the dominant reaction pathway, a nonexis-
tent process in reactions catalyzed by aprotic Lewis acidis or metal catalysts. This paradigm
changed when Williams and Johnston reported that in the presence of a competitive Lewis
base (azomethine nitrogen), diazo decomposition by protonation is slow even in the presence
of very strong Brønsted acid (triflic acid). The presumed iminium triflate ion pair is excep-
tionally reactive towards ethyl diazoacetate; the reaction proceeds smoothly at −78 ◦C to
give cis-aziridines 29 in high diastereoselection with good catalyst turnover (Scheme 1.18).59
Since that work was published, Brønsted acid activation of azomethines towards diazoalka-
nes has developed into a dynamic area of research with a range of useful carbon–carbon bond
forming reactions.
Scheme 1.18. Triflic acid-catalyzed aza-Darzens reaction.
R H
N CHPh2
O
EtCN, –78 °C, 2 h
25 mol %, TfOH
OEt R
N
CHPh2
O
OEt
N2
up to 89% yield
up to 95:5 cis:trans
29
12
In 2005 the Terada group developed the first enantioselective addition of tert-butyl di-
azoacetate to N -acyl imines 32 using axially chiral phosphoric acid 34. α-Diazo esters 33
form in good yields and excellent enantioselectivities that don’t seem to be influenced by
either electronics of the nitrogen protecting group or by electronics of the parent aldimine
(Scheme 1.19).60 Products presumably form via an addition/deprotonation pathway. The
diazonium intermediate doesn’t close to an aziridine ring but instead loses a proton to give
an α-diazo amine, a formal C–H insertion product (see also Figure 1.3).
Scheme 1.19. Terada’s phosphoric acid-catalyzed synthesis of α-diazoamines.
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Similar reactivity was recognized by Maruoka in 2007. An axially chiral dicarboxylic acid
37 activates N -Boc imines towards tert-butyl diazoacetate or dimethyl (diazomethyl)phos-
phonate (Scheme 1.20) to yield the the corresponding α-diazo-β-amino esters or α-diazo-β-
amino phosphonates 36 in good yield and excellent enantioselectivity.61 An intriguing aspect
of this report is the fact that when compared to Terada’s system (Scheme 1.19), catalysts
34 and 37 are homochiral but deliver opposite enantiomers, suggesting that stereoselection
might be rooted in the nitrogen substituent. Somewhat lower reactivity of diazophosphonates
has been later improved by Peng and co-workers.62
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Scheme 1.20. Maruoka’s synthesis of α-diazoamine esters and phosphonates.
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There seems to be a delicate balance between the aminodiazonium structure and its end
product. Akiyama and co-workers reported a chiral phosphoric acid-catalyzed aziridination
reaction where a more electrophilic azomethine with an electron-rich nitrogen is used. In
contrast to Terada’s system, catalyst 39 favors formation of cis-aziridine 40 with a small
amount of vinylogous amide 41 (Scheme 1.21).63
Scheme 1.21. Phosphoric acid-catalyzed cis-aziridination of glyoxal-derived aldimines.
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For years since the first successful reaction, publications of stereoselective aza-Darzens
aziridinations reported cis-product as the major diastereomer. This changed in 2008 when
the Maruoka group reported a Brønsted acid-catalyzed enantioselective trans-aziridination
of N -Boc benzaldimines with α-diazo amide 42 to give trans-aziridine amides 43 in mod-
erate yield and high enantioselection (Scheme 1.22). The main byproduct was vinylogous
amide 44, the result of a 1,2-aryl shift.64 Compared to their previous work (Scheme 1.20),
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diastereoselectivity reversal to trans-aziridine seems to be solely correlated to the use of a
diazo amide compound capable of hydrogen bond donation.
Scheme 1.22. trans-Selective asymmetric aziridination.
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A model was advanced to explain this observation. A hydrogen bond donation from
the amide N−H hydrogen bonds to the Boc group positions the diazo compound for anti
carbon–carbon bond formation (Scheme 1.22, A). Cyclization of the amine nitrogen onto
the diazonium carbon afords trans product. Since α-diazo amide 42 is larger than ethyl
diazoacetate, syn-aminodiazonium required for cis-aziridine (Scheme 1.22, B) is disfavored.
Furthermore, when less acidic N -Bn diazoamide was used, the yield suffered considerably.
Shortly after, other groups reported asymmetric trans-aziridinations. The Zhong group
optimized the reaction by using axially chiral phosphoric acid 34, imine 45, and N -PMP di-
azoamide 46. With just 5mol% of the catalyst at low concentration in CH2Cl2, the reaction
proceeds in 89–97% yield and 88–98% ee for various aldimine substrates (Scheme 1.23).65
In 2010, the Wulff group reported that α-diazoamides are compatible with their reaction
system, providing both alkyl and aryl N -benzhydryl trans-aziridine products in very high
yield and ee (Scheme 1.23).66
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Scheme 1.23. Improved asymmetric trans-aziridination of benzaldimines.
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To complete the spectrum of asymmetric aziridination of imines, efforts were directed
at methods for the synthesis of trisubstituted aziridines. Early examples utilized substrate
control to achieve acceptable levels of diastereoselection. The Maruoka group presented in
2010 a Brønsted acid-catalyzed reaction of α-substituted α-diazocarbonyl compound 48,
containing camphorsultam chiral auxiliary, and N -Boc imines. In the presence of a substoi-
chiometric amount of triflic acid, the desired trisubstituted aziridine 49 forms in acceptable
yield favoring the trans diastereomer exclusively (Scheme 1.24).67
Scheme 1.24. Substrate controlled synthesis of trisubstituted aziridines.
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This area of research was significantly improved in 2011 when the asymmetric Brønsted
acid-catalyzed aza-Darzens reaction was published simultaneously by groups of Maruoka68
and Wulff.69 Both groups utilized their signature catalysts, 52 and 53 respectively, and a
diazo compound 50 derived from N -acyl oxazolidinone. Other α-substituted diazo donors
were not reactive enough in this reaction. Empirical investigation of substrate scope es-
tablished that only N -Boc imines are suitable substrates, a limitation of this methodology.
Uniformly excellent asymmetric induction was observed for nearly all tested aldimines except
ortho-substituted aldimines which were unreactive (Scheme 1.25).
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Scheme 1.25. Brønosted acid-catalyzed asymmetric synthesis of trisubstituted aziridines.
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1.3 Origins of selectivity in the aza-Darzens aziridine synthesis
Since the first examples of cis-aziridine synthesis from diazo compounds and imines,
the underlying mechanism responsible for high cis-selectivity was not known. The most
frequently proposed mechanism suggested a syn carbon–carbon bond creation to arrive at
α-aminodiazonium C which undergoes SNi cyclization to form a cis-aziridine. Intermediacy
of C (Figure 1.5), however, is not directly supported with published experimental evidence.
In 2011, Johnston and co-workers established experimentally that cis-aziridine forms ex-
clusively from independently generated syn-aminodiazonium C.70,71 The main hypothesis
behind the study was that the Brønsted acid-promoted fragmentation of a triazoline ring
would provide an intermediate that would mechanistically intersect with the aza-Darzens
reaction. This simple model utilizes a Brønsted acid as a catalyst which has an advan-
tage over Lewis acids and metal catalysts because redox pathways involving carbenoids and
azomethine ylides are excluded from the discussion.
Figure 1.5 shows mechanistic pathways studied, and the relative stereochemistry of the
products was used to inverstigate the reaction outcome. Using a chiral substituent on the N3
of the triazoline, relative stereochemistry determination was possible by proton NMR. trans-
Triazoline A, when subjected to a Brønsted acid will fragment the N–N bond to reveal the
intermediate B, the same intermediate required for cis-aziridination. An alternative route
is also possible, where protonation of the ester oxygen causes C–N bond fragmentation to
give E. Ring closure of E occurs with retention of the relative stereochemistry and produces
trans-aziridine F.
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Figure 1.5. Mechanistic outline connecting aza-Darzens and triazoline decomposition re-
actions in the presence of a Brønsted acid.
Although the aza-Darzens reaction proceeds efficiently with a substoichiometric amount
of triflic acid, a study of the fragmentation of four stereoisomers of trans-triazonlines 54–57
was performed using a full equivalent of TfOH to ensure kinetic control. All four triazo-
lines provided only two products (in varying ratio)—cis-aziridine and α-diazo-β-amino-ester
(Scheme 1.26, r=regioisomer, d=diastereomer). The diazo by-product is a result of proton
transfer and doesn’t give aziridine when resubjected to reaction conditions. In each case,
only cis-aziridine was observed which was confirmed by 1H NMR and X-ray crystallography.
These results are consistent with the hypothesis illustrated in Figure 1.5, that trans-triasoline
conversion is a stereospecific process with inversion of configuration at diazonium carbon. If
intermediate E was a product of fragmentation, trans-aziridine would be observed instead.
Formation of E is unlikely because it requires an energetically unfavorable C−N bond frag-
mentation.
The stereochemical fate of triazoline fragmentation is detailed in Scheme 1.27. Upon
protonation, the triazoline ring fragments to an α-aminodiazonium species but the resulting
gauche conformation is not productive. Rotation around the C–C bond to the antiperiplanar
arrangement is followed by cyclization to aziridine product 58. Further support, albeit more
circumstantial, was a finding that substoichiometric triflic acid (as low as 7mol%) was suf-
ficient to drive aza-Darzens reactions to completion.59 This contrasted with the observation
that excess triflic acid was necessary to fully convert triazolines 54–57 and suggests that
18
Scheme 1.26. Stereochemical outcome of Brønsted acid-promoted fragmentation of chiral
trans-triazolines to cis-aziridines.
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initial [2 + 1] cycloaddition between the imine and diazo to form triazoline is unlikely.
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The creation of the C–C bond between diazo and imine is theoretically reversible. This
is important whenever enantioselective reactions are discussed, as the retro process is a
potential path for racemization. When ethyl diazoacetate and imine 64 (retro products of 65)
were subjected to triflic acid, aziridines 58 and 60 formed nonselectively. This established
that under the standard reaction conditions, the retro-Mannich reaction of aminodiazonium
65 is not operative (Scheme 1.27).
Scheme 1.27. Fate of α-diazonium intermediate.
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1.4 Results and discussion
Johnston and co-workers demonstrated in 2005 that strong Brønsted acid promotes a
reaction of alkyl azides with electron deficient alkenes.72 In reaction with acrylates, benzyl
azide funished aziridines but when the dipolarophile contains a pendant nucleophile (such
as 66), anti-oxazolidine dione is the product. In the follow-up publication, trans-triazoline
67 was proposed to be a resting state and perhaps an intermediate (Scheme 1.28).
Scheme 1.28. Brønsted acid-promoted formal aminohydroxylation of α,β-unsaturated
imides.
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The mechanism of formation of anti-68 might intersect the aza-Darzens reaction at the
vic-aminodiazonium intermediate. We sought to determine the stereochemical outcome of
the reaction between α-diazo imide 69 and imine. The end goal is the development of a
new carbon–carbon bond forming reaction as a complementary approach to anti-oxazolidine
dione scaffolds (Figure 1.6).
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Figure 1.6. Intersecting paths of triazoline imide fragmentation and α-diazo imide addi-
tion to imines.
1.4.1 Stereochemistry of triazoline imide fragmentation
Triazoline imide 72 was prepared by a thermal cycloaddition reaction of α,β-unsaturated
imide 71 with diphenylmethyl azide. We hypothesized that analogous to triazoline esters 54–
57, acid treatment of 72 will form syn-aminodiazonium intermediate 73 which will undergo
cis-aziridine formation. If protonated aziridine 74 is sufficiently activated, the carbamate will
undergo cyclization to open the cis-aziridine to give syn-oxazolidine dione 75. Alternatively,
direct carbamate 5-exo displacement of dinitrogen in 73 (without prior aziridine formation)
would lead to anti-oxazolidine dione 75 (Figure 1.7).
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Figure 1.7. Outline of triazoline imide decomposition.
Treatment of 72 with 100mol% of TfOH at −78 ◦C in propionitrile returned unreacted
starting material (Table 1.1, entry 1). In dichloromethane, under the same reaction condi-
tions, very slow conversion (ca. 40%) was observed, and the anti-oxazolidine dione forms
predominantly (Table 1.1, entry 2). In order to achieve moderate yield, reaction in propioni-
trile has to be carried at a higher temperature; after 5 h at 0 ◦C, anti-oxazolidine dione 75 was
isolated in 37% yield and 4:1 dr (Table 1.1, entry 3). The same reaction in dichloromethane
was more efficient and significantly more selective (Table 1.1, entry 4). Addition of water
accelerates the reaction rate73 but has no effect on the selectivity of the reaction (Table 1.1,
entry 5). Water-accelerated conditions allowed us to perform the reaction at −20 ◦C to
achieve optimal yield (78%) and exclusive anti selectivity (Table 1.1, entry 6). These results
demonstrate that the 5-exo cyclization to form a 5-membered ring is significantly faster than
formation of the syn-product by cis-aziridine formation and its diastereospecific opening.
Rate acceleration by a secondary catalyst (water) is consistent with our previous studies.73,74
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Table 1.1. Fragmentation of triazoline 73.
x mol % TfOH
y mol % H2O
O N
O
O
Ph
N
DPM
EtO2C
H
N
N
NDPM
EtO2C
O
N
Ph
CO2Me
72
75
entry TfOH H2O solvent T time yield dra
mol% mol% (◦C) (h) (%)
1 100 0 EtCN −78 5 0b —
2 100 100 CH2Cl2 −78 5 —c 10:1
3 100 0 EtCN 0 5 37 4:1
4 100 0 CH2Cl2 0 5 55 15:1
5 100 100 EtCN 0 5 61 4:1
6 200 100 EtCN −20 6 78 20:1
aDiastereoselectivity was estimated using 1H NMR of the crude reaction mix-
true. bStarting material was fully recovered. cProduct not isolated (40% con-
version measured by 1H NMR).
During chromatographic purification of 72 we noticed that this compound readily iso-
merizes to α-diazo amine 76. Exposure of this vic-amino diazo compound to triflic acid at
−78 ◦C returned unreacted starting material. But the reaction carried out at −20 ◦C pro-
vided the oxazolidine dione as a 1:2.6 anti:syn mixture of diastereomers and no cis-74 was
observed (Scheme 1.29). This established that 1) the intermediate diazonium triflate is a
competent precursor to oxazolidine dione product, and 2) if the diazonium triflate forma-
tion is not diastereoselective (no facial selectivity for C−N2 bond protonation), a mixture of
oxazolidine dione diastereomers will result, 3) carbamate cyclization is substantially faster
than aziridine formation if discrete diazonium triflate 73 (analogous to 65, Scheme 1.27) is
formed in the conversion of 72 to 75. This contrasts the highly selective transformation of
trans-triazoline to anti-oxazolidine dione (Table 1.1), which presumably differs by diastere-
ospecific fragmentation to the intermediate diazonium triflate, followed by diastereospecific
cyclization to the anti-75.
Scheme 1.29. Brønsted acid-promoted conversion of α-diazoamine 76.
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To test syn–anti interconversion under the reaction conditions, a 3:1 anti–syn oxazoli-
dine dione mixture was resubjected to the reaction conditions, returning the same ratio of
diastereomers following reaction workup (Scheme 1.30), which established that the diastere-
omeric oxazolidine diones do not interconvert under the reaction conditions. This observation
supports the contention that diastereomeric ratios observed represent kinetic selectivities.
Scheme 1.30. Control experiment testing syn–anti interconversion.
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H
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1.4.2 Stereochemistry of the carbon–carbon bond formation in α-diazo imide
addition to azomethines
This stereochemical course provided a behavioral test for the intermediacy of vic-aminodi-
azonium 73 in the examination of the triflic acid-catalyzed aza-Darzens reaction. α-Diazo
imide 69 was prepared (see Section sec:diazo-prep for synthesis) for that purpose. We ex-
pected that compound 69 will react similarly to ethyl diazoacetate in reaction with ben-
zhydryl imine 77 in presence of triflic acid. The syn carbon–carbon bond formation will
provide the intemediate 73 and cross mechanistic path of triazoline imide 72 fragmentation
(Table 1.1). As described above, we expected 5-exo carbamate cyclization to be faster than
aziridine formation and anti-75 was expected to be the major product (Figure 1.8).
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Figure 1.8. Diazo imide–imine reaction hypothesis.
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To our surprise, when imine 77 and diazo 69 are treated with 200mol% of triflic acid in
propionitrile at −20 ◦C, the reaction afforded oxazolidine dione 75 in 65% yield in 9:1 ratio
favoring the syn diastereomer. At low temperature (−78 ◦C, including reaction quench),
the result was similar but on a few occasions this combination led to a mixture of syn-
oxazolidine dione 75 and cis-aziridine 74. No evidence for trans-aziridine was ever observed
(Scheme 1.31). The selective formation of cis-aziridine 74 suggests that diazoimide 69
behaves similarly to ethyl diazoacetate in the mechanism of the aza-Darzens reaction but
if the cis-aziridine and syn-oxazolidine dione were to share the intermediacy of discrete
diazonium triflate syn-73, however, anti-oxazolidine dione 75 would have resulted.
Scheme 1.31. Unexpected diastereoselectivity in diazo imide–imine reaction.
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To probe the origins of aziridine and oxazolidine dione in the triflic acid-catalyzed α-diazo
imide–imine reaction a series of control reactions was completed. A reaction carried out in
dichloromethane at −78 ◦C favored syn-oxazolidine dione 75 and cis-aziridine 74 was never
observed (a, Scheme 1.32). Addition of 100mol% of water resulted in formation of compound
78 next to syn-75 in 1:1.6 ratio (b, Scheme 1.32). The triflic acid catalyzed addition of α-
imino methyl and ethyl esters (77 and 79 respectively) with α-diazoimide in propionitrile
at −20 ◦C yields the respective products cleanly and with 10:1 and 11:1 syn-selectivity as
evidenced by 1H NMR analysis of their crude reaction mixtures (c, Scheme 1.32).
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Scheme 1.32. Diazo imide–imine control reactions.
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The purified aziridine from the reaction in Scheme 1.31 was resubjected to the low tem-
perature reaction conditions, but would not convert to the oxazolidine dione. However, at
higher temperatures (−20 ◦C or above), the cis-aziridine converted to the syn-oxazolidine
dione without formation of the anti diastereomer (Scheme 1.33). Although this outcome is
consistent with a diastereospecific, intramolecular aziridine ring opening it was not clear if
cis-aziridine 74 is the intermediate of syn-75 or if they form in two distinctive and indepen-
dent pathways.
Scheme 1.33. Acid-promoted diastereospecific aziridine opening.
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While these reactions established the apparent stability of the cis-aziridine at low tem-
perature, an experiment was designed to show unequivocally that the cis-aziridine and syn-
oxazolidine dione are produced independently of one another (Scheme 1.34). The ethyl ester
variant of the cis-aziridine 74 was added (50mol%) to a reaction of α-imino methyl ester
79 and α-diazo imide 69. Triflic acid was added, and following low temperature quench, the
crude reaction mixture was analyzed by 1H NMR (Figure 1.9). Production of the expected
syn-oxazolidine dione 80 (spectrum c in stacked plot) was observed in the crude reaction
mixture (spectrum e). Unchanged cis-aziridine ethyl ester 74 (spectrum a) added at the
reaction start is also observed (quartet at 4.18 ppm), and the diagnostic dq at 4.3 ppm of the
syn-oxazolidine dione ethyl ester 75 (spectrum b) is absent.
Scheme 1.34. Cross-over experiment testing aziridine intermediacy diazo imide–imine
reaction.
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Figure 1.9. 1HNMR (CDCl3) of a) aziridine cis-74, b) oxazolidine dione syn-80, c)
oxazolidine dione syn-75, d) oxazolidine dione anti-75, and e) crude reaction mixture
(Scheme 1.34). The resonance at 4.28 ppm (dq) corresponding to the oxazolidine dione
syn-75 is absent in the spectrum of the crude reaction mixture. Resonances marked with an
asterisk (*) are assigned to the aziridine methyl ester.
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1.4.3 Diazoalkane scope of the aza-Darzens reaction
It was clear to us that stereoselectivity of carbon–carbon bond formation is correlated
with the structure of a diazo compound as ethyl diazoacetate prefers syn C–C bond formation
and α-diazo imide forms anti-aminodiazonium. This prompted us to evaluate other diazo
compounds in the reaction with benzhydryl imine 79 (Table 1.2).
Table 1.2. Scope of the syn-glycolate Mannich reaction.a
R H
N CHPh2
R
NPh2HC
O N
O
O
Ph
100 mol % TfOH
EtCN, –78 °C
H
N2
O
N
Ph
CO2iPr
entry R product cis:transb yieldc
(%)
1 81 >20:1 88
2 82 >20:1 83
3 S 83 >20:1 81
4 Cl 84 >20:1 81d
5 CO2Et 85 >20:1 48
6 Ph 86 >20:1 67
7
Br
87 >20:1 67
8 P(OEt)2
O
88 >20:1 92e
aAll reactions were 0.3m in imine. bDetermined by 1H NMR
analysis. cIsolated yield. dProduct suffers from elimination dur-
ing chromatography. Yield estimated using 1H NMR. eReaction
was carriec out at −20 ◦C for 18h.
Diazoketones bearing cyclopropyl, cyclohexyl or heteroaromatic substituents delivered
the corresponding cis-aziridines in high yield (Table 1.2 entries 1–3). Diazoalkanes containing
a primary chloride gave selectively the chloroethyl substituted aziridine, which was evident
from the proton NMR spectrum but it suffered from elimination during chromatography
(entry 4). An ester substituted diazoalkane delivered aziridine in lower yield but without loss
in diastereoselection (entry 5). A diazo with a remote 2-bromophenyl substituent, utilized
in our approach to ambiguine G,75 afforded the corresponding aziridine in 67% yield (entry
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7). Diethyl (diazomethyl)phosphonate delivered the cis-aziridine exclusively in very high
yield but required a full equivalent of triflic acid and higher reaction temperature (Table
6, entry 8). We speculate that this is due to the Lewis basicity of the phosphonate group
that competes with imine for the proton catalyst.76 In all examples presented in Table 1.2,
cis-aziridine was the only observed isomer. This suggests that the structure of the α-diazo
imide responsible for the unique rectivity when compared to other diazo donors.
1.4.4 Summary and conclusions
This divergent behavior of diazoacetate and α-diazo imide in the Brønsted acid promoted
reaction with azomethines is a result of different stereoselectivity of C–C bond formation.
In the case of ethyl diazoacetate, as described in section 1.3, the reaction proceeds with syn-
selectivity (intermediate 89, Figure 1.10). Hence, the aza-Darzens synthesis of aziridines is
exclusively cis-selective.
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Figure 1.10. Origin of stereoselectivity in Brønsted acid-promoted diazo–azomethine re-
actions.
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In case of α-diazo imide 69, our results and observations suggest the following:
1. The syn-Aminodiazonium generated by fragmentation of trans-triazoline 72 leads di-
rectly to the anti-oxazolidine dione product.
2. Proton transfer isomerization of the syn-aminodiazonium 73 to α-diazo amine 76 prior
to cyclization is unlikely because acid-promoted conversion of 76 to oxazolidine dione
is very slow at −78 ◦C and nonselective at −20 ◦C.
3. Cyclization of syn-73 to anti-oxazolidine dione (5-exo-tet) is significantly faster than
cyclization to trans-aziridine (3-exo-tet).
4. Carbon–carbon bond formation between α-diazo imide and azomethine electrophile
favors anti-aminodiazonium intermediate, a precursor to syn-75. Preference for anti
bond formation might be caused by steric interactions between the carbamate and
substituten on the imine carbon. In addition to steric factors, extended hydrogen
bonding of the pendant carbamate group could also be involved.
5. Under certain conditions (low temperature, propionitrile solvent) C–C bond formation
occurs with syn-selectivity and the 3-exo-tet cyclization product, cis-aziridine 74 is
produced. Additionally, aziridine 74 does not convert further to syn-oxazolidine dione
which suggests that it forms independently of, and is not an intermediate to, syn-
oxazolidine dione.
6. Diastereomer interconversion (syn–anti) under the reaction conditions does not con-
tribute to the observed selectivity.
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CHAPTER 2
Stereoselective reactions of α-diazo imides
2.1 Stereoselective approaches to α-oxy-β-amino acid motif
2.1.1 Olefin functionalization
Biological activity of natural products and pharmaceuticals is often a result of their
unique structure. Some structural motifs, however, are prevelent in a diverse range of
important natural and synthetic small molecules. 1,2-Aminoalcohol is one of these mo-
tifs and can be found in natural amino acids such as serine and threonine. Regioisomeric
α-hydroxy-β-amino acid backbone has been found in clinically valuable antitumor agents
such as Taxol R©,77–80 aminopeptidase inhibitors like bestatin,81,82 and recent isolates like
the microsclerodermins83 and pedeins84 (Figure 2.1). The presence of this moiety and the
stereochemistry of the hydroxy as well as the amino group play a vital role in the biological
activity of the molecules containing it and as a result they are the target of a variety of
synthetic methods.
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Figure 2.1. Natural products containing vic-aminoalcohol fragment.
An addition of the amino and the hydroxy group across a carbon–carbon double bond,
commonly known as alkene aminohydroxylation was first described in 1975.85 Over 20 years
later, catalytic asymmetric aminohydroxylation was reported86 and is now one of the most
reliable methods for the synthesis of 1,2-aminoalcohols from alkenes. Exclusive formation of
only one diastereomer is guaranteed by the stereospecificity of the addition that proceeds
through the cyclic intermediate. Typical conditions involve treatment of an olefin with an
osmium oxidant, (typically K2[OsO2(OH)4]), a chiral ligand, benzyl carbamate as a nitrogen
source and the tert-butyl hypochlorite in a water–tBuOH mixture (Scheme 2.1).87
Scheme 2.1. Synthesis of Taxol side chain via Sharpless asymmetric aminohydroxylation.
Ph OMe
O
5 mol % (DHQ)2PHAL
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Ph OMe
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(65%)
>91:9 regioselectivity
95% ee
Regioselectivity is the main drawback of this method, especially for unsymmetrical alkenes.
This problem has been somewhat addressed by Donohoe and co-workers by tethering the
nitrogen source (such as carbamate) to an allylic alcohol 90 (Scheme 2.2).88 However, this
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approach limits the scope of aminohydroxylation to allylic alcohols.
Scheme 2.2. Donohoe’s intramolecular asymmetric aminohydroxylation.
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The toxicity of osmium stimulated development of other milder methods and led to
discoveries of alternatives, such as palladium catalyzed reactions. An interesting example
has been demonstrated by the Sorensen group. Aminoacetoxylation of a range of alkenes
with high levels of regio- and stereocontrol can be achieved using a tethered N -Ts carbamate
as a nitrogen source to give syn- (91) and anti- products in good diastereoselection.89 An
intermolecular example of the same reaction was reported by Liu and Stahl. Oxidation with
PhI(OAc)2 and the phthalimide as a nitrogen source affords 1,2-aminoalcohol derivatives 92
in good yield and regioselectivity (Scheme 2.3).90
Scheme 2.3. Aminoacetoxylation approach to vic-aminoalcohol derivatives.
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Nitrogen and oxygen can also be installed on a carbon–carbon double bond using a
single reagent. Yoon et al. reported a copper(II)-catalyzed regioselective aminohydroxyla-
tion of alkenes using the N -sulfonyl oxaziridine 93 (Scheme 2.4).91,92 Although this method
addresses regioselectivity issues associated with Sharpless aminohydroxylation of styrene
derivatives, such as 94, only moderate cis:trans selectivity can be achieved. In 2010 the Yoon
group reported that by a careful choice of the catalyst, regioselectivity of aminohydroxyla-
tion can be controlled. If CuCl2 is used, 1,3-oxazolidine 95 forms as the major product but
under conditions utilizing an iron(III) catalyst, regioisomer 96 dominates (Scheme 2.4).93
Scheme 2.4. Yoon’s radical aminohydroxylation using oxaziridines.
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A conceptually different approach to olefin functionalization was illustrated by Johnston
and co-workers in 2005. Benzyl azide undergoes a Brønsted acid promoted 1,3-dipolar cy-
cloaddition with the α,β-unsaturated imide 66. Intermediate triazolines can be isolated or
fragmented by warming to room temperature which is followed by cyclization of a latent
oxygen nucleophile onto an α-diazonium intermediate (see Scheme 1.28, section 1.4) to af-
ford anti-oxazolidine dione products 68 with very high dr (Scheme 2.5).72 Fragmentation of
the triazoline at low temperature can be triggered by use of water as a secondary catalyst.74
Scheme 2.5. Brønsted acid-promoted formal aminohydroxylation of α,β-unsaturated
imides.
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Another metal-free oxidative approach to functionalization of alkenes was shown by
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Cochran and Michael. Intramolecular oxyamination of olefins with PhI−O using a tethered
urea as an oxygen and nitrogen source proceeds with high diastereoselection (Scheme 2.6).
The strength of the acid catalyst determines the reaction outcome. Strong acids, such as tri-
flic acid, prefer an oxyamination pathway, whereas weak acids yield diamination products.94
Scheme 2.6. Metal free, acid promoted intramolecular oxyamination.
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2.1.2 Vicinal aminoalcohols via C–C bond forming reactions
With the advent of asymmetric catalysis, a significant development was achieved in the
area of carbon–carbon bond forming reactions between imines and glycolic acid enolates or
their equivalents.95,96 Early work in the asymmetric glycolate Mannich reaction involved silyl
ketene acetals as nucleophiles. In 1998 Kobayashi and co-workers demonstrated the first cat-
alytic diastereo- and enantioselective glycolate Mannich reaction (Scheme 2.7). Metal com-
plex 99 catalyzes addition of the silyl ketene acetal 98 to benzaldimines 97 to form Mannich
adducts 100 with very high stereoselection.97 A hydroxy group on the imine substituent is
needed for effective binding to the catalyst. Later, Akiyama reported that the same reaction
can be catalyzed by chiral phosphoric acid 101. α-Hydroxy-β-amino esters such as 100 form
as a single diastereomer in high ee when a large triphenylsilyl group is used (Scheme 2.7).98
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Scheme 2.7. Kobayashi’s asymmetric glycolate Mannich reaction with silyl ketene acetal
nucleophiles.
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In 2002 List99 and Barbas100 independently showed that l-proline is a very efficient
organocatalyst in the direct Mannich reaction. The imino ester 102 in reaction with α-
hydroxyacetone (103) delivers serine derivative 104 essentially as a single stereoisomer
(Scheme 2.8).
Scheme 2.8. Proline catalyzed direct Mannich reaction of α-hydroxy ketones.
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Trost utilized α-hydroxy acetophenone in a direct Mannich reaction catalyzed by dinu-
clear zinc Lewis acid complex 105. Phosphinoyl imines 106 react with the hydroxyketone
nucleophile 107 to deliver trans-adducts 108 with exceptional enantioselection. However,
high levels of diastereoselection weren’t observed for all substrates. It was also observed
that N -Boc imines deliver amino alcohol derivatives with the opposite relative stereochem-
istry.101,102 A significant contribution to this field has been brought by Shibasaki and co-
workers. Zinc and indium(III) complexes with the linked BINOL ligand 109 were shown to
be excellent catalysts in the direct glycolate Mannich reaction.103–106 Similar to the obser-
vation made by Trost, a correlation between the syn–anti stereoselection and the protecting
group on the imine nitrogen was noted.105 Phosphinoyl and tosyl imines yield syn adducts,
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whereas N -Boc imines give anti products. Reaction conditions tolerate a variety of aryl and
alkyl106 imines as well as glycolate equivalents as nucleophiles and deliver products with
good dr and excellent enantioselectivity (Scheme 2.9).
Scheme 2.9. Enantioselective Lewis acid catalyzed glycolate Mannich reactions.
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Vicinal aminoalcohols can also be prepared through a vinylogous Mannich reaction. The
pioneering work in this area was published by Martin and co-workers in their 1999 publi-
cation. They demostrated vinylogous Mannich reaction of triisopropylsilyloxyfurans with
aldimines catalyzed by the (S)-BINOL–Ti(OiPr)4 complex that produces syn-aminoalcohol
derivatives in up to 44% ee.107 A vast improvement upon this reaction was brought about
by the groups of Hoveyda and Snapper. In presence of AgOAc and amino acid derived
phosphine 113, commercially available siloxyfuran 111 engages with aldimines in an asym-
metric vinylogous Mannich reaction.108,109 The reaction protocol is very simple and doesn’t
require anhydrous conditions or solvents (Scheme 2.10). Later the scope of this reaction was
extended to alkyl imines formed in situ in a three component reaction between alkyl aldehy-
des, aniline and siloxyfuran to deliver vinylogous Mannich products as a single diastereomer
and often in nearly enantiopure form.110
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Scheme 2.10. Hoveyda’s silver-catalyzed vinylogous Mannich reaction of siloxyfurans.
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2.2 Diastereoselective Brønsted acid-catalyzed glycolate Mannich reaction
2.2.1 Large scale synthesis of α-diazo imide
Scheme 2.11 depicts our initial synthesis of the α-diazo imide 69 which is based on
the procedure reported by Doyle. It commences with the synthesis of the methyl phenyl-
carbamate 114 from aniline and methyl chloroformate in 57% yield after recrystallization.
Acetylation of 114 with acetyl chloride delivered N -acetyl derivative 115 in 77% yield. The
lithium enolate of 115 generated with LDA was reacted with 2,2,2-trifluoroethyl trifluoroac-
etate (TFEA). The intermediate enol 116 is not purified, and is immediately subjected to
the diazo transfer reaction with 4-acetamidobenzenesulfonyl azide (p-ABSA) 117 to deliver
α-diazo imide 69 in 32% yield over two steps.70
Scheme 2.11. Small scale preparation of α-diazo imide 69
nBuLi, THF
N OMe
O
Ph
O
F3C
not isolated
0 °C to rt, 3 h
Et3N, CH3CN
AcHN
SO2N3
N OMe
O
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O
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Cl OMe
O PhNH2, Et3N
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O
Ph
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N OMe
O
Ph
O
Me
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OH
–78 °C, 30 min
LDA, THF
then TFEA
–78 °C, 30 min
114 115
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Reaction conditions applied in the reaction of α-diazo imide 69 with imine 79 didn’t
translate well to other substrates. The main problem was a subsequent reaction that pro-
duced N -alkyl transfer product 118 next to 80. We hypothesized that by increasing the size
of the carbamate this undesired pathway will be suppressed. Indeed, when α-diazo imide
119 with 2-propyl carbamate was used, N -alkyl transfer product was no longer observed
(Table 2.1).70
Scheme 2.12. Alkyl transfer side reaction of α-diazo imide addition to imines.
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100 mol % BF3•OEt2
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MeO2C
N
O N
O
O
Ph
Ph2HC Me
up to 1:1 ratio
79 69 80 118
One challenge of large scale preparation of α-diazo imide 69 was the preparation of the
active fluorinated intermediate 116. It is not stable to common purification techniques.
Therefore, near complete conversion of precursor 115 must be achieved for the subsequent
step to be successful. If unreacted 115 is present after the diazo transfer step, it is im-
possible to separate it from the diazo product by conventional chromatography techniques.
Additionally, purification of 69 required chromatography at 0 ◦C in order to suppress silica
gel promoted decomposition (vide infra).
Before investigating the syn-glycolate Mannich reaction in more detail, our goal was to
establish a reliable preparative protocol for the synthesis of α-diazo imide 119. The synthesis
of acetylated intermediate 121 in nearly quantitative yield without purification was achieved
by acylation of aniline with isopropyl chloroformate at room temperature. We established
that crystallization of the isopropyl phenyl carbamate (120) was not necessary—after aque-
ous work-up, the purity of the crude product exceeded 97% by gas chromatography. The
acetylation reaction proceeds without any sign of side-products but suffers from incomplete
conversion at −78 ◦C. Warming the reaction mixture to room temperature drove the reac-
tion to completion and afforded N -acetyl imide 121 in nearly quantitative yield without the
need for chromatography (> 97% purity by GC).
A second challenge in the preparation of fluorinated intermediate 122 was overcome
by substitution of lithium diisopropylamide with lithium hexamethyldisilazide. Although
careful temperature control normally provides full conversion of 121, attempts to perform
this reaction at a scale larger than 25 g were unsuccessful. Straightforward trituration with
a nonpolar organic solvent, such as hexanes, effects the removal of 121, should incomplete
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conversion occur in this step. Spectroscopic data of the solid obtained by trituration were
in agreement with the hydrate of the trifluoromethyl ketone and not the enol form observed
by Doyle (Scheme 2.13).23
Scheme 2.13. Large scale preparation of α-diazo imide 119
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Although the yield of the diazo transfer remained lower than reported examples, the
desired diazo imide can be prepared as a pure crystalline solid, as determined by combustion
analysis.111 The technique used for purification of the final product also limits the scale of
the reaction. We have found that the rate of decomposition of the α-diazo imide during chro-
matography was slow when silica gel was deactivated with triethylamine. This modification
eliminated the use of a custom-made jacketed flash column.
The nucleophilic carbamate moiety of the α-diazo imide is its key innovative feature for
cascade reaction development. However, its use is not without complication. As we have
shown, nucleophilic additions can be followed by cyclization. But at the same time, under
acidic conditions, the α-diazo imide can undergo self-cyclization to oxazolidine dione 123.
When isopropyl 2-diazoacetyl(phenyl)carbamate (119) alone is subjected to triflic acid at
room temperature, oxazolidine dione 123 forms exclusively (Figure 2.2). Alternatively, when
119 is treated with silica gel in ethyl acetate, carbonate 124 forms as a single product. We
postulate that both by-products share the same intermediate, the orthoester 125.112 After
protonation 5-exo-tet cyclization leads to an oxonium intermediate which can be trapped
in the presence of water. Proton transfer to isopropoxide, collapse of the tetrahedral inter-
mediate and elimination of 2-propanol leads to 123. If proton transfer occurs to the amide
nitrogen instead, collapse of the tetrahedral intermediate affords carbonate 124 (Figure 2.2).
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Figure 2.2. Decomposition pathways of α-diazo imide.
2.2.2 Optimization of reaction conditions and substrate scope
Through a series of experiments we established optimal conditions for syn-glycolate Man-
nich reaction of α-diazo imide 119 and imine 79. A screen of Brønsted acids revealed that
acids with pKa values∗ below −10 perform best (Table 2.1, entries 1–3). Acids within a
pKa range of −10 to 2 are still able to promote the reaction but at the cost of competitive
decomposition of the diazo imide which decreases yield dramatically (entries 4, 5). The diazo
imide is slowly converted to oxazolidine dione 123 when exposed to a Brønsted acid in the
absence of imine (see section 2.2.1). Weak acids (pKa above 3) were not able to promote the
reaction (entries 6–9). Additionally, the rate of α-diazo imide decomposition was also very
slow when using weak Brønsted acids such as benzoic acid. Even after 24 h at rt, diazo 119
was still present in the reaction mixture. Although HBF4 delivered the product in highest
yield, TfOH provided an optimal combination of reactivity, availability, convenience (readily
dried, distilled, and measured as a liquid), and isolated product yield (entry 2).
We also investigated nitrogen protecting groups on the imine substrate since the nature
of this substituent will determine the azomethine proton affinity and the basic character of
the nitrogen in the product oxazolidine dione. We chose derivatives of 4-chlorobenzaldehyde
∗Values in water.
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Table 2.1. syn-Glycolate Mannich reaction: Brønsted acid survey.a
MeO2C H
N CHPh2
N2
N
O
CO2Me
Ph MeO2C
N
O N
O
O
Ph
Ph2HC
100 mol % H–X
H
EtCN O N
O
O
Ph
79 119 80 123
entry X–H T time conv yieldb
(◦C) (h) (%) (%)
1 HBF4 −78 1 100 83
2 TfOH −78 1 100 76
3 Tf2NH −78 1 100 71
4 TFA −78 1 65 42
5 TsOH −78 1 100 43
6 PhCO2H rt 24 <5 –
7 AcOH rt 24 <5 –
8 PPTS rt 24 <5 –
9 NH4Cl rt 24 <5 –
aAll reactions were 0.15m in imine and used 1.2 equiv of
diazo imide. bIsolated yield. cProduct not isolated (40%
conversion measured by 1H NMR).
126 because it allowed us to prepare a large number of imines. Overall, the benzhydryl group
is optimal, delivering product in 59% yield and 10:1 dr (Table 2.2, entry 1). The bulkier
trityl group resulted in an imine that is completely unreactive towards diazo 119 (entry 2).
Electron rich protecting groups also lower the reactivity of the imine (entries 3, 4 and 6).
Phenyl imine exhibited nearly the same conversion and yield as benzydryl imine (entry 5)
but the degree of diazo decomposition was much higher. Full imine conversion and slightly
higher yield was observed for N -Boc imine but at the cost of diastereoselection (entry 9).
These trends suggest a balance between azomethine activation by the nitrogen substituent
and the Brønsted acid activating agent. Although a DPM group provides little azomethine
polarization it should be readily protonated, succumbing to the full activation potential of
the proton. Conversely, a carbamate provides substantial native azomethine polarization.
Binding to the proton may be weaker but the combined effect lowers the activation barrier.
The reasons for the large difference in diastereoselection, however, are less clear.
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Table 2.2. Screen of N -protecting group on the imine substrate.a
H
N PG
N2
N
O
CO2iPr
Ph R
N
O N
O
O
Ph
PG
100 mol % TfOH
H
O N
O
O
PhEtCN
–78 °C, 20 hCl
126 119 127 123
entry PG conv. yield drb 127:123c
(%) (%) (%)
1 Ph2CH 67 59 10:1 >20:1
2 Ph3C – – – >1:20
3 PhCH2 52 19 10:1 1:1
4 PMB 53 22 10:1 1:2
5 Ph 71 50 10:1 1:1
6 PMP 8 4 – 1:10
7 allyl 53 4 – 1:10
8 2-pyridyl 38 15 2:1 1:1
9 Boc 100 16 2:1 4:1
10 Ts – – – –
aAll reactions were 0.15m in imine and used 1.2 equiv of diazo
imide. bIsolated yield. cDetermined by 1H NMR.
Optimization studies suggest that glyoxal-derived imines are more reactive than simple
aldimines. We prepared a series of α-keto imines and employed them in the syn-glycolate
Mannich reaction as a complement to aryl imines. Substrates 128–134 were synthesized from
the corresponding hydrates (Table 2.3). Aryl derivatives were accessed from the oxidation of
various aryl methyl ketones (method A). Aliphatic glyoxals were prepared as their hydrates
by DMDO oxidation of the corresponding diazoketones according to a reported procedure
(method B).113
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Table 2.3. Synthesis of α-keto imines
Me
O
R SeO2
dioxane/H2O
55 °C, 6 h
O
R
H
OHHO Ph2CHNH2
4 Å MS, CH2Cl2
rt, 1 h O
R
H
N CHPh2
O
R
N2
DMDO
acetone
0 °C, 1h
R = aryl
R = alkyl
method A
method B
entry R imine yield (%) entry R imine yield (%)
1
O
Me
128 68 5
tBu
O
132 99
2
O
F
129 43 6
O
133 65
3
O
F3C
130 45 7
O
134 65
4
O
S 131 69
Table 2.4 is representative of the scope of the syn-glycolate Mannich reaction. Aryl α-
keto imines with both electron rich and electron poor substituents provided oxazolidine dione
products with high diastereoselection and good to excellent yield (entries 2–4). Heteroaro-
matic substrate 131 yielded the adduct with lower diastereoselection at the 6:1 level (entry
5). Diastereoselection was even lower for α-keto imines bearing alkyl substituents (entries
6–8) but this was compensated by the nearly quantitative yield. Characteristic crystallinity
of the oxazolidine diones allowed a single diastereomer of 139 to be isolated by recrystal-
lization in 62% yield without need for chromatography (Scheme 2.14). Lower reactivity was
observed across the array of aryl imines (entries 9–13). Despite an extended reaction time
(18 hours), yields were generally lower with dr maintained at the 10:1 level.
Scheme 2.14. Preparative procedure for the synthesis of the 139.
recrystallization 88% yield, 4:1 dr
62% yield; 20:1 dr(EtOAc/hex)
H
N CHPh2
N
O
O
Ph2HC
O N
O
O
Ph
100 mol % TfOH
EtCN, –78 °C
H
N2
O
N
Ph
CO2iPr
133 119 139
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Table 2.4. Scope of the syn-glycolate Mannich reaction.a
R H
N CHPh2
R
NPh2HC
O N
O
O
Ph
100 mol % TfOH
EtCN, –78 °C
H
N2
O
N
Ph
CO2iPr
entry R product time dr yield
(h) (%)
1
MeO
O
80 1 >20:1 76
2
O
Me
135 1 >20:1 79
3
O
F
136 1 >20:1 81
4
O
F3C
137 1 >20:1 72
5
O
S 138 1 6:1 80
6
O
139 1 4:1 88
7
O
140 1 4:1 98
8
tBu
O
141 1 1:1 97
9
O2N
142 18 10:1 69
10
F
143 18 10:1 48
11 Cl
Cl
144 18 10:1 53
12
OPh
145 18 10:1 37
13
CN
146 18 10:1 36
aAll reactions were 0.15m in imine and used 1.2 equiv of diazo imide.
bIsolated yield. cDetermined by 1H NMR.
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2.2.3 Functionalization of the oxazolidine dione ring
The oxazolidine diones produced by this method are masked α-hydroxy-β-amino acids.
In order to access this functional motif, the oxazolidine dione ring has to be hydrolyzed and
the diphenylmethyl group removed. Deprotection of the secondary amine can be achieved
under mild conditions. Hydrogenation of compound 147 in the presence of palladium(II)
hydroxide in ethanol delivers the free amine 148 in 71% yield (Scheme 2.15).
Scheme 2.15. Hydrogenation of the benzhydryl group.
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Ph
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Functionalization of the oxazolidine dione ring proved more challanging. When the ox-
azolidine dione 149 was treated with a catalytic amount of sodium hydroxide in benzyl
alcohol in a microwave reactor, no reaction was observed at 120 ◦C. After heating for 15min
at 150 ◦C, the α,β-unsaturated cyclic amide 150 was isolated as a single compound in 51%
yield (Scheme 2.16). A possible mechanism for this reaction is shown in Scheme 2.16 where
the carbamate carbonyl might be more reactive toward nucleophiles than the amide car-
bonyl. Hydrolysis of the carbamate followed by cyclization of the amide nitrogen onto the
ketone and subsequent elimination of the carbonate delivers compound 150, where both
stereocenters set during the syn-glycolate Mannich reaction are lost.
Scheme 2.16. Preliminary result of oxazolidine dione hydrolysis
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When the same conditions were applied toward compound 147, the desired α-hydroxy
amide 151 was observed. Unfortunately, the diastereomeric integrity of the parent molecule
was low; nearly a 1:1 ratio of the two diastereomers was isolated (Table 2.5, entry 1). An
identical result was obtained when oxazolidine dione 147 was treated with lithium methox-
ide at room temperature. Full conversion of the substrate was observed after just 15min,
but syn stereochemistry wasn’t retained (entry 2). The diastereomers were separated and
fully characterized to confirm the outcome of the reaction. We hypothesized that prior to
nucleophilic attack, a deprotonation–protonation occurs which is responsible for the loss of
diastereoselection. Thermal ring opening was also unsuccessful. Heating of 147 in methanol
and ethanol in a microwave reactor at 150 ◦C and 170 ◦C, respectively, failed to deliver the
desired product (entries 3 and 4). Despite full conversion, only decomposition products were
observed in the crude reaction mixture when analyzed by 1H NMR. The same results were
obtained when oxazolidine dione was heated at 125 ◦C in methanol saturated with HCl (entry
5). Heating with benzylamine in the microwave at 100 ◦C for 1 hour, a conversion of 90%
was determined by NMR analysis but still the final product formed in nearly 1:1 dr (entry
6). A saturated solution of ammonia in methanol at 80 ◦C delivered aminoalcohol 151 in 2:1
dr (entry 7).
Table 2.5. Opening of oxazolidine dione using alcohol nucleophiles.
Ph
NH
O N
O
Ph
O
conditions
Ph2HC
Ph
NH
OH
N
H
O
Ph
Ph2HC
147 151
entry conditions conv dr
(%)
1 BnOH, NaOH, 150 ◦C, 15min 80 1:1
2 MeOH, LiOH, rt, 15min 100 1:1
3 MeOH, 150 ◦C, 1 h 100 1:1
4 EtOH, 170 ◦C, 1 h 100 1:1
5 MeOH, HCl, 125 ◦C, 1 h 100 1:1
6 BnNH2, 100 ◦C, 1 h 90 1:1
7 NH3 ·MeOH, 80 ◦C, 15min 80 2:1
When the reaction with ammonia was carried out at room temperature, carbamate 152 in
4:1 dr was the major product together with traces of aminoalcohol 151 (Scheme 2.17). Isola-
tion of 152 was unsuccessful and there is no analytical data to support structure 152.† How-
†Our later experience with NH3 ·MeOH conditions showed that the product of oxazolidine dione opening
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ever, when 152 was subjected to ammonia in methanol at 80 ◦C for 1 h, the relative amount
of 152 decreased significantly and the major product became a 4:1 mixture of aminoalcohol
151, albeit with incomplete conversion. When the reaction temperature was −30 ◦C, com-
pound 147 was only sparingly soluble, and no reaction was observed. Use of a polar protic
solvent appears to be necessary since reactions with ammonia in other solvents, such as
propionitrile and dioxane, resulted in no reaction even at room temperature (Scheme 2.17).
Scheme 2.17. Opening of oxazolidine dione ring using alcohol solution of ammonia.
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The potent nucleophilic reactivity of hydroxylamine evident in many transformations is
thought to arise as a consequence of the α-effect,114,115 a behavior observed in a variety
of nucleophiles which possess a heteroatom in the α position to the attacking nucleophilic
atom. We hypothesized that hydroxylamine might be a better nucleophile than ammonia
and the rate of addition might then dominate over deprotonation. Unfortunately, when 153
was exposed to hydroxylamine only partial conversion was observed and the desired product
wasn’t observed in the 1HNMR of the crude reaction mixture (Scheme 2.18).
Scheme 2.18. Opening of the oxazolidine dione using more reactive nucleophiles.
NH
O N
O
Ph
O
Ph2HC
complex mixture
0 °C, MeOH
100 mol %
NH2OH•HCl
100 mol % Et3N
Cl
154
is a methyl carbonate, not primary carbamate, see section 3.4.3
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Sulfur nucleophiles provide enhanced nuclophilicity without significant increase in ba-
sicity. When diastereomerically pure oxazolidine dione 153 was treated with ethyl thiolate
at −78 ◦C overnight no ring opening was observed. Although starting material was fully
recovered, it was a mixture of both diastereomers in a 3:1 ratio (Scheme 2.19).
Scheme 2.19. Opening of oxazolidine dione with ethyl thiolate.
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We then turned to carbon nucleophiles but reagents such as methyl magnesium bromide
provided a complex mixture of products. In a reaction where 154 was stirred with 10 equiv
of TMS lithium acetylide at −20 ◦C for 24 h, the 1H NMR of the crude reaction mixture
showed traces of both diastereomers of the starting material and benzhydryl imine 155 as a
major product. retro-Mannich products have never been observed in diazo 119 additions to
imines but this result clearly demonstrates that the retro pathway can operate under certain
conditions. A mechanism explaining the outcome of the reaction is shown in Scheme 2.20.
Scheme 2.20. Opening of oxazolidine dione with lithium acetylide.
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Clearly, the Brønsted basicity of the reagents used, as well as a potential retro-Mannich
pathway, is responsible for a decrease in the diastereomeric ratio during the ring opening of
oxazolidine dione. We therefore turned to Lewis acid activation of the oxazolidine dione ring
towards milder nucleophiles such as methanol. A screen of various Lewis acids is presented in
Table 2.6. When oxazolidine dione 80 was exposed to methanol in the presence of 200mol%
of titanium(IV) isopropoxide, 30% conversion to the diester 156 was observed (entry 1).
Increased amounts of titanium reagent as well as higher reaction temperatures didn’t improve
conversion (entries 2 and 3). Shortly after titanium(IV) tetraisopropoxide is added to the
reaction mixture, a copious amount of white precipitate forms. We hypothesized that in
the presence of a large excess of methanol, solid titanium(IV) tetramethoxide forms, and
the Lewis acid is in fact removed from the reaction medium. Application of Ti(OiPr)4 in
THF with 50 equivalents of methanol was unsuccessful (entry 4). Aluminum Lewis acids are
considered to have relatively similar reactivity to titanium Lewis acids but when aluminum-
based reagents of varying Lewis basicity were evaluated, no sign of product was observed
(entries 5–7).
Table 2.6. Lewis acid-assisted opening of oxazolidine dione ring.
MeO2C
NH
O N
O
Ph
O
Ph2HC
Lewis acid MeO2C
NH
O
H
N
Ph
O
Ph2HC
CO2Me
X equiv MeOH
80 156
entry Lewis Acid x conva
(equiv) (%)
1 200mol% Ti(OiPr)4 excess 30 (16)
2 200mol% Ti(OiPr)4 excess 30
3 500mol% Ti(OiPr)4 excess 30
4 200mol% Ti(OiPr)4 50 –
5 100mol% AlClEt2 2 –
6 100mol% AlCl2Et 2 –
7 100mol% AlCl3 2 –
aMeasured by 1H NMR.
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On one occasion, when hydrogenation of the oxazolidine dione 80 in the presence of
20mol% of Pearlman’s catalyst was carried out for a prolonged period of time (20 h), 15%
conversion to the ring opening product 157 was observed, without any sign of epimerization.
Interestingly, when 80 was subjected to the same conditions without a hydrogen source, the
reaction didn’t take place, suggesting that ring opening occurs after DPM deprotection.
This is probably not due to increased reactivity of the primary amine compared to N -DPM
compound 80, but simply to relative solubility. Oxazolidine diones have limited solubility in
alcohols at room temperature and once the benzydryl group is removed and the oxazolidine
dione free base is in solution, the rate of the regioselective methanolysis increases. If the
reaction was carried out for 3 days, aminoalcohol 157 is produced in 45% yield as a single
diastereomer. If the reaction is allowed to stir for a longer time, slow decomposition of the
product was observed (Scheme 2.21).
Scheme 2.21. Opening of the oxazolidine dione 80 and structural assignment of the
methanolysis product.
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The O,N -acyl transfer product 157 is proposed based on the analysis of the C–H het-
eronuclear correlations. A new methyl group correlates to the carbonyl carbon at 152 ppm
which is more consistent with the structure 157 rather than 158. The carbonyl shift for
both the carbamate and the carbonate cannot be used for the assignment because both
are expected in the 150–160 ppm range. However, the HMBC correlation between H2 at
4.89 ppm to all three carbonyl carbons supports structure 157. Additionally, in structure
158, correlation between H2 and carbonyl at 157 ppm is unlikely due to the 4 bond distance.
Also, alack of correlation between H3 and the carbonate carbon at 157 ppm suggests that
structure 158 is not plausible (Scheme 2.21).
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2.3 Development of enantioselective glycolate Mannich reaction
2.3.1 Evaluation of chiral Brønsted acids in reactions of α-diazo imide with
azomethines
The Brønsted acid catalyzed syn-glycolate Mannich reaction is a novel method for the
diastereoselective synthesis of syn-1,2-amino alcohols. An enantioselective variant of this
reaction is a logical extension of this methodology. As it was presented in section 1.2.2 there
are many efficient and stereoselective reactions of diazo compounds and azomethines cata-
lyzed by chiral Brønsted acids, and development of the enantioselective glycolate Mannich
reaction that utilizes the chiral Brønsted acid catalysts became our next goal.
H,QuinBam•HOTf PBAM•HOTf
N N
H HH H
NN H
OTf
N N
H HH H
NN H
OTf
N N
159 160
Figure 2.3. Bis(amidine) (BAM) catalysts for enantioselective aza-Henry reaction.
In reaction of α-diazo imide with N -Boc imines we saw a moderate reactivity and diastere-
oselection when triflic acid was used as a catalyst (Table 2.2, entry 9). We also knew that
N -Boc imines can be succesfully activated towards nucleophilic addition using chiral proton
catalysts such as H,QuinBam (159) or PBAM (160) (Figure 2.3).116–118 This prompted us
to evaluate chiral Brønsted catalysts in the syn-glycolate Mannich reaction. No reaction was
observed when benzaldimine 161 was reacted with α-diazo imide 119 in presence of catalyst
159 at −78 ◦C. Reaction was warmed to −20 ◦C and after 3 days 6% of the oxazolidine
dione 162 was isolated in 3:1 dr (Scheme 2.22). Enantioselection measured for the major
diastereomer was only 15% (51% for the minor diastereomer). Reactions carried out with
substoichiometric amount of the catalyst failed to show catalyst turnover.
To gain a broader perspective on the type of organocatalyst needed for glycolate Mannich
reaction, we evaluated several popular catalysts based on axially chiral phosphoric acid (163
and 34), and chiral thiourea catalysts 164 and 165 (Scheme 2.23). To our disappointment,
in all cases no reaction was observed after 18 h at room temperature. Reaction catalyzed by
thiourea 165 was carried out in CDCl3 and observed by 1H NMR. Throughout reaction time
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Scheme 2.22. Glycolate Mannich reaction promoted by chiral Brønsted acid.
H
N
Boc
N2
N
O
CO2iPr
Ph
EtCN, –20 °C
N
O N
O
O
Ph
Boc H
3 days
H,QuinBAM•HOTf
100 mol%
(69%)
3:1 dr, 15/51% ee
Cl Cl
161 119
162
imine and α-diazo imide 119 remained unreacted. This is in agreement with our previous
study of the correlation between Brønsted acid strength and reaction outcome (Section 2.2.2).
Imine activation can only be achieved with very strong Brønsted acids without significant
protonative diazo decomposition. Moderately strong Brønsted acids deliver a mixture of
oxazolidine dione product 162 and oxazolidine dione by-product 123. Weak acids can neither
activate imine nor decompose α-diazo imide. Clearly the thiourea family of catalysts falls
into the latter category. The 1H NMR spectrum of the reaction carried out in CDCl3 didn’t
show characteristic singlet at 4.80 ppm corresponding to the methylene protons of compound
123. Although phosphoric acids 163 and 34 are stronger which is evidenced by presence
of the by-product 123 in the 1H NMR spectrum of the crude reaction mixture, they don’t
possess sufficient strength to activate the imine towards productive carbon–carbon bond
formation. We concluded that Brøsted acid catalyzed enantioselective glycolate Mannich
reaction is unlikely to be developed with these acids simply because of the high potential
for protonative decomposition of diazo imide 119 that competes with effective azomethine
activation. However, it is important to understand that the factors that affect the rate of
protonative decomposition remain unclear.
2.3.2 Evaluation of Lewis acids in the syn-glycolate Mannich reaction
The results obtained with the chiral Brønsted acids as catalysts were disappointing (sec-
tion 2.3.1) so in order to extend the area of our search for an effective chiral catalyst we
performed a survey of Lewis acidic metal catalysts that could serve as a foundation for the
development of an enantioselective reaction. A series of Lewis acids was evaluated in the re-
action of the N -benzhydryl α-imino ester 79 and α-diazo imide 119. Although titanium(IV)
tetraisopropoxide didn’t promote the reaction, more Lewis acidic titanium(IV) tetrachloride
delivered syn-oxazolidine dione 80 in 32% yield (Table 2.7, entry 8). Boron trifluoride ether-
ate promoted the reaction to a much higher degree and the product was isolated in 79%
yield (entry 9). It is important to note that when the reaction was carried at −20 ◦C for
16 h, a mixture of diastereomers was isolated in 93% yield but now in favor of the anti-
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Scheme 2.23. Chiral Brønsted acid screen
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diastereomer (entry 10). It is not clear how the anti-diastereomer forms but it appears that
the syn-stereoisomer is a kinetic product and forms exclusively when reaction time is rela-
tively short (Table 2.7, entry 9). Recently Aggarwal and co-workers proposed that BF2OTf,
generated from BF3 ·OEt2 and TMSOTf is a stronger Lewis acid than BF3.119 When we
evaluated this reagent in the syn-glycolate Mannich reaction, slight enhancement in yield was
observed (Table 2.7, entry 11). Aggarwal also proposed that BF3 ·OEt2, TMSOTf, BF2OTf
and TMSF exist in equilibrium (Figure 2.4) and therefore it is possible that TMSOTf is
the active Lewis acid under these conditions. When TMSOTf was used in the reaction, the
oxazolidine dione product was isolated in 93% yield (Table 2.7, entry 12). Iron(III) choride
was also an active catalyst but required longer reaction time at room temperature. The
reaction catalyzed by copper(II) triflate and indium(III) triflate afforded oxazolidine dione
80 in 65% and 80% yield respectively (entry 14 and 15).
TMSOTf+ BF3 ·OEt2 −−⇀↽− BF2OTf ·OEt+ TMSF
Figure 2.4. Equilibrium reaction between BF3 ·OEt2 and TMSOTf.
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Table 2.7. Evaluation of Lewis acid catalysts in the syn-glycolate Mannich reaction.a
MeO2C H
N CHPh2
N2
N
O
CO2iPr
Ph
CH2Cl2, –78 °C
MeO2C
NH
O N
O
O
Ph
Ph2HC
100 mol % Lewis acid
79 119 80
entry Lewis acid T time syn:anti yieldb
(◦C) (h) (%)
1 AgOTf rt 6 – –
2 (CuOTf)2 · toluene rt 24 – –
3 Sc(OTf)3 rf 24 – –
4 Mg(OTf)2 rt 24 – –
5 Zn(OTf)2 rt 24 – –
6 Yb(OTf)3 rt 24 – –
7 Ti(OiPr)4 rt 24 – –
8 TiCl4 −78 24 >20:1 32
9 BF3 ·OEt2 −78 1 >20:1 79
10 BF3 ·OEt2 −78 16 1:2 93
11 BF2OTf ·OEt2 −78 1 >20:1 81
12 TMSOTf −78 1 >20:1 93
13 FeCl3 rt 15 >20:1 72
14 In(OTf)3 −78 6 >20:1 80
15 Cu(OTf)2 −78 2 >20:1 65
aAll reactions were 0.15m in imine and used 1.2 equiv of diazo imide.
bIsolated yield.
During development of the syn-glycolate Mannich reaction, N -Boc benzaldimines showed
slightly better reactivity towards α-diazo imide 119 but moderate diastereoselection. We
decided to also evaluate N -Boc imine 161 in Lewis acid catalyzed addition of α-diazo imide
119 (Table 2.8). Lewis acids based on Mg(II), Yb(III), La(III) and Ti(IV) didn’t promote
the reaction even at room temperature (Table 2.8, entries 1–5). Scandium(III) triflate (entry
6) was able to promote the reaction at −20 ◦C but the product formed in 1:1 dr. Modest
reactivity was observed when the reaction was promoted by BF3 ·OEt2 and Zn(OTf)2 which
yielded oxazolidine dione in 48% and 43% yield, respectively (Table 2.8, entries 7 and 9).
Suprisingly, TMSOTf wasn’t a better Lewis acid than BF3 ·OEt2 and delivered the desired
product only in 39% yield and 1:1 dr (entry 8). Copper(II) triflate and indium(III) triflate
showed similar activity affording 162 in 59% and 55% yield, respectively (Table 2.8).
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Table 2.8. Evaluation of Lewis acid catalysts in the syn-glycolate Mannich reaction.a
H
N
Boc
N2
N
O
CO2iPr
Ph
CH2Cl2, 18 h
NH
O N
O
O
Ph
Boc
100 mol % Lewis acid
Cl Cl
161 119 162
entry Lewis acid T syn:anti yieldb
(◦C) (%)
1 Mg(OTf)2 rt – –
2 Yb(OTf)3 rt – –
3 La(OTf)3 rt – –
4 Ti(OiPr)4 rt – –
5 TiCl4 rt – –
6 Sc(OTf)3 −20 1:1 nd
7 BF3 ·OEt2 −78 3:1 48
8 TMSOTf −78 1:1 39
9 Zn(OTf)2 −78 3:1 43
10 In(OTf)3 −78 3:1 59
11 Cu(OTf)2 −78 3:1 55
aAll reactions were 0.15m in imine and used 1.2 equiv of
diazo imide. bIsolated yield.
Encouraged by the fact that BF3 ·OEt2 performed very well in this reaction we decided
to employ α-diazo imide in the enantioselective aziridination conditions developed by Antilla
and Wulff.53,54 Similarities between the α-diazo imide and ethyl diazo acetate suggested that
this chemistry might be a good foundation for the development of the asymmetric variant
of the syn-glycolate Mannich reaction.
Chiral boron complexes used in this reaction are prepared via a strict protocol. We
began with a control experiment to evaluate the degree to which we are able to reproduce
the published result. The imine 166 was reacted with ethyl diazoacetate in the presence
of the (S)-VAPOL–borate Lewis acid (Scheme 2.24) to afford the cis-aziridine product 167
in 67% yield and 83% ee (76% yield, 87% ee in original publication56). However, when
benzaldimine 166 was reacted with α-diazo imide 119 under identical conditions, neither
aziridine nor oxazolidine dione 147 was observed in the reaction mixture (Scheme 2.24).
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Scheme 2.24. Evaluation of chiral borate complexes in syn-glycolate reaction.
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We demonstrated earlier that benzaldimines are substantially less reactive towards α-
diazo imide 119 when compared to α-keto imines. It was speculated that low reactivity
of the imine resulted in no acquisition of the desired product. To aid the reactivity of
the electrophile, we turned our attention to α-keto imine 168. When reacting 168 with
ethyl diazo acetate in presence of a catalytic amount of (S)-VAPOL–borate complex, the
corresponding cis-aziridine 169 forms in 53% yield and moderate enantioselection (70% ee,
Scheme 2.25). However, when imine 168 was reacted with the α-diazo imide under otherwise
identical reaction conditions, the reaction returned only starting materials. Additionally, no
reactivity was observed when the reaction mixture was heated to reflux. It is important
to note, however, that α-diazo imide 119 appears to be relatively stable under elevated
temperatures since only partial decomposition was evident from the 1H NMR spectrum.
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Scheme 2.25. Evaluation of chiral borate complexes in the syn-glycolate reaction with
glyoxal imines.
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Inspired by work of Shibasaki in the area of the Lewis acid-catalyzed asymmetric di-
rect glycolate Mannich103 reaction and with our finding that indium is a competent Lewis
acid for our reaction (Table 2.7), we turned our attention to indium-based Lewis acids
for the development of the diastereo- and enantioselective syn-glycolate Mannich reaction.
Indium–BINOL or indium–VAPOL complexes prepared from indium(III) triflate catalyzed
the reaction to the same extent as In(OTf)3. The obtained product, however, was racemic.
We attribute this partly to the complex preparation procedure. It is possible that upon
mixing In(OTf)3 with the BINOL ligand, triflic acid is generated and can serve as the actual
catalyst. On this basis, we hypothesized that indium(III) triisopropoxide should be first
mixed with the BINOL ligand, followed by evacuation of the isopropanol under high vacuum
and high temperature to generate InOiPr–BINOL complex 171 (Scheme 2.26).
Scheme 2.26. Evaluation of indium(III)–BINOL complexes in the syn-glycolate reaction.
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When such a complex was evaluated as the catalyst in the addition of α-diazo imide to
N -benzhydryl α-imino ester 79, the reaction was very sluggish and only 40% conversion to
the product was observed after 20 h (Scheme 2.26). This supported our hypothesis about
the nature of the acid catalyst. It seems that in the InOiPr–BINOL complex, Lewis acidity
of indium is significantly reduced and the product forms as a racemate. This suggests that
the chiral environment around indium metal doesn’t provide facial discrimination for an
enantioselective reaction. Also, no reaction was observed when N -Boc benzaldimine 161
was reacted with α-diazo imide in the presence of complex 171.
2.3.3 Glycolate Mannich reaction catalyzed by chiral Cu(II)–BOX complexes
There are several reasons for the extensive use of copper Lewis acids in stereoselective
transformations: 1) well established and easily predictable coordination geometry about the
metal, 2) availability, 3) two oxidation states with two distinct reactivity profiles, and mod-
erate Lewis acidity that can be tuned with a choice of ligands and counter-ions. Copper(II)
complexes usually adopt a square planar, square pyramidal, or trigonal bipyramidal geome-
try, wheras Cu(I) complexes prefer the tetrahedral geometry.120 Literature accounts suggest
that copper(II)-based catalysts operate as Lewis acid promoters in a very similar manner as
boron trifluoride.121 This similarity appears to be true in the case of our reaction (Table 2.7,
entry 9 and 15).
Among priviledged ligands for asymmetric synthesis , bis(oxazoline) 172 is widely rec-
ognized as a broadly effective chiral ligand for copper(II) salts. Encouraged by the results
obtained with Cu(OTf)2, we wanted to evaluate copper(II) complexes with ligand 172. We
chose iminoester 79, a substrate that was most reactive in the syn-glycolate reaction with
a hypothesis that the imine nitrogen, along with the ester carbonyl, will engage in biden-
tate complexation to the copper center. Unfortunately, no product was observed when
copper(II)–172 complex was used as catalyst. It seems that in presence of bis(oxazoline),
the azomethine nitrogen can no longer bind to copper. This could be attributed to steric
(large DPM group) or electronic (electron-poor imine) effects. After analyzing the molecular
model, we believe that despite involvement of the oxygen of the ester carbonyl in biden-
tate chelation with copper, the benzydryl substituent on the imine nitrogen is too sterically
demanding to keep the substrate bound to the catalyst as it is shown in Scheme 2.27.
Our previous studies suggest that imine activation can be achieved only for a limited
group of substrates. Similar performance of N -Boc imines in Cu(OTf)2 promoted the gly-
colate Mannich reaction, indicating that the N -Boc benzaldimine 161 might be a better
substrate for α-diazo imide 119 in the presence of the copper(II)–bis(oxazoline) complex.
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Scheme 2.27. Preliminary results of Cu(II)–bis(oxazoline) catalyzed glycolate Mannich
reaction of benzhydryl imines.
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Although the structure N -Boc benzaldimine 161 does not provide additional Lewis base
character that could coordinate to the metal center, the steric bulk of tert-butyl carbamate
might be beneficial for enantioselection. Contrary to the N -DPM imine, the N -Boc imine
reacted with the diazoalkane in the presence of the copper complex with ligand 172 and de-
livered oxazolidine dione 162 as a 2:1 mixture of diastereomers in 30% yield. Unfortunately,
chiral HPLC analysis established that both diastereomers were racemates. Conversely, when
carrying this reaction out with bis(oxazoline) 173, the product was acquired in substantial
ee. The major diastereomer formed in 80% ee; the minor was nearly racemic (Scheme 2.28).
Scheme 2.28. Preliminary results of Cu(II)–bis(oxazoline) catalyzed glycolate Mannich
reaction of N -Boc benzaldimines.
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Ligand 173 not only differed from 172 in capacity towards asymmetric induction, they
also behaved differently in this particular reaction. The complex with ligand 172 provided a
green color throughout the reaction and upon quench and work-up, the copper was success-
fully washed away. Characteristic signals for the ligand were observed in 1H NMR spectrum
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of the crude reaction mixture. As for the case of ligand 173, the solution was green prior
to addition of the substrate. Upon addition of the imine and α-diazo imide, the reaction
mixture turned brown and eventually purple. The substance responsible for the purple tint
was not water soluble nor separable from the product by chromatography. Evidence of the
paramagnetic broadening of the proton NMR spectrum suggested that colored impurities
might be the result of residual copper. Additionally, recovery of the ligand from the reaction
was fruitless.
Intrigued by this result we decided to use ligand 173 in substoichiometric amount to
avoid high concentration of the by-product and aid purification. However, when 30mol%
of the [Cu(Ph2BoxH)](OTf)2 was used, the concentration of the purple byproduct remained
relatively high and the product had to be purified twice by silica gel chromatography. Despite
this effort, the faint purple color persisted.
Chiral HPLC analyses were often inconsistent. The purest fractions after silica gel chro-
matography that contained only the major diastereomer gave ee values up to 95%. However,
combined fractions containing both diastereomers were determined provided the major di-
astereomer in only 82% ee. Oxazolidine diones are only slightly soluble in ethanol and since
HPLC samples are prepared in an ethanol–hexanes solution, solubility became an issue. We
hypothesized that during HPLC sample preparation, racemic oxazolidine dione 162 crys-
tallizes, thereby enriching the mother liquor in one enantiomer. Enantiomeric excess values
for the newly formed crystals were low. When the sample was dissolved in hot ethanol and
analyzed immediately after cooling to room temperature, consistent ee values were obtained.
For reproducability and accuracy, HPLC samples were prepared in hot ethanol, cooled to
room temperature, immediately injected onto the chiral HPLC, and analyzed before any
crystallization could occur.
Literature suggests that the role of the counter-ion in the active copper–bis(oxazoline)
complex is as important as the structure of the ligand. Combination of the substituents on
the oxazoline ring with the nature of the anion imposes a degree of distortion from copper’s
native square planar geometry, which influences the orientaion of substrates inside the chiral
environment of the complex. A more dissociated counter-ion can increase the relative Lewis
acidity of the copper metal, e.g., copper(II) acetate is less Lewis acidic than copper(II)
trifluoroacetate. Additionally, formation of the naked copper Lewis acid is important in
transformations that require strong activation of the substrate or the reagent by Lewis acid.
For example, when the counter-ions are chlorine, bromine, tetrafluoroborate (BF4) or triflate
TfO, they do not dissociate very easily upon addition of moderately strong Lewis basic donors
(ligands). Complete dissociation is observed when the counter-ions are non-coordinating,
such as SbF6.122
63
Copper(II) triflate is commercially available, yet copper(II) salts with other counter-ions
have to be prepared in situ by anion exchange between a CuCl2 complex and a silver salt of
the desired counter-ion. Silver chloride precipitate is removed and the Cu(II)–ligand complex
with counter-ion of choice remains in solution (Scheme 2.29).
Scheme 2.29. Preparation of bis(oxazoline) complexes with different counterions.
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Stereoinduction in α-diazo imide additions to N -Boc benzaldimines clearly depends on
the counter-ion. Trifluoromethanesulfonate and tetrafluoroborate (Table 2.9, entry 1 and
2) provided the oxazolidine dione product 162 in higher enantioselection (50% ee and 49%
ee) than non-coordinating hexafluorophosphate (31% ee) and hexafluoroantimonate (9% ee)
counter-ions. Since the geometry of the transition state may be different for each counter-ion,
strongly coordinating ligands can therefore provide a geometry that will result in a higher
degree of enantioselection.
Table 2.9. Correlation between enantioselection and the counter-ion for copper.a
H
N
Boc
N2
N
O
CO2iPr
Ph
CH2Cl2, –20 °C, 6 h
N
O N
O
O
Ph
Boc
ClCl
H50 mol % CuCl2
100 mol % AgX
50 mol %
161 119 162
173
entry X dr ee (%)
1 TfO 3:1 50
2 BF4 3:1 49
3 PF6 3:1 31
4 SbF6 3:1 9
aAll reactions were 0.15m in imine
and used 1.2 equiv of diazo imide.
The isolated yields were low (20%–
30%
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For enantioselective reactions, the selectivity for one enantiomer over the other is typically
related indirectly to temperature. When a reaction is under kinetic control, the energy
difference between the transition states determines the relative rates of the two competing
reactions and thereby also the ratio of the products formed. For a kinetically controlled
process, the product ratio can be calculated from the free energy differences between the
transition states or, vice versa.123 If experimentally determined enantioselection is close to
theoretically estimated values over a range of temperatures it is reasonable to assume that
the same two reaction pathways are operating over the temperature range. Energy profile
studies are carried out to reveal background reactions which is usually evidenced by sudden
drop in enantioselectivity.
The temperature profile for the syn-glycolate reaction is shown in Table 2.10. According
to the Arrhenius equation123 two diastereomeric transition states differ by 2.81 kcal/mol
(70% ee at −78 ◦C). The same free energy difference at −40 ◦C and −20 ◦C corresponds
to 62% ee and 58% ee, respectively, which is close to the values obtained experimentally
(Table 2.10, entries 4 and 5). This suggests that lower enantioselection observed at higher
temperatures is not due to a nonselective reaction pathway.
Table 2.10. Temperature profile of the reaction catalyzed by copper(II)–bis(oxazoline)
166 complex.a
H
N
Boc
N2
N
O
CO2iPr
Ph
CH2Cl2, T °C, 18 h
N
O N
O
O
Ph
Boc
ClCl
H
30 mol % Cu(OTf)2
33 mol %
161 119 162
173
entry T eeb eec
◦C (%) (%)
1 −78 75 –
2 −60 70 70
3 −50 67 –
4 −40 66 62
5 −20 59 58
aAll reactions were 0.15m in elec-
trophile and used 1.2 equiv of diazo
imide. bMeasured by chiral HPLC.
cValues predicted using Arrhenius
equation and correlation tables (ref.
111).
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Addition of α-diazo imide to N -Boc imines appears to be insensitive to the solvent used
with one exception (Table 2.11). When the reaction was carried out in propionitrile, enan-
tioselection dropped dramatically. As a polar and strongly coordinating solvent, propionitrile
is a competitive ligand for copper(II) which leads to nearly racemic product (Table 2.10, en-
try 1). Dichloromethane is the optimal solvent for this transformation delivering product
in 75% ee (entry 2). When the reaction was carried out in 1,2-dichloroethane at −20 ◦C,
the enantiomeric excess was 75% (Table 2.11, entry 6) which is simlar to CH2Cl2 at −78 ◦C.
However, when the same reaction was carried out at −35 ◦C, only 60% ee was observed. This
is probably due to the fact that at temperatures close to the melting point of the solvent
(−35 ◦C), the reaction mixture becomes viscous and lowers the selectivity.
Table 2.11. Copper–bis(oxazoline) catalyzed glycolate Mannich reaction: solvent screen.a
H
N
Boc
N2
N
O
CO2iPr
Ph
solvent, T °C, 18 h
N
O N
O
O
Ph
Boc
ClCl
H
30 mol % Cu(OTf)2
33 mol %
161 119 162
173
entry solvent T eeb
◦C (%)
1 EtCN −78 5
2 CH2Cl2 −78 75
3 THF −78 60
4 Et2O −78 nd
5 CH3NO2 −20 60
6 1,2-DCE −20 75
7 1,2-DCE −35 60
8 toluene −20 60
9 CH2Cl2–CH3NO2 (9:1) −78 53
aAll reactions were 0.15m in imine and used 1.2 equiv
of diazo imide. A typical yield oscillated around 20%
bMeasured by chiral HPLC.
The inconsistent ee values observed during optimization studies suggested that the method
for reaction termination might influence enantioselection. To evaluate this hypothesis the re-
action of the benzaldimine 161 with α-diazo imide in the presence of 30mol% of copper–173
complex was quenched by addition of different reagents (Table 2.12). The reaction quenched
with satd aq NaHCO3 delivered the product in reduced enantioselection (63% ee, entry 1)
and when pyridine was used, the product was formed in 75% ee (Table 2.12, entry 2). We
were surprised that the reaction quenched by a solution of HCl in methanol resulted in de-
composition with only traces of product identified in the crude reaction mixture (Table 2.12,
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entry 3). When the reaction was allowed to warm to room temperature after reacting for
20 h at −78 ◦C, enantioselection of the oxazolidine dione was determined to be 70% (entry
4) which suggests that once the reaction is complete, no racemization occurs upon warming.
Table 2.12. Correlation between enantioselection reaction termination protocol.a
H
N
Boc
N2
N
O
CO2iPr
Ph
CH2Cl2, –78 °C, 6 h
N
O N
O
O
Ph
Boc
ClCl
H
30 mol % Cu(OTf)2
33 mol %
161 119 162
173
entry quench ee (%)
1 NaHCO3 63
2 pyridine 75
3 HCl/MeOH –b
4 warm to rt 70
aAll reactions were 0.15m in imine
and used 1.2 equiv of diazo imide.
bDecomposition.
We then searched for the ligand that might provide a higher level of reactivity, diastero-
and enantioselection. We planned to evaluate derivatives of bis(oxazoline) ligand 173 that
are both commercially available and prepared in the laboratory. Preliminary studies sug-
gested that substitution of the carbon that connects the two oxazoline rings is important, as
well as substitution at the 5-position of the oxazoline (cf. 173, Scheme 2.30).
A common intermediate for the derivatives of the Ph2BoxH ligand 173 is the optically
pure 2-amino-1,2-diphenylethanol (174). The synthesis commences with a Sharpless asym-
metric dihydroxylation (SAD) of the trans-stilbene (175) using osmium(IV) tetroxide, dihy-
droquinidine 4-chlorobenzoate as a ligand and NMO as a co-oxidant to arrive at enantiopure
R,R-(+)-1,2-diphenylethane-1,2-diol (176) in 78% yield after recrystallization. Diol 176
was converted to the cyclic carbonate 177 which was then opened with sodium azide. Re-
sulting azido alcohol 178 was reduced to the amine to give the aminoalcohol 174 in 79%
yield over 3 steps.124–126 Condensation of 174 with the diethylmalonimidate hydrochloride
yielded bis(oxazoline) ligand 173 in 50% yield (Scheme 2.30).127
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Scheme 2.30. Synthesis of bis(oxazoline) 166.
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To evaluate the relationship between ligand reactivity and substitution at the carbon
bridging two oxazoline rings, we prepared trans- and cis-Ph2BoxMe ligands (cf. 179 and 180,
Scheme 2.31). Commercially available 2,2-dimethylmalonic acid (181) was converted to the
acid chloride and then reacted with aminoalcohol 174 to deliver symmetric amidoalcohol 182
in 65% yield. Cyclization according to the conditions reported by Evans and co-workers128
didn’t deliver the trans-diphenyl bis(oxazoline) 179 and only the unreacted diamide 182
and partially cyclized derivative 183 were isolated. Treatment of the compound 183 with
methanesulfonyl chloride in the presence of triethylamine and DMAP in dichloromethane at
room temperature afforded ligand 179 in 62% yield (Scheme 2.31).
Scheme 2.31. Synthesis of bis(oxazoline) 172.
CH2Cl2, rt 2 h
HO
O
OH
O
MeMe
(89%)
2.
(65%)
H
N
O
H
N
O
MeMe
Ph
OH
Ph
Ph
OH
Ph
(13%)
H
N
O N
MeMe
Ph
OH
Ph O
Ph
Ph
N N
MeMe
O
Ph
Ph
CH2Cl2, rt
O
Ph
Ph
1. (COCl)2, DMF (cat)
Et3N, MsCl, DMAP
CH2Cl2, rt
(62%)
, Et3N, CH2Cl2
Et3N, TsCl
DMAP
181
174
182
183 179
The derivative that has two phenyl substituents in a cis-relationship was prepared ac-
cording to the procedure published by Desimoni.129 Diamide 182 was subjected to thermal
dehydration in presence of diphenyl tin dichloride. The cyclization proceeded smoothly and
delivered the bis(oxazoline) 180 in 54% yield (Scheme 2.32).
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Scheme 2.32. Synthesis of bis(oxazoline) 173.
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Results obtained with complex 173 (when compared to 172) suggest that the substitution
at the 5-position of the oxazoline is necessary for high ee (Scheme 2.28). We hypothesized
that a larger substituent in positions 4- and 5- would increase enantioselection. To test this
hypothesis, a ligand with a 1-naphthyl substituent in 4- and 5- positions was prepared in a
similar manner to 173.
The olefin needed for the Sharpless asymmetric dihydroxylation (SAD) was synthesized
from 1-naphthalenemethanol (184) which was converted to primary chloride using HCl gas
in dichloromethane, followed by Arbuzov reaction with triethyl phosphite to deliver phospho-
nate ester 185 in 87% overall yield over two steps. Phosphonate 185 was then reacted with
1-naphthaldehyde in a Wadsworth–Emmons reaction to provide the (E)-1,2-di(naphthalen-
1-yl)ethene (186) in 77% yield. Under Sharpless asymmetric dihydroxylation conditions,
diol 187 suffered from oxidative cleavage to the 1-naphthaldehyde, low substrate conversion
and low enantioselection that was increased by fractional crystallization but at the expense
of yield (29% yield and 95% ee after recrystallization). This compound was then subjected
to dimethyl carbonate in the presence of a catalytic amount of NaOH while slight vacuum
was applied to evacuate the methanol by-product and drive the reaction to completion.
The resulting cyclic carbonate 188 was opened with sodium azide to give the correspond-
ing azide in 87% yield. Hydrogenation of the azide to the free amine delivered the desired
aminoalcohol 189 in 60% yield (3 steps) and 95% ee (Scheme 2.33).
Scheme 2.33. Synthesis of the 1-naphthyl substututed aminoalcohol.
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Synthesis of trans-1Naph2BoxMe 190 and 1Naph2BoxH 191 was accomplished via the
same route as 4,5-diphenyl derivatives 173 and 179. Synthesis of diamide 192 was very
efficient and the product was used without further purification. However, cyclization of 192
to 190 suffered from low conversion and delivered multiple products. Only a small amount
of the ligand was isolated after extensive chromatography. Cyclization of 189 with diethyl
malonimidate hydrochloride was also very sluggish. Only partial conversion to 191 was
completed after 3 days at rt and afforded bis(oxazoline) in 35% yield.
Scheme 2.34. Synthesis of 1-naphthyl substituted bis(oxazolines).
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Prepared bis(oxazolines) 173, 179, 180, 190 and 191 together with commercially avail-
able ligands 172, 193–196 were tested in the syn-glycolate Mannich reaction (Scheme 2.35).
The behavior of ligands having two methyl substituents on the bridging carbon, 179, 180,
190 and 172 was significantly different from ligands without substitution; the former were
far less reactive. Reactions catalyzed by 179 and 180 had to be carried out at −20 ◦C. Ad-
ditionally, substitution of the bridging carbon appears to influence enantioselection as well.
tert-Butyl substituted ligand 193 delivered oxazolidine dione in 31% ee but bis(oxazoline)
172 with a substituted bridge gave racemic product. Results for the diphenyl substituted lig-
ands 173, 179 and 180 suggest that a substituent at the 5 position is necessary for reactivity
and enantioselection (173 and 179). However, there is no clear correlation between relative
stereochemistry of the phenyl substituents on the oxazoline, because ligands 173, 179 and
180 delivered oxazolidine dione in 59% ee at −20 ◦C. Increased steric bulk appears to help
in enantioselection. When bis(oxazoline) 197 with two 1-naphthyl substituents was used as
a ligand, oxazolidine dione formed in 85% ee. A derivative of this ligand with substituted
bridge was far inferior. trans-1Naph2BoxMe 190 was able to promote the reaction but higher
reaction temperature (−20 ◦C) was required and oxazolidine dione product formed in only
40% ee. Throughout this series of ligands, diastereoselection remained practically constant,
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forwarding a hypothesis that the catalyst only activates imine towards caron–carbon bond
formation and diastereoselective cyclization to oxazolidine dione is not influenced by the acid
catalyst.
Scheme 2.35. Survey of various bis(oxazoline) ligands in the copper(II) catalyzed glyco-
late Mannich reaction.
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The copper(II) complex with ligand 191 was used to survey the scope of the enantios-
elective glycolate Mannich reaction (Table 2.13). Unfortunately, the high enantioselection
observed for 4-chlorobenzaldimine 161 was not general for all substrates. Isolated yields of
products were less than satisfactory with only one product forming in yield higher than 50%.
Imine derived from 2-naphthaldehyde afforded oxazolidine dione in 55% yield and 78% ee
(Table 2.13, entry 4). Generally, reactions of α-diazo imide with N -Boc imines in presence of
chiral copper(II)–bis(oxazoline) ligands suffered from a low level of reproducibility in terms
of enantioselection. Reaction on the model substrate, N -Boc imine 161 (entry 2), showed
that enantioselection can be as low as 55% and as high as 85% but most generally oscillating
around 70%. Excessive purification lowered the yield of the product, due to a purple colored
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side-product formed in all reactions that were catalyzed by complexes of bis(oxazolines) with
the unsubstituted bridge.
Table 2.13. Substrate scope of the enantioselective glycolate Mannich.a
Ar H
N
Boc
N2
N
O
CO2iPr
Ph
CH2Cl2, –78 °C, 20 h
then aq.  NH4OH–NaCl
Ar
N
O N
O
O
Ph
Boc H
30 mol % Cu(OTf)2
33 mol %
45 119 198
191
entry R yieldb drc ee
(%) (%)
1
191
45 3:1 70
2
Cl191
48 3:1 55–85
3
AcO191
39 2:1 70
4
191
55 2:1 78
aAll reactions were 0.15m in imine and used 1.2 equiv
of diazo imide. bCombined isolated yield for both di-
astereomers. cMeasured by 1H NMR.
2.3.4 New reactivity of α-diazo imide in presence of copper(I) catalysts
Limited success of the copper(II) catalyzed syn-glycolate Mannich reaction, mainly due
to low reactivity of N -Boc benzaldimines towards α-diazo imide 119, motivated us to search
for a more reactive catalyst. It is often assumed that reactions of diazoalkanes with imines
catalyzed by copper(I) catalysts involve diazo decomposition and the resulting metallocar-
bene reacts with the imine. An azomethine ylide intermediate can then afford aziridine as
illustrated in Figure 1.2 (Section 1.2).47 Copper(I) can also act as a Lewis acid but unlike
copper(II) that coordinates in square planar geometry, copper(I) adopts a tetrahedral ge-
ometry. Lectka and co-workers demonstrated that copper(I)–(R)–tol-BINAP complex is an
excellent catalyst for the diastereo- and enantioselective alkylation of α-imino esters, such as
199, with enolsilane nucleophiles (Scheme 2.36). When we employed α-diazo imide 119 in
the reaction with tosyl α-imino ester 199 in presence of 25mol% of the copper(I) triflate–
toluene complex, only decomposition products were observed and no desired oxazolidine
dione 202 was seen in the 1H NMR of the crude reaction mixture (Scheme 2.36).
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Scheme 2.36. Lewis acid activation of imines using copper(I) complexes.
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During optimization studies for the syn-glycolate Mannich reaction, copper(I) triflate
did not deliver any identifiable products (section 2.3.2, Table 2.7, entry 2). However, during
these investigations we discovered that the quality of CuOTf is crucial to the success of the
reaction. When the same reaction was repeated using a fresh (CuOTf)2 · toluene catalyst,
the cis-aziridine imide 203 was identified in the reaction mixture together with the vinyl-
ogous carbamate 204 (Scheme 2.37). Interestingly, only 10mol% of the catalyst (20mol%
in copper) was required for the full conversion and no sign of the oxazolidine dione 80 was
observed (Scheme 2.37). This was the first time that addition occurred selectively to cis-
aziridine without evidence of intramolecular cyclization to oxazolidine dione. This suggests
that the copper(I) catalyst is able to activate the imine towards α-diazo imide, but is unable
to promote aziridine opening to oxazolidine dione. Also, the presence of the vinylogous car-
bamate 204 byproduct suggests that the reaction operates via Lewis acid-catalyzed addition
of the diazoalkane to azomethine48,49 rather than through a metallocarbene intermediate.
The observation of N -DPM cis-aziridine 203 in this reaction suggests that the stereose-
lectivity of the carbon–carbon bond formation is different than the one proposed for Brønsted
acid promoted syn-glycolate Mannich reaction (see section 1.4.4). We advocate an anti ad-
dition of diazo 119 to imine when triflic acid is an azomethine acivator, but the reaction
catalyzed by Cu(I) seems to go through the syn-amino diazonium intermediate∗ (Figure 2.5).
∗See section 1.4 for discussion
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Scheme 2.37. Copper(I) aziridination of imines using α-diazo imide.
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Figure 2.5. Origin of stereoselectivity in Brønsted acid-promoted diazo–azomethine reac-
tions.
The reaction of imine 79 with α-diazo imide does not seem to be influenced by metal
counterion. Copper(I) triflate and tetrakis(acetonitrile) copper(I) perchlorate catalyze the
reaction to the same extent (Table 2.14, entry 1 and 2). Although the former afforded
aziridine in slightly higher yield, the ratio of 203 to 204 remained unchanged. Although
lowering the reaction temperature significantly increased chemoselectivity, a fair number of
side-products were observed. Chemoselectivity seems also to be a function of the solvent with
trifluoromethyl benzene being optimal solvent in terms of chemoselectivity (entry 5). De-
spite high conversion and selectivity, reactions in polar solvents delivered complex mixtures
(Table 2.14, entries 6–8).
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Table 2.14. Optimization of the copper(I) catalyzed reaction of α-diazo imide with N -
DPM imines.a
MeO2C H
N CHPh2
O
catalyst
N
N2 CO2iPr
Ph
conditions MeO2C
N
O
N
CO2iPr
Ph
CHPh2
MeO2C
NH
N
OPh2HC
Ph
CO2iPr
15 mol %
79 119 203 204
entry catalyst solvent T time 203:204b conv
celsius (h) (%)
1 (CuOTf)2 · toluene CH2Cl2 −20 6 63:37 90 (49)c
2 CuClO4 · 4MeCN CH2Cl2 −20 15 61:39 90
3 CuClO4 · 4MeCN CH2Cl2 −78 20 91:9 80d
4 CuClO4 · 4MeCN toluene −20 15 85:15 90
5 CuClO4 · 4MeCN PhCF3 −20 15 95:5 90
6 CuClO4 · 4MeCN THF −20 15 88:12 90
7 CuClO4 · 4MeCN Et2O −20 15 88:12 90
8 CuClO4 · 4MeCN EtCN −20 15 60:40 85
aAll reactions were 0.10m in electrophile and used 1.2 equiv of diazo imide. bSubstrate conver-
sion was calculated from 1H NMR of the crude reaction mixture. cIsolated yield. dSignificant
amount of unknown side-products.
Our ultimate goal was to achieve enantioselective reactions with diazo imide 119. One
advantage of copper(I) Lewis acids over the copper(II) counterparts lays in their affin-
ity to a broader range of ligands. Chiral phosphine and diamine ligands, together with
bis(oxazolines), are often used to prepare chiral copper(I) catalysts for stereoselective reac-
tions. It is commonly observed that metal complexes are weaker Lewis acids than metal salts
and our results confirm this trend.120 A survey of an array of different ligands is presented in
Scheme 2.38. We identified that the aziridination can proceed in up to 20% conversion and
only up to 29% ee albeit with high chemoselectivity towards cis-aziridine. Longer reaction
times and higher catalyst loading didn’t improve the yield.
After discovery of the novel reactivity of α-diazo imide towards N -DPM imines in re-
actions catalyzed by copper(I), we suspected that this behavior might be more general and
applicable to a wider group of imines with different nitrogen substituents. The Brønsted
acid catalyzed reaction worked only for the narrow set of N -benzhydryl imines. Again we
picked derivatives based on 4-chlorobenzaldehyde since they are easier to prepare. Results
demonstrate a strong dependence of the reaction on the nitrogen protecting group not only
in terms of reactivity but also the chemoselectivity.
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Scheme 2.38. Lewis acid activation of imines using copper(I) complexes.
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Aryl N -DPM imines behave similarly to imino ester 79 but are much less reactive. De-
spite low conversion, high chemoselectivity for cis-aziridine 215 was observed (35% yield).
Increasing (N -Tr) and reducing (N -Bn) the number of phenyl rings relative to the ben-
zhydryl group resulted in no reaction. The same effect was observed for the N -phenyl and
N -(2-hydroxy)phenyl group (Scheme 2.39).
Scheme 2.39. Copper(I) promoted α-diazo imide dimerization.
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In instances when azomethine was unreactive towards the α-diazo imide, a significant
amount of the α-diazo imide homocoupling products 216 and 217 was observed (Scheme 2.40).
When the reaction was carried out without imine, E- and Z - olefin 216 and 217 were iso-
lated in 86% combined yield as a nearly 1:1 mixture. We did not observe homocoupling
products in reactions catalyzed by triflic acid, even in slow reactions with aryl aldimines.
The only byproduct was the oxazolidine dione 123. Following this observation we retro-
spectively analyzed copper(II) catalyzed additions to N -Boc aldimines and many reactions
contained 216 and 217 as by-products.
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Scheme 2.40. Copper(I) promoted α-diazo imide dimerization.
O
CuClO4•4MeCN
N
N2 CO2iPr
Ph
10 mol%
CH2Cl2, 0 °C, 1 h
O
N
CO2iPr
PhN
O
Ph
CO2iPr O
N
CO2iPr
Ph
N O
Ph
iPrO2C
(86%)
119 216 217
2.3.5 Exploration of α-diazo imide–copper(I) system
Radically different reactivity was observed for N -Boc, N -Ts and N -silyl imines. The reac-
tion between N -Boc benzaldimine 161 and α-diazo imide in presence of copper(I) perchlorate
proceeded very quickly. After gas evolution ceased (ca. 15min) at room temperature, nearly
full conversion was observed by 1H NMR. Oxazolidine dione 162 (ca. 2:1 dr) was present
together with N -Boc oxazolidinone 218 (Scheme 2.41).
Scheme 2.41. Reactivity of N -Boc imines and α-diazo imide in presence of copper(I)
catalysts.
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Encouraged by this result we decided to explore the new and unique reactivity of N -
Boc imines with α-diazo imide 119. To suppress homocoupling of 119, the solution of
the diazo in toluene was added to the solution of the N -Boc 4-chlorobenzaldimine 161
via automated syringe pump over a period of 30min. After quench with the saturated
aqueous solution of ammonium chloride in brine (2:1), the reaction mixture was analyzed
by 1H NMR. The spectrum showed three products 218, 219, and 162 in 67:6:27 ratio,
respectively (Scheme 2.42).
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Scheme 2.42. Result of slow addition of α-diazo imide to N -Boc imines in the presence
of copper(I) catalyst.
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The observed products presumably are derived from the diazonium intermediate anti-220
(Figure 2.6). The carbon–carbon bond formation is followed by the acyl transfer that gives
intermediate 221. Cyclization of the isopropyl carbamate produces oxazolidinone 218 as
the major product; the alternative oxazolidinone 222 was not observed (Figure 2.6, pathway
c). It is worth mentioning that the rate of the acyl transfer appears to be higher than
aziridination because no aziridine products were observed. Competitive to the acyl transfer
is a direct cyclization of the aminodiazonium 220. If the Boc group participates in this
process, oxazolidinone 219 formation will result (pathway a). Alternatively, if the isopropyl
carbamate oxygen displaces dinitrogen, syn-oxazolidine dione 162 (pathway b) is formed.
The syn-diastereomer of the minor product, oxazolidine dione 162, is derived from syn C–C
bond formation and direct cyclization, which is highly unfavored.
Stereochemistry of the oxazolidinone ring has been assigned as trans, analogous to known
examples,102 and confirmed by NOE. We suggest that stereoselectivity for trans-218 is due
to the fact that the anti-aminodiazonium intermediate 220 experiences less steric stress
compared to the syn intermediate.
The outcome of this reaction depends on the way it is terminated. Our initial conditions
required quenching with the solution of ammonium hydroxide in brine, in which case the
oxazolidinone 219 forms in very small amounts (Table 2.15, entry 1). When the reaction
was quenched with aqueous EDTA or pyridine, oxazolidinones 218 and 219 formed in nearly
equal amounts but with slightly higher conversion for the latter (Table 2.15, entry 2 and 4).
The relative amount of compound 219 compared to oxazolidinone 218 increased when the
reaction was quenched with aq HCl (entry 3). When the reaction was not quenched, but
instead filtered through a pad of silica gel, products 218 and 219 dominated and formation
of the oxazolidine dione 162 was not significant (Table 2.15, entry 5). Filtration through a
pad of neutral alumina resulted in a mixture that contained predominantly N -Boc product
218, albeit with lower conversion (entry 6). However, in this case, diazo addition and
stirring time was shorter which suggested that product 218 and 219 are the kinetic and
thermodynamic product, respectively. This hypothesis was supported by further experiments
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Figure 2.6. Mechanistic pathways of the α-aminodiazonium formed from N -Boc imine
and α-diazo imide.
when reactions quenched by filtration through silica gel after 30min, 1, 3, and 18 h clearly
show that early in the reaction, oxazolidinone 218 dominates but with time the ratio of
products reverses and favors product 219. Applying a protocol later developed for N -Ts
imines (quench with 100mol% of triflic acid, vide infra) resulted in N -Boc removal and the
N -H oxazolidinone 223 was isolated in 53% yield. When the reaction was carried out in polar
solvents, higher amounts of the oxazolidine dione were observed in comparison to nonpolar
solvents such as toluene. No correlation was found between the ratio of products and the
reaction temperature, concentration or catalyst loading. A set of substrates was subjected to
optimized reaction conditions (entry 7) but high chemoselectivity towards a single product
couldn’t be obtained and yields oscillated around 35% for N -Boc oxazolidinones of type
218.
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Table 2.15. Correlation between reaction termination protocol and product outcome.a
R H
N
Boc
N2
N
O
CO2iPr
Ph
toluene, 0 °C, time
15 mol %
[Cu(CH3CN)4]ClO4
R
ON
O
Boc
R
HN
Boc
O N
O
O
Ph
>20:1 dr 2:1 dr>20:1 dr
then quench
R = pClC6H4
>20:1 dr
N
O
H
Ph R
OHN
O
N
O
CO2iPr
Ph R
OHN
O
N
O
H
Ph
161 119
218 219 162223
entry quench time convb 218:219:162b
(h) (%)
1 NH4OH/NaCl 1 >95 67:6:27
2 EDTA 1 83 44:37:19
3 HCl 1 88 37:55:8
4 pyridine 1 >95 47:34:19
5 silica gel 1 >90 54:38:8
6 neutral alumina 1 79 92:7:1
7c silica gel 0.5 80 85:3:12
8c silica gel 3 >90 27:63:10
9c silica gel 18 >95 22:67:12
10 TfOH 1 >90 –d
aAll reactions were 0.10m in imine and 1.2 equiv of diazo imide was
added via syringe pump over 30min. bEstimated from 1H NMR. c4-
Methoxybenzaldimine was used as a substrate. dN -Boc deprotected
oxazolidinone 223 was observed as a major product.
Although the synthesis of 218 was not our initial goal, this reaction is an interesting
example of diazo reactivity. To determine if this reaction can be carried out enantioselec-
tively, a series of chiral ligands was evaluated. Ligands 172, 173 and 212 delivered product
as racemates. Slight enantioselection was observed for bis(oxazolines) 195, 224 and 191.
Moderate enantioselection was delivered by ligand 196 (50% ee). Application of PyBOX
225 and axially chiral phosphine 226 resulted in no reaction.
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Scheme 2.43. Evaluation of chiral copper(I) complexes
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Dependence of enantioselection upon counterion was then assessed for ligand 196. Nei-
ther triflate nor hexafluoroantimonate were able to positively influence the enantioselection.
In both instances the oxazolidinone product formed in low enantioselection (Table 2.16).
Table 2.16. Correlation between enantioselection and counterion
H
N
Boc
N2
N
O
CO2iPr
Ph
R
Cl
10 mol % CuX
12 mol %
CH2Cl2, –20 °C, 18 h
then neutral alumina
ONBoc
O
O
N
H
Ph
161 119
196
218
entry X ee (%)
1 ClO4 48
2 TfO 34
3 SbF6 40
aAll reactions were 0.15m in
imine and used 1.2 equiv of
diazo imide.
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We expected to see compound 227 as a major product of reaction of imine 161 with
ethyl diazoacetate. After addition of the diazo compound, the Boc group is the only ester
that can cyclize onto the diazonium carbon. When we performed this control experiment
neither 227 nor aziridine 228 was observed by 1H NMR. Clearly, the difference in reactivity
between ethyl diazoacetate and α-diazo imide is substantial.
Scheme 2.44. Control reaction of ethyl diazoacetate with N -Boc imines in the presence
of copper(I) catalyst.
H
N
Boc
N2
CO2Et
R
Cl
CH2Cl2, –20 °C, 18 h
then neutral alumina
OHN
O
O
OEt
10 mol % CuClO4 N
R CO2Et
Boc
not observed
161 227 228
N -Tosyl imines also revealed new reactivity towards α-diazo imide. The reaction of the N -
tosyl benzaldimine 229 with α-diazo imide is quite fast. After ca. 15min nitrogen evolution
is no longer observed and a complex mixture of products is present by 1H NMR (Figure 2.7,
spectrum a). Attempts to isolate a single compound from the crude reaction mixture were
unsuccessful. To our surprise, when 100mol% of triflic acid was added to the reaction prior
to the quench, 1H NMR showed oxazolidine dione 230 as the only product with a small
amount of 4-chlorobenzaldehyde and p-toluenesulfonamide as minor side-products (spectrum
b). Although diastereoselection was negligible, we were struck by the chemoselectivity of the
overall reaction, knowing how complicated the mixture is prior to addition of triflic acid. We
established that optimal conditions for this transformation involve 10mol% of the copper(I)
catalyst in dichloromethane with slow addition of the α-diazo imide followed by treatment
with 100mol% of triflic acid, and the oxazolidine dione can be isolated in 82% yield albeit
as a 1.2:1 mixture of diastereomers.
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Figure 2.7. Brønsted acid promoted formation of N -Ts oxazolidine dione 230. (a)
1H NMR (CDCl3) spectrum of the crude reaction mixture without addition of triflic acid (b)
1H NMR (CDCl3) spectrum of the crude reaction mixture after addition of triflic acid.
We knew that triflic acid is not able to promote addition of diazo 119 to imine 229 (see
section 2.2.2, Table 2.2) but it was not clear if the reaction occurs only under copper(I)
catalysis, or perhaps copper(II) is also able to catalyze reaction to oxazolidine dione. When
10mol% of Cu(OTf)2 was used as a catalyst at 0 ◦C for 3 h, oxazolidine dione 230 was
observed in the crude reaction mixture only in trace amounts among multiple unidentified
side-products. A second control experiment revealed that, like in case of N -Boc imine, no
reaction was observed with ethyl diazoacetate.
We hypothesized that diastereoselection could be increased by use of a sterically de-
manding aryl sulfonamide as the protecting group for the imine nitrogen. Reaction of the
3,5-di(tert-butyl)phenyl sulfonamide protected imine 231 derived from the butyraldehyde
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under optimized conditions delivered oxazolidine dione 232 in moderate yield but without
improvement in diastereoselection (Scheme 2.45). Although our hypothesis turned out to
be false, it is important to note that the reaction conditions seem to tolerate alkyl imines
which is promising as reactions with alkyl imines are not as well developed as reactions with
aldimines.
Scheme 2.45. Glycolate Mannich reaction with bulky sulfonyl alkyl imines.
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N S
O
N
N2 CO2iPr
Ph
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O N
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O ArO
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Me
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(42%)
tBu
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Ar =
CuClO4•4MeCN
10 mol %
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To explain the reaction outcome we propose a cyclic sulfonimidate intermediate 233 as
a precursor to the oxazolidine dione in reaction of the N -tosyl imines catalyzed by cop-
per(I). Addition of the diazo nucleophile results in the formation of the vic-amino diazonium
intermediate 234. Cyclization of the sulfonamide oxygen onto diazonium carbon leads to
the cyclic sulfonimidate 233. The stereogenic sulfur atom increases the number of possible
stereoisomers. This might explain the multiple products observed in the 1H NMR spectrum
before addition of triflic acid. Sensitivity of the cyclic sulfonimidate 233 towards Brønsted
acids is not surprising. Treatment with TfOH causes sulfonimidate ring opening that is
followed by the oxazolidine dione ring formation to arrive at the structure 230 where the
stereocenter at sulfur no longer exists.
Scheme 2.46. Postulated mechanism of formation of N -Ts glycolate Mannich products.
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Even more puzzling was the result of the α-diazo imide addition to the trimethylsilyl
imine 235. The reaction produced very cleanly two major products in 1.5:1.0 ratio. Although
1H NMR of the minor product suggested an aziridine product, the resonances for the methine
doublets were shifted downfield and appeared at 3.93 and 3.53 ppm (3.51 and 2.83 ppm for
N -DPM aziridine). After isolation and full characterization, we assigned oxazoline 236 and
aziridine 237 as products of this reaction (41% and 44% yield respectively, Scheme 2.47)
Scheme 2.47. The outcome of the reaction of α-diazo imide with N -TMS imine.
H
N TMS
N2
N
O
CO2iPr
Ph
CH2Cl2, 0 °C, 1 h
10 mol %
[Cu(CH3CN)4]ClO4
then NH4OH/NaClCl R
ON
OiPr
R
NH
O
O
N
iPrO
Ph
41%yield 44% yield
O
N
Ph
H
235 119 236 237
Our experience with the N -Boc imine under copper(I) catalysis (Table 2.15) suggested
that this reaction might also be sensitive to the solvent and the way it is terminated. Our
hypothesis turned out to be true. Filtration through a pad of neutral alumina reversed
the ratio of the products with cis-aziridine being the major product (Table 2.17, entry 2).
In deuterated chloroform the ratio favoring cis-aziridine was the highest observed and 236
was isolated in 70% yield (Table 2.17, entry 3). In acetonitrile the reaction didn’t occur
because the catalyst was not soluble in this solvent (entry 4). A reaction carried out in
hexanes produced the cis-aziridine exclusively but suffered from low conversion, the reaction
mixture was not homogeneous in this case (entry 5). In toluene almost an equal amount of
trans-aziridine 238 formed next to the cis-isomer but oxazoline was still the major product
(Table 2.17, entry 6). A clear example of the effect of the quench is shown in entries 7 and 8.
Reaction in trifluoromethylbenzene delivers both products in nearly 1:1 ratio when filtered
through alumina but strongly favors oxazoline 236 when filtered through silica gel.
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Table 2.17. Solvent and quench-dependent product distribution in α-diazo imide addition
to silyl imines.a
H
N TMS
N2
N
O
CO2iPr
Ph
solvent, 0 °C, 1 h
15 mol %
[Cu(CH3CN)4]ClO4
quenchCl R
ON
OiPr
R
NH
O
O
N
iPrO
Ph
R
NH
O
O
N
iPrO
Ph
O
N
H
Ph
235 119 236 237 238
entry solvent quench 236:237:238b yield (%)c
1 CH2Cl2 NH4OH/NaCl 60:38:2 –
2 CH2Cl2 neutral alumina 36:61:3 –
3 CDCl3 neutral alumina 20:72:8 70
4 CH3CN neutral alumina – –
5 hexanes neutral alumina 5:90:5d –
6 toluene neutral alumina 55:28:17 –
7 PhCF3 neutral alumina 44:54:2 –
8 PhCF3 silica gel 89:7:3 55
aAll reactions were 0.15m in imine and used 1.2 equiv of diazo imide.
bEstimated from 1H NMR of the crude reaction mixture. cIsolated yield.
dReaction mixture was not homogeneous and unreacted diazo and aldehyde
were major products.
The following mechanism might explain the outcome of the reaction (Figure 2.8). Tetra-
hedral coordination geometry of the copper(I) catalyst allows for binding of the imine nitro-
gen and both carbonyl oxygens of the diazo imide (A). Carbon–carbon bond formation is
followed by acyl transfer from the diazo to the imine nitrogen to give structure C. Carbamate
anion collapse triggers N–O transfer of the silyl group to afford the diazonium intermediate
239 which can cyclize to give aziridine or oxazoline. A correlation between reaction quench
and the ratio between oxazoline 236 and cis-aziridine 237 and the fact that the reaction
is terminated after nitrogen evolution is complete, suggests that transformation of 239 to
either 236 or 237 is probably not as straightforward as it is depicted in Figure 2.8.
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Figure 2.8. Postulated mechanism for the formation of 236 and 237.
Among imines evaluated in reactions with α-diazo imide, the nucleophilicity of the silyl
imine nitrogen is relatively high when compared to N -Boc, N -Ts or even N -DPM. The
evidence that supports this hypothesis was obtained when we tried to influence the reaction
outcome by use of a weak Brønsted acid, such as benzoic acid as an additive. In this case, a
new compound formed and no sign of the expected oxazoline or aziridine was present in the
1H NMR spectrum. The new compound had two characterictic doublets at 4.66 and 4.56 ppm
as well as a sharp singlet at 8.62 ppm. The coupling constant of the doublets was quite high
(14.3Hz) which suggested a diastereotopic methylene group. Based on analysis of HSQC
and HMBC correlations we proposed structure 240 to be the product. Compound 240 is
probably a result of the addition of the imine nitrogen to the oxonium intermediate 241
(Scheme 2.48). As it was the case with N -Boc and N -Ts imines, no reaction was observed
with EDA.
One of the key questions we had about the reaction of α-diazo imide with N -silyl imines
was whether the reaction is Lewis acid catalyzed, or does it involve diazo decomposition
to a metallocarbene. The latter hypothesis is consistent with the observation of the diazo
homocoupling products. We carried out a control experiment in which we employed α-diazo
imide in a cyclopropanation reaction with the excess of methyl acrylate under otherwise
identical conditions (Scheme 2.49). The product, what at first appeared to be the expected
cyclopropane, was the orthoester 242. The key correlations that allowed us to elucidate
the structure of compound 242 were heteronuclear correlations to the quartenary carbon
at 115 ppm. The methine protons as well as diastereotopic methylene protons show HMBC
correlation to the resonance at 115 ppm. We suggest that the product is a result of a Michael
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Scheme 2.48. Reaction of α-diazo imide with N -TMS imine in the presence of a proton
source.
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241
addition of the oxonium ylide 243 to the methyl acrylate followed by the addition of the
enolate to the carbamate oxocarbenium to give 242. Alternatively, compound 242 can arise
from a cycloaddition between the methyl acrylate and the oxonium ylide 243 (Scheme 2.49).
Scheme 2.49. Attempted cyclopropanation with the α-diazo imide.
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The reaction of N -TMS imine with the α-diazo imide in the presence of dipolarophiles
such as diethyl fumarate is a test for the presence of azomethine ylide in the reaction.47
When α-diazo imide 119 was reacted with the imine 235 in the presence of a 2 fold excess
of diethyl fumarate, only oxazoline 236 and aziridine 237 were observed in the 1H NMR
spectrum of the crude reaction mixture. The absence of a pyrrolidine of type 244 suggests
that intermediacy of an azomethine ylide as noted by Jacobsen47 is unlikely (Scheme 2.50).
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Scheme 2.50. Control experiment for the formation of an azomethine ylide.
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2.3.6 Summary and conclusions
In this chapter we presented the development of a highly diastereoselective Brønsted
acid-promoted addition of α-diazo imide 119 to N -DPM imines. This reaction is a viable
alternative to glycolate additions to imines in cases where diastereoselection is a challenge.
By use of the novel α-diazo imide reagent, diastereoselectivity of aminoalcohol formation is
controlled by intramolecular oxygen delivery.
We also explored asymmetric reactions of the α-diazo imide with various azomethine elec-
trophiles. We found that certain copper(II)–bis(oxazoline) complexes allow for the formation
of N -Boc oxazolidine diones in good enantiomeric excess and moderate dr.
Reactions catalyzed by copper(I) catalysts revealed new reactivity of the α-diazo imide.
The reaction with N -DPM imines produces aziridines 203 that do not cyclize further to
oxazolidine dione. The reactivity of N -silyl and N -sulfonyl imines follows new pathways,
not observed under Brønsted acid catalysis.
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CHAPTER 3
Progress towards the total synthesis of (+)-zwittermicin A
3.1 Background
3.1.1 Isolation, structural assignment and biological activity
Understanding of plant protection at the molecular level is an important endeavor that
brings together efforts from disciplines such as agricultural and environmental sciences, mi-
crobiology, and chemistry. Through a mutual relationship with microbes, plants receive
protection from diseases by small molecules which are an attractive source for researchers to
discover new biologically active compounds.
Bacillus cereus UW85 was shown to suppress diseases in a variety of plants.130–133 In one
study, it was the only strain of 700 tested that reduced alfalfa seedling mortality caused by
Phytophthora megasperma f. sp. medicaginis to 0%.130 Bacillus cereus UW85 also suppresses
diseases of tobacco,131 cucumber,132 and peanuts133 caused by pathogenic fungi.
(+)-Zwittermicin A (245) was identified as a secondary metabolite produced by Bacillus
cereus UW85 that is responsible for the aformentioned biological acitvity.134,135 It has a
broad spectrum of activity, inhibiting certain gram-positive, gram-negative, and eukaryotic
microorganisms.136 It also potentiates the insecticidal activity of the protein toxin produced
by Bacillus thuringiensis, increasing mortality of insects that are typically recalcitrant to
killing, such as gypsy moths reared on willow leaves.130,137,138
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Figure 3.1. (+)-Zwittermicin A
When isolation and structural elucidation of 245 was disclosed in 1994,134 only the rel-
ative stereochemistry of the C8–C10 fragment was proposed. The complete relative and
absolute configuration was first speculated about in 2007 by Rogers and Molinski.139 Pair-
wise 13C NMR chemical shift difference analysis of six diastereomeric 2,6-diamino-1,3,5,7-
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heptatetraols allowed for the relative stereochemistry of the C9–C15 portion of 245 to be es-
tablished. The absolute stereochemistry of this fragment was proposed based on biosynthetic
grounds. It was assumed that the starting unit for the non-ribosomal peptide synthetase
(NRPS)–polyketide synthase (PKS) megasynthase is l-Ser and the absolute stereochemistry
at C14 is the same as in the amino acid. The stereochemistry of the remaining C1–C4 frag-
ment was established by amide hydrolysis and derivatization of natural 245 and comparison
to a known amino acid S -albizziine.
3.1.2 Revision of the absolute stereochemistry
To confirm the proposed structural and stereochemical assignment, Molinski and co-
workers pursued a total synthesis of the natural product. The synthesis starts from azidodiol
246, which was prepared from l-Ser as part of the NMR studies. The terminal alcohol was
protected as a TBDPS ether, the secondary alcohol was protected as a MOM ether, and the
TBDPS group was removed to give 247 in 85% over 3 steps. Azide 247 was hydrogenated,
the free amine was benzylated, and the primary alcohol was oxidized to give aldehyde 248.
Compound 248 was employed in a diastereoselective Evan’s aldol addition of the chiral
glycolate auxiliary 249 to give, after hydrolysis, carboxylic acid 250 in 74% and 96:4 dr.
Coupling of acid 250 with amine 251 and global deprotection yielded (−)-253 (Scheme 3.1).
Although the 1H NMR spectrum of the C10–C15 fragment of 253 was almost identical to the
natural sample of 245, a pronounced difference occurred at H8. Also, the specific rotation
of (−)-253 was of opposite sign and of larger magnitude than for natural (+)-245.
Scheme 3.1. Synthesis of the initially proposed stereoisomer of zwittermicin A.
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To resolve this discrepancy, compound 250 was coupled with 254, the enantiomer of 251,
to give adduct 255. Global deprotection of compound 255 afforded (−)-245, the enantiomer
of the isolated natural product. The specific rotation of (−)-245 was opposite in sign and
equal in magnitude to natural (+)-zwittermicin A (Scheme 3.2).140
Scheme 3.2. Synthesis of zwittermicin A enantiomer
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These findings suggested that the assignment of the relative stereochemistry of the C10–
C15 fragment was correct and the mismatch resulted from the inversion of all configurations
in the diaminopolyol–carboxylate moiety of (−)-253. This result refuted the original hy-
pothesis on the origin of stereochemistry at C14 and now suggests that d-Ser rather than
l-Ser is incorporated during biosynthesis.
A formal total synthesis of (+)-zwittermicin A (245) was recently accomplished by the
Molinski group.141 The C9–C15 portion of (+)-245 was prepared in a two-directional ap-
proach from the known bis(epoxide) 256.142 Double Miyashita-type opening143 of the epox-
ide afforded bis(azide) 257 in 80% yield. Compound 257 was desymmetrized by placing
a trityl group on the terminal alcohol to get to 258 in 69% yield. The 1,3-diol was con-
verted to acetonide 259, followed by protection of the secondary alcohol as a MOM ether.
Simultaneous removal of the trityl group and reduction of both azides was accomplished
by hydrogenation to give diamine 261 that was protected as a dibenzylamine using benzyl
bromide (Scheme 3.3). A formal synthesis of (+)-zwittermicin (245) can be achieved by
utilizing 262 instead of 247 in a synthetic path depicted in Scheme 3.1.
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Scheme 3.3. Formal Total Syntheis of (+)-Zwittermicin A
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3.1.3 Biosynthesis
The aminopolyol chain of (+)-zwittermicin A (ZmA) may imply that it is a product
of carbohydrate metabolism, but it is in fact a polyketide. Emmert and co-workers first
suggested in 2004 that the biosynthesis of zwittermicin A arises from a non-ribosomal pep-
tide synthetase (NRPS)–polyketide synthase (PKS) megasynthase.144 This hypothesis was
recently validated by Kevany and co-workers, who characterized the complete zwittermicin
A biosynthesis gene cluster from Bacillus cereus UW85.145 In order to explain the formation
of the terminal amide group,146 they suggested that 245 is initially produced as part of a
larger metabolite that is processed twice, resulting in formation of the natural product and
two additional metabolites.
Based on analysis of the NRPS/PKS components and other enzymes encoded by the
biosynthesis gene cluster, Kevany and colleagues proposed the following biosynthesis (Fig-
ure 3.2).145 The zmaO module of the NRPS/PKS megasynthase activates l-Asn, condenses
it with a fatty acid, and epimerizes the l-Asn to d-Asn to form the fatty acyl-d-Asn-S -zmaO
intermediate. The next five NRPS/PKS modules form the backbone of zwittermicin A by
condensing the fatty acyl-d-Asn intermediate with l-Ser, malonate, (2S)-aminomalonate,
(2R)-hydroxymalonate, and β-Uda. During the condensation of these precursors, the stere-
ochemistry of the l-Ser unit is changed to d-Ser to result in the stereochemistry of the
final product. It is not yet clear how this occurs because an epimerase (E) domain is not
found in the NRPS module that incorporates l-Ser. However, the module immediately
upstream of the l-Ser-associated module contains an E domain. The growing fatty acyl-
peptide/polyketide is extended by an additional amino acid, l-Ala, to form a covalently
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linked intermediate on the second PCP domain of zmaB. At this stage, the backbone of
ZmA has a fatty acyl-d-Asn at its N terminus and l-Ala at its C terminus, both of which
must be removed to make the antibiotic. The authors propose that the fatty acyl-d-Asn
intermediate is released by oxidation by zmaL and removal of the fatty acyl-d-Asn piece by
zmaM which leads to 245 and two metabolites (Figure 3.2).145
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Figure 3.2. Proposed biosynthesis of zwittermicin A (adapted from ref. 145)
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3.2 Two-directional synthesis
3.2.1 Introduction
Acyclic molecules with underlying symmetry may be approached using a two-directional
strategy instead of the more prevalent one-directional strategy. In a linear approach, the
synthetic target is built in one direction by homologation of the existing fragment and is most
useful for the synthesis of short chains. A one-directional convergent strategy is often utilized
by chemists for the synthesis of complex natural products that are assembled from smaller
fragments. Whenever an underlying element of symmetry is present in the target molecule or
fragment, two-directional synthesis may be applied. Performing two structure building trans-
formation simultaneously at chain ends reduces the number of steps required but, depending
on the symmetry element, can require a challenging desymmetrization step(Figure 3.3).147,148
linear
convergent
two-directionalone-directional
desymmetrization
Figure 3.3. General strategies for the synthesis of acyclic compounds.
3.2.2 Two-directional synthesis of natural products
The chemical literature is rich in examples of two-directional synthesis, and early ex-
amples have been summarized by Schreiber147 and Magnuson.148 In 2004 Nelson demon-
strated a two-directional synthesis of compound 267 in a total synthesis of hemibrevetoxin
B (Scheme 3.4). The trans-epoxydiketone 263 undergoes acid-catalyzed cyclization to give
diacetal 264, which after four additional steps gives centrosymmetric diepoxide 265. Desym-
metrization is achieved via enantioselective epoxide opening with water in a transformation
catalyzed by cobalt complex 266. Diol 267 forms in 98% yield and 95% ee.149
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Scheme 3.4. Two-directional synthesis of the intermediate in a total synthesis of hemi-
brevetoxin B.
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Inoue and co-workers demonstrated an elegant two-directional synthesis of (±)-merrilac-
tone A (Scheme 3.5).150 Photocycloaddition of dichloroethylene and dimethyl maleic anhy-
dride produces dichloride 268. Further two-directional elaboration affords cyclobutene 269.
After the protection of alcohols as benzyl ethers, an Upjohn dihydroxylation was performed,
and the resulting diol was oxidized to a diketone and reacted in situ with allyl magnesium
bromide to give cyclobutane 270 in 78% overall yield. Treatment of 270 with Grubbs I
catalyst at elevated temperature causes cyclooctane ring formation which is followed by ad-
dition of Pb(OAc)4 to deliver key intermediate 271. At this point desymmetrization was
performed via a transannular aldol reaction. Using LiN(TMS)2 as a base, desired compound
272 forms in 3:1 dr and 85% yield.150
Scheme 3.5. Two-directional synthesis of merrilactone A.
OH
O
O
O
O
O
H
H
Cl
Cl
O
Me
Me
O
O
+
hν O
Me
Me
O
O
Cl
Cl
1. Zn, TMSCl
Ac2O, 85 °C
2. LiAlH4, THF
(47%)
Me
Me
OH
OH
1. BnBr, NaH
2. Upjohn
3. Swern
then allylMgBr
Me
MeHO
HO OBn
OBn
i) Grubbs I
ii) Pb(OAc)4
(95%)
Me
Me
OBn
OBnO
O
LiHMDS
THF
–100 °C OBn
OBn
O
H Me
HO MeOBn
OBn
O
H Me
HO Me
18 steps
(±)-merrilactone Amajorminor 4:1
268 269 270
271
272
97
In 2008, Stockmann and co-workers applied a two-directional approach to the formal
synthesis of anatoxin-a.151 Starting from 3-butenyl bromide, key aldehyde 278 is prepared
in just 6 steps (Scheme 3.6). Double Grignard addition to ethyl formate produces alcohol
274. The alcohol is converted to N -Boc sulfonamide 275 in a Mitsunobu reaction. The Boc
group is removed, and bis(alkene) 276 is cyclized to cycloheptene 277 under Grubbs ring
closing metathesis conditions. Desymmetrization of the alkene is carried out via ozonolysis
and in situ addition of the sulfonamide nitrogen to form hemiaminal 278. Elaboration of
278 allows for the formal synthesis of anatoxin-a (Scheme 3.6).151
Scheme 3.6. Assembly of an intermediate for a formal synthesis of anatoxin-a.
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Enzymatic reactions are often utilized for desymmetrization. High specificity of enzymes
for substrates allows for selective transformations in cases where conventional reagents give a
statistical mixture of products (Scheme 3.7).152 Simple meso-diol 279 can be desymmetrized
and resolved in an enzymatic reaction with acetic anhydride to give essentially enantiopure
acetate 280 as shown in Scheme 3.7.153
Scheme 3.7. Enzymatic desymmetrization–resolution of meso-epoxides.
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An example of synthetic utility of enzymes in two-directional synthesis was disclosed by
the Pons group in their the total synthesis of (+)-crocacin C (281).154 The oxabicycle 282155
was reduced diastereoselectively, and the resulting alcohol 283 was etherified using methyl
iodide. Ether 284 was subjected to ozonolysis with reductive work-up, which gave meso-diol
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285 in 70% over three steps. Desymmetrization was performed using Rhizomucor miehei in
the presence of vinyl acetate in diisopropyl ether giving acetate 286 in 87% yield and over
98% ee. This desymmetrization protocol unmasked five contiguous stereogenic centers in a
single operation (Scheme 3.8).154
Scheme 3.8. Enzymatic desymmetrization en route to (+)-crocacin C.
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In 2011, Sammakia and co-workers utilized this approach in their synthesis of dermo-
statin A (Scheme 3.9).156 Starting with glutarate ester 288, alcohol protection followed by
reduction of the ester provided the bis(aldehyde) 289. Desymmetrization was achieved via a
diastereoselective acetate aldol reaction with N -acetylthiazolidinethione that provided prod-
uct 290 as a single diastereomer in 70% yield. Reductive removal of the auxiliary and
protection of the resulting 1,3-diol as the p-anisaldehyde dimethyl acetal gave compound
291. The termini of pseudo-C 2 symmetric compound 291 were differentiated via acetal
group migration. The central alcohol was deprotected with TBAF and then treated with
PPTS in toluene at 100 ◦C. Only the group that provided syn-acetal migrated during this
reaction, to yield key intermediate 292 for the completion of the synthesis of dermostatin
A.156
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Scheme 3.9. Synthesis of the pseudo-C 2-symmetric bisacetal en route to dermostatin A.
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3.2.3 Approach to (+)-zwittermicin A via a two-directional azide–alkene cyclo-
addition
In our synthesis of (+)-zwittermicin A, we plan to use the amide functionality at C7 for
the main retrosynthetic disconnection. A Passerini reaction will be used to bring together two
fragments and form the amide as well as the secondary alcohol at C8. The isonitrile (293)
required for this step will carry all necessary functional groups for maximum convergence.
It will be derived from the known amino acid l-albizziine (294). Bis(oxazolidine dione)
295 represents a masked form of the aldehyde needed for the Passerini reaction and has all
stereocenters of the C9-C15 aminopolyol chain.
A stereoselective approach to 295 is the main pillar of our strategy. Taking advantage of
the pseudo-C 2-symmetry of the C9–C15 chain of zwittermicin A, we will establish terminal
aminoalcohols in a bidirectional approach. Bis(oxazolidine dione) 295 will come from a ste-
reospecific fragmentation of bis(triazoline) 296. Compound 296 will be formed using a triflic
acid-promoted Huisgen cycloaddition reaction between bis(imide) 297 and benzyl azide. Di-
astereoselectivity of this transformation will be controlled by the protecting group at the
central anti-1,3-diol. Bis(imide) 297 will be synthesized via a Horner–Wadsworth–Emmons
reaction between the aldehyde derived from 298 and imidophosphonate 299. Compound 298
will be prepared asymmetrically from pentane-2,4-dione 300 using published procedures.
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Scheme 3.10. Retrosynthetic analysis
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3.3 Previous work
3.3.1 Diastereoselective azide–alkene reaction: a model study
We began investigation of substrate-controlled diastereoselection in the Brønsted acid-
promoted azide–alkene reactions by studying a reaction of 301 and benzyl azide.73 This
chiral non-racemic imide was equipped with the TBDPS group to provide the necessary bulk
for a substrate-controlled diastereoselective [3+2] cycloaddition. Reaction under thermal
conditions delivered modest yield and diastereoselection for the desired anti,anti-triazoline
(302) over the syn,anti diastereomer (303) (Scheme 3.11). Stereoselectivity originates from
the arrangement of the C–O bond orthogonal to the pi-plane as observed in stereoselective
addition reactions of organocuprates157 to α,β-unsaturated esters.158
Although the bulky TBDPS ether influences the selectivity of the reaction, further low-
ering of the reaction temperature to increase dr is not practical for thermal reactions. On
the other hand, activation of the imide by Brønsted acid operates at an acceptable rate at
temperatures as low as −20 ◦C. Using triflic acid in acetonitrile at −20 ◦C, the same reaction
proceeded with exceptional selectivity and delivered the desired anti,anti-triazoline (302) in
40% yield, albeit with nearly equal amounts of SN2’ elimination product 304 (Scheme 3.11).
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Scheme 3.11. Substrate-controlled diastereoselectivity in [3+2] cycloaddition
OTBDPS
N
O
Bn
O
OMe
BnN3 (excess)
microwave reactor
120 °C, 5 min
(40%)
TBDPSO
N
NN
Bn
O
N
BnMeO2C
H
H TBDPSO
N
NN
Bn
O
N
BnMeO2C
H
H
via
H
OR
R COX
H
N3 Bn anti,anti(desired)
syn,anti
OTBDPS
N
O
Bn
O
OMe
200 mol % TfOH
150 mol % BnN3
CH3CN, –20 °C
then 200 mol % Et3N TBDPSO
N
NN
Bn
O
N
BnMeO2C
H
H
anti,anti
(45%)
O N
O
O
Bn
TBDPSOH
thermal
acid-promoted
301
301
302
302 303
304
Selectivity was confirmed by NMR (1D and 2D) analysis of both 302 and 303 as well as
their fragmentation products, oxazolidine diones 305 and 306 respectively (Scheme 3.12).73
This procedure which involves [3+2] Huisgen cycloaddition and acid-promoted triazoline
fragmentation in separate steps avoids the possibility of SN2’ product formation.
Scheme 3.12. Diastereoselectivity in acid-promoted reaction
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3.3.2 Synthesis of bis(imide) 312
Synthesis of the key substrate for the [3+2] cycloaddition reaction, bis(imide) 312, com-
mences with preparation of (2R,4R)-1,5-dichloropentane-2,4-diol (309) according to a known
literature procedure.159 First, 1,3-pentane dione (307) is subjected to a reversible acetylation
reaction and the product, 1,5-dichloropentane-2,4-dione, is trapped as copper(II) complex
308 in 55% yield. Treatment of 308 with sulfuric acid revealed the 1,3-dione, which was
subjected to asymmetric Noyori reduction to yield diol 309 in 40% yield.159 Conversion of
309 to bis(alkene) 310 was achieved in 71% yield in two steps. A reaction of 310 with a
large excess of dimethylsulfonium methylide160 was followed by protection of the 1,3-diol as a
di-tert-butylsilyl ether.161 Aldehyde obtained by ozonolysis of 310 was immediately reacted
with the stabilized phosphonate ester anion in a Horner–Wadsworth–Emmons reaction to
give 311 in 53% yield. Ethyl ester 311 was saponified, converted to the corresponding
acid chloride, and coupled with the lithium benzyl(methoxycarbonyl)amide to yield desired
bis(imide) 312 in 41% yield (Scheme 3.13).
Scheme 3.13. Preparation of the di(tert-butl)silyl bis(imide).
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The attempt to obtain a bis(triazoline) from 312 via Brønsted acid-promoted [3+2]
cycloaddition with benzyl azide was unsuccessful. The major product was a 5:1 mixture of
anti-anti- and syn-anti-oxazolidine dione, 313 and 314 respectively, where only half of the
imide reacted∗. When 313 was resubjected to the reaction conditions with a large excess of
benzyl azide, no further reaction was observed (Scheme 3.14).
An alternative approach to the bis(triazoline) is a reaction of 312 with benzyl azide
under thermal conditions. We observed full conversion of bis(imide) 312 after a reaction in
neat benzyl azide at 100 ◦C for 1 h in the microwave reactor. Similar to our prior experience,
∗For a complete nOe conformational analysis of the products see: ref 73
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Scheme 3.14. Attempted Two-Directional Triflic Acid-Catalyzed [3+2] Reaction
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the reaction was not selective. We obtained a statistical mixture of three diastereomeric
triazolines in 74% yield. Extensive chromatography was necessary to isolate bis(triazoline)
315 but the isolated yield was significantly diminished (13%). The relative stereochemical
identity of the product was confirmed by analysis of NOE correlations.
With 315 in hand, we tested the triflic acid-promoted triazoline fragmentation–cyclization
reaction to 316. Compound 315 was treated with TfOH in acetonitrile at rt for several hours
and provided bis(oxazolidine dione) 316 in 82% yield. Analysis of the NOE correlations
provided evidence that the relative stereochemistry of 316 is anti,anti as in zwittermicin A
(Scheme 3.15).
Scheme 3.15. Thermal Two-Directional [3+2] Reaction
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To shorten the synthesis of the bis(imide), a Horner–Wadsworth–Emmons reaction with
imidophosphonate 320 was pursued. Phosphonate 320 can be easily prepared from di-
ethylphosphonoacetic acid 317 in three steps. Conversion of 317 to the acid chloride and
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a reaction with benzylamine yields amidophosphonate 318 in nearly quantitative yield. An
attempt to install a methyl ester using dimethyl dicarbonate (DMDC) and DMAP was
unsuccessful but the same reaction with Boc anhydride proceeded smoothly and afforded
bis(imide) 321 in 74% yield. Although a variety of protocols was applied, the yield of
the ozonolysis–olefination sequence with imidophosphonate 320 was very low (10–22%) and
required extensive chromatographic purification of product 321 (Scheme 3.16).
Scheme 3.16. Horner–Wadsworth–Emmons reaction with tert-butyl imidophosphonate.
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A seemingly insignificant change of the ester functional group (methyl to tert-butyl) in the
bis(imide) caused a serious problem. Nearly identical reactivity and selectivity was observed
for bis(imide) 321 in the microwave-assisted reaction with benzyl azide. Unfortunately,
chromatographic purification of the desired anti,anti-bis(triazoline) proved to be difficult
and we were unable to obtain a pure sample using conventional chromatography techniques.
3.3.3 Summary of previous work
This work provided evidence that the bis(oxazolidine dione) is a viable intermediate in
the synthesis of zwittermicin A. The fragmentation–cyclization of anti,anti-triazoline 315
proceeds as planned and provides an intermediate with the required relative stereochemistry
of zwittermicin A. However, there are several challenges that need to be addressed before the
synthesis of the natural product can be pursued further. The synthesis of the key interme-
diates, bis(imide) 312 and bis(triazoline) 315, is far from efficient. The overall yield of the
transformation of 310 to 315 (6 steps) is ca. 2%. The Brønsted acid-catalyzed aminohydrox-
105
ylation reaction is diastereoselective, but only one half of the bis(imide) molecule engages in
the reaction. On the other hand, both alkenes react in a microwave-assisted [3+2] reaction
of 312 with benzyl azide, but the reaction is neither chemo- nor diastereoselective. Isolation
of 315 is laborious and low yielding.
3.4 Results and discussion
3.4.1 Optimization of the synthesis of bis(imide) 312
Before approaching the problem of diasteroselectivity in bis(triazoline) formation we
needed to establish a more convergent and better yielding route to 312. We first focused our
efforts on the optimization of the Horner–Wadsworth–Emmons reaction, specifically the syn-
thesis of the imidophosphonate methyl ester 319. Our previous attempts at an acyl transfer
from dimethyl dicarbonate to the amidophosphonate 318 were unsuccessful (Section 3.3).
We were pleased to observe a nearly quantitative conversion of 318 to 319 when the lithium
amide of 318, generated with 2 equiv of LiHMDS, was acylated with methyl chloroformate
(Scheme 3.17).
Scheme 3.17. Synthesis of the imidophosphonate.
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To improve the formation of 312 we turned to examination of ozonolysis of 310. Although
full consumption of the alkene was observed after 30min at −78 ◦C we were unable to isolate
the bis(aldehyde) 322. Various work-up procedures gave rise to ill-defined multicomponent
reaction mixtures, while only small amounts of the aldehyde functionality was observed in
the 1H NMR spectrum.
With identification of the problematic step, we moved to implement a dihydroxylation–
diol cleavage protocol to access the bis(aldehyde) 322. First we evaluated a one-pot pro-
cedure developed by Nicolaou and co-workers162 that employs PhI(OAc)2 in presence of
2,6-lutidine to cleave the diol in situ after dihydroxylation with catalytic OsO4 and NMO.
Although we observed clean conversion to the aldehyde, the product was not compatible
with silica gel chromatography and only a trace amount of 322 was obtained. As a solution
to this problem we turned to a two-step procedure. Dihydroxylation of 310 gave compound
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323 as a mixture of diastereomers in 65% yield. With the preparation of 323 accomplished,
Johnson-Lemieux oxidation163 was undertaken using the protocol developed by Zhong and
Shing.164 The reaction with silica gel-supported NaIO4 delivered bis(aldehyde) 322 in quan-
titative yield without need for chromatography. Crude 322 was reacted with a large excess
of the potassium anion of imidophosphonate 319 in presence of 18-crown-6 (Scheme 3.18).
The desired bis(imide) 312 was obtained in 78% yield as an E,E-isomer.
Scheme 3.18. Improved synthesis of the bis(imide) 312
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With this more convergent route to 312 in hand, we were able to fully address the
question of reactivity and selectivity of the [3+2] cycloaddition reaction. We hypothesized
that by modifying the 1,3-diol protecting group we would be able to obtain the desired
reactivity and selectivity. Our initial plan was to use an acyclic bis(silyl ether) protection
of 1,3-diol, but such alkenes were unstable under ozonolysis conditions. With the improved
preparation, we revisited acyclic silyl derivatives 324. Although dihydroxylation proceeded
without complication, the resulting polyols (325) didn’t afford the corresponding aldehydes
326 when subjected to oxidative cleavage. Silyl protected polyols (325) with varying degree
of steric bulk yielded complex reaction mixtures when subjected to NaIO4 (Scheme 3.19).
At this point it became clear to us that the central 1,3-diol had to be protected as a cyclic
silyl ether, with the belief that conformational constraint and added steric hindrance might
lower the nascent aldehyde reactivity.
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Scheme 3.19. Unsuccesful synthesis of acyclic silyl ether aldehydes.
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Low reactivity and selectivity with bis(imide) 312 can be attributed to two factors, the
size of the siloxane ring and size of the substituent on the silicon atom. The first hypoth-
esis can be adressed by incorporation of the 1,3-diol into an 8-membered ring by reaction
with TIPDSCl2 (1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane) in DMF in the presence of
imidazole. This protecting group was originally developed for the selective protection of
nucleosides.165,166 In contrast to the 6-membered DTBS ring (compound 312), the TIPDS
ring is more flexible and might improve the reactivity and selectivity of the bis(imide) in the
cycloaddition reaction. The reaction of diol 327 with TIPDSCl2 was straightforward and af-
forded the product 328 in 66% yield. Upjohn dihydroxylation delivered polyol 329 (in 84%
yield) that was subjected to oxidative cleavage with NaIO4 · SiO2 and immediately reacted
with the anion of the imidophosphonate 330 generated with KHMDS and 18-crown-6. We
were disappointed to see very low yield (23%) of the desired bis(imide) 331 (Scheme 3.20).
Scheme 3.20. Preliminary synthesis of the TIPDS bis(imide).
Acetone/H2O
(84%)
OsO4, NMOO
Si O Si
O
iPr
iPr iPr
iPr
O
Si O Si
O
iPr
iPr iPr
iPr
OH
HO HO OH
OH OH DMF, rt, 15 h
(66%)
TIPDSCl2
imidazole
NaIO4/SiO2
KHMDS
18-crown-6
THF
–78 °C, 1 h
O
Si O Si
O
iPr
iPr iPr
iPr
NN
O O
Bn
O
MeO
Bn
OMe
O
23% yield
–78 °C, 5 h
327
328
329
329
319
331
A careful analysis of the mass balance of this reaction revealed that a major by-product
of this reaction is phosphonate 334 (Figure 3.4). We speculated that formation of trans-
oxaphosphetane 332 is slow (Figure 3.4, path A) and the competetive acyl transfer occurs
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(path B) to give phosphonate carbonate 333, which produces compound 334 upon methyl
carbonate elimination (Figure 3.4). The proton, carbon and phosphorus NMR as well as
mass spectrometry data were in agreement with the proposed structure (334).
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Figure 3.4. Mechanism of the competitive acyl transfer during Horner–Wadsworth–
Emmons reaction
To address this problem, we increased the steric demand of the ester group to limit
the rate of the undesired acyl transfer. Bis(imide) 335 was prepared in 82% yield when
imidophosphonate 320 was used. Unfortunately, when we reacted 335 with benzyl azide,
we observed gas evolution immediately after addition of triflic acid. The bis(amide) 336 was
isolated as the only product (Scheme 3.21) which suggests that removal of the Boc group is
significantly faster than [3 + 2] reaction with benzyl azide, even at −20 ◦C.
It became clear to us that the bulky ester does increase the yield of the Horner–Wadsworth–
Emmons reaction by limiting the pathway to elimination, however it should not be acid-labile.
Therefore, we hypothesized that the isopropyl ester, while providing steric bulk, would not
as easily succumb to decomposition. Instead of preparing the imidophosphonate required
for the Horner–Wadsworth–Emmons reaction, we could test this hypothesis by preparing
bis(imide) 337 through acylation of 336. Compound 336 was treated with two equiva-
lents of nBuLi followed by addition of isopropyl chloroformate to arrive at 337 in 51% yield
(Scheme 3.22).
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Scheme 3.21. Removal of the N -Boc group during Brønsted acid-promoted reaction with
benzyl azide.
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Scheme 3.22. Synthesis of the isopropyl bis(imide).
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3.4.2 Studies of facial discrimination in the acid-promoted azide–olefin cyclo-
addition
We then investigated diastereoselectivity of the cycloaddition as a function of size of
the cyclic silyl group. We began with a thermal reaction of the bis(imide) 312. After
45min at 100 ◦C under microwave irradiation in neat benzyl azide, all three stereoisomers
formed nonselectively (1:2:1 ratio) (Table 3.1). The desired 2,3-anti diastereomer 315a
was separated and the relative stereochemistry was assigned through a spectroscopic study
(NOESY).73 Although the overall yield was satisfactory, purification of the desired 2,3-
anti/2’,3’-anti diastereomer 315a was cumbersome.
We then turned our attention to triflic acid-promoted triazoline formation. When imide
312 was reacted with BnN3 in the presence of triflic acid at −20 ◦C in acetonitrile, again,
all three bis(triazolines) were isolated in 67% yield (Table 3.1, entry 2). In this experiment,
however, the 2,3-syn diastereomer 315b was favored and the desired 315a formed as a minor
product. We found that a change of the carbamate fuctionality from Me to iPr slightly
improves selectivity but delivered mostly undesired bis(triazolines) 339b and 339c (entry
3) in 54% combined yield with the desired 339a forming in trace amounts. Bis(imide) 340
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with a smaller diisopropyl silyl ring, decomposed under the reaction conditions providing
the mixture of triazolines in only 7% yield∗ (Table 3.1, entry 4).
Table 3.1. Substrate-Controlled Double (3+2) Cycloaddition
OO
N N
OO
Bn
CO2RCO2R
Bn conditions
a
2,3-anti/2',3'-anti
(desired)
cb
2,3-anti/2',3'-syn
Si
2,3-syn/2',3'-syn
OO
Si
NN
N
Bn
O
N
RO2C Bn
H
H
N
NNH
H
O
NBn CO2R
Bn
3'
OO
3
4,4' 2'2
Si
1
NN
N
Bn
O
N
RO2C Bn
H
H
1'
N
NNH
H
O
NBn CO2R
Bn
OO
Si
NN
N
Bn
O
N
RO2C Bn
H
H
N
NNH
H
O
NBn CO2R
Bn
entry alkene Si R conditions product a:b:c yield
%
1 312 Si
tBu tBu
Me A 315 1:2:1 72
2 312 Si
tBu tBu
Me B 315 1:2.5:5.4 67
3 338 Si
tBu tBu
iPr B 339 1:9:9 54
4 340 SiiPr iPr
iPr B 341 ND 7
5 331 Si O SiiPriPr iPr
iPr Me B 342 18:1:1 27
6 337 Si O SiiPriPr iPr
iPr iPr B 343 18:1:1 79
a Conditions A: BnN3 (neat), microwave 100 ◦C, 1 h; Conditions B: TfOH (5 eq), BnN3 (10 eq)
MeCN 0.2m, 20 ◦C, 18h. b Ratio of products was measured by 1H NMR analysis of the crude
reaction mixtrue. c Combined isolated yield. d ND = not determined due to signal overlap by
1H NMR.
Our original expectation was that the siloxane protected 1,3-anti-diol would assume
a twist-boat conformation in order to maintain its two alkene substituents in a pseudo-
equatorial arrangement (A, Figure 3.5). We reasoned that expansion of the ring from six to
eight members through the formation of a disiloxanylidene derivative might better achieve
∗The ratio could not be determined from the 1H NMR spectrum
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this goal by providing greater flexibility around the oxygen-substituted edge (B, Figure 3.5).
Accordingly, the 8-membered ring methyl carbamate 331 incorporating a tetraisopropoxy-
disiloxanylidene group167,168 (TIPDS) was prepared. Not only did bis(imide) 331 provide
the bis(triazoline) with high diastereoselection (Table 3.1, entry 5), it favored the desired
anti,anti-342a in 30% yield. Introduction of the isopropyl carbamate in bis(imide) 337 led
to a significant increase in the yield of the 2,3-anti bis(triazoline) 343a (79%) without loss
of diastereoselection (Table 3.1, entry 6).
H
tBu
O
Si
tBuO
H
A B
R
R
Si
O
H
iPr
iPr
iPr
iPr
O
SiO
H
R
R
Figure 3.5. Depictions of the likely major conformations of the siloxane (A) and disiloxane
(B) rings.
The relative stereochemistry of the TIPDS-protected bis(triazoline) 343 was confirmed by
comparison to previously assigned73 anti,anti-bis(oxazolidine dione) 316. The bis(triazoline)
343 was treated with triflic acid at room temperature and gave the bis(oxazolidine dione)
344 in 71% yield. The silyl group in compound 316 and 344 was removed in the reaction
with HF · pyridine and both bis(oxazolidine dione) substrates converged at the diol 345
(Scheme 3.23).
112
Scheme 3.23. Confirmation of the relative stereochemistry of TIPDS bis(oxazolidine
dione).
OO
N N
NN
N N
BnBn
H
N
H
N O O
Bn
CO2iPr
Bn
iPrO2C
TIPDS
OO
N N
NN
N N
BnBn
H
N
H
N O O
Bn
CO2Me
Bn
MeO2C
Si
tBu tBu
TfOH
O O
N
O NBn
O
O
N
OBnN
O
O
Bn H H Bn
TIPDS
O O
N
O NBn
O
O
N
OBnN
O
O
Bn H H Bn
Si
tBu tBu
OH OH
N
O NBn
O
O
N
OBnN
O
O
Bn H H Bn
CH3CN
rt, 18 h
(71%)
HF•pyridine
THF, 0 °C to rt
TfOH
CH3CN
rt, 18 h
(51%)
HF•pyridine
THF, 0 °C to rt
(38%)
(43%)
343 344
315 316
345
3.4.3 Functionalization of the bis(oxazolidine dione)
With efficient access to the key bis(oxazolidine dione), we attempted functionalization
of the compound 344 in preparation for the Passerini coupling. Unfortunately, as in our
previous studies (see section 2.2.3), hydrolytic opening of the oxazolidine dione ring was
challenging (Table 3.2). Compound 344 was treated with KOH in 1,4-dioxane only to
return the unreacted starting material after 1 h at rt (entry 1), extending the reaction time
led to decomposition (entry 2). No reactivity was observed for LiOH in methanol–water
mixture at room temperatrue (entry 3) and use of more nucleophilic lithium hydroperoxide
led to decomposition (entry 4). Conditions that allowed for methanolysis of the oxazolidine
dione in syn-glycolate Mannich products (i.e. Pd(OH)2, H2, MeOH) also did not provide the
desired product (entry 5). The heterogeneous hydroxide reagent (Me3SnOH) was not reactive
towards the oxazolidine dione, even at elevated temperatures (entry 6). The oxazolidine dione
344 was not compatible with strong protic hydrolysis conditions (entry 7), mild hydride
reduction (entry 8) or Lewis acid-promoted addition of methanol (entry 9).
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Table 3.2. Functionalization of the bis(oxazolidine dione) 345.
entry conditions result
1 KOH, 1,4-dioxane, rt no reaction
2 KOH, 1,4-dioxane, rt decomposition
3 LiOH, MeOH–H2O, rt no reaction
4 LiOH, H2O2, THF, H2O decomposition
5 Pd(OH)2, H2, MeOH, rt no reaction
6 Me3SnOH, 1,2-DCE, 78 ◦C no reaction
7 HCl, MeOH, H2O decomposition
8 DIBAL, THF, rt no reaction
9 Ti(OiPr)4, methanol no reaction
Unsuccesful functionalization of compound 344 was attributed to the low electrophilicity
of oxazolidine dione carbonyls caused by the electron-rich benzyl substituent. We hypoth-
esized that by changing the benzyl group to a phenyl substituent, which was successfuly
functionalized previously in our syn-glycolate chemistry, we can increase the reactivity of
the oxazolidine dione. The synthesis of the N -phenyl bis(oxazolidine dione) 346 was car-
ried out according to the optimized route. The imidophosphonate 347 was synthesized in
two steps from diethylphosphonoacetic acid (348) as described in Section 3.4.1. We found
a simple protocol for an efficient Horner–Wadsworth–Emmons reaction that avoided use of
the expensive 18-crown-6 reagent. Deprotonation of the imidophosphonate 347 with sodium
hydride in THF at room temperature followed by addition of aldehyde 349 was found to
provide the desired bis(imide) 350 with similar efficiency (70–75%). The electronic effect of
the phenyl group was revealed during the [3+2] cycloaddition reaction, where we observed
higher reactivity towards the benzyl azide. The reaction was complete in 6 h and provided
the desired bis(triazoline) 351 in 70% yield† (Scheme 3.24).
What was beneficial for reactivity in the azide–alkene reaction, proved to be detrimen-
tal in fragmentation of the bis(triazoline) 351. Under standard conditions, 2 equivalents
of TfOH in acetonitrile at rt, conversion of 351 to 346 was very sluggish. After 48 h, a
considerable amount of bis(triazoline) was still present together with the product 346 and
partially converted triazoline (Table 3.3, entry 1). Attempts to accelerate the reaction rate
by addition of water74 caused decomposition. When the reaction was carried out in propi-
onitrile at elevated temperature (55–60 ◦C), full conversion was achieved after 6 h but these
harsh conditions contributed to decomposition which lowered isolated yields (20–40%) (Ta-
ble 3.3, entry 2). The reaction in toluene at 50 ◦C saw even higher degree of decomposition
(entry 3). Surprisingly, less acidic methanesulfonic acid, promoted the reaction and full con-
version was observed after only 15min at room temperature. The 1H NMR spectrum of the
†The key cycloaddition reaction can be carried out at 20 g scale without loss of yield or diastereoselectivity.
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Scheme 3.24. Synthesis of the N -Ph substituted bis(triazoline).
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crude reaction mixture was very clean but the isolated yield was much lower than expected
(Table 3.3, entry 4). Similar conversion was observed when the reaction was quenched with
water (entry 5) or aqueous base (entry 7). When the reaction was quenched with aqueous
HCl, no bis(oxazolidine dione) 346 was obtained (entry 6). The attempt to purify the re-
action mixture directly without aqueous work-up met with limited success, as only 10% of
compound 346 was obtained (entry 8). We hypothesized that when methanesulfonic acid is
not washed away during work-up, the CH3SO3H salt of the product is too polar for chro-
matographic purification. Indeed, when the reaction mixture was filtered through a small
pad of silica gel and eluted extensively with ethyl acetate, 40–65% yield of the product was
obtained in a pure form (Table 3.3, entry 9). However, this procedure was not practical on
a large scale since a large volume of ethyl acetate was necessary for purification. We then
established an optimal procedure in which the reaction is performed using 4 equivalents of
TsOH · H2O in dichloromethane at room temperature. The excess acid is neutralized by
addition of solid sodium bicarbonate, and the reaction mixture is filtered, concentrated, and
purified by chromatography to give the product in 86–90% yield (Table 3.3, entry 10)
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Table 3.3. Optimization of fragmentation of the bis(triazoline) to bis(oxazolidine dione).
conditions
O O
N
NN
Bn
H
H
N
O
CO2iPrPh
NN
N
Bn
H
N
O
iPrO2C Ph
H
TIPDS
O O
HN
O NPh
O
O
NH
OPhN
O
O
Bn Bn
TIPDS
351 346
entry acid solvent T time quench conversiona yieldb,c
(equiv) (◦C) (h) (%) (%)
1 TfOH (3) EtCN 23 18 aq NaHCO3 25 nd
2 TfOH (3) EtCN 50 5 aq NaHCO3 95 40
3 TfOH (4) toluene 50 5 aq NaHCO3 90 >20
4 MsOH (3) EtCN 23 0.25 aq NaHCO3 >95 52
5 MsOH (3) EtCN 23 0.50 H2O >95 nd
6 MsOH (3) EtCN 23 0.50 aq HCl — —
7 MsOH (3) EtCN 23 0.50 aq NaOH >95 nd
8 MsOH (3) EtCN 23 0.25 SiO2 >95 10
9 TsOH ·H2O (3) CH2Cl2 23 1 SiO2 >95 40–65
10 TsOH ·H2O (4) CH2Cl2 23 1 solid NaHCO3 >95 86–90
aMeasured by 1H NMR. bIsolated yield. cnd = not determined.
With an optimized procedure for the synthesis of the compound 346 we returned to the
investigation of conditions for opening the oxazolidine dione rings. The conditions utilizing
a mild heterogeneous hydroxide, as described in Section 2.2.3, did not afford the desired
product, and more conventional hydroxide- or alkoxide-based reagents caused decomposition
or epimerization. Again, we turned our attention to Lewis acid activation of the oxazolidine
dione carbonyls toward alcohol nucleophiles. When the strong Lewis acid TiCl4 was used in
methanol, no reaction occurred. However, a stoichiometric amount of a milder Ti(OiPr)4 in
methanol, gave 55% yield of bis(ester)‡ 352 after 2 days at room temperature (Scheme 3.25).
Scheme 3.25. Lewis acid-promoted opening of the bis(oxazolidine dione) 347.
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‡The chemoselectivity towards the amide carbonyl is consistent with our previous observations (see chap-
ter 2, section 2.2.3)
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Gratifyingly, the crystalline nature of the bis(ester) 352 allowed us to corroborate our
assignment of the relative stereochemistry§ that was established during the alkene–azide
cycloaddition reaction (Figure 3.6, Figure 3.7).
Figure 3.6. Perspective view of the disiloxane view in bis(ester) 352.
§Assignment by NOE correlations was completed by Dr. Ki Bum Hong. See ref. 73
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Figure 3.7. The X-ray structure of the bis(ester) 352.
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Unfortunately, this reaction suffered from irreproducibility and low conversion of the
starting material even at prolonged reaction times. This was complicated by the fact that
the product 352 could not be separated from substrate 346 by chromatography, and modi-
fication of the reaction conditions (temperature, concentration, Lewis acid) did not improve
this situation. We hypothesized that we could subject compound 352 to hydrolysis to
cleave the carbamate group and the resulting alcohol product might be easily separable from
bis(oxazolidine dione) 346. Treatment of a sample containing 75% of compound 352 and
25% of 346 with aqueous HCl, at reflux for 12 h, caused decomposition. When the same ma-
terial was subjected to a methanol solution of ammonia, very slow conversion was observed.
Although the reaction was not selective (more than one product observed by TLC), it was
interesting to see that both bis(ester) 352 and bis(oxazolidine dione) 346 were consumed.
In fact, when pure bis(oxazolidine dione) 346 was subjected to the same reaction conditions
the same major component was observed. The product of both reactions was assigned as
the bis(oxazolidinone) 353 using heteronuclear correlations of the methylene protons of the
benzyl group to the carbamate carbonyl carbon (Scheme 3.26).
Scheme 3.26. Base promoted cyclization to bis(oxazolidinone).
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We postulate that the product 353 arrives from a methoxide attack on the carbamate
carbonyl to give methyl carbonate 354. Under basic conditions, N -benzyl amine attacks the
carbonate to form the oxazolidinone ring (Scheme 3.27). This mechanism is supported by
the intercepted intermediate 355 that can be isolated in small quantities (8% yield) from the
same reaction. The 1D and 2D NMR spectra are in agreement with the proposed structure.
The key correlation that allowed for the assignment of 355 was the HMBC correlation of
the methyl group to the carbonate carbonyl at 161 ppm (Scheme 3.27). If it were a part of
the ester group, the shift of the corresponding carbon would be higher, around 170 ppm like
in compound 352. The convergence of 352 and 346 to 353 also suggests that ammonia in
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methanol establishes an equilibrium from 352 to 346
Scheme 3.27. Mechanism of the base-promoted isomerization of 347.
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3.4.4 Desymmetrization and synthesis of the aldehyde for Passerini coupling
The base-promoted isomerization of the bis(oxazolidine dione) 346 to bis(amide) 353
not only released the termini of the molecule for further functionalization but also protected
the secondary amine in the same reaction. In preparation for the Passerini reaction we
directed our efforts toward two goals, desymmetrization and removal of one of the terminal
carbons. When compared with the C9-C15 fragment of zwittermicin A, bis(amide) 353
has an additional carbon, so a strategy was devised in which the desymmetrization will be
performed on the bis(alcohol) 356 by monoprotection. The remaining alcohol in compound
357 could be oxidized to aldehyde 358 and coupled with the isonitrile 293 in a Passerini
reaction. The terminal carbon could be removed at the late stage of the synthesis by oxidative
cleavage–reduction sequence (Scheme 3.28).
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Scheme 3.28. A strategy for desymmetrization and removal of C16 carbon.
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With compound 353 in hand, we attempted a hydrolysis of the phenyl amide by the
nitrosation–hydrolysis sequence published by Evans and co-workers.169,170 Unfortunately, re-
action of bis(amide) 353 with NaNO2 produced complex mixtures. The alternative activation
of the amide by conversion to an N -Boc carbamate proceeded smoothly and delivered 359
in 61% yield. The saponification with lithium hydroperoxide in THF–H2O mixture at 0 ◦C
was very facile and delivered the bis(carboxylic acid) 360 in 95% yield without purification
(Scheme 3.29).
Scheme 3.29. Preparation of bis(carboxylic acid) 361.
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Handling of carboxylic acid 360 was challenging due to its high affinity to silica gel,
rendering this compound incompatible with conventional chromatography purification tech-
niques. Therefore the bis(carboxylic acid) 360 was converted to the corresponding bis(ester)
361 to aid purification by treatment of 360 with an etheral solution of diazomethane (99%
yield).
Preparation of the bis(alcohol) 356 was not stratightforward. Treatment of the bis(ester)
with LiAlH4 or RedAl in THF at −78 ◦C for 4 h produced a complex mixture (Table 3.4,
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entries 1 and 2). The same result was observed when bis(carboxylic acid) was treated with
borane–THF complex (entry 3). No reaction was observed when the bis(ester) 362 was
reacted with DIBAL, even at room temperature (entry 4). We were pleased to see very
clean and efficient reaction with sodium borohydride in methanol at room temperature that
yielded the desired bis(alcohol) 356 in 92% isolated yield (Table 3.4, entry 5).
Table 3.4. Optimization of the reduction of bis(ester).
conditions
OO
NN
BnBn
OO
OO
TIPDS
OO
NN
BnBn
OO
OO
TIPDS
OHHOOR O R
entry R conditions yieldb
(%)
1 OMe LiAlH4, THF, −78 ◦C, 4 h —
2 OMe RedAl, THF, −78 ◦C, 4 h —
3 OH BH3 · THF, THF, rt, 6h —
4 OMe DIBAL, THF, rt, 6 h —
5 OMe NaBH4, MeOH, rt, 1 h 92
Compound 356 was reacted with a substoichiometric amount of trityl chloride in pyridine
at 60 ◦C for 12 h and provided the desymmetrized alcohol∗ 357 in 30% yield (86% brsm).
With the compound 357 we were ready to explore the key Passerini reaction that will bring
the aminopolyol and isonitrile fragments together (Scheme 3.30).
Scheme 3.30. Desymmetrization of alcohol 357.
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Oxidation of alcohol 357 was problematic. Treatment of 357 with 2.1 equiv of Dess–
Martin periodinane in CH2Cl2 at room temperature delivered a complex mixture following
a standard aqueous work-up171 (Table 3.5, entry 1). Extending the reaction time did not
improve the outcome of the reaction (entry 2). We saw much higher reactivity when a con-
∗Initially, bis(alcohol) 356 was monoprotected as a TBS ether but we later found that a converstion to
a trityl ether gives us more control over the conversion to the bisprotected compound.
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trolled amount of water was added to the reaction172 but no aldehyde was observed in the
1HNMR of the crude reaction mixture (entry 3). When an equimolar amount of DMP was
used and the reaction was diluted with diethyl ether and filtered, about 60% conversion
was estimated by proton NMR analysis (entry 4). Catalytic N -oxide radical-based oxida-
tion conditions (TEMPO/PhI(OAc)2) consumed 357 within 1 h, but delivered a product of
overoxidation, as did Ley oxidation (entry 6). Among activated DMSO methods, we evalu-
ated Parikh–Doering and Swern oxidation conditions. When alcohol 357 was treated with
3 equiv of SO3 · pyridine complex in DMSO–CH2Cl2, no reaction was observed even after
20 h (entry 7). Under the standard Swern oxidation conditions, no product was observed
whenever aqueous work-up was performed (entry 8). Relatively clean conversion to the alde-
hyde 363 was observed when the reaction was diluted with ether, filtered, and concentrated
(entry 9). Attempts to purify the aldehyde by chromatography were fruitless. It was appar-
ent that aldehyde 363 is sensitive to water and/or air so it was used in a subsequent step
without work-up or purification.
Table 3.5. Survey of oxidation conditions for the synthesis of aldehyde 364.
O O
TIPDS
N
O O
N
BnBn OO
HO OCPh3
conditions
O O
TIPDS
N
O O
N
BnBn OO
O OCPh3H
357 363
entry reagent equiv work-up conva
(%)
1 DMP 2.1 aqueous —b
2 DMP 2.1 aqueous —b
3 DMPc 2.1 aqueous —b
4 DMP 1.0 filtration 60
5 TEMPO/PhI(OAc)2 2.1 filtration —d
6 TPAP/NMO 2.0 filtration —d
7 SO3 · pyridine 1.0 filtration no reaction
8 (COCl)2, DMSO 3.0 aqueous —b
9 (COCl)2, DMSO 3.0 filtration 60–80
aEstimated by 1H NMR analysis of the crude reaction mixture. bReaction
resulted in a complex mixture. cWet dichloromethane was used as solvent.
dOveroxidation to carboxylic acid occurred.
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3.4.5 Synthesis of the isonitrile fragment
As outlined in section 3.2.3, for the most convergent approach, the isonitrile fragment
should be functionalized with a urea and a primary amide. Although the isonitrile 293 has no
precedence in the literature, amine 251 has been previously prepared by Rogers and Molin-
ski.140 Modification of the amine by formylation and dehydration should provide the isonitrile
364. The synthesis of 251 commences with the preparation of l-1,3-diaminopropionic acid
(365) (l-DAP) from l-Asp as described by Rao.173 (Scheme 3.31). The Schmidt reaction of
l-Asp afforded l-DAP in 71% yield which was then subjected to copper(II) sulfate in water
at pH 5 to chelate the carboxylate and secondary amine to form 366. The primary amine
of the complex 366 was selectively reacted with potassium cyanate in water at 58 ◦C while
maintaining pH 5 using HCl.174–177 After the reaction, decomplexation by treatment with
sodium sulfide and copper(II) sulfide gave albizziine (294) as the only product.
Attempts to convert the carboxylic acid of 294 to a primary amide failed. Preparation
of the mixed anhydride and treatment with ammonium hydroxide returned only the starting
material, most likely due to the insolubility of 294 in THF. We then treated 294 with
thionyl chloride in refluxing methanol which returned the methyl ester 367 quantitatively.
Unfortunately, treatment with either ammonia in methanol or ammonium hydroxide didn’t
provide the desired primary amide 251.
Scheme 3.31. Synthesis of albizziine-derived isonitrile
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Following the protocol used by Molinski and co-workers178 in their synthesis of zwitter-
micin A, we temporarily protected the secondary amine with a Boc group. Sonication of
albizziine in methanol in the presence of Boc2O and solid NaHCO3 gave 368 in 60% yield.
Formation of the mixed anhydride, followed by addition of ammonium hydroxide provided
the primary amide 369 in 70% conversion. This material was treated with trifluoroacetic
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acid and the secondary amine was liberated. Compound 369 was then subjected to several
formylation conditions which unfortunately didn’t deliver the desired N -formyl precursor to
the isonitrile.
Scheme 3.32. Synthesis of albizziine amide-derived isonitrile
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Formylation of the amine in compound 367 also proved to be difficult. Several literature
procedures were evaluated179–182 but none of them allowed for high conversion of 367. On
one occasion,180 65% conversion to 370 was achieved and this mixture was subjected to
dehydration conditions developed by Danishefsky and co-workers.183 Although the crude re-
action mixture contained isonitrile, as evidenced by a characteristic IR stretch at 2250 cm−1,
purification of the desired compound 371 was unsuccesful.
Scheme 3.33. Synthesis of albizziine methyl ester-derived isonitrile
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We hypothesized that the terminal urea functional group is not compatible with dehy-
dration conditions. To overcome this difficulty we proceeded to synthesize isonitrile 377,
where the terminal amine is prepared from an azide. Commercially available N -Boc serine
methyl ester 372 was converted to the mesylate and then subjected to sodium azide in DMF
at rt. This reaction provided the desired azide 373 in 30% yield with mesylate elimination
product as the major component. Deprotection of 373 with TFA and subsequent treatment
with acyl formate provided the formamide 374 in 70% yield over two steps. A more con-
venient route to 374 can be achieved from l-serine methyl ester. Formamide formation of
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commercially available 375 using formic acid anhydride184 was sluggish. A more reactive
formyl group donor, pentafluorophenyl formate,185 afforded the formyl derivative 376 in 90%
yield. Mitsunobu displacement of the terminal alcohol using hydrazoic acid in the presence of
PPh3 and DEAD afforded the desired azide 374 in 62% yield. Dehydration of 374 was also
problematic. Although respectable levels of conversion to the desired isonitrile 377 could be
achieved, purification was problematic as the product decomposed during aqueous work-up
or chromatography. An attempt to use crude isonitrile 377 in the Passerini reaction with
benzaldehyde was unsuccesful.
Scheme 3.34. Synthesis of albizziine methyl ester-derived isonitrile
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After exploring the synthesis of isonitrile 293 it became clear to us that protection of
the primary amine in the isonitrile fragment could not be avoided.167 l-DAP (365) was
converted to methyl ester 378. The primary amine was selectively protected using Boc2O
and triethylamine in dichloromethane, as described by Egbertson and co-workers,186 and the
secondary amine 379 was formylated using pentafluorophenyl formate to give formamide 380
in 89% yield. Dehydration of 380 proceeded smoothly and afforded the desired isonitrile 381
in 70% yield. Direct conversion of the methyl ester to primary amide 382 was unsuccessful.
Therefore, this functional group will be modified after the Passerini coupling.
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Scheme 3.35. Synthesis of DAP methyl ester-derived isonitrile
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3.4.6 First generation synthesis of the Passerini adduct and its functionalization
The next desired step was a key Passerini reaction that brings together the aminopolyol
fragment and the isonitrile 383. As described in the previous section, alcohol 357 was
oxidized to aldehyde 363 by Swern oxidation† and immediately reacted with isonitrile 383
and benzoic acid. After 2 days at room temperature, the desired Passerini adduct 384
formed in 65% yield as an inseparable mixture of diastereomers in 2:1 ratio (Scheme 3.36).
We anticipate that further functionalization will allow for the separation of diastereomers,
and stereochemical identity will be assigned later by comparison to the natural product.
Scheme 3.36. Synthesis of the fist generation Passerini adduct.
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†We found that longer activation time was crucial to reproducibility and conversion.
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The next task was functional group manipulation of the western fragment of adduct
384. Direct transformation of the methyl ester in compound 384 to a primary amide was
unsuccessful. In our preliminary attempts at a direct CO2Me to CONH2 conversion‡ using
ammonium hydroxide in toluene at 80 ◦C returned the starting material. Other conditions,
including ammonia in methanol and NH4OH in THF–water at 100 ◦C in a microwave resulted
in decomposition. We then pursued a two-step sequence in which the methyl ester is saponi-
fied and then activated to be converted to an amide. Standard hydrolysis protocols such as
K2CO3 or LiOH in methanol were effective at saponifying the methyl ester and cleaving the
benzoate but erosion of dr was observed. Due to high acidity of the proton in α position
to the amide, we decided to rely on a selective methyl ester hydrolysis method developed
for compounds prone to epimerization.187 Methyl ester 384 was reacted with trimethyltin
hydroxide in 1,2-dichloromethane at 80 ◦C for 3 h to give the corresponding carboxylic acid
(385) in 42% combined yield, and the diastereomers could now be separated by HPLC (25%
and 17% yield respectively). Next, each diastereomer was converted to a mixed anhydride
in reaction with isobutyl chloroformate and N -methylmorpholine followed by ammonium
hydroxide. This reaction afforded the corresponding amide diastereomers 386 in 86% and
59% yield respectively (Scheme 3.37).
Scheme 3.37. Functionalization of the Passerini adduct: transformation of a methyl ester
to primary amide.
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‡Reactions were carried out on a TBS protected adduct.
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Next we pursued deprotection of the terminal amine and attachment of the urea moiety.
Carbamate 386 was treated with TFA in CH2Cl2 at room temperature in order to cleave
the Boc group as well as remove the trityl ether. After purification, what looked as a single
compound by HPLC was in fact a 2:1 mixture of diastereomers of compound 387. We hy-
pothesized that under acidic conditions, the α position to the amide undergoes epimerization
(Scheme 3.38).
Scheme 3.38. Removal of the Boc and trityl groups.
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To solve this problem we conducted the functionalization in a different order. We planned
to remove the benzoate ester and hydrolyze the oxazolidinone rings before removing the Boc
and trityl groups. Despite the fact that strongly basic conditions promote epimerization, we
attempted a global hydrolysis of Passerini adduct 384 to determine if methyl ester, benzoate
and oxazolidinone can be hydrolyzed in a single reaction to give compound 388. A number of
hydroxide- and alkoxide-based conditions were used but without much success. Even though
some were effective at removing the benzoate ester to give 389, oxazolidinone rings were not
reactive under these conditions and reactions at elevated temperature caused decomposition
(Scheme 3.39).
It became evident that oxazolidinone rings with N -benzyl substituent might not be suffi-
ciently electrophilic for mild hydrolysis to occur. On the other hand, application of harsher
conditions leads to decomposition. We wanted to explore the reactivity of oxazolidinones
towards hydrolysis using a model based on the C 2-symmetric compound 390. In order to
increase the electrophilicity of the oxazolidinone carbonyl, the benzyl group was replaced
with a Boc group. Birch reduction efficiently removed the benzyl substituent and gave
bis(carbamate) 391 in 82% yield. Compound 392 was synthesized in nearly quantitative
yield by reacting 391 with Boc2O and DMAP in dichloromethane (Scheme 3.40). When
compound 392 was treated with Cs2CO3 in methanol at 60 ◦C or K2CO3 at room temper-
ature, decomposition occurred. Use of lithium hydroperoxide in THF–H2O led to partial
conversion at room temperature after 20 h. The main product was identified as desym-
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Scheme 3.39. Global hydrolysis of the Passerini adduct.
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metrized compound 393 that arises from N -Boc oxazolidinone ring opening where the re-
sulting secondary alcohol attacks the tert-butyl carbamate to form 393 after elimination of
tert-butanol (Scheme 3.40). Although we obtained an undesired product, our hypothesis
about low electrophilicity of the N -Bn oxazolidinone ring was further confirmed.
Scheme 3.40. Undesired opening–cyclization of N -Boc bis(oxazolidinone).
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To prevent recyclization after hydrolysis, we pursued an N -Ts derivative of 391. Treat-
ment of bis(carbamate) 391 with nBuLi followed by 4-toluenesulfonyl chloride§ delivered
bis(sulfonamide) 394 in 91% yield. When compound 394 was reacted with Cs2CO3 in
methanol at room temperature for 24 h, the desired acyclic aminopolyol 395 was isolated in
51% yield (Scheme 3.41)
§We found that high yields are only obtained when freshly recrystallized tosyl chloride is used.
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Scheme 3.41. Successful hydrolysis of N -Ts derivative 395.
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3.4.7 Studies towards the desymmetriation and decarbonylation
It was apparent that the late stage removal of the carbon at C16 will be more challeng-
ing than we originally anticipated. Our alternative plan was to achieve desymmetrization
and decarbonylation before the Passerini reaction, preferentially, at the bis(carboxylic acid)
stage. A direct desymmetrization by decarbonylation was met with limited success as the
stoichiometry of product formation from 360 was difficult to control. Activation of the
bis(carboxylic acid) as an acid chloride followed by addition of tert-butyl hydroperoxide and
pyridine returned the starting material (Table 3.6, entry 1). Attempts to prepare the tert-
butyl perester via DCC or EDC coupling were also fruitless (entries 2, 3); activation and in
situ Barton decarbonylation gave the same result (Table 3.6, entry 4). Preparation of the
bis(selenoester) 396 required significant optimization. Treatment of 359 with benzenese-
lenol and triethylamine at 50 ◦C returned the starting material, as did the reaction with the
lithium phenyl selenide (entries 5 and 6, respectively). We first observed the product when
the bis(carboxylic acid) 360 was reacted with diphenyl diselenide and tributyl phosphine in
dichloromethane at room temperature, but the reaction stalled at about 40% conversion and
the product decomposed during purification (Table 3.6, entry 7). A reasonable conversion
was seen when the acid chloride of 360 was treated with benzeneselenol and triethylamine.
The bis(selenoester) 396 is highly prone to hydrolysis which was observed during chromato-
graphic purification and is probably the main factor that lowers the isolated yield (21%,
entry 8).
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Table 3.6. Synthesis of the symmetric phenylselenoester.
O O
TIPDS
N
O O
N
BnBn OO
R1 R1O O O OTIPDS
N
O O
N
BnBn OO
R2 R2O O
conditions
entry R conditions yieldb
(%)
1 Cl tBuOOH, pyridine —
2 OH tBuOOH, DCC, iPr2EtN —
3 OH tBuOOH, EDC, iPr2EtN —
4 Cl Barton salt, toluene, hν, 100 ◦C —
5 N(Ph)Boc PhSeH, Et3N, DMF, 50 ◦C —
6 N(Ph)Boc PhSeH, LHMDS, THF, rt —
7 OH PhSeSePh, nBu3P, CH2Cl2, rt 5
8 Cl PhSeH, Et3N, rt, 30min 21
With compound 396 in hand we tested the radical decarbonylation conditions. Although
the reaction of 396 with 1 equiv of nBu3SnH and 1 equiv of AIBN in toluene at 110 ◦C was
very fast (full conversion after 30min) the main product was bis(carboxylic acid) 360. To
ensure that the reaction operates under strictly anhydrous conditions, the selenoester was
dried over P2O5 under vacuum, dry toluene and freshly recrystallized AIBN were used.
After only 10min of reaction, full conversion of the bis(selenoester) 396 was achieved and
the bis(oxazolidinone) 397 formed in 80% yield (Scheme 3.42).
Scheme 3.42. Radical decarbonylation of the bis(selenoester) 397.
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With a successful removal of the C16 carbon we turned our attention to desymmetrization
of the bis(carboxylic acid) through a selective formation of monoester 398. We were able to
obtain the monester via Fischer esterification in refluxing methanol, but the process was labor
intensive. The reaction was stopped at ca. 60% conversion when formation of bis(ester) 361
was observed (Scheme 3.43). The mixture of both products and unreacted starting material
was separated by preparative HPLC as conventional chromatography was ineffective. Very
low selectivity and yield (41%) prompted us to investigate other monoesterification methods.
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Scheme 3.43. Fischer esterification of the bis(carboxylic acid).
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Monoesterification of simple dicarboxylic acids can be selectively achieved via correspond-
ing cyclic anhydrides. Long dicarboxylic acids can be monoprotected in the reaction with
diazomethane188,189 or dimethyl sulfate190 by monocarboxylate chemisorption on alumina.
Methods utilizing phase-transfer catalysis have also been reported,191 and enzyme-based
methods for monoalkylation of dicarboxylic acids have experienced an increased interest
among organic chemists.192 Nishiguchi and co-workers reported a highly selective monoes-
terification of dicarboxylic acids with 4–14 carbon chains. Transesterification catalyzed by
the DOWEX 50WX2 resin (50–100mesh) is achieved in an alkane–HCO2nBu mixture at high
temperature. The rate of monoesterification of diacids was found to be much higher than
that of the monocarboxylic acids because it mostly happens in the water layer surrounding
the DOWEX resin (ca. 50% water by weight).193,194
We hypothesized that by applying Nishiguchi’s conditions we can obtain better selectivity
towards the monoester. When dicarboxylic acid 360 was reacted in 1:10 mixture of n-
butyl acetate and octane at 70 ◦C in presence of the DOWEX resin for 1 h, we measured
60% conversion and ca. 5:1 ratio of monoester 399 to bis(ester) 400 (Table 3.7, entry 1).
After 2 h, the conversion increased to 70% but only the amount of the diester increased.
However, the ratio of components after preparative HPLC didn’t match the amounts we
observed when we analyzed the reaction mixture. The overall conversion was lower (62%)
and the ratio of the monoester to diester was 6.5:1 (entry 2). This confirms Nishiguchi’s
claim that the dicarboxylic acid is mainly in the water layer surrounding the resin. Our
analysis of the reaction mixture was limited to the organic layer that is clearly enriched in
the ester components. Following the findings reported by Nishiguchi and co-workers, we
hypothesized that we can achieve better yield and selectivity by reducing the amount of
the resin and decreasing the amount of nBuOAc in octane. After 1 h the ratio between the
diacid, monoester and diester was 44:40:16, respectively (entry 3). Although the ratio of the
diester increased with time (entry 4) we continued the reaction for total of 4 hours. At that
point, HPLC analysis of the reaction mixture (organic layer) showed 9:35:55 ratio. Once the
resin was filtered and washed with methanol, the ratio was 41:42:17 (Table 3.7), entry 5).
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Table 3.7. Selective monoesterification promoted by DOWEX ion-exchange resin.a
O O
TIPDS
N
O O
N
BnBn OO
HO OHO O
DOWEX 50WX8
nBuOAc–octane
70 °C O O
TIPDS
N
O O
N
BnBn OO
nBuO OHO O O OTIPDS
N
O O
N
BnBn OO
nBuO OnBuO O
360 399 400
entry resin time nBuOAc–octane 360:399:400a
(g/mmol) (h)
1 4 1 1:10 42:51:7
2 2 29:50:21
(62:33:5)b
3 2 1 1:20 44:40:16
4 2 23:44:33
5 4 9:35:55
(41:42:17)b
aDetermined by HPLC analysis of the reaction mixture. bDetermined by
analysis of the reaction mixture after the work-up during preparative HPLC.
Further optimization of this protocol established that if the reaction is performed in an n-
butyl formate–toluene mixture with 2 g of the resin per mmol of substrate, the desired n-butyl
ester 399 can be isolated in 57% yield. We also found that careful column chromatography
using a mixture of AcOH–MeOH–CH2Cl2 (gradient 1:2:97 to 1:8:91 and then 1:20:79) as
solvent allows for preparative purification of monoester 399 without the need for multiple
HPLC runs.
3.4.8 Second generation synthesis of the Passerini adduct
With an efficient strategy for desymmetrization and decarbonylation in hand, we pursued
a synthesis of the Passerini adduct with C16 removed. Monoester 399 was transformed into a
selenoester by first reaction with oxalyl chloride and catalytic DMF in dichloromethane at rt.
The crude acid chloride was added to a solution of benzeneselenol¶ and 4-methylmorpholine
at 0 ◦C and provided corresponding selenoester 401. Compound 401 was not isolated, but
after extensive drying over P2O5 under vacuum, was treated with 2 equiv of nBu3SnH and
1 equiv of freshly recrystallized AIBN in toluene at 100 ◦C. After 7min the reaction was
complete by TLC, and column chromatography of the concentrated reaction mixture gave
desired ester 402 in 67–96% over 2 steps (Scheme 3.44).
¶We found that the order of addition is important for high conversion.
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Scheme 3.44. Preparation and decarbonylation of the selenoester 402.
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In preparation for the Passerini reaction, the ester 402 was reduced with NaBH4 in
methanol and the resulting alcohol was protected as a MOM ether with MOMCl and
iPr2NEt. Birch reduction of 403 efficiently removed both benzyl groups and afforded the
bis(carbamate) 404 in 78% over 3 steps. Next, deprotonation with LDA followed by addi-
tion of freshly recrystallized tosyl chloride afforded the N -Ts derivative 405 in 77% yield.
The removal of the MOM group was achieved in 82% yield by reaction with 60% TFA in
DCM at rt to give 406 (Scheme 3.45).
Scheme 3.45. Elaboration of the monoester 403.
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Again, the oxidation of the alcohol turned out to be a challenge. A series of oxidation
conditions was evaluated and the results are presented in Table 3.8. Dess–Martin oxidation
and activated DMSO methods (Swern, Parikh–Doering) resulted in decomposition (entries
1–3). Excess PCC in dichloromethane in the presence of Celite did not react after 12 h but
upon addition of activated molecular sieves, conversion of the starting material was observed
but to decomposition products (entry 4, 5). A stoichiometric amount of TPAP in CH2Cl2 at
room temperature consumed the starting material in only 15min but returned the product
of overoxidation which was confirmed by LCMS analysis (entry 6). TEMPO oxidation also
resulted in production of the corresponding carboxylic acid when excess bleach was used
(entry 7). Use of stoichiometric amount of Ca(OCl)2 195 showed only 5% conversion after 1 h
at rt (entry 8). More exotic oxidation methods, RuCl2(PPh3)3 in benzene or AgCO3 · Celite
did not engage in a reaction with the alcohol 406 (entry 9, 10).
Table 3.8. Survey of oxidation conditions for the synthesis of the aldehyde 408.
O O
TIPDS
N
O O
N
TsTs OO
HO
conditions
O O
TIPDS
N
O O
N
TsTs OO
O
406 407
entry conditions result
1 DMP, CH2Cl2, rt, aqueous work-up decomposition
2 SO3 · pyridine, DMSO, rt decomposition
3 (COCl)2, DMSO, iPr2EtN, CH2Cl2 decomposition
4 PCC, Celite, CH2Cl2, rt, 12 h no reaction
5 PCC, Celite, 4Å MS, CH2Cl2, rt, 8 h decomposition
6 TPAP (1 equiv), CH2Cl2, rt, 15min overoxidation
7 TEMPO, bleach, KBr, NaHCO3, rt, 30min overoxidation
8 TEMPO, Ca(OCl)2, CH2Cl2–NaHCO3, rt, 1 h ca 5% conv.
9 RuCl2(PPh3)3, benzene, rt, 12 h no reaction
10 AgCO3 · Celite, benzene, reflux, 12 h no reaction
To gain more insight into the decomposition pathway we performed the Dess–Martin
reaction in CDCl3 and followed the reaction by 1H NMR. To our amazement, the reaction
proceeded very smoothly and selectively. After 5min, already 50% conversion to 407 was
observed by 1H NMR analysis (Figure 3.8, spectrum B). The reaction was complete after
15min (Figure 3.8, spectrum C) and the reaction mixture did not change composition even
after an additional 3 h (spectrum D). This experiment showed very clearly that problems
with oxidation of 406 are correlated with exposure to water and/or air. To the NMR tube
containing aldehyde 407 was added 12 equiv of benzoic acid which did not affect the aldehyde.
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Addition of PhCO2H was followed by addition of 2 equiv of isonitrile 383 and at the time
when the 1H NMR spectrum was acquired (ca. 5min) the reaction was already complete
with the Passerini adduct 408 (1.6:1 dr) as the major product (Figure 3.8, spectrum E). This
shows very high reactivity of the aldehyde 407. Normally, Passerini reactions require long
reaction times, even at room temperature,196 but in our case, aldehyde 407 is significantly
more reactive but this comes at a cost of sensitivity to decomposition.
With this study we established a very straightforward protocol for the synthesis of the
Passerini adduct 408. The alcohol 406 is treated with 1.05 equiv of Dess–Martin periodinane
in CDCl3 at rt. After 1 h to the reaction is added 10–15 equiv of benzoic acid and the reaction
mixture is cooled to −78 ◦C. The isonitrile 383 (1.5 equiv) is then added in one portion and
the reaction is warmed to −20 ◦C. With this protocol, 3.7:1 ratio of diastereomers of the
adduct 408 is obtained in 50% isolated yield (Scheme 3.46).
Scheme 3.46. One-pot oxidation and Passerini coupling.
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Figure 3.8. Dess–Martin oxidation of 406 followed by 1H NMR. (A) Alcohol 406; (B)
Reaction mixture after 5 min; (C) reaction mixture after 15 min; (D) reaction mixture after
addition of PhCO2H; (E) reaction mixture after addition of isonitrile 383.
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3.4.9 The end game strategy
The proposed sequence for the elaboration of adduct 408 starts with saponification of
the methyl ester with trimethyltin hydroxide to give terminal acid 409. Activation of the
carboxylic acid as a mixed anhydride, followed by treatment with aqueous ammonia will
provide primary amide 410. After removal of the Boc group, the resulting terminal amine
will be reacted with trimethylsilyl isocyanate to provide the terminal urea functionality in
compound 411. Treatment of compound 411 with Cs2CO3 in methanol will cleave the ben-
zoate group as well as open the oxazolidinone rings. The 4-toluenesulfonamide substituent
in compound 412 will be removed by Birch reduction197 to give the aminopolyol 413. Fi-
nally, treatment of 413 with HF · pyridine complex will remove the TIPDS group and afford
the (+)-zwittermicin A 245 (Scheme 3.47). As described in earlier sections, many of these
operations has been performed successfully on various intermediates. An unknown aspect,
however, is the identity of the favored epimer in the conversion of 406 to 408. Should the
major diastereomer be a precursor to epi-zwittermicin A, an additional substitution step will
be added to the end game outlined. Alternatively, the Passerini coupling can be performed
at room temperature to increase the amount of the minor diastereomer.
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Scheme 3.47. End-game strategy for the synthesis of zwittermicin A.
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APPENDIX A
Experimental Section
Compounds relevant to Chapter 1
N
N
N
EtO2C
O
N
CO2Me
Ph
Ph2HC
EtO2C
NPh2HC
O N
O
O
Ph
H
200 mol % TfOH
100 mol % H2O
CH3CN, –20 °C, 6 h
then 200 mol % Et3N
Oxazolidine dione anti-75. To a cold (−20 ◦C) solution of triazoline (50.0mg, 100 µmol) in
acetonitrile (500 µL) was added TfOH (18 µL, 200 µmol) followed by water (1.8 µL, 100 µmol) and
the solution was stirred at −20 ◦C for 6 h. The reaction was quenched with triethylamine (28µL,
200 µmol) and concentrated to a yellow oil that was purified using flash chromatography (SiO2,
10–20% ethyl acetate in hexanes) to afford the oxazolidine dione as a colorless oil (34mg, 78%).
Rf = 0.25 20% (EtOAc/hexanes); IR (film) 3328, 3058, 3017, 2982, 1821, 1751 cm−1 1H NMR
(400MHz, CDCl3) δ 7.49–7.22 (m, 15H), 5.28 (d, J = 2.5Hz, 1H), 5.09 (d, J = 4.6Hz, 1H),
4.33 (dq, J = 10.8, 7.2Hz, 1H), 4.25 (dd, J = 10.8, 7.2Hz, 1H), 3.98 (dd, J = 8.4, 2.5Hz, 1H),
2.75 (dd, J = 8.4, 4.6Hz, 1H), 1.29 (t, J = 7.2Hz, 3H); 13C NMR (100MHz, CDCl3) ppm 169.7,
169.0, 154.2, 142.7, 141.8, 130.8, 129.5, 129.3, 129.1, 129.0, 128.7, 128.6, 128.5, 127.7, 127.6, 127.58,
127.55, 127.3, 127.2, 125.6, 125.5, 80.4, 66.2, 62.5, 59.2, 14.1; HRMS (ESI): Exact mass calcd for
C26H24N2NaO5 [M+Na]
+ 467.1583, found 467.1581.
N
N
N
EtO2C
O
N
CO2Me
Ph
Ph2HC
silica gel
EtOAc–hexanes (1:3)
rt, 48 h
EtO2C
NPh2HC
N2
N
O
CO2Me
Ph
H
α-Diazoamine 76. A slurry of silica gel (2 g) and triazoline (64mg, 130 µmol) in hexanes–ethyl
acetate (3:1, (3mL)) was stirred for 48h at rt and then filtered, concentrated, and purified using
flash chromatography (SiO2, 20% ethyl acetate in hexanes) to afford the α-diazoamine as a yellow
oil (38mg, 59%). Rf = 0.33 20% (EtOAc/hexanes); IR (film) 3334, 3028, 2956, 2096, 1736,
1665 cm−1 1H NMR (400MHz, CDCl3) δ 7.40–7.20 (m, 13H), 7.15 (d, J = 7.8Hz, 2H), 4.97 (s,
1H), 4.25 (s, 1H), 4.21 (dq, J = 10.7, 7.2Hz, 1H), 4.17 (dq, J = 10.7, 7.2Hz, 1H), 3.80 (s, 3H), 2.70
(br s, 1H), 1.25 (t, J = 7.2Hz, 3H); 13C NMR (100MHz, CDCl3) ppm 169.9, 166.1, 154.0, 142.8,
141
142.0, 129.2, 128.7, 128.5, 127.9, 127.5, 127.4, 127.3, 64.4, 62.0, 56.2, 53.9, 14.1; HRMS (ESI):
Exact mass calcd for C27H27N4O5 [M+H]
+ 487.1981, found 487.1968.
N2
O
N CO2Me
PhEtO2C
N
H
CHPh2
EtO2C
N
O N
O
Ph
Ph2HC H
MeO OMe
100 mol % H2O
100 mol % TfOH
CH2Cl2, –78 °C, 1 h
then 100 mol % Et3N
Orthoamide 78. To a cold solution (−78 ◦C) of imine (26.7mg, 100 µmol) and α-diazo imide
(26.3mg, 120µmol) in dichloromethane (500 µL) was added TfOH (9 µL, 100 µmol), and the solution
was stirred at −78 ◦C for 1 h. The reaction was quenched with satd aq NaHCO3 and extracted with
ethyl acetate. The organic layers were dried and concentrated, and the resulting solid was purified
using flash chromatography (SiO2, 10% ethyl acetate in hexanes) to afford the orthoamide as a
colorless oil (6.4mg, 13%). Rf = 0.22 20% (EtOAc/hexanes); IR (film) 3448, 2962, 2935, 2894,
2860, 1739 cm−1 1H NMR (600MHz, CDCl3) δ 7.60 (dd, J = 8.7, 2.1Hz, 1H), 7.45 (d, J = 7.5Hz,
1H), 7.44 (d, J = 7.1Hz, 1H), 7.40–7.38 (m, 3H), 7.35–7.24 (m, 7H), 7.21–7.17 (m, 2H), 5.02 (s,
1H), 4.90 (d, J = 2.7Hz, 1H), 4.26 (dq, J = 10.6, 2.6Hz, 2H), 3.87 (dd, J = 11.8, 2.6Hz, 1H),
3.41 (s, 3H), 3.38 (s, 3H), 2.72 (dd, J = 12.0, 2.0Hz, 1H), 1.30 (t, J = 7.1Hz, 3H); 13C NMR
(150MHz, CDCl3) ppm 171.5, 168.1, 144.3, 141.9, 133.8, 129.1, 128.5, 128.3, 127.8, 127.3, 127.2,
127.1, 127.0, 124.7, 121.2, 79.3, 64.9, 61.4, 59.1, 51.7, 51.1, 14.2; HRMS (ESI): Exact mass calcd
for C28H30N2NaO6 [M+Na]
+ 513.2002, found 513.1995.
H
N CHPh2
N2 N
CHPh2
O O
O
MeO
MeO
O
25 mol % TfOH
CH3CH2CN
–78 °C, 6 h
Methyl 1-benzhydryl-3-(cyclopropanecarbonyl)aziridine-2-carboxylate (81). To a solu-
tion of the imine (115mg, 454µmol) and diazoketone (60mg, 540 µmol) in propionitrile (1.5mL)
at −78 ◦C was added triflic acid (10.0 µl, 114µmol). The reaction mixture was stirred at −78 ◦C
for 6 h and then was quenched with satd aq sodium bicarbonate. The mixture was extracted with
ethyl acetate and the combined organic layers were washed with brine, dried and concentrated. The
resulting oil was purified using flash chromatography (SiO2, 20% ethyl acetate in hexanes) to afford
the aziridine as a white solid (133mg, 88%). Mp 116–117 ◦C; Rf = 0.33 (20% EtOAc/hexanes);
IR (film) 3062, 1748, 1688, 1453 cm−1; 1H NMR (500MHz, CDCl3) δ 7.55 (d, J = 7.8Hz, 2H),
7.49 (d, J = 7.8Hz, 2H), 7.37–7.29 (m, 4H), 7.28–7.23 (m, 2H), 3.87 (s, 1H), 3.71 (s, 3H), 2.75 (d,
J = 7.1Hz, 1H), 2.73 (d, J = 7.1Hz, 1H), 2.60–2.51 (m, 1H), 1.09–1.00 (m, 1H), 0.95–0.82 (m,
3H); 13C NMR (125MHz, CDCl3) 205.6, 167.8, 141.7, 141.5, 128.57, 128.55, 127.6, 127.4, 127.3,
142
127.0, 77.2, 52.3, 50.7, 45.0, 18.3, 12.4, 11.3 ppm; HRMS (ESI): Exact mass calcd for C21H21NNaO3
[M+Na]+ 358.1414, found 358.1419.
H
N CHPh2
N2 N
CHPh2
O O
O
MeO
MeO
O
25 mol % TfOH
CH3CH2CN
–78 °C, 6 h
Methyl 1-benzhydryl-3-(cyclohexanecarbonyl)aziridine-2-carboxylate (82). To a solu-
tion of the imine (97.2mg, 384µmol) and diazoketone (70.0mg, 460 µmol) in propionitrile (1.2mL)
at −78 ◦C was added triflic acid (8.0µl, 90µmol). The reaction mixture was stirred at −78 ◦C for
6 h and then was quenched with satd aq sodium bicarbonate. The mixture was extracted with
ethyl acetate, and the combined organic layers were washed with brine, dried and concentrated.
The resulting oil was purified using flash chromatography (SiO2, 10–25% ethyl acetate in hex-
anes) to afford the aziridine as a white solid (121mg, 83%). Mp 154–156 ◦C; Rf = 0.20 (10%
EtOAc/hexanes); IR (film) 3062, 1742, 1700, 1450 cm−1; 1H NMR (500MHz, CDCl3) δ 7.51 (d,
J = 7.6Hz, 2H), 7.43 (d, J = 7.3Hz, 2H), 7.35 (d, J = 7.5Hz, 2H), 7.31 (d, J = 7.9Hz, 2H),
7.28–7.22 (m, 2H), 3.77 (s, 1H), 3.70 (s, 3H), 2.89 (tt, J = 11.5, 3.0Hz, 1H), 2.73 (d, J = 6.9Hz,
1H), 2.61 (d, J = 6.9Hz, 1H), 1.71 (m, 1H), 1.59 (m, 2H), 1.46 (m, 1H), 1.38–1.14 (m, 2H), 1.13–
0.95 (m, 3H), 0.71 (ddd, J = 15.6, 12.2, 3.7Hz, 1H); 13C NMR (125MHz, CDCl3) 208.8, 168.5,
141.7, 141.4, 128.6, 128.5, 127.9, 127.8, 127.3, 126.8, 109.4, 77.6, 52.4, 49.1, 47.5, 44.7, 28.4, 26.3,
26.0, 25.8, 25.04 ppm; HRMS (ESI): Exact mass calcd for C24H27NNaO3 [M+Na]
+ 400.1883, found
400.1889.
H
N CHPh2
N2 N
CHPh2
O O
O
MeO
MeO
O
25 mol % TfOH
CH3CH2CN
–78 °C, 6 h
S S
Methyl 1-benzhydryl-3-(thiophene-2-carbonyl)aziridine-2-carboxylate (83). To a solu-
tion of the imine (85.5mg, 318µmol) and diazoketone (58.0mg, 380 µmol) in propionitrile (1.0mL)
at −78 ◦C was added triflic acid (7.0µl, 80µmol). The reaction mixture was stirred at −78 ◦C for
6 h and then was quenched with satd aq sodium bicarbonate. The mixture was extracted with
ethyl acetate and the combined organic layers were washed with brine, dried and concentrated.
The resulting oil was purified using flash chromatography (SiO2, 15–30% ethyl acetate in hex-
anes) to afford the aziridine as a pale yellow solid (97mg, 81%). Mp 172–173 ◦C; Rf = 0.28 (20%
EtOAc/hexanes); IR (film) 3087, 3062, 1747, 1660, 1452 cm−1; 1H NMR (500MHz, CDCl3) δ 7.60
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(d, J = 4.6Hz, 1H), 7.57 (d, J = 7.7Hz, 2H), 7.50 (d, J = 7.5Hz, 2H), 7.46 (d, J = 3.9Hz, 1H),
7.38–7.33 (m, 2H), 7.33–7.28 (m, 4H), 6.96 (dd, J = 4.5, 4.2Hz, 1H), 3.97 (s, 1H), 3.66 (s, 3H), 3.25
(d, J = 6.7Hz, 1H), 2.82 (d, J = 6.7Hz, 1H); 13C NMR (125MHz, CDCl3) 185.3, 167.8, 142.3,
141.3, 141.2, 134.5, 133.6, 128.7, 128.6, 128.0, 127.9, 127.8, 127.5, 127.2, 77.8, 52.3, 48.0, 45.0 ppm;
HRMS (ESI): Exact mass calcd for C22H19NNaO3S [M+Na]
+ 400.0978, found 400.0974.
H
N CHPh2
N2 N
CHPh2
O O
O
MeO
MeO
O
25 mol % TfOH
CH3CH2CN
–78 °C, 6 hOEt OEt
O O
Methyl 1-benzhydryl-3-(2-ethoxy-2-oxoacetyl)aziridine-2-carboxylate (85). To a solu-
tion of the imine (127mg, 500 µmol) and diazoketone (85.0mg, 600 µmol) in propionitrile (1.6mL)
at −78 ◦C was added triflic acid (11.0 µl, 120µmol). The reaction mixture was stirred at −78 ◦C
for 6 h and then was quenched with satd aq sodium bicarbonate. The mixture was extracted with
ethyl acetate and the combined organic layers were washed with brine, dried and concentrated. The
resulting oil was purified using flash chromatography (SiO2, 10–30% ethyl acetate in hexanes) to
afford the aziridine as a white solid (88mg, 48%). Mp 98–100 ◦C; Rf = 0.29 (20% EtOAc/hexanes);
IR (film) 3062, 1733, 1452 cm−1; 1H NMR (500MHz, CDCl3) δ 7.50 (d, J = 7.9Hz, 2H), 7.48 (d,
J = 8.0Hz, 2H), 7.34–7.29 (m, 4H), 7.27–7.22 (m, 2H), 4.29 (dq, J = 10.8, 7.1Hz, 1H), 4.25 (dq,
J = 10.7, 7.2Hz, 1H), 3.95 (s, 1H), 3.70 (s, 3H), 3.31 (d, J = 6.7Hz, 1H), 2.89 (d, J = 6.7Hz,
1H), 1.31 (t, J = 7.1Hz, 3H); 13C NMR (125MHz, CDCl3) 186.4, 167.1, 160.0, 141.1, 128.6, 128.5,
127.6, 127.3, 127.2, 77.2, 62.6, 52.6, 46.6, 45.9, 13.8 ppm; HRMS (ESI): Exact mass calcd for
C21H21NNaO5 [M+Na]
+ 390.1312, found 390.1311.
H
N CHPh2
N2 N
CHPh2
O O
O
MeO
MeO
O
25 mol % TfOH
CH3CH2CN
–78 °C, 6 hPh Ph
Methyl 1-benzhydryl-3-(2-phenylacetyl)aziridine-2-carboxylate (86). To a solution of the
imine (152mg, 600 µmol) and diazoketone (160mg, 720 µmol) in propionitrile (2.0mL) at −78 ◦C
was added triflic acid (13.0 µl, 150 µmol). The reaction mixture was stirred at −78 ◦C for 6 h and
then was quenched with satd aq sodium bicarbonate. The mixture was extracted with ethyl acetate
and the combined organic layers were washed with brine, dried and concentrated. The resulting oil
was purified using flash chromatography (SiO2, 10% ethyl acetate in hexanes) to afford the aziridine
as a white solid (175mg, 67%). Mp 159–160 ◦C; Rf = 0.36 (20% EtOAc/hexanes); IR (film) 3062,
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1743, 1716 cm−1; 1H NMR (500MHz, CDCl3) δ 7.57 (d, J = 7.5Hz, 2H), 7.52 (d, J = 7.2Hz, 2H),
7.43–7.36 (m, 4H), 7.36–7.22 (m, 5H), 7.05 (d, J = 7.0Hz, 2H), 4.24 (d, J = 17.4Hz, 1H), 3.87 (s,
1H), 3.75 (s, 3H), 3.68 (d, J = 17.3Hz, 1H), 2.81 (d, J = 6.9Hz, 1H), 2.73 (d, J = 6.9Hz, 1H);
13C NMR (125MHz, CDCl3) 203.4, 168.4, 141.7, 141.3, 133.8, 129.7, 128.8, 128.6, 128.3, 128.0,
127.8, 127.5, 126.9, 126.7, 77.3, 52.5, 49.8, 47.2, 45.0 ppm; HRMS (ESI): Exact mass calcd for
C25H23NNaO3 [M+Na]
+ 408.1576, found 408.1565. Anal calcd for C25H23NO3: C, 77.90; H, 6.01;
N, 3.65; found: C, 78.13; H, 6.01; N, 3.65.
H
N CHPh2
O
CH3CH2CN
–78 °C, 6 h
25 mol %, TfOHMeO
O
Br
MeO
O
N
CHPh2
O
Br
N2
Aziridine (87). To a solution of the imine (38.0mg, 150µmol) and diazoketone (45.6mg, 180 µmol)
in propionitrile (0.5mL) at −78 ◦C was added triflic acid (3.5 µl, 150 µmol). The reaction mixture
was stirred at −78 ◦C for 6 h and then was quenched with satd aq sodium bicarbonate. The mixture
was extracted with ethyl acetate and the combined organic layers were washed with brine, dried and
concentrated. The resulting oil was purified using flash chromatography (SiO2, 18% ethyl acetate
in hexanes) to afford the aziridine as a yellow oil (45.0mg, 67%). Rf = 0.25 (10% EtOAc/hexanes);
IR (film) 3062, 3028, 2952, 2848, 1745, 1708, 1636, 1599, 1567, 1494, 1471, 1453 cm−1; 1H NMR
(400MHz, CDCl3) δ 7.53–7.49 (m, 3H), 7.43 (d, J = 7.0Hz, 2H), 7.35–7.15 (m, 8H), 7.06 (dd,
J = 7.8, 1.8Hz, 1H), 3.79 (s, 1H), 3.67 (s, 3H), 3.20–3.12 (m, 1H), 2.92–2.81 (m, 2H), 2.78–2.66
(m, 3H); 13C NMR (100MHz, CDCl3) 205.0, 168.2, 141.6, 141.3, 140.3, 132.6, 130.5, 128.7, 128.6,
127.9, 127.7, 127.6, 127.37, 127.42, 126.8, 124.4, 77.5, 52.4, 49.8, 44.9, 40.5, 29.4 ppm; HRMS (ESI):
Exact mass calcd for C26H24BrNaNO3 [M+Na]
+ 500.0837, found 500.0850.
CH3CH2CN
–78 °C, 6 h
100 mol % TfOH
P(OEt)2
N2
OH
N CHPh2
MeO
O
MeO
O
N
P(OEt)2
CHPh2
O
Methyl 1-benzhydryl-3-(diethoxyphosphoryl)aziridine-2-carboxylate (88).
To a solution of the imine (45.1mg, 178 µmol) and diazophosphonate (38.0mg, 213µmol) in propi-
onitrile (0.6mL) at −78 ◦C was added triflic acid (16µl, 180 µmol). The reaction was slowly warmed
to −20 ◦C, stirred for 18h, and then was quenched with satd aq sodium bicarbonate. The mixture
was extracted with ethyl acetate and the combined organic layers were washed with brine, dried
and concentrated. The resulting oil was purified using flash chromatography (SiO2, 48:50:2 ethyl
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acetate–hexanes–methanol) to afford the aziridine as a white solid (65.8mg, 92%). Mp 110–111 ◦C;
Rf = 0.24 (48:50:2 ethyl acetate–hexanes–methanol); IR (film) 3462, 3062, 3028, 2953, 2929, 1852,
1753, 1637, 1600, 1494, 1477, 1453 cm−1; 1H NMR (400MHz, CDCl3) δ 7.57 (d, J = 7.4Hz, 2H),
7.41 (ddd, J = 8.3, 1.9, 1.5Hz, 2H), 7.33–7.21 (m, 6H), 4.03–3.88 (m, 3H), 3.84–3.74 (m, 1H),
3.77 (s, 3H), 3.69 (s, 1H), 2.64 (dd, J = 7.2, 5.3Hz, 1H), 2.15 (dd, J = 17.0, 7.2Hz, 1H), 1.21
(dd, J = 7.1, 7.0Hz, 3H), 1.12 (dd, J = 7.2, 7.0Hz, 3H); 13C NMR (100MHz, CDCl3) 167.5 (d,
J = 2.8Hz), 141.5, 141.3, 128.43, 128.42, 128.0, 127.7, 127.3, 127.2, 78.8 (d, J = 6.0Hz), 62.7 (d,
J = 6.4Hz), 62.4 (d, J = 5.9Hz), 52.3, 43.3 (d, J = 5.5Hz), 39.9, 37.7, 16.2 (d, J = 7.3Hz),
16.1 (d, J = 7.3Hz) ppm; HRMS (ESI): Exact mass calcd for C21H26NaNO5P [M+Na]
+ 426.1446,
found 426.1436.
H
N CHPh2
N2
N
CHPh2
O
OEt
OEt
O
Ph
O
Ph
O
5 mol % (S)-VAPOL
20 mol % B(OPh)3
5 mol % H2O
toluene, rt, 24 h
(2R,3S)-ethyl 1-benzhydryl-3-benzoylaziridine-2-carboxylate (414). A 25mL flask (Schlenk
with a Teflon valve) containing a stir bar was flame-dried and cooled under argon. To the flask was
added (S)-VANOL (13.5mg, 29µmol) and triphenylborate (29mg, 100 µmol) Under an argon flow,
dry toluene (1.0mL) was added to dissolve the two reagents, and this was followed by the addition
of water (0.5 µL, 25µmol). The Teflon valve was closed and the flask was heated at 80 ◦C for 1h.
The threaded Teflon valve was opened to gradually apply high vacuum (0.1mmHg) to remove the
solvent. The vacuum was maintained for a period of 30min at a temperature of 80 ◦C. The flask
was then filled with argon and the catalyst mixture was allowed to cool to room temperature. To
the flask containing the catalyst was first added aldimine (145mg, 500 µmol) and then dry toluene
(1mL). Ethyl diazoacetate (63µL, 600 µmol) was added via syringe, the Teflon valve was closed,
and the reaction mixture was stirred at room temperature for 24h. The mixture was then diluted
with hexanes (15mL) and transferred to a (100mL) round-bottomed flask. The reaction flask
was rinsed twice with dichloromethane (5mL), and the rinse was added to the round-bottom flask
and the solution was concentrated. Crude aziridine was purified by trituration to give the desired
aziridine as a clear oil (101mg, 53%). The optical purity was determined to be 70% ee by HPLC
analysis (Chiralcel OD-H, 10% iPrOH–hexanes, 0.70mLmin−1, tr(major) = 23.4min, tr(minor)
= 17.1min. Rf = 0.25 (10% EtOAc/hexanes); IR (film) 3462, 3062, 3028, 2953, 2929, 1852, 1753,
1637, 1600, 1494, 1477, 1453 cm−1; 1H NMR (400MHz, CDCl3) δ 7.75 (d, J = 8.1Hz, 2H), 7.59
(d, J = 7.3Hz, 4H), 7.51 (dd, J = 7.5, 7.3Hz, 1H), 7.37–7.27 (m, 8H), 4.12 (q, J = 7.1Hz, 2H),
3.99 (s, 1H), 3.34 (d, J = 6.7Hz, 1H), 2.85 (d, J = 6.9Hz, 1H), 1.12 (t, J = 7.1Hz, 3H); 13C NMR
(100MHz, CDCl3) 192.2, 167.6, 141.6, 141.6, 136.0, 133.2, 129.0, 128.6, 128.5, 128.4, 127.9, 127.7,
127.4, 127.3, 77.9, 61.2, 47.9, 45.0, 13.9 ppm; HRMS (ESI): Exact mass calcd for C25H23NNaO3
[M+Na]+ 408.1576, found 408.1585.
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Compounds relevant to Chapter 2
H
N CHPh2
4 Å MS
0 °C to rt
R
O
H
R
O
OHHO PhCHNH2
CH2Cl2
General procedure for the synthesis of benzhydryl imines. Imines were prepared by
condensation of the corresponding hydrate113 with diphenylmethylamine (1 equiv) using 4Å MS in
dichloromethane at 0 ◦C and warmed to rt. Solution was filtered through Celite and concentrated.
Unless otherwise stated the imine was recrystallized from toluene–petroleum ether.
H
N CHPh2
O
S
(Benzhydrylimino)-1-(thiophen-2-yl)ethanone (131). The hydrate
(1.25 g, 7.90mmol) was treated with diphenylmethylamine (1.36mL, 7.9mmol)
according to the general procedure. The reaction was stirred for 1h and concen-
trated to light yellow oil. Column chromatography (SiO2, 20% ethyl acetate
in hexanes) of the residue provided the title compound as light brown solid
which was recrystallized from hexanes to give brown crystals (0.66 g, 69%).
Mp 71–74 ◦C; Rf = 0.20 (10% EtOAc/hexanes); IR (film) 3085, 3061, 3027, 2867, 1632, 1599 cm−1;
1H NMR (400MHz, CDCl3) δ 8.32 (dd, J = 3.8, 1.0Hz, 1H), 8.07 (s, 1H), 7.77 (dd, J = 5.0, 1.2Hz,
1H), 7.44–7.43 (m, 4H), 7.40–7.35 (m, 4H), 7.31–7.28 (m, 2H), 7.18 (dd, J = 4.8, 4.0Hz, 1H), 5.69
(s, 1H); 13C NMR (100MHz, CDCl3) 182.2, 142.2, 138.5, 136.7, 136.0, 128.7, 128.5, 127.7, 127.5,
78.2 ppm; HRMS (ESI): Exact mass calcd for C19H15NNaOS [M+Na]
+ 328.0772, found 328.0772.
H
N CHPh2
Me3C
O
1-(Benzhydrylimino)-3,3-dimethylbutan-2-one (132). The hydrate
(1.00 g, 7.57mmol) was treated with diphenylmethylamine (1.3mL, 7.6mmol)
according to the general procedure. The reaction was stirred for 1 h and con-
centrated to clear oil (2.09 g, 99%). IR (film) 3298, 3061, 3028, 2968, 2879,
1683 cm−1; 1H NMR (400MHz, CDCl3) δ 7.38 (s, 1H), 7.18 (d, J = 4.4Hz,
8H), 7.30–7.24 (m, 2H), 5.49 (s, 1H) 1.38 (s, 9H); 13C NMR (100MHz, CDCl3)
205.7, 158.8, 142.5, 128.6, 127.3, 78.6, 43.8, 26.7 ppm; HRMS (ESI): Exact mass calcd for C19H21NO
[M+H]+ 280.1705, found 280.1696.
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2-(Benzhydrylimino)-1-cyclopropylethanone (133). The hydrate
(670mg, 5.8mmol) was treated with diphenylmethylamine (1.0mL, 5.8mmol)
according to the general procedure. The reaction was stirred for 1 h and con-
centrated to clear oil and recrystallized from hexanes to give colorless crys-
tals (990mg, 65%). Mp 64–66 ◦C; IR (film) 3085, 3061, 3027, 3007, 2865,
1683 cm−1; 1H NMR (400MHz, CDCl3) δ 7.80 (s, 1H), 7.37–7.27 (m, 10H),
5.66 (s, 1H), 3.14 (dddd, J = 4.8, 4.7, 1.1, 1.0Hz, 1H), 1.20–1.16 (m, 2H), 1.08–1.03 (m, 2H);
13C NMR (100MHz, CDCl3) 201.2, 159.8, 142.1, 128.6, 127.6, 127.4, 77.4, 15.7, 12.6 ppm; HRMS
147
(ESI): Exact mass calcd for C18H18NO [M+H]
+ 264.1388, found 264.1395.
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2-(Benzhydrylimino)-1-cyclopropylethanone (134). The hydrate
(298mg, 1.88mmol) was treated with diphenylmethylamine (325 µL,
1.89mmol) according to the general procedure. The reaction was stirred for
1 h and concentrated to light yellow solid and recrystallized from hexanes to
give colorless crystals (397mg, 65%). Mp 50–51 ◦C; IR (film) 3061, 2930, 2854,
1691 cm−1; 1H NMR (400MHz, CDCl3) δ 7.69 (s, 1H), 7.37–7.27 (m, 10H),
5.60 (s, 1H), 3.49 (br, 1H), 1.88 (m, 2H), 1.82 (m, 2H), 1.44–1.33 (m, 4H), 1.27–1.22 (m, 1H);
13C NMR (100MHz, CDCl3) 204.8, 159.0, 142.2, 128.7, 127.5, 127.5, 77.5, 44.4, 28.5, 25.9, 25.6
ppm; HRMS (ESI): Exact mass calcd for C21H22NO [M-H]
+ 304.1701, found 304.1682.
R H
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Ph EtCN, –78 °C, 1 h R
100 mol% TfOH
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General procedure for the syn-glycolate Mannich reaction. To a cold−78 ◦C solution
of the imine (1.0 equiv) and α-diazo imide (1.2 equiv) in propionitrile (0.15m) was added dry
TfOH (1.0 equiv), and the solution was stirred at −78 ◦C. The reaction was quenched with satd aq
NaHCO3 and extracted with ethyl acetate. The organic layers were dried, concentrated, and the
resulting solid was purified by silica gel flash chromatography.
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syn-Oxazolidine dione 138. Imine (46mg, 150µmol) was treated
with α-diazo imide (44mg, 180 µmol) and dry TfOH (13 µL, 150 µmol)
according to the general procedure and stirred for 1 h. Purified by
flash chromatography (SiO2, 15–25% ethyl acetate in hexanes) to af-
ford the oxazolidine dione as colorless oil (57mg, 80%) . Rf = 0.14 (20%
EtOAc/hexanes); IR (film) 3063, 3027, 2926, 1824, 1750, 1711, 1665,
1597 cm−1; 1H NMR (400MHz, CDCl3) δ 7.89 (dd, J = 5.0, 0.8Hz, 1H),
7.61 (dd, J = 3.8, 0.7Hz, 1H), 7.59–7.54 (m, 2H), 7.54–7.48 (m, 3H), 7.39–7.11 (m, 10H), 7.17 (dd,
J = 4.8, 3.9Hz, 1H), 5.21 (d, J = 2.4Hz, 1H), 4.90 (d, J = 3.8Hz, 1H), 4.71 (dd, J = 11.2, 2.4Hz,
1H), 3.24 (dd, J = 11.2, 3.4Hz, 1H); 13C NMR (100MHz, CDCl3) 188.8, 169.8, 153.8, 142.7, 141.4,
141.1, 135.8, 133.1, 130.8, 129.4, 129.3, 129.0, 129.0, 128.6, 128.6, 128.5, 127.7, 127.6, 127.5, 127.2,
125.7, 125.5, 79.1, 67.6, 65.3, 61.0 ppm; HRMS (CI): Exact mass calcd for C28H23N2O4S [M+H]
+
483.1373, found 483.1368.
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syn-Oxazolidine dione 139. Imine (132mg, 500 µmol) was treated
with α-diazo imide (148mg, 600 µmol) and dry TfOH (44µL, 500 µmol)
according to the general procedure and stirred for 1 h. Purified by flash
chromatography (SiO2, 10–20% ethyl acetate in hexanes) to afford the
148
oxazolidine dione as colorless oil (215mg, 98%) which was recrystallized
from 10% EtOAc in hexanes to give colorless crystals (136.5mg, 62%).
Mp 167–168 ◦C; Rf = 0.23 (20% EtOAc/hexanes); IR (film) 3406, 3027,
2923, 1820, 1748, 1707, 1598 cm−1; 1H NMR (400MHz, CDCl3) δ 7.57–7.49 (m, 2H), 7.49–7.43
(m, 3H), 7.37–7.20 (m, 10H), 5.34 (d, J = 1.6Hz, 1H), 4.86 (d, J = 4.6Hz, 1H), 4.17 (dd,
J = 10.1, 1.7Hz, 1H), 2.99 (dd, J = 10.1, 4.7Hz, 1H), 1.98 (m, 1H), 1.24–1.17 (m, 1H), 1.17–1.09
(m, 1H), 1.07–0.96 (m, 2H); 13C NMR (100MHz, CDCl3) 205.8, 170.1, 154.0, 142.7, 141.7, 130.8,
129.4, 129.0, 128.6, 128.5, 127.5, 127.3, 125.7, 78.5, 65.6, 64.8, 18.8, 12.6, 11.5 ppm; HRMS (ESI):
Exact mass calcd for C27H24N2O4 [M]
+ 440.1736, found 440.1756.
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syn-Oxazolidine dione 140. Imine (46mg, 150 µmol) was treated with
α-diazo imide (44mg, 180 µmol) and dry TfOH (13µL, 150 µmol) ac-
cording to the general procedure and stirred for 1 h. Purified by flash
chromatography (SiO2, 5–15% ethyl acetate in hexanes) to afford the
oxazolidine dione as colorless oil (215mg, 98%) which was recrystallized
from 10% EtOAc in hexanes to give colorless crystals (70.0mg, 97%).
Rf = 0.37 (20% EtOAc/hexanes); IR (film) 2930, 2854, 1820, 1750, 1712,
1598 cm−1; 1H NMR (400MHz, CDCl3) δ 7.56–7.23 (m, 15H), 5.18 (d, J = 2.6Hz, 1H), 4.81 (d,
J = 4.8Hz, 1H), 4.11 (d, J = 10.1Hz, 1H), 3.06 (dd, J = 10.1, 5.7Hz, 1H), 2.52 (m, 1H), 1.85–1.12
(m, 10H); 13C NMR (100MHz, CDCl3) 208.6, 170.2, 153.9, 142.4, 141.8, 130.8, 129.4, 129.0, 128.6,
128.5, 127.5, 127.5, 125.7, 78.0, 65.8, 62.7, 47.5, 28.8, 27.7, 25.5, 25.4, 25.1 ppm; HRMS (ESI):
Exact mass calcd for C30H31N2O4 [M+H]
+ 483.2278, found 483.2228.
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syn-Oxazolidine dione 141. Imine (43mg, 150 µmol) was treated with
α-diazo imide (45mg, 180 µmol) and dry TfOH (13µL, 150 µmol) ac-
cording to the general procedure and stirred for 1 h. Purified by flash
chromatography (SiO2, 15–25% ethyl acetate in hexanes) to afford the
oxazolidine dione as colorless oil (59.5mg, 88%) . Rf = 0.29 (20%
EtOAc/hexanes); IR (film) 3308, 3028, 2967, 1824, 1771, 1708, 1598 cm−1; 1H NMR (500MHz,
CDCl3) δ 7.55–7.21 (m, 15H), 5.11 (d, J = 3.6Hz, 1H), 4.93 (d, J = 5.6Hz, 1H), 4.27 (dd,
J = 9.9, 3.4Hz, 1H), 2.88 (dd, J = 10.0, 5.6Hz, 1H), 1.17 (s, 9H); 13C NMR (125MHz, CDCl3)
211.4, 170.1, 154.3, 142.4, 141.8, 129.3, 129.0, 128.7, 128.6, 127.7, 127.6, 127.6, 127.3, 125.8, 77.1,
66.0, 60.2, 44.0, 26.9 ppm; HRMS (ESI): Exact mass calcd for C28H29N2O4 [M+H]
+ 457.2122,
found 457.2067.
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syn-Oxazolidine dione 162. Imine (24.0mg, 100µmol) was treated
with α-diazo imide (29.7mg, 120 µmol) and dry TfOH (8.8µL, 100 µmol)
according to the general procedure and stirred for 6 h at −20 ◦C. The
resulting oil (3:1 dr, 1H NMR) was purified by flash chromatography
(SiO2, 5–20% ethyl acetate in hexanes) to afford the oxazolidine dione
as colorless oil (30mg, 72%). Chiral HPLC analysis (Chiralcel OD-H,
30% iPrOH–hexanes, 0.70mLmin−1, tr(d1e1) = 11.2min, tr(d1e2) =
11.8min, tr(d2e1) = 28.2min, tr(d2e2) = 41.2min. Major diastereomer : Colorless solid; Mp 213–
214 ◦C; Rf = 0.35 (20% EtOAc/hexanes); IR (film) 3361, 2978, 2933, 1819, 1746, 1598, 1503, 1456,
1407 cm−1; 1H NMR (400MHz, CDCl3) δ 7.46–7.36 (m, 5H), 7.32 (d, J = 8.5Hz, 2H), 7.10 (dd,
J = 8.4, 1.5Hz, 2H), 5.58 (d, J = 8.9Hz, 1H), 5.44 (d, J = 7.0Hz, 1H), 5.17 (d, J = 3.3Hz, 1H),
1.43 (s, 9H); 13C NMR (150MHz, CDCl3) 170.0, 154.5, 153.4, 134.9, 134.0, 130.0, 129.4, 129.2,
129.2, 128.5, 125.4, 81.0, 79.3, 53.4, 28.2 ppm; HRMS (ESI): Exact mass calcd for C21H21ClNaN2O5
[M+Na]+ 439.1037, found 439.1054.
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syn-Oxazolidine dione 415. Imine (103mg, 500 µmol) was treated
with α-diazo imide (98.9mg, 400 µmol) and dry TfOH (36µL, 400 µmol)
according to the general procedure and stirred for 6 h at −20 ◦C. The
resulting oil (2:1 dr, 1H NMR) was purified by flash chromatography
(SiO2, 5–20% ethyl acetate in hexanes) to afford the oxazolidine dione
as colorless oil (78.1mg, 51%). Chiral HPLC analysis (Chiralcel OD-H,
20% iPrOH–hexanes, 0.70mLmin−1, tr(d1e1) = 11.6min, tr(d1e2) =
13.8min, tr(d2e1) = 18.0min, tr(d2e2) = 69.3min. Rf = 0.33 (25% EtOAc/hexanes); IR (film)
3354, 3034, 2977, 2930, 1821, 1746, 1599, 1502, 1455, 1455 cm−1; 1H NMR (600MHz, CDCl3) δ
7.42–7.31 (m, 16H), 7.07 (d, J = 7.4Hz, 2H), 6.77–6.75 (m, 2H), 5.62 (d, J = 8.3Hz, 1H), 5.46–5.44
(m, 3H), 5.35 (br, 1H), 5.19 (d, J = 3.4Hz, 1H), 1.47 (s, 9H), 1.44 (s, 9H); 13C NMR (150MHz,
CDCl3) 170.1, 168.8, 154.7, 153.5, 130.2, 130.0, 129.3, 129.20, 129.23, 129.1, 129.0, 128.9, 128.8,
128.6, 128.5, 128.2, 127.7, 127.1, 125.6, 80.8, 80.7, 79.6, 79.5, 55.8, 54.1, 28.3, 28.2 ppm;
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syn-Oxazolidine dione 416. To an oven-dried vial with stir bar was
added imine (51.1mg, 200 µmol), copper(II) triflate (36.2mg, 100 µmol)
and propionitrile (1.5mL). The solution was cooled to −78 ◦C and so-
lution of α-diazo imide (54.4mg, 220 µmol) in dichloromethane (0.5mL)
was added via cannula and the solution was stirred at −20 ◦C for 6h.
The reaction was then quenched with NH4OH in brine (2:1) and extracted with ethyl acetate. The
organic layers were dried, concentrated, and the resulting oil (1.4:1 dr by 1H NMR) was purified
by flash chromatography (SiO2, 10–25% ethyl acetate in hexanes) to afford (48.1mg, 55%) of the
oxazolidine dione as colorless oil. An analytical sample of the major diastereomer was obtained
by chromatography (SiO2, 10% ethyl acetate in hexanes). Chiral HPLC analysis (Chiralcel AD,
10% iPrOH–hexanes, 1.0mLmin−1, tr(d1e1) = 32.0min, tr(d1e2) = 36.0min, tr(d2e1) = 44.2min,
tr(d2e2) = 53.2min. Rf = 0.31 (25% EtOAc/hexanes); IR (film) 3345, 3060, 2980, 2934, 1823,
1749, 1598, 1503, 1457 cm−1; 1H NMR (600MHz, CDCl3) δ 7.87–7.82 (m, 4H), 7.52–7.50 (m,
2H), 7.44–7.41 (m, 1H), 7.23–7.16 (m, 3H), 6.60–6.57 (m, 2H), 5.56–5.51 (m, 3H), 1.48 (s, 9H);
13C NMR (150MHz, CDCl3) 154.7, 153.6, 133.3, 133.0, 130.7, 129.8, , 129.2, 129.09, 129.12, 128.4,
128.2, 127.6, 127.4, 126.9, 126.8, 125.4, 124.6, 81.0, 80.9, 55.9, 28.3 ppm; HRMS (ESI): Exact mass
calcd for C25H24NaN2O5 [M+Na]
+ 455.1583, found 455.1585.
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syn-Oxazolidine dione 417. To an oven-dried vial with stir bar was
added imine (52.7mg, 200 µmol), copper(II) triflate (36.2mg, 100 µmol)
and propionitrile (1.5mL). The solution was cooled to −78 ◦C and so-
lution of α-diazo imide (54.4mg, 220 µmol) in dichloromethane (0.5mL)
was added via cannula and the solution was stirred at −20 ◦C for 6h.
The reaction was then quenched with NH4OH in brine (2:1) and ex-
tracted with ethyl acetate. The organic layers were dried, concentrated,
and the resulting oil (1.4:1 dr by 1H NMR) was purified by flash chromatography (SiO2, 10–25%
ethyl acetate in hexanes) to afford (48.1mg, 55%) of the oxazolidine dione as colorless oil. An
analytical sample of the major diastereomer was obtained by chromatography (SiO2, 15% ethyl
acetate in hexanes). Chiral HPLC analysis (Chiralcel IA, 10% iPrOH–hexanes, 1.0mLmin−1,
tr(d1e1) = 28.6min, tr(d1e2) = 36.4min, tr(d2e1) = 42.3min, tr(d2e2) = 53.2min. Rf = 0.27 (25%
EtOAc/hexanes); IR (film) 3363, 2979, 2934, 1819, 1754, 1711, 1607, 1598, 1504 cm−1; 1H NMR
(600MHz, CDCl3) δ 7.45–7.39 (m, 3H), 7.27 (d, J = 8.0Hz, 2H), 7.21 (d, J = 8.0Hz, 2H), 7.11
(d, J = 7.7Hz, 2H), 5.55 (d, J = 8.4Hz, 1H), 5.43 (d, J = 7.8Hz, 1H), 5.19 (d, J = 3.3Hz, 1H),
2.37 (s, 9H), 1.45 (s, 9H); 13C NMR (150MHz, CDCl3) 170.2, 170.2, 154.7, 153.6, 138.8, 130.3,
129.6, 129.3, 129.1, 127.0, 125.6, 80.7, 79.6, 53.9, 28.2, 21.1 ppm; HRMS (ESI): Exact mass calcd
for C23H24NaN2O7 [M+Na]
+ 463.1481, found 463.1486.
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MeOH, 3 h
NH2
syn-5-(amino(phenyl)methyl)-3-phenyloxazolidine-2,4-dione (418). To a solution of ox-
azolidine dione (123mg, 123 µmol) in ethanol (1.0mL) and ethyl acetate (1.0mL) was added
Pd(OH)2 (23mg, 12µmol, 20% wt. on carbon). The flask was put under an atmosphere of hydro-
gen and the solution was stirred at ambient temperature for 5 h. The reaction was filtered through
Celite, concentrated, and the resulting solid was purified by chromatography (SiO2, 30% ethyl ac-
etate in hexanes) to afford the amine as a clear oil (24.1mg, 69%). Rf = 0.1 (30% EtOAc/hexanes);
IR (film) 3388, 3062, 1815, 1744, 1598, 1502 cm−1; 1H NMR (600MHz, CDCl3) δ 7.47–7.39 (m,
7H), 7.37–7.34 (m, 1H), 7.30–7.28 (m, 2H), 5.08 (d, J = 2.5Hz, 1H), 4.58 (br, 1H), 2.83 (br, 2H);
13C NMR (150MHz, CDCl3) 170.9, 154.3, 130.7, 129.3, 129.1, 129.0, 128.9, 128.3, 128.1, 127.4,
126.6, 125.7, 125.6, 82.7, 56.0 ppm; HRMS (ESI): Exact mass calcd for C16H12NO3 [M–NH3]
+
266.0817, found 266.0594.
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4-(Benzhydrylamino)-5-hydroxy-1,5-diphenyl-1H -pyrrol-2(5H )-one (150).
To a microwave vial (0.5mL) was added benzyl alcohol (0.5mL), sodium hydroxide (1.0mg,
25µmol) and oxazolidine dione (50.0mg, 105 µmol). The vial was sealed and heated in the mi-
crowave at 150 ◦C for 15min. The reaction mixture was cooled, poured into water, and layers were
separated. The organic layer was dissolved in ethyl acetate, washed with water, dried and concen-
trated to an oil that was purified using flash chromatography (SiO2, 20% ethyl acetate in hexanes)
to afford the amide as a clear oil (133mg, 88%). Rf = 0.21 (25% EtOAc/hexanes); IR (film) 3403,
3199, 3061, 3029, 2924, 2853, 1664, 1533, 1600, 1495 cm−1; 1H NMR (600MHz, CDCl3) δ 7.74 (dd,
J = 8.5, 0.8Hz, 2H), 7.46 (dd, J = 8.5, 1.2Hz, 2H), 7.30–7.19 (m, 11H), 7.03–6.99 (m, 3H), 6.75
(dd, J = 5.8, 2.1Hz, 2H), 6.65 (s, 1H), 4.80 (d, J = 4.6Hz, 1H), 4.60 (d, J = 4.4Hz, 1H), 4.34
(s, 1H); 13C NMR (150MHz, CDCl3) 173.6, 164.9, 140.9, 139.5, 137.2, 137.2, 128.6, 128.4, 128.3,
128.2, 127.9, 127.8, 127.3, 126.6, 125.8, 124.0, 123.3, 91.8, 88.4, 62.3 ppm; HRMS (CI): Exact mass
calcd for C29H24N2O2 [M]
+ 432.1838, found 432.1832.
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4-(Benzhydrylamino)-5-hydroxy-1,5-diphenyl-1H -pyrrol-2(5H )-one (151).
To a solution of oxazolidine dione (123mg, 123 µmol) in methanol 1.0mL was added a saturated
solution of lithium hydroxide in methanol (200 µL). The solution was stirred at rt for 30min,
poured into water, and extracted with ethyl acetate. The combined organic layers were dried and
concentrated to give a yellow oil (1:1 ratio of diastereomers by 1H NMR). The residue was purified
by flash chromatography (SiO2, 10% ethyl acetate in hexanes) to afford the syn-diastereomer as a
clear oil (8.2mg, 35%) and anti diastereomer as a clear oil (7.2mg, 31%).
syn-product: Rf = 0.18 (20% EtOAc/hexanes); IR (film) 3362, 3060, 3026, 2922, 2851, 1663, 1599,
1532, 1493 cm−1; 1H NMR (600MHz, CDCl3) δ 8.55 (br s, 1H), 7.50 (d, J = 7.8Hz, 2H), 7.37–7.33
(m, 6H), 7.30–7.24 (m, 9H), 7.23–7.20 (m, 2H), 7.13 (dd, J = 7.3, 7.3Hz, 1H), 4.74 (s, 1H), 4.26 (d,
J = 4.1Hz, 1H), 4.15 (d, J = 4.1Hz, 1H), amine N–H and alcohol O–H not observed; 13C NMR
(150MHz, CDCl3) 169.9, 143.2, 142.3, 140.0, 137.0, 128.6, 128.4, 128.3, 128.2, 127.9, 127.8, 127.3,
124.8, 119.7, 74.4, 63.9, 61.8 ppm; HRMS (ESI): Exact mass calcd for C28H26NaN2O2 [M+Na]
+
445.1892, found 445.1904.
anti-product: Rf = 0.15 (20% EtOAc/hexanes); IR (film) 3366, 3060, 3027, 2922, 2851, 1665, 1599,
1531, 1493 cm−1; 1H NMR (600MHz, CDCl3) δ 8.73 (br s, 1H), 7.39–7.22 (m, 19H), 7.13–7.09 (m,
1H), 4.80 (s, 1H), 4.40 (d, J = 6.3Hz, 1H), 4.08 (d, J = 6.7Hz, 1H), 3.74 (br s, 1H), amine N–H
not observed; 13C NMR (150MHz, CDCl3) 169.6, 143.2, 142.1, 138.1, 136.9, 128.9, 128.8, 128.7,
128.6, 128.2, 128.0, 127.7, 127.5, 127.3, 127.1, 124.5, 120.1, 73.3, 63.8, 62.6 ppm; HRMS (ESI):
Exact mass calcd for C28H26NaN2O2 [M+Na]
+ 445.1892, found 445.1870.
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syn-Methyl 2-amino(2,4-dioxo-3-phenyloxazolidin-5-yl)acetate (156). To a solution of ox-
azolidine dione (20.0mg, 46.0 µmol), in methanol (0.5mL) was added titanium(IV) tetraisopropox-
ide (26µL, 92µmol). The solution was stirred at room temperature for 4 h, poured into water and
extracted with ethyl acetate. The combined organic layers were dried and concentrated to give a
yellow residue which was purified using flash chromatography (SiO2, 20% ethyl acetate in hexanes)
affording the title compound as a clear oil (3.4mg, 16%). Rf = 0.35 (20% EtOAc/hexanes); IR
(film) 3343, 3061, 3028, 2953, 2924, 2852, 1745, 1602, 1537, 1501 cm−1; 1H NMR (600MHz, CDCl3)
δ 7.32 (d, J = 7.2Hz, 2H), 7.28 (d, J = 7.2Hz, 2H), 7.27 (d, J = 7.2Hz, 2H), 7.24–7.20 (m, 6H),
7.18–7.12 (m, 2H), 6.99 (dd, J = 7.65, 7.20Hz, 1H), 6.78 (br s, 1H), 5.45 (d, J = 2.5Hz, 1H), 4.83
(s, 1H), 3.78 (d, J = 2.6Hz, 1H), 3.72 (s, 3H), 3.70 (s, 3H), 2.50 (br s, 1H); 13C NMR (150MHz,
CDCl3) 171.5, 167.9, 151.6, 143.7, 141.8, 137.1, 129.0, 128.6, 128.4, 127.8, 127.6, 127.3, 127.2, 123.9,
118.6, 73.7, 65.1, 59.2, 52.6, 52.4 ppm; HRMS (ESI): Exact mass calcd for C26H27N2O6 [M+H]
+
463.1869, found 463.1869.
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syn-Aminoalcohol (157). Oxazolidine dione (100mg, 232 µmol) was suspended in methanol
(2.0mL) and Pd(OH)2 (33mg, 23µmol, 20% wt. on carbon) was added in one portion. The flask
was put under an atmosphere of hydrogen and the solution was stirred at ambient temperature
for 3d. It was then filtered through Celite and concentrated. The residue was dissolved in ethyl
acetate, washed with satd NH4Cl, dried, and concentrated. The residue was purified using flash
chromatography (SiO2, 50% ethyl acetate in hexanes) to afford amido alcohol (30.9mg, 45%) as
colorless solid. Mp 146–148 ◦C; Rf = 0.14 (50% EtOAc/hexanes); IR (film) 3341, 2955, 2924, 2851,
1723, 1600, 1537 cm−1; 1H NMR (600MHz, CDCl3) δ 8.66 (s, 1H), 7.53 (d, J = 8.4Hz, 2H), 7.32
(dd, J = 8.4, 7.2Hz, 2H), 7.13 (dd, J = 7.6, 7.2Hz, 1H), 5.87 (d, J = 8.0Hz, 1H), 4.99 (br, 1H),
4.89 (dd, J = 9.4, 2.6Hz, 1H), 4.72 (dd, J = 6.6, 2.6Hz, 1H), 3.77 (s, 3H), 3.66 (s, 3H); 13C NMR
(150MHz, CDCl3) 170.9, 169.0, 157.7, 136.8, 129.0, 124.9, 120.0, 72.7, 56.5, 53.0, 52.9 ppm; HRMS
(ESI): Exact mass calcd for C13H16N2NaO6 [M+Na]
+ 319.0901, found 319.0895.
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Aziridine 203 and vinylogous amide 204. Copper(I) triflate (2:1 complex with toluene, 8.0mg,
15µmol) was dissolved in dichloromethane (1.7mL) and stirred at room temperature for 15min.
The clear yellow catalyst solution was cooled to −78 ◦C, and a solution of the imine (76.0mg,
300 µmol)in CH2Cl2 (300µL) was added via cannula, followed by a solution of diazoimide (1.0m
in dichloromethane, 330µL, 330 µmol) via syringe. The solution was stirred at −78 ◦C for 1h,
warmed to −20 ◦C, and then stirred for 18h. A satd solution of NaHCO3 (1.0mL) was added
and stirring continued for 30min at rt. The layers were separated, and the aqueous layer was
extracted with dichloromethane. The combined organic layers were washed with 1.0m NH4OH and
brine, dried with MgSO4, and concentrated to an oil that was purified using flash chromatography
(SiO2, 20% ethyl acetate in hexanes) affording aziridine as colorless solid (68.7mg, 49%). A second
chromatography (SiO2, 30% ethyl acetate in hexanes) afforded the vinylogous amide as colorless
solid (20.3mg, 22%).
Aziridine: Mp 158–160 ◦C; Rf = 0.39 (25% EtOAc/hexanes); IR (film) 3063, 3029, 2984, 2952, 1747,
1597, 1492 cm−1; 1H NMR (600MHz, CDCl3) δ 7.66 (d, J = 7.6Hz, 2H), 7.47 (d, J = 7.0Hz, 2H),
7.40 (d, J = 7.2Hz, 1H), 7.39 (d, J = 7.6Hz, 1H), 7.35 (d, J = 7.2Hz, 1H), 7.33 (d, J = 2.7Hz,
1H), 7.32 (d, J = 3.0Hz, 2H), 7.30 (d, J = 3.2Hz, 1H), 7.25 (dd, J = 8.4, 7.4Hz, 1H), 7.22 (dd,
J = 7.6, 7.4Hz, 1H), 7.12 (dd, J = 7.5, 1.5Hz, 2H), 4.92 (dq, J = 6.3, 6.2Hz, 1H), 4.11 (s, 1H),
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3.73 (s, 3H), 3.51 (d, J = 6.7Hz, 1H), 2.83 (d, J = 6.7Hz, 1H), 1.14 (d, J = 6.2Hz, 3H), 1.13 (d,
J = 6.2Hz, 3H); 13C NMR (150MHz, CDCl3) 168.7, 168.2, 153.4, 141.7, 141.6, 137.3, 128.8, 128.4,
128.3, 128.2, 128.0, 127.7, 127.5, 127.4, 127.2, 76.7, 71.3, 52.4, 48.3, 43.9, 21.4, 21.3 ppm; HRMS
(ESI): Exact mass calcd for C28H28NaN2O5 [M+Na]
+ 495.1890, found 495.1888. Anal calcd for
C28H28N2O5: C, 71.16; H, 5.98; N, 5.93; found: C, 70.90; H, 5.92; N, 5.91.
Vinylogous amide: Mp 174.0–176.5 ◦C; Rf = 0.22 (25% EtOAc/hexanes); IR (film) 3317, 3062,
3029, 2981, 2932, 1731, 1681, 1600, 1546, 1497 cm−1; 1H NMR (600MHz, CDCl3) δ 9.38 (br,
1H), 7.67 (d, J = 7.6Hz, 2H), 7.42 (d, J = 7.5Hz, 1H), 7.41 (d, J = 7.7Hz, 1H), 7.27–7.26 (m,
4H), 7.21 (ddd, J = 7.5, 2.1, 2.1Hz, 1H), 7.19–7.06 (m, 6H), 6.94 (s, 1H), 6.06 (br, 1H), 4.97–4.88
(m, 1H), 3.64 (s, 3H), 1.09–0.81 (m, 6H); 13C NMR (150MHz, CDCl3) 164.6, 162.1, 137.4, 134.2,
129.2, 128.3, 127.4, 124.8, 119.8, 71.0, 67.9, 52.7, 21.5 ppm; HRMS (ESI): Exact mass calcd for
C28H28NaN2O5 [M+Na]
+ 495.1890, found 495.1887.
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Aziridine 215. A suspension of tetrakis(acetonitrile) copper(I) perchlorate (6.5mg, 20 µmol) and
imine (61.2mg, 200µmol) in dichloromethane (1.0mL) was stirred at rt for 1h until no solid was
observed. The reaction was then cooled to 0 ◦C, treated with diazo imide (60.0mg, 243 µmol) in
dichloromethane (1.0mL) slowly via syringe, and stirred at 0 ◦C for 2h. A solution of NH4OH–NaCl
2:1 (2mL) was then added, and the solution was vigorously stirred for 5min. The layers were sep-
arated and the aqueous layer was extracted with dichloromethane. The combined organic extracts
were dried, concentrated, and purified using flash chromatography (SiO2, 10–25% ethyl acetate in
hexanes) to afford the aziridine as a yellow oil (39.8mg, 25%). Rf = 0.46 (25% EtOAc/hexanes);
IR (film) 3063, 3028, 2982, 2924, 2852, 1737, 1597, 1591 cm−1; 1H NMR (400MHz, CDCl3) δ 7.75
(d, J = 7.4Hz, 2H), 7.50 (d, J = 7.4Hz, 2H), 7.42 (d, J = 8.3Hz, 2H), 7.36 (d, J = 7.4Hz, 1H),
7.34 (d, J = 7.7Hz, 1H), 7.31–7.24 (m, 8H), 7.21–7.17 (m, 1H), 6.51–6.49 (m, 2H), 4.92 (septet,
J = 6.4Hz, 1H), 4.13 (s, 1H), 3.68 (d, J = 7.0Hz, 1H), 3.33 (d, J = 7.0Hz, 1H), 1.12 (dd=,
J = 5.8Hz, 3H), 1.11 (dd=, J = 5.8Hz, 3H); 13C NMR (100MHz, CDCl3) 168.4, 153.2, 142.8,
142.5, 137.2, 134.3, 133.1, 128.8, 128.8, 128.4, 128.1, 127.9, 127.9, 127.4, 127.4, 127.3, 127.1, 77.2,
71.1, 52.0, 47.0, 21.46, 21.37 ppm; HRMS (ESI): Exact mass calcd for C32H29ClNaN2O3 [M+Na]
+
547.1759, found 547.1746.
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E-Alkene 216 and Z-Alkene 217. To a suspension of tetrakis(acetonitrile) copper(I) perchlo-
rate (6.5mg, 20µmol) in dichloromethane (1.0mL) was added a solution of diazo imide (49.5mg,
200 µmol) in dichloromethane (1.0mL) via syringe over a 10min period. The reaction was stirred at
0 ◦C, and once gas evolution ceased (ca. 1h), the reaction mixture was concentrated. The resulting
oil was purified using flash chromatography (SiO2, 10–20% ethyl acetate in hexanes) to afford the
(Z )-olefin as a clear oil (9.2mg, 21%). A second chromatography (SiO2, 25% ethyl acetate in
hexanes) afforded the (E)-olefin as colorless crystals (10.9mg, 25%).
(Z)-Alkene: Rf = 0.30 (25% EtOAc/hexanes); IR (film) 3064, 2963, 2926, 2854, 1738, 1732, 1698,
1694, 1682, 1596 cm−1; 1H NMR (600MHz, CDCl3) δ 7.40–7.34 (m, 3H), 7.20–7.19 (m, 2H), 6.83
(s, 1H), 4.98 (septet, J = 6.2Hz, 1H), 1.16 (d, J = 6.2Hz, 6H); 13C NMR (150MHz, CDCl3)
168.0, 153.4, 137.4, 130.6, 129.0, 128.4, 128.2, 71.5, 21.5 ppm; HRMS (ESI): Exact mass calcd for
C24H26NaN2O6 [M+Na]
+ 461.1683, found 461.1673.
(E)-Alkene: Mp 211–213 ◦C; Rf = 0.34 (25% EtOAc/hexanes); IR (film) 2983, 2920, 2850, 1732,
1685, 1492 cm−1; 1H NMR (600MHz, CDCl3) δ 7.68 (s, 1H), 7.42 (dd, J = 7.8, 7.2Hz, 2H), 7.37
(ddd, J = 7.7, 1.5, 1.3Hz, 1H), 7.14 (d, J = 7.6Hz, 2H), 5.03 (septet, J = 6.3Hz, 1H), 1.20 (d,
J = 6.4Hz, 6H); 13C NMR (150MHz, CDCl3) 166.9, 153.3, 137.6, 134.2, 129.1, 128.3, 128.1, 71.9,
21.5 ppm; HRMS (ESI): Exact mass calcd for C24H26NaN2O6 [M+Na]
+ 461.1683, found 461.1678.
Anal calcd for C24H26N2O6: C, 65.73; H, 5.98; N, 6.39. Found: C, 65.63; H, 5.93; N, 6.35.
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N -Boc oxazolidinone 218 and oxazolidinone 219. A solution of the imine (28.0mg, 120 µmol)
and tetrakis(acetonitrile) copper(I) perchlorate (5.0mg, 18µmol) in dichloromethane (700 µL) was
stirred at rt for 10min. The resulting yellow solution was cooled to −78 ◦C, a solution of α-diazo
imide (37.1mg, 150 µmol) in dichloromethane (300µL) was added via cannula, and the solution
was slowly warmed to −20 ◦C and stirred for 6 h. The reaction mixture was filtered through a
pad of silica gel (5 g), eluted with ethyl acetate, and concentrated prior to flash chromatography
(SiO2, 25% ethyl acetate in hexanes) to afford the N -Boc oxazolidinone 419 as a white solid
(25.0mg, 50%). A second chromatography (SiO2, 25–50% ethyl acetate in hexanes) afforded N−H
oxazolidinone as a white solid, (11.0mg, 23%).
N -Boc oxazolidinone 218: Mp 166–168 ◦C; Rf = 0.35 (25% EtOAc/hexanes); IR (film) 3328,
2981, 2933, 1822, 1749, 1691, 1600, 1543, 1493 cm−1; 1H NMR (400MHz, CDCl3) δ 8.45 (s, 1H),
7.64 (dd, J = 1.9, 1.0Hz, 1H), 7.61 (dd, J = 2.1, 1.1Hz, 1H), 7.42–7.30 (m, 6H), 7.18 (ddd,
J = 7.4, 7.4, 1.1, 1.0Hz, 1H), 5.50 (d, J = 4.4Hz, 1H), 4.67 (d, J = 4.4Hz, 1H), 1.30 (s, 9H);
13C NMR (100MHz, CDCl3) 165.4, 150.6, 147.8, 129.4, 129.1, 127.1, 125.5, 120.3, 85.0, 77.4, 61.3,
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27.6 ppm; HRMS (ESI): Exact mass calcd for C21H21ClNaN2O5 [M+Na]
+ 439.1037, found 0.0000.
N -H oxazolidinone 219: Mp 183–184 ◦C; Rf = 0.05 (25% EtOAc/hexanes); IR (film) 3312, 2984,
2934, 1769, 1736, 1596, 1493 cm−1; 1H NMR (600MHz, CDCl3) δ 7.44–7.37 (m, 7H), 7.13–7.11 (m,
2H), 5.89 (br, 1H), 5.76 (d, J = 4.0Hz, 1H), 5.14 (dd, J = 4.0, 0.9Hz, 1H), 4.95 (sept, J = 6.3Hz,
1H), 1.14 (d, J = 6.0Hz, 3H), 1.13 (d, J = 6.0Hz, 3H); 13C NMR (150MHz, CDCl3) 170.1, 157.9,
153.1, 137.7, 136.8, 134.8, 129.2, 128.6, 128.0, 127.9, 81.6, 72.5, 58.3, 21.5, 21.3 ppm; HRMS (ESI):
Exact mass calcd for C20H19ClNaN2O5 [M+Na]
+ 425.0880, found 425.0880.
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Oxazolidinone 223. A solution of [Cu(CH3CN)4]ClO4 (6.5mg, 20µmol) and the imine (48.0mg,
200 µmol) in dichloromethane (1.5mL) was stirred at rt for 1 h. The resulting yellow solution was
cooled to 0 ◦C, a solution of α-diazo imide (62.0mg, 250µmol) in dichloromethane (500µL) was
added via cannula, and the solution was slowly warmed to 0 ◦C and stirred for 1 h. This mixture
was treated with triflic acid (18 µL, 200µmol) via syringe in one portion, and the reaction was
warmed to rt and stirred for 1 h prior to quenching with NH4OH–brine (2:1). The aqueous layer
was extracted with dichloromethane and the combined organic extracts were dried, concentrated,
and purified using flash chromatography (SiO2, 10–30% ethyl acetate in hexanes) to afford the
product as a white solid (33.2mg, 52%). Mp 224–225 ◦C; Rf = 0.10 (25% EtOAc/hexanes); IR
(film) 3319, 1770, 1682, 1600, 1543, 1492 cm−1; 1H NMR (400MHz, DMSO-d6) δ 10.3 (br, 1H),
8.56 (br, 1H), 7.60 (d, J = 8.0Hz, 2H), 7.48 (d, J = 8.3Hz, 2H), 7.40 (d, J = 8.5Hz, 2H), 7.34
(d, J = 7.7Hz, 1H), 7.32 (d, J = 7.8Hz, 1H), 7.11 (dd, J = 7.1, 5.0Hz, 1H), 4.98 (d, J = 5.0Hz,
1H), 4.80 (d, J = 5.3Hz, 1H); 13C NMR (100MHz, CDCl3) 168.1, 159.1, 140.7, 139.4, 134.7, 130.5,
130.5, 130.0, 126.2, 121.9, 82.1, 59.6 ppm; HRMS (ESI): Exact mass calcd for C15H13ClNaN2O
[M+Na]+ 339.0512, found 339.0493.
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Oxazolidinone 236. A solution of tetrakis(acetonitrile) copper(I) perchlorate and the imine
(54.7mg, 200 µmol) in CH2Cl2 (1.5mL) was stirred at rt for 1h. The resulting yellow solution was
cooled to 0 ◦C, a solution of α-diazo imide (62.0mg, 250µmol) in dichloromethane (500µL) was
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added via cannula, and the solution was slowly warmed to 0 ◦C and stirred for 1 h. This mixture
was treated with triflic acid (18.0µL, 200 µmol) via syringe in one portion, and the reaction was
warmed to rt and stirred for 1 h prior to quenching with NH4OH–brine (2:1). The aqueous layer
was extracted with dichloromethane and the combined organic extracts were dried, concentrated,
and purified using flash chromatography (SiO2, 10–30% ethyl acetate in hexanes) to afford the
product as a colorless solid (43.9mg, 49%). Mp 224–225 ◦C; Rf = 0.11 (25% EtOAc/hexanes);
IR (film) 3329, 3063, 1825, 1748, 1690, 1600, 1543, 1494 cm−1; 1H NMR (400MHz, DMSO-d6) δ
8.23 (s, 1H), 7.58 (d, J = 7.6Hz, 2H), 7.42–7.24 (m, 9H), 7.19 (dd, J = 7.6, 7.5Hz, 1H), 7.09 (dd,
J = 7.6, 1.5Hz, 2H), 5.58 (d, J = 4.2Hz, 1H), 5.21 (d, J = 12.1Hz, 1H), 5.06 (d, J = 12.0Hz,
1H), 4.71 (d, J = 4.0Hz, 1H); 13C NMR (100MHz, CDCl3) 165.0, 150.1, 149.4, 136.9, 136.1,
135.0, 133.9, 129.6, 129.4, 129.3, 129.2, 128.7, 128.6, 128.5, 128.3, 127.2, 125.6, 125.5, 120.3, 77.7,
69.2, 61.0 ppm; HRMS (ESI): Exact mass calcd for C23H19ClNaN2O3 [M+Na]
+ 473.0880, found
473.0883.
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Oxazolidinone 420. A solution of [Cu(CH3CN)4]ClO4 (4.8mg, 15µmol) and the imine (24.7mg,
100 µmol) in toluene (0.7mL) was stirred at rt for 10min. The resulting yellow solution was
cooled to −78 ◦C, a solution of α-diazo imide (30.9mg, 125 µmol) in toluene 300 µL was added via
cannula, and the solution was slowly warmed to −20 ◦C and stirred for 6 h. The reaction mixture
was filtered through a pad of silica gel (5 g), eluted with ethyl acetate, and concentrated prior to
flash chromatography (SiO2, 25% ethyl acetate in hexanes) to afford the amide as a white solid
(17.0mg, 41%). Mp 164–166 ◦C; Rf = 0.15 (25% EtOAc/hexanes); IR (film) 3322, 2980, 2935, 1821,
1731, 1689, 1602, 1546, 1515, 1500, 1494 cm−1; 1H NMR (600MHz, CDCl3) δ 8.58 (s, 1H), 7.67 (d,
J = 7.7Hz, 2H), 7.37 (d, J = 7.7Hz, 1H), 7.35 (d, J = 8.0Hz, 1H), 7.31 (dd, J = 3.0, 2.1Hz, 1H),
7.29 (dd, J = 2.7, 2.1Hz, 1H), 7.18 (dd, J = 7.5, 7.4Hz, 1H), 6.95 (dd, J = 2.8, 2.3Hz, 1H), 6.93
(dd, J = 2.7, 2.2Hz, 1H), 5.47 (d, J = 4.4Hz, 1H), 4.72 (d, J = 4.4Hz, 1H), 3.83 (s, 3H), 1.30 (s,
9H); 13C NMR (100MHz, CDCl3) 165.7, 159.8, 151.0, 148.0, 136.5, 131.1, 128.9, 127.0, 125.2, 120.4,
114.4, 84.4, 77.9, 61.6, 55.3, 27.5 ppm; HRMS (ESI): Exact mass calcd for C22H28N3O6 [M+Na]
+
430.1978, found 430.1985. Anal calcd for C22H24N2O6: C, 64.05; H, 5.87; N, 6.79. Found: C, 63.77;
H, 5.79; N, 6.77.
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Oxazolidine dione 230. A solution of the imine (59mg, 200µmol) and tetrakis(acetonitrile) cop-
per(I) perchlorate (6.5mg, 20µmol) in CH2Cl2 (1.5mL) was stirred at rt for 1h. The resulting yel-
low solution was cooled to 0 ◦C, a solution of α-diazo imide (60.0mg, 240 µmol) in dichloromethane
(500µL) was added via automated syringe pump over 1 h, and the resulting yellow solution was
treated with triflic acid (18.0 µL, 200 µmol) via syringe in one portion, and the reaction was warmed
to rt and stirred for 1 h prior to quenching with NH4OH–brine (2:1). prior to quenching with
NH4OH–brine (2:1). The aqueous layer was extracted with dichloromethane and the combined
organic extracts were dried, concentrated, and purified using flash chromatography (SiO2, 25%
ethyl acetate in hexanes) to afford the sulfonamide as a yellow solid (78.2mg, 83%, 1:1 dr by
1H NMR). The analytical samples for both diastereomers were obtained by flash chromatography
(SiO2, 10–25% ethyl acetate in hexanes).
Diastereomer 1 : Yellow solid; Mp 195–200 ◦C; Rf = 0.22 (25% EtOAc/hexanes); IR (film) 3271,
3068, 2963, 1819, 1748, 1598, 1504, 1494 cm−1; 1H NMR (600MHz, CDCl3) δ 7.55 (d, J = 8.3Hz,
2H), 7.41–7.39 (m, 3H), 7.15 (dd, J = 8.5, 1.6Hz, 2H), 7.12 (d, J = 3.4Hz, 1H), 7.11 (d, J = 2.3Hz,
1H), 7.09 (m, 1H), 7.08 (m, 2H), 7.06 (s, 1H), 6.03 (br, 1H), 5.11 (d, J = 2.8Hz, 1H), 5.06 (d,
J = 2.8Hz, 1H), 2.33 (s, 3H); 13C NMR (150MHz, CDCl3) 169.4, 153.5, 143.9, 136.8, 134.9, 133.1,
130.1, 129.5, 129.3, 129.2, 129.0, 128.5, 127.0, 125.6, 80.3, 56.3, 21.4 ppm; HRMS (ESI): Exact
mass calcd for C23H20ClN2O5S [M+H]
+ 471.0776, found 471.0774.
Diastereomer 2 : Yellow solid; Mp 177–178 ◦C; Rf = 0.17 (25% EtOAc/hexanes); IR (film) 3271,
3068, 2963, 1819, 1748, 1598, 1504, 1494 cm−1; 1H NMR (600MHz, CDCl3) δ 7.58 (d, J = 8.3Hz,
2H), 7.36–7.34 (m, 3H), 7.18–7.17 (m, 1H), 7.16 (dd, J = 2.3, 2.0Hz, 1H), 7.14 (d, J = 8.0Hz,
2H), 7.06 (dd, J = 2.5, 1.7Hz, 1H), 7.05 (dd, J = 2.5, 1.7Hz, 1H), 6.79–6.78 (m, 2H), 5.82 (br,
1H), 5.36 (d, J = 2.9Hz, 1H), 5.04 (d, J = 2.7Hz, 1H), 2.36 (s, 3H); 13C NMR (150MHz, CDCl3)
168.2, 153.1, 144.1, 136.6, 135.4, 130.6, 129.8, 129.7, 129.4, 129.4, 129.3, 129.1, 129.0, 127.0, 125.4,
81.3, 57.4, 21.4 ppm; HRMS (ESI): Exact mass calcd for C23H20ClN2O5S [M+H]
+ 471.0776, found
471.0774.
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Oxazolidine dione 232. A suspension of the imine (64.7mg, 200 µmol) and tetrakis(acetonitrile)
copper(I) perchlorate (6.5mg, 20µmol) in CH2Cl2 (1.5mL) was stirred at rt for 1h. The re-
sulting yellow solution was cooled to 0 ◦C, a solution of α-diazo imide (61.8mg, 250 µmol) in
dichloromethane (500 µL) was added via automated syringe pump over 1 h, and the resulting yellow
solution was treated with triflic acid (18µL, 200µmol) via syringe in one portion, and the reac-
tion was warmed to rt and stirred for 30min prior to quenching with NH4OH–brine (2:1). The
aqueous layer was extracted with dichloromethane and the combined organic extracts were dried,
concentrated, and purified using flash chromatography (SiO2, 25% ethyl acetate in chloroform)
to afford the sulfonamide as a yellow solid (42.0mg, 42%, 1.0:0.8 dr by 1H NMR). Data for both
diastereomers: Mp 182–188 ◦C; Rf = 0.38 (25% EtOAc/hexanes); IR (film) 3429, 2963, 2872, 1818,
1749, 1599, 1503, 1458 cm−1; 1H NMR (600MHz, CDCl3) δ 7.74 (d, J = 1.8Hz, 2H), 7.70 (d,
J = 1.8Hz, 2H), 7.64 (dd, J = 1.7, 1.7Hz, 1H), 7.63 (dd, j = 1.7, 1.7Hz, 1H), 7.48–7.39 (m, 6H),
7.35–7.33 (m, 2H), 7.22–7.21 (m, 2H), 5.03 (d, J = 2.4Hz, 1H), 4.94 (d, J = 9.8Hz, 1H), 4.84
(d, J = 2.0Hz, 1H), 4.84 (d, J = 8.3Hz, 1H), 4.04–3.99 (m, 1H), 3.87–3.83 (m, 1H), 1.61–1.53
(m, 2H), 1.46–1.40 (m, 2H), 1.40–1.22 (m, 38H) 1.20–1.13 (m, 1H), 1.09–1.00 (m, 1H), 0.75 (dd,
J = 7.3, 7.3Hz, 3H), 0.68 (dd, J = 7.3, 7.3Hz, 3H); 13C NMR (150MHz, CDCl3) 169.7, 169.3,
154.1, 153.5, 152.5, 152.4, 139.6, 139.0, 130.4, 129.4, 129.3, 129.1, 129.0, 127.3, 127.1, 125.8, 125.5,
121.3, 121.2, 81.3, 79.7, 54.0, 53.5, 35.2, 35.2, 31.2, 18.7, 18.5, 13.3, 13.1 ppm; HRMS (ESI): Exact
mass calcd for C27H40N3O5S [M+NH4]
+ 518.2689, found 518.2535.
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Oxazolidine dione 421. A suspension of the imine (45.5mg, 143 µmol) and tetrakis(acetonitrile)
copper(I) perchlorate (7.4mg, 22µmol) in CH2Cl2 (0.7mL) was stirred at rt for 1h. The re-
sulting yellow solution was cooled to 0 ◦C and a solution of α-diazo imide (44.5mg, 180µmol) in
dichloromethane (300µL) was added via automated syringe pump over 15min. The resulting yellow
solution was treated with triflic acid (13.0µL, 150 µmol) via syringe in one portion and the reaction
was warmed to rt, stirred for 30min, and concentrated. The resulting oil was purified using flash
chromatography (SiO2, 5–10% ethyl acetate in chloroform) to afford the sulfonamide as a clear oil
(52.5mg, 75%, 2.3:1 dr by 1H NMR). Major diastereomer : Rf = 0.09 (25% EtOAc/hexanes); IR
(film) 3282, 3066, 2955, 1821, 1754, 1598 cm−1; 1H NMR (400MHz, CDCl3) δ 7.47–7.36 (m, 5H),
7.30–7.20 (m, 5H), 7.18–7.13 (m, 2H), 7.10–7.06 (m, 2H), 6.23 (s, 1H), 6.15 (s, 1H), 3.66 (s, 3H),
2.36 (s, 3H); 13C NMR (100MHz, CDCl3) 168.6, 168.4, 152.9, 143.3, 137.8, 131.2, 130.4, 129.3,
129.3, 129.3, 129.16, 129.19, 129.1, 128.3, 128.1, 127.0, 125.6, 78.7, 68.5, 53.9, 21.4 ppm; HRMS
(ESI): Exact mass calcd for C25H22NaN2O7S [M+Na]
+ 517.1045, found 517.1046.
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Oxazoline 236 and aziridine 237. A suspension of the tetrakis(acetonitrile) copper(I) per-
chlorate (7.4mg, 22 µmol) in dichloromethane (2.0mL) was cooled to 0 ◦C and the imine (53µL,
250 µmol was added via syringe. The solution was stirred for 15min at 0 ◦C and a solution of α-diazo
imide (74.2mg, 300 µmol) in dichloromethane (500 µL) was added via syringe and the reaction was
stirred at 0 ◦C for 1 h. The reaction mixture was filtered through a pad of silica gel (10mL), eluted
with ethyl acetate, and concentrated prior to flash chromatography (SiO2, 10% ethyl acetate in
hexanes) to afford oxazoline as a clear oil that solidified on standing (39.0mg, 44%). A second
flash chromatography (SiO2, 25% ethyl acetate in hexanes) afforded cis-aziridine as a yellow solid
(37.0mg, 39%).
Oxazoline 236: Mp 108–109 ◦C; Rf = 0.55 (25% EtOAc/hexanes); IR (film) 3396, 3315, 3061,
2983, 1673, 1601, 1537, 1492 cm−1; 1H NMR (600MHz, CDCl3) δ 8.08 (s, 1H), 7.60 (d, J = 7.5Hz,
2H), 7.42 (d, J = 8.5Hz, 2H), 7.38–7.34 (m, 4H), 7.18 (dd, J = 7.6, 7.5Hz, 1H), 5.34 (d, J = 6.4Hz,
1H), 5.09 (sept, J = 6.3Hz, 1H), 4.74 (d, J = 6.4Hz, 1H), 1.49 (d, J = 6.2Hz, 3H), 1.45 (d,
J = 6.3Hz, 3H); 13C NMR (150MHz, CDCl3) 167.6, 160.2, 140.7, 136.5, 133.6, 129.2, 128.8, 127.7,
125.2, 120.1, 84.0, 76.4, 70.6, 21.8, 21.7 ppm; HRMS (ESI): Exact mass calcd for C19H19ClNaN2O3
[M+Na]+ 381.0976, found 381.0980.
Aziridine 237: Mp 144–145 ◦C; Rf = 0.55 (25%EtOAc/hexanes); IR (film) 3316, 3061, 2983, 2937,
1728, 1686, 1599, 1532, 1496 cm−1; 1H NMR (400MHz, CDCl3) δ 7.71 (s, 1H), 7.36 (d, J = 8.8Hz,
2H), 7.28 (dd, J = 2.3, 2.0Hz, 1H), 7.26 (dd, J = 2.5, 1.9Hz, 1H), 7.23 (m, 1H), 7.23–7.19 (m, 3H),
7.07 (ddd, J = 7.0, 1.6, 1.6Hz, 1H), 5.03 (sept, J = 6.2Hz, 1H), 3.94 (d, J = 7.0Hz, 1H), 3.54 (d,
J = 7.1Hz, 1H), 1.34 (d, J = 6.3Hz, 3H), 1.34 (d, J = 6.2Hz, 3H); 13C NMR (100MHz, CDCl3)
163.3, 160.8, 136.0, 134.4, 131.3, 129..0, 128.9, 128.8, 128.7, 124.9, 120.2, 77.2, 71.8, 44.4, 44.3, 21.7
ppm; HRMS (ESI): Exact mass calcd for C19H19ClNaN2O3 [M+Na]
+ 381.0976, found 381.0968.
H
N SiMe3
N2
N
O
CO2iPr
Ph
10 mol%
[Cu(CH3CN)4]ClO4
Cl
N
NH
OCl
O OiPr
Ph
toluene, 0 °C, 1 h
trans-Aziridine 238. A suspension of the tetrakis(acetonitrile) copper(I) perchlorate (24.5mg,
75.0 µmol) in toluene (2.0mL) was cooled to 0 ◦C and the imine (160 µL, 750 µmol) was added via
syringe. The solution was stirred for 15min at 0 ◦C and the α-diazo imide (123.6mg, 500.0 µmol)
was added in one portion, and stirring was continued for 1 h. The reaction mixture was filtered
through a pad of neutral alumina (10mL), eluted with ethyl acetate, and concentrated prior to flash
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chromatography (SiO2, 10% ethyl acetate in hexanes) to afford oxazoline as a clear oil (6.9mg, 4%).
Rf = 0.07 (10% EtOAc/hexanes); IR (film) 3145, 3060, 2982, 2933, 1697, 1602, 1552, 1495 cm−1;
1H NMR (600MHz, CDCl3) δ 7.97 (s, 1H), 7.53 (d, J = 7.9Hz, 2H), 7.34–7.30 (m, 4H), 7.24–7.26
(m, 2H), 7.13 (dd, J = 7.4, 7.4Hz, 1H), 4.92 (sept, J = 6.2Hz, 1H), 3.86 (d, J = 2.5Hz, 1H),
3.30 (d, J = 2.6Hz, 1H), 1.27 (d, J = 6.2Hz, 3H), 1.05 (d, J = 6.3Hz, 3H); 13C NMR (150MHz,
CDCl3) 163.7, 159.2, 137.0, 134.6, 132.7, 129.1, 128.9, 128.2, 124.9, 119.8 ppm; HRMS (ESI): Exact
mass calcd for C19H19ClNaN2O3 [M+Na]
+ 381.0976, found 381.0984.
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Orthoamide 240. A suspension of the CuClO4 · 4MeCN (9.6mg, 30µmol) in toluene (1.0mL)
was cooled to 0 ◦C and the imine (64µL, 300 µmol) was added via syringe followed by benzoic
alcid (24.4mg, 300 µmol). The yellow solution was stirred for 15min at 0 ◦C and the α-diazo
imide (49.4mg, 300 µmol) was added in one portion, and stirring was continued for 1 h. The
reaction mixture was concentrated prior to flash chromatography (SiO2, 10% ethyl acetate in
hexanes with 2% Et3N) to afford the title compound as a clear oil (37.7mg, 21%). Rf = 0.20
(25% EtOAc/hexanes); IR (film) 3066, 2976, 2871, 1731, 1645, 1595, 1572, 1498 cm−1; 1H NMR
(600MHz, CDCl3) δ 8.60 (s, 1H), 7.76 (d, J = 8.5Hz, 2H), 7.63 (d, J = 7.7Hz, 2H), 7.41 (d,
J = 8.4Hz, 2H), 7.39 (d, J = 8.0Hz, 2H), 7.28 (t, J = 7.4Hz, 1H), 4.65 (d, J = 14.3Hz, 1H), 4.43
(d, J = 14.2Hz, 1H), 4.14 (sept, J = 6.2Hz, 1H), 1.30 (d, J = 6.1Hz, 3H), 1.03 (d, J = 6.2Hz,
3H); 13C NMR (150MHz, CDCl3) 168.7, 160.7, 138.4, 134.3, 133.1, 130.6, 129.1, 128.8, 127.1, 125.4,
118.8, 67.8, 67.3, 24.0, 23.1 ppm;
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Orthoamide 242.A suspension of the CuClO4 · 4MeCN (6.5mg, 20 µmol) in CH2Cl2 (2.0mL) was
cooled to 0 ◦C and the methyl acrylate (360µL, 4.0mmol) was added via syringe. The solution was
stirred for 5min at 0 ◦C and a solution of the α-diazo imide (74.2mg, 300 µmol) in dichloromethane
(500µL) was added via automated syringe pump over 1 h. The resulting solution was concentrated
and purified using flash chromatography (SiO2, 10–25% ethyl acetate in hexanes) to afford the
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adduct as a white solid (51mg, 41%). Mp 133–135 ◦C; Rf = 0.30 (25% EtOAc/hexanes); IR
(film) 2979, 2950, 1744, 1698, 1599, 1496 cm−1; 1H NMR (600MHz, CDCl3) δ 7.49–7.47 (m, 2H),
7.42–7.39 (m, 2H), 7.19 (dddd, J = 7.4, 7.3, 1.0, 1.0Hz, 1H), 4.83 (d, J = 5.8Hz, 1H), 4.26 (sept,
J = 6.2Hz, 1H), 3.81 (s, 3H), 3.42 (dd, J = 8.4, 4.7Hz, 1H), 2.68 (ddd, J = 12.7, 5.7, 4.7Hz, 1H),
2.08 (dd, J = 12.7, 8.4Hz, 1H), 1.23 (d, J = 6.1Hz, 3H), 0.84 (d, J = 6.3Hz, 3H); 13C NMR
(150MHz, CDCl3) ppm 171.0, 170.3, 134.9, 128.9, 125.2, 120.6, 115.7, 75.3, 71.6, 52.4, 49.0, 31.3,
23.5, 22.4; HRMS (ESI): Exact mass calcd for C16H19NaNO5 [M+Na]
+ 328.1161, found 328.1169.
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Compounds relevant to Chapter 3
OH OH
tBuSi(OTf)2
DMF, 0 °C to rt O OSi
tBu tBu
(4R,6R)-2,2-Di-tert-butyl-4,6-divinyl-1,3,2-dioxasilinane (310). To a solution of the diol
(2.75 g, 21.5mmol) in DMF (12mL) at 0 ◦C was added tBuSi(OTf)2 (7.0mL, 22mmol). The
mixture was warmed to rt, stirred for 18h and then poured onto a silica gel column and eluted
with 5% ethyl acetate in hexanes (ca. 500mL) to give the desired product as a clear oil (5.25 g,
91%). [α]20D +11.4 (c 3.50, CHCl3); Rf = 0.70 (30% EtOAc/hexanes); IR (film) 3014, 2963, 2859,
1645, 1474 cm−1; 1H NMR (400MHz, CDCl3) δ 5.91 (ddd, J = 17.2, 10.8, 5.2Hz, 1H), 5.29 (ddd,
J = 17.2, 1.6, 1.6Hz, 1H), 5.10 (ddd, J = 10.8, 1.6, 1.6Hz, 1H), 4.64–4.59 (m, 1H) 1.88 (t, J =
3.2Hz, 1H), 1.00 (s, 9H); 13C NMR (100MHz, CDCl3) ppm 140.5, 114.0, 70.7, 39.8, 27.2, 21.1;
HRMS (ESI): Exact mass calcd for C15H27O2Si [M-H]
+ 267.1775 , found 267.1775.
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Methyl benzyl(2-(diethoxyphosphoryl)acetyl)carbamate (319). To a solution of HMDS
(23.0mL, 110mmol) in THF (130mL) at −78 ◦C was added n-butyllithium (2.5m in hexanes,
44mL, 110mmol) via syringe. The solution was warmed to 0 ◦C, stirred for 15min, and then cooled
to −78 ◦C. A solution of the amidophosphonate (14.3 g, 50.0mmol) was added in one portion. The
solution was warmed to 0 ◦C, (15min), cooled to −78 ◦C and then methyl chloroformate (4.7mL,
60mmol) was added via syringe and the solution was slowly warmed to rt. The reaction was
quenched with satd aq ammonium chloride and extracted with diethyl ether. The combined organic
layers were dried and concentrated to give the imidophosphonate as a yellow oil (17.2 g, 99%) and
was used without further purification. Rf = 0.45 (50% EtOAc/hexanes); IR (film) 3482, 2984,
1740, 1695 cm−1; 1H NMR (600MHz, CDCl3) δ 7.32–7.22 (m, 5H), 4.95 (s, 2H), 4.12 (dq, J =
15.0, 7.0Hz, 4H), 3.83 (d, J = 22.3Hz, 2H), 3.81 (s, 3H), 1.28 (t, J = 7.0Hz, 6H); 13C NMR
(100MHz, CDCl3) ppm 167.4 (d, J = 6.8Hz, 155.0, 137.1, 128.3, 127.7, 127.3, 62.5 (d, J = 6.8Hz),
54.0, 47.6, 37.2 (d, J = 132Hz), 16.2 (d, J = 6.4Hz); 31P NMR (162MHz, CDCl3, δ): 22.5; HRMS
(ESI): Exact mass calcd for C15H22NNaO6P [M+Na]
+ 366.1082, found 366.1099.
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(4R,6R)-2,2-Di-tert-butyl-1,3,2-dioxasilinane-4,6-dicarbaldehyde (322). To a suspension
of the silica gel-supported NaIO4 (1.00 g) in CH2Cl2 (5mL) at rt was added crude polyol (90mg,
270 µmol) in one portion. The slurry was stirred for 15min, filtered through Celite, washed with
chloroform and concentrated to give the aldehyde as clear oil (72 g, 99%) which was used with-
out further purification. Rf = 0.35 (5% MeOH/CHCl3); IR (film) 2962, 2935, 2894, 2860, 2810,
1742 cm−1; 1H NMR (600MHz, CDCl3) δ 9.75 (s, 1H), 4.38 (t, J = 5.7Hz, 1H), 2.25 (t, J = 5.7Hz,
1H), 1.06 (s, 9H); 13C NMR (150MHz, CDCl3) ppm 201.9, 75.2, 29.1, 26.9, 21.2; HRMS (ESI):
Exact mass calcd for C13H25O4Si [M+H]
+ 273.1517, found 273.1519.
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Bisimide 312. To a solution of the KHMDS (0.5m in toluene, 2.3mL, 890 µmol) and 18-crown-6
(235mg, 890 µmol) in THF (2mL) at 0 ◦C was added imidophosphonate (306mg, 1.15mmol) and
the solution was stirred at 0 ◦C for 1h. The solution was cooled to −78 ◦C and the solution of
the aldehyde (40mg, 150µmol) in tetrahydrofuran (0.5mL) was added via cannula. The resulting
yellow solution was stirred for 3h at −78 ◦C and quenched with satd aq NH4Cl warmed to rt and
concentrated. The reaction mixture was diluted with ethyl acetate, the layers were separated and
the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with
brine, dried and concentrated and the resulting yellow oil was purified using flash chromatography
(SiO2, 10–20% ethyl acetate in hexanes) to afford the bis-imide as clear oil (75.4mg, 78%). [α]20D
−32.4 (c 0.73, CHCl3); Rf = 0.35 (20% EtOAc/hexanes); IR (film) 3032, 2934, 3859, 1730, 1683,
1634, 1561 cm−1; 1H NMR (400MHz, CDCl3) δ 7.31–7.23 (m, 5H), 7.17 (dd, J = 14.9, 1.6Hz, 1H),
6.98 (dd, J = 15.0, 4.1Hz, 1H), 4.97 (s, 2H), 4.87–4.83 (m, 1H), 3.80 (s, 3H), 2.04 (dd, J = 5.4,
4.1Hz, 1H), 1.06 (s, 9H); 13C NMR (100MHz, CDCl3) ppm 168.0, 154.9, 148.6, 137.5, 128.4, 127.7,
127.3, 123.1, 69.5, 53.8, 47.7, 38.6, 27.1, 21.2; HRMS (ESI): Exact mass calcd for C35H46N2NaO8Si
[M+Na]+ 673.2921, found 673.2923.
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Bis(silyl ether) 422. To a solution of the diol (2.50 g, 19.5mmol) and imidazole (4.0 g, 60mmol)
in DMF (20mL) at 0 ◦C was added TBSCl (9.0 g, 60mmol). The mixture was warmed to rt, stirred
for 4 h and then poured onto a silica gel column and eluted with 5% ethyl acetate in hexanes (ca.
500mL) to give the desired product as a clear oil (6.75 g, 97%). [α]20D −7.3 (c 2.40, CHCl3); Rf =
0.40 (10% EtOAc/hexanes); IR (film) 2956, 2929, 2887, 2857 cm−1; 1H NMR (400MHz, CDCl3) δ
5.81 (ddd, J = 17.0, 10.5, 7.4Hz, 1H), 5.12 (br d, J = 17.0Hz, 1H), 5.03 (d, J = 10.5Hz, 1H), 4.18
(dt, J = 6.8, 6.6Hz, 1H), 1.69 (dd, J = 6.5, 6.4Hz, 1H), 0.89 (s, 9H), 0.06 (s, 3H), 0.03 (s, 3H);
13C NMR (100MHz, CDCl3) ppm 141.9, 114.1, 71.3, 47.3, 25.9, 18.2, −3.9 , −4.7 ; HRMS (ESI):
Exact mass calcd for C19H41O2Si2 [M+H]
+ 357.2640, found 357.2650.
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DMF, 0 °C to rt O OSi
iPr iPr
(4R,6R)-2,2-Diisopropyl-4,6-divinyl-1,3,2-dioxasilinane (423). To a solution of the diol
(256mg, 2.00mmol) and imidazole (410mg, 6.00mmol) in DMF (1mL) at 0 ◦C was added DIPSCl2
(556mg, 3.00mmol). The mixture was warmed to rt and stirred for 6h and then poured onto a
silica gel column and eluted with 2% ethyl acetate in hexanes (ca. 200mL) to give the desired
product as a clear oil (303mg, 63%). [α]20D −14.0 (c 0.15, CHCl3); Rf = 0.28 (hexanes); IR (film)
3080, 3013, 2945, 2895, 2868 cm−1; 1H NMR (400MHz, CDCl3) δ 5.92 (ddd, J =16.8, 10.6, 5.1Hz,
1H), 5.32 (ddd, J = 17.0, 1.5, 1.5Hz, 1H), 5.14 (ddd, J = 10.4, 1.4, 1.4Hz, 1H), 4.64 (m, 1H), 1.89
(t, J = 5.2Hz, 1H), 1.07–1.02 (m, 7H); 13C NMR (100MHz, CDCl3) ppm 140.2, 114.3, 70.6, 40.6,
16.9, 16.8, 13.5; HRMS (ESI): Exact mass calcd for C13H25O2Si [M+H]
+ 241.1618, found 241.1610.
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(6S,8S)-2,2,4,4-Tetraisopropyl-6,8-divinyl-1,3,5,2,4-trioxadisilocane (328). To a solution
of the diol (1.00 g, 7.81mmol) in DMF (10mL) at 0 ◦C was added diisopropylsilyl bis(triflate)
(4.7mL, 16mmol) over 5 min. Reaction was warmed to rt and stirred for 20 h. Reaction mixture
was poured into water (50mL) and the resulting solution was extracted with ethyl acetate. The
combined organic layers were washed with 5% aq LiCl, dried and concentrated. The resulting oil
was purified using flash chromatography (SiO2, 2–5% ethyl acetate in hexanes) to afford the alkene
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as a clear oil (1.75 g, 60%). [α]20D −13.1 (c 0.35, CHCl3); Rf = 0.31 (hexanes); IR (film) 2944,
2895, 2868, 1465, 1402 cm−1; 1H NMR (400MHz, CDCl3) δ 5.88 (ddd, J = 17.1, 10.5, 4.9Hz, 1H),
5.25 (dd, J = 17.1, 1.7, 1.7Hz, 1H), 5.05 (dd, J = 10.5, 1.6, 1.6Hz, 1H), 4.49 (m, 1H), 1.55 (dd,
J = 5.7, 5.6Hz, 1H), 1.10–0.93 (m, 14H); 13C NMR (150MHz, CDCl3) ppm 140.8, 113.1, 68.4,
44.7, 17.4, 17.4, 17.3, 17.2, 13.4, 12.8; HRMS (ESI): Exact mass calcd for C19H39O3Si2 [M+H]
+
371.2450 , found 371.2432.
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Bisimide 331.To a solution of KHMDS (2.5 g, 12mmol) and 18-crown-6 (3.3 g, 12mmol) in THF
(80mL) at 0 ◦C was added imidophosphonate (4.3 g, 12mmol) and the solution was stirred at 0 ◦C
for 1 h. The resulting yellow suspension was cooled to −78 ◦C. In a separate flask, to a suspension
of silica gel-supported164 NaIO4 (10.0 g) in CH2Cl2 at rt was added polyol 329 (1.10 g, 1.51mmol)
in one portion. The slurry was stirred for 15min, filtered through Celite, washed with chloroform
and concentrated. The resulting crude aldehyde was diluted with THF (5mL) and was added
to the cold suspension of the imidophosphonate via cannula. The reaction mixture was stirred
for 3 h at −78 ◦C, quenched with satd aq NH4Cl, warmed to rt, and concentrated. The residue
was diluted with ethyl acetate, the layers were separated, and the aqueous layer was extracted
with ethyl acetate. The combined organic layers were washed with brine, dried, concentrated
and the resulting yellow oil was purified using flash chromatography (SiO2, 10–25% ethyl acetate
in hexanes) to afford the bisimide as a clear oil (410mg, 22%). [α]20D −0.9 (c 13.50, CHCl3);
Rf = 0.61 (25% EtOAc/hexanes); IR (film) 3034, 2946, 2867, 1740, 1685, 1639 cm−1; 1H NMR
(400MHz, CDCl3) δ 7.33–7.21 (m, 5H), 7.14 (dd, J = 15.1, 1.6Hz, 1H), 7.01 (dd, J = 15.1, 3.9Hz,
1H), 4.97 (d, J = 15.4Hz, 1H), 4.94 (d, J = 15.3Hz, 1H), 4.72 (m, 1H), 3.79 (s, 3H), 1.66 (dd,
J = 8.4, 5.8Hz, 1H), 1.12–0.99 (m, 14H); 13C NMR (100MHz, CDCl3) ppm 167.5, 167.4, 155.0,
137.1, 128.3, 127.7, 127.3, 62.5, 62.4, 54.0, 47.6, 37.6, 36.7, 16.3, 16.2; HRMS (ESI): Exact mass
calcd for C39H56N2O9Si2 [M+Na]
+ 753.3597 , found 753.3609.
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Bisimide 335. To a solution of the imidophosphonate (701mg, 1.82mmol) in tetrahydrofuran
(10mL) at −78 ◦C was added sodium hydride (44mg, 1.8mmol). The solution was warmed to rt,
stirred for 15min, cooled to −78 ◦C and the solution of the aldehyde 349 (194mg, 374 µmol) in
tetrahydrofuran (5mL) was added via cannula. The reaction was warmed to −20 ◦C stirred for 18h
and quenched with water (1mL). The reaction mixture was concentrated and diluted with ethyl
acetate. The aqueous layer was extracted with ethyl acetate and the combined organic layers were
dried and concentrated. The resulting yellow oil was purified using flash chromatography (SiO2,
10% ethyl acetate in hexanes) to afford the bisimide as a colorless oil (360mg, 83%). [α]20D −25.1
(c 24.50, CHCl3); Rf = 0.35 (10% EtOAc/hexanes); IR (film) 3065, 3033, 2945, 2867, 1732, 1682,
1641, 1496 cm−1; 1H NMR (400MHz, CDCl3) δ 7.30–7.18 (m, 5H), 7.06 (dd, J = 14.9, 1.5Hz, 1H),
6.95 (dd, J = 15.0, 3.4Hz, 1H), 4.90 (d, J = 14.9Hz, 1H), 4.86 (d, J = 15.0Hz, 1H), 4.75–4.66
(m, 1H), 1.67 (dd, J = 8.1, 4.9Hz, 1H), 1.39 (s, 9H), 1.10–0.97 (m, 14H); 13C NMR (100MHz,
CDCl3) ppm 168.4, 152.9, 148.1, 138.1, 128.3, 127.5, 127.0, 122.6, 83.2, 67.2, 47.8, 42.9, 27.8, 17.4,
17.2, 13.2, 12.8; HRMS (ESI): Exact mass calcd for C45H68N2NaO9Si2 [M+Na]
+ 859.4361, found
859.4404.
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Acrylamide 336. To a solution of the bisimide (450mg, 538 µmol) and benzyl azide (585mg,
5.15mmol) in acetonitrile (4.0mL) at −20 ◦C was added triflic acid (220 µL, 2.50mmol). The
reaction was stirred at −20 ◦C for 18h and then quenched with triethylamine (360 µL, 2.6 µmol)
and warmed to rt. The reaction mixture was extracted with ethyl acetate and the combined
organic layers were washed with brine, dried and concentrated. The resulting yellow solid was
purified using flash chromatography (SiO2, 50% ethyl acetate in hexanes) to afford the bis(amide)
as a white powder (241mg, 70%). [α]20D −28.5 (c 0.17, CHCl3); Rf = 0.38 (50% EtOAc/hexanes);
IR (film) 3268, 3065, 3031, 2944, 2894, 1671, 1633, 1552 cm−1; 1H NMR (400MHz, CDCl3) δ 7.34–
7.35 (m, 5H), 6.89 (dd, J = 15.0, 3.6Hz, 1H), 6.87 (dd, J = 15.0, 1.5Hz, 1H), 6.02 (t, J = 5.7Hz,
1H), 4.65 (m, 1H), 4.53 (dd, J = 14.7, 5.8Hz, 1H), 4.45 (dd, J = 14.7, 5.6Hz, 1H), 1.57 (ddd,
J = 13.8, 8.1, 8.1Hz, 1H), 1.08–0.90 (m, 14H); 13C NMR (100MHz, CDCl3) ppm 165.4, 146.1,
168
138.1, 128.7, 127.8, 127.5, 121.6, 66.9, 43.7, 43.2, 17.4, 17.3, 17.2, 17.2, 13.2, 12.7; HRMS (ESI):
Exact mass calcd for C35H53N2O5Si2 [M+H]
+ 637.3493, found 637.3523.
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Bisimide 337. To a solution of the imidophosphonate (2.50 g, 6.70mmol) in tetrahydrofuran
(20mL) at −78 ◦C was added sodium hydride (180mg, 6.7mmol). The solution was warmed to 0 ◦C,
stirred for 30min, cooled to −78 ◦C, and then treated with a solution of aldehyde (prepared164 from
736mg, 1.68mmol of tetraol 329) in tetrahydrofuran (5mL) was added via cannula. The reaction
was warmed to −20 ◦C stirred for 18h and quenched with satd NH4Cl. The reaction mixture was
concentrated, diluted with ethyl acetate, separated, and the aqueous layer was extracted further
with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated.
The yellow residue was purified using flash chromatography (SiO2, 10–20% ethyl acetate in hexanes)
to afford the bisimide as a colorless oil (1.09 g, 80%). [α]20D −20.2 (c 0.44, CHCl3); Rf = 0.69
(25% EtOAc/hexanes); IR (film) 3033, 2945, 2893, 2867, 1732, 1682, 1639, 1495 cm−1; 1H NMR
(400MHz, CDCl3) δ 7.32–7.20 (m, 5H), 7.15 (dd, J = 15.1, 1.5Hz, 1H), 7.00 (dd, J = 15.0, 4.0Hz,
1H), 4.99 (sept, J = 6.3Hz, 1H), 4.95 (s, 2H), 4.73 (m, 1H), 1.69 (ddd, J = 13.8, 8.0, 8.0Hz, 1H),
1.23 (d, J = 6.2Hz, 3H), 1.22 (d, J = 6.3Hz, 3H), 1.15–0.85 (m, 14H); 13C NMR (100MHz,
CDCl3) ppm 168.3, 153.7, 148.7, 137.9, 128.2, 127.7, 127.1, 122.5, 71.1, 67.2, 47.6, 43.0, 21.6, 17.3,
17.2, 17.2, 13.2, 12.7; HRMS (ESI): Exact mass calcd for C43H64N2NaO9Si2 [M+Na]
+ 831.4048,
found 831.4023.
ii) iPrO2CCl
–78 to rt, 1 h
i) nBuLi, THF
–78 °C to rt, 15 min
O Si O
tBu tBu
N
H
N
H
O O
Bn Bn
O Si O
tBu tBu
NN
O O
Bn
CO2iPr CO2iPr
Bn
Bisimide 338. A solution of the bis(amide) (65.0mg, 121µmol) in THF (1.0mL) was cooled to
−78 ◦C and n-butyllithium (2.5m in hexanes, 120 µL, 304 µmol) was added via syringe. The brown
solution was stirred for 30min and isopropyl chloroformate (1.0m in toluene, (360 µL, 360 µmol) was
added via syringe. The reaction was warmed to rt, stirred for additional 30min and then quenched
with aq satd NH4Cl. The aqueous layer was extracted with ethyl acetate and the combined organic
layers were dried and concentrated. The residue was purified using flash chromatography (SiO2,
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15% ethyl acetate in hexanes) to afford the desired product as a colorless oil (52.7mg, 62%). [α]20D
−23.2 (c 0.25, CHCl3); Rf = 0.55 (25% EtOAc/hexanes); IR (film) 3033, 2934, 3858, 1732, 1683,
1637, 1559 cm−1; 1H NMR (400MHz, CDCl3) δ 7.33–7.21 (m, 5H), 7.16 (dd, J = 15.1, 1.7Hz, 1H),
6.97 (dd, J = 15.1, 4.2Hz, 1H), 4.98 (sept, J = 6.45Hz, 1H), 4.95 (s, 2H), 4.87–4.83 (m, 1H), 2.05
(dd, J = 5.4, 5.3Hz, 1H), 1.22 (d, J = 6.3Hz, 3H), 1.20 (d, J = 6.3Hz, 3H), 1.06 (s, 9H); 13C NMR
(100MHz, CDCl3) ppm 168.3, 153.8, 147.9, 137.8, 128.3, 127.8, 127.2, 123.4, 77.3, 77.2, 77.0, 76.7,
71.2, 69.6, 47.6, 38.7, 27.0, 21.6, 21.6, 21.1; HRMS (ESI): Exact mass calcd for C39H53N2NaO8Si
[M-H]+ 705.3571, found 705.3569.
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Bis(triazoline) 339. The imide (48.4mg, 68.5 µmol) was treated with benzyl azide (91.1mg,
685 µmol) according to the general procedure and purified using flash column chromatography
(SiO2, 30% ethyl acetate in hexanes) to afford the triazoline mixture (1:9:9) as a yellow oil (36.0mg,
54%).
Data for the 2,3-syn/2’,3’-syn bis(triazoline): [α]20D +92.8 (c 0.75, CHCl3); Rf = 0.20 (50%
Et2O/hexanes); IR (film) 3064, 3032, 2932, 2858, 1740, 1692 cm−1; 1H NMR (600MHz, CDCl3) δ
7.31–7.12 (m, 10H); 6.40 (d, J = 9.6Hz, 1H); 5.03 (sept, J = 6.4Hz, 1H); 5.00 (d, J = 15.4Hz,
1H); 4.90 (d, J = 15.2Hz, 1H); 4.86 (d, J = 15.2Hz, 1H); 4.58 (d, J = 15.6Hz, 1H); 4.17 (ddd, J =
10.4, 5.1, 5.1Hz, 1H); 3.85 (dd, J = 9.1, 4.7Hz, 1H); 1.54 (t, J = 5.6Hz, 1H); 1.26 (d, J = 6.3Hz,
3H); 1.17 (d, J = 6.3Hz, 3H); 0.92 (s, 9H); 13C NMR (150MHz, CDCl3) ppm 169.9, 153.7, 137.2,
135.6, 128.7, 128.4, 128.0, 127.8, 127.5, 127.3, 82.0, 71.9, 67.9, 62.5, 53.0, 48.2, 33.2, 27.0, 21.7,
21.4, 21.3; HRMS (ESI): Exact mass calcd for C53H69N8O8Si [M+H]
+ 973.5008, found 973.4994.
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Bisimide 340. To a solution of the imidophosphonate (700mg, 1.88mmol) in tetrahydrofuran
(2.0mL) at −78 ◦C was added sodium hydride (50mg, 2.1mmol). The solution was warmed to
0 ◦C, stirred for 30min, cooled to −78 ◦C and a solution of aldehyde (prepared164 from 128mg,
415 µmol of the corresponding tetraol) in tetrahydrofuran (2mL) was added via cannula. The
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reaction was warmed to −20 ◦C stirred for 6h and quenched with satd NH4Cl. The reaction
mixture was concentrated and diluted with ethyl acetate, separated, and the aqueous layer was
extracted further with ethyl acetate. The combined organic layers were washed with brine, dried
and concentrated. The resulting yellow oil was purified using flash chromatography (SiO2, 10–15%
ethyl acetate in hexanes) to afford the Bisimide as a colorless oil (181mg, 64%). [α]20D −23.5 (c
0.61, CHCl3); Rf = 0.66 (25% EtOAc/hexanes); IR (film) 3033, 2981, 2944, 2866, 1732, 1682, 1639,
1496 cm−1; 1H NMR (400MHz, CDCl3) δ 7.36–7.22 (m, 5H), 7.17 (dd, J = 15.0, 1.8Hz, 1H), 6.95
(dd, J = 15.0, 4.2Hz, 1H), 4.98 (sept, J = 6.5Hz, 1H), 4.95 (s, 2H), 4.87 (ddd, J = 5.2, 4.1, 1.8Hz,
1H), 2.03 (dd, J = 5.6, 5.2Hz, 1H), 1.29–1.20 (m, 7H), 1.11–0.99 (m, 6H); 13C NMR (100MHz,
CDCl3) ppm 168.3, 153.8, 147.7, 137.9, 128.6, 128.3, 127.8, 127.2, 123.6, 71.3, 69.4, 47.6, 39.3, 22.1,
21.6, 21.6, 16.8, 16.7, 13.4 ppm; HRMS (ESI): Exact mass calcd for C37H50N2NaO8Si [M+Na]
+
701.3234, found 701.3215.
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Bis(triazoline) 341. To a solution of the bisimide 340 (80.0mg, 118 µmol) and benzyl azide
(160mg, 1.2mmol) in acetonitrile (500 µL) at −20 ◦C was added triflic acid (52µL, 590µmol) and
the solution was stirred at −20 ◦C for 18h. The reaction was quenched with triethylamine (83µL,
590 µmol) and warmed to rt. The reaction mixture was poured into water and extracted with
ethyl acetate. The combined organic layers were washed with brine, dried and concentrated. The
resulting brown oil was purified using flash chromatography (SiO2, 50% ethyl acetate in hexanes)
to afford the triazoline as a yellow oil (8mg, 7%). Rf = 0.28 (50% Et2O/hexanes); IR (film) 3064,
3032, 2943, 2866, 1813, 1741, 1687, 1604 cm−1; 1H NMR (600MHz, CDCl3) δ 7.31–7.15 (m, 18H),
7.10–7.07 (m, 2H), 6.30 (d, J = 9.6Hz, 1H), 6.02 (d, J = 9.6Hz, 1H), 5.30 (d, J = 15.3Hz, 1H),
5.08–5.00 (m, 2H), 4.97 (d, J = 15.1Hz, 1H), 4.88 (d, J = 9.6Hz, 1H), 4.81 (d, J = 15.5Hz, 1H),
4.61 (d, J = 15.2Hz, 1H), 4.50 (d, J = 15.2Hz, 1H), 4.29–4.25 (m, 1H), 4.05 (dd, J = 9.6, 5.5Hz,
1H), 3.85 (dd, J = 9.4, 4.1Hz, 1H), 3.82 (dd, J = 10.0, 1.3Hz, 1H), 1.28–0.78 (m, 30H); 13C NMR
(150MHz, CDCl3) ppm 170.02, 169.98, 153.9, 153.7, 137.32, 137.29, 135.7, 135.4, 128.8, 128.7,
128.6, 128.5, 128.4, 128.3, 128.0, 127.83, 127.75, 127.6, 127.4, 127.3, 127.2, 82.0, 81.3, 72.0, 71.9,
67.7, 66.4, 62.6, 62.2, 53.2, 52.7, 48.3, 48.1, 35.6, 33.6, 29.7, 21.8, 21.7, 21.4, 21.3, 17.5, 17.44, 17.43,
16.9, 16.8, 16.6, 16.5, 13.9, 13.04, 12.98; HRMS (ESI): Exact mass calcd for C51H64N8NaO8Si
[M+Na]+ 945.4695, found 945.4741.
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Triazoline 342. To a solution of the bisimide (410mg, 540 µmol) and benzyl azide (665mg,
5.00mmol) in CH3CN (2.0mL) at −20 ◦C was added triflic acid (200µL, 2.20mmol) and the so-
lution was stirred at −20 ◦C for 40h. The reaction was quenched with triethylamine (300 µL,
2.20mmol) and warmed to rt. The reaction mixture was poured into water and extracted with
ethyl acetate. The combined organic layers were washed with brine, dried and concentrated. The
resulting brown oil was purified using flash chromatography (SiO2, 25% ethyl acetate in hexanes)
to afford the triazoline as yellow oil (150mg, 27%). [α]20D +56.9 (c 0.23, CHCl3); Rf = 0.37
(25% EtOAc/hexanes); IR (film) 3031, 2945, 2866, 1740, 1691, 1496 cm−1; 1H NMR (600MHz,
CDCl3) δ 7.26–7.18 (m, 8H), 7.10–7.08 (m, 2H), 6.08 (d, J = 10.2Hz, 1H), 5.28 (d, J = 15.4Hz,
1H), 4.95 (d, J = 15.2Hz, 1H), 4.86 (d, J = 15.2Hz, 1H), 4.49 (d, J = 15.4Hz, 1H), 4.24 (ddd,
J = 7.8, 5.9, 1.5Hz, 1H), 3.82 (dd, J = 10.2, 1.4Hz, 1H), 3.79 (s, 3H), 1.20 (dd, J = 8.1, 5.7Hz, 1H),
1.07–1.08 (m, 6H), 1.01–0.96 (m, 4H), 0.90–0.85 (m, 4H); 13C NMR (150MHz, CDCl3) ppm 169.9,
154.9, 137.0, 135.3, 128.6, 128.5, 128.0, 127.8, 127.3, 127.3, 81.3, 66.1, 62.3, 54.0, 52.7, 48.2, 36.2,
17.5, 17.5, 17.4, 16.9, 13.9, 12.6; HRMS (ESI): Exact mass calcd for C53H70N8NaO9Si2 [M+Na]
+
1041.4702 , found 1041.4757.
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Triazoline 343. To a solution of the bisimide 337 (35mg, 43µmol) and benzyl azide (57mg,
430 µmol) in acetonitrile (200 µL) at −20 ◦C was added triflic acid (19µL, 210 µmol) and the solu-
tion was stirred at −20 ◦C for 3 h. The reaction was quenched with triethylamine (30µL, 220 µmol)
and warmed to rt. The reaction mixture was poured into water and extracted with ethyl ac-
etate. The combined organic layers were washed with brine, dried and concentrated. The resulting
brown oil was purified using flash chromatography (SiO2, 25% ethyl acetate in hexanes) to af-
ford the triazoline as yellow oil (34.9mg, 75%). [α]20D +132.9 (c 0.85, CHCl3); Rf = 0.50 (25%
EtOAc/hexanes); IR (film) 3064, 3032, 2943, 2866, 1734, 1685, 1496 cm−1; 1H NMR (400MHz,
CDCl3) δ 7.28–7.16 (m, 8H), 7.13–7.07 (m, 2H), 6.03 (d, J = 9.9Hz, 1H), 5.32 (d, J = 15.6Hz,
1H), 5.03 (sept, J = 6.3Hz, 1H), 4.98 (d, J = 15.1Hz, 1H), 4.82 (d, J = 15.1Hz, 1H), 4.51 (d,
J = 15.6Hz, 1H), 4.33–4.25 (m, 1H), 3.83 (dd, J = 10.5, 1.5Hz, 1H ); 1.29 (d, J = 6.3Hz, 3H),
1.23 (dd, J = 8.1, 5.8Hz, 1H), 1.17 (d, J = 6.3Hz, 3H), 1.12–0.80 (m, 14H); 13C NMR (100MHz,
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CDCl3) ppm 170.0, 153.8, 137.3, 135.4, 128.6, 128.3, 128.0, 127.7, 127.4, 127.1, 81.2, 77.2, 71.9,
66.4, 62.2, 52.7, 48.1, 35.6, 21.8, 21.3, 17.5, 17.4, 17.4, 16.8, 13.8, 12.5; HRMS (ESI): Exact mass
calcd for C57H78N8NaO9Si2 [M+Na]
+ 1097.5328, found 1097.5304.
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Bis(oxazolidine dione) 316 To a solution of triazoline (125mg, 136 µmol) in acetonitrile (500 µL)
at 0 ◦C was added triflic acid (26µL, 300 µmol) via syringe. The solution was slowly warmed to rt
and stirred for 15h and then quenched with triethylamine (42µL, 300 µmol). The reaction mixture
was poured into water and extracted with ethyl acetate. The combined organic layers were washed
with brine, dried and concentrated. The resulting yellow oil was purified using flash chromatography
(SiO2, 25% ethyl acetate in hexanes) to afford the bis(oxazolidine dione) as a yellow oil (58mg,
51%) [α]20D −49.3 (c 1.5, CHCl3); Rf = 0.30 (25% EtOAc/hexanes); IR (film) 3341, 3031, 2931,
2857, 1815, 1735, 1496 cm−1; 1H NMR (600MHz, CDCl3) δ 7.46–7.38 (m, 3H); 7.33–7.15 (m, 7H);
4.69 (d, J = 4.0Hz, 1H); 4.68 (s, 2H); 4.49 (ddd, J = 11.0, 4.9 4.9Hz, 1H); 3.91 (d, J = 12.6Hz,
1H); 3.75 (d, J = 12.6Hz, 1H); 3.07 (dd, J = 5.5, 4.1Hz, 1H); 1.97 (dd, J = 5.8, 4.8Hz, 1H); 1.92
(brs, 1H); 0.98 (s, 9H); 13C NMR (150MHz, CDCl3) ppm 171.8, 155.2, 139.5, 134.6, 129.0, 128.9,
128.8, 128.73, 128.67, 128.6, 128.5, 128.4, 128.3, 127.2, 79.5, 69.7, 62.8, 53.6, 43.7, 33.9, 27.1, 21.2;
HRMS (ESI): Exact mass calcd for C47H57N4O8Si [M+H]
+ 833.3946, found 833.3946.
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Bis(oxazolidine dione) 344. To a solution of triazoline (150mg, 145 µmol) in acetonitrile
(1.0mL) at −20 ◦C was added triflic acid (40µL, 450µmol) via syringe. The solution was slowly
warmed to rt and stirred for 10h and then quenched with triethylamine (63µL, 450µmol). The
reaction mixture was poured in to water and extracted with ethyl acetate. The combined organic
layers were washed with brine, dried and concentrated. The resulting yellow oil was purified using
flash chromatography (SiO2, 20% ethyl acetate in hexanes) to afford the bis(oxazolidine dione) as
a yellow oil (96mg, 71%) [α]20D 25.1 (c 7.10, CHCl3); Rf = 0.38 (25% EtOAc/hexanes); IR (film)
3064, 3031, 2945, 2867, 1815, 1738, 1496 cm−1; 1H NMR (600MHz, CDCl3) δ 7.38–7.36 (m, 2H),
7.28–7.21 (m, 6H), 7.14–7.12 (m, 2H), 4.94 (d, J = 4.3Hz, 1H), 4.68 (d, J = 14.5Hz, 1H), 4.65
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(d, J = 14.6Hz, 1H), 4.31 (ddd, J = 7.5, 5.2, 5.2Hz, 1H), 3.81 (d, J = 13.0Hz, 1H), 3.73 (d, J
= 13.0Hz, 1H), 3.13 (d, J = 4.5, 4.6Hz, 1H), 1.86 (dd, J = 7.6, 5.7Hz, 1H), 1.09–0.98 (m, 14H)
N-H peak was not observed; 13C NMR (150MHz, CDCl3) ppm 171.4, 155.1, 139.4, 134.6, 129.0,
128.9, 128.8, 128.6, 128.6, 128.4, 128.3, 128.2, 127.2, 79.9, 68.0, 63.6, 53.2, 43.6, 36.8, 17.6, 17.5,
17.4, 17.2, 13.6, 12.8; HRMS (ESI): Exact mass calcd for C51H67N4O9Si2 [M+H]
+ 935.4446, found
935.4454.
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Bis(oxazolidine dione) 345. To a solution of the bis(oxazolidine dione) (100mg, 107 µmol) in
tetrahydrofuran (500 µL, 123µmol) was added HF–pyridine (70:30 by wt., 65µL) and the reac-
tion was stirred at rt for 1 h. The reaction mixture was poured into water and extracted with
dichloromethane. The combined organic layers were dried, concentrated and purified using flash
chromatography (SiO2, 50–70% ethyl acetate in hexanes) to afford the diol as a colorless oil (28mg,
38%). [α]20D −30.0 (c 0.54, CHCl3); Rf = 0.45 (50% EtOAc/hexanes); IR (film) 3482, 3031, 2924,
1811, 1732 cm−1; 1H NMR (400MHz, CDCl3) δ 7.38–7.34 (m, 2H), 7.28–7.22 (m, 6H), 7.18–7.13
(m, 2H), 4.95 (d, J = 2.0Hz, 1H), 4.61 (d, J = 15.2Hz, 1H), 4.57 (d, J = 15.2Hz, 1H), 3.81
(d, J = 12.5Hz, 1H), 3.76 (ddd, J = 11.0, 5.7, 5.7Hz, 1H), 3.67 (d, J = 12.8Hz, 1H), 3.05 (dd,
J = 9.1, 2.0Hz, 1H), 1.80 (dd, J = 5.6, 5.3Hz, 1H), 1.70 (br. 2H); 13C NMR (100MHz, CDCl3)
ppm 172.5, 155.9, 138.6, 134.5, 128.7, 128.7, 128.6, 128.5, 128.2, 127.5, 79.3, 68.9, 62.4, 52.4, 43.7,
41.0; HRMS (ESI): Exact mass calcd for C39H41N4O8 [M+H]
+ 693.2924, found 693.2953.
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Isopropyl benzyl(2-(diethoxyphosphoryl)acetyl)carbamate (424). To a solution of hexam-
ethyldisilazane (9.67mL, 59.9mmol) in THF (50mL) at −78 ◦C was added n-butyllithium (2.5m
in hexanes, 12.5mL, 59.8mmol) via syringe. The solution was warmed to 0 ◦C, stirred for 15min,
and then cooled to −78 ◦C. A solution of the amidophosphonate (7.76 g, 27.2mmol) was added
in one portion. The solution was warmed to 0 ◦C (15min), cooled to −78 ◦C and then isopropyl
chloroformate (1.0m in toluene, 41mL) was added via syringe and the solution was slowly warmed
to rt. The reaction was quenched with satd aq ammonium chloride and concentrated. The yellow
residue was diluted with ethyl acetate and layers were separated. The aqueous layer was extracted
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with ethyl acetate, and the combined organic layers were dried and concentrated. The residue was
purified using flash chromatography (SiO2, 50% ethyl acetate in hexanes) to afford the imidophos-
phonate as a yellow oil (4.02 g, 40%). Rf = 0.25 (50% EtOAc/hexanes); IR (film) 3031, 2983, 2936,
1734, 1695 cm−1; 1H NMR (400MHz, CDCl3) δ 7.27–7.18 (m, 5H), 4.95 (septet, J = 6.2Hz, 1H),
4.91 (s, 2H), 4.09 (dq, J = 15.0, 7.1Hz, 4H), 3.82 (d, J = 22Hz, 2H), 1.25 (t, J = 7.0Hz, 6H),
1.19 (d, J = 6.3Hz, 6H); 13C NMR (100MHz, CDCl3) ppm 167.6 (d, J = 6.4Hz), 153.8, 137.4,
128.2, 127.7, 127.2, 71.6, 62.4 (d, J = 130Hz), 47.4, 37.1 (d, J = 133.3Hz), 36.4, 21.5, 16.2 (d, J =
6.4Hz); 31P NMR (162MHz, CDCl3, δ): 21.7; HRMS (ESI): Exact mass calcd for C17H26NNaO6P
[M+Na]+ 394.1395, found 394.1405.
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Isopropyl (2-(diethoxyphosphoryl)acetyl)(phenyl)carbamate (347). To a solution of hex-
amethyldisilazane (2.40mL, 11.6mmol) in THF (20mL) at −78 ◦C was added n-butyllithium (2.5m
in hexanes, 4.70mL, 11.7mmol) via syringe. The solution was warmed to 0 ◦C, stirred for 30min
and then cooled to −78 ◦C. Amidophosphonate (1.57 g, 5.79mmol) was added in one portion and
the solution was warmed to 0 ◦C and stirred for 30min. The reaction mixture was cooled to −78 ◦C,
isopropyl chloroformate (1.0m in toluene, 8.7mL, 8.7mmol) was added via syringe and the solution
was slowly warmed to rt. The reaction was quenched with water (1.0mL), concentrated, and the
residue was purified using flash chromatography (SiO2, 25% ethyl acetate in hexanes) to afford the
imidophosphonate as a brown oil (1.66 g, 86%). Rf = 0.50 (EtOAc); IR (film) 3473, 3065, 2984,
2936, 1738, 1732, 1713, 1698, 1651, 1596, 1538 cm−1; 1H NMR (400MHz, CDCl3) δ 7.30–7.28 (m,
3H), 7.09 (dd, J = 6.6, 1.6Hz, 2H), 4.95 (sept, J = 6.1Hz, 1H), 4.21 (dq, J = 8.0, 7.3Hz, 4H),
3.94 (d, J = 21.8Hz, 2H), 1.37 (d, J = 7.2Hz, 6H), 1.35 (d, J = 7.1Hz, 6H); 13C NMR (100MHz,
CDCl3) ppm 167.7 (d, J = 6.5Hz), 153.6, 138.0, 128.9, 128.0, 71.5, 62.5 (d, J = 6.5Hz), 36.8 (d,
J = 130Hz), 21.3, 16.2 (d, J = 6.5Hz); 31P NMR (162MHz, CDCl3, δ: 20.4; HRMS (ESI): Exact
mass calcd for C16H24NNaO6P [M+Na]
+ 380.1239, found 380.1236. Anal calcd for C13H24NO6P:
C, 53.76; H, 6.77; N, 4.06; found C, 52.92; H, 6.85; N, 4.10.
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TMP1
Bisimide 350. To a solution of the imidophosphonate 347 (815mg, 2.28mmol) in tetrahydrofu-
ran (10mL) at −78 ◦C was added sodium hydride (55mg, 2.3mmol). The solution was warmed
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to 0 ◦C, stirred for 15min, cooled to −78 ◦C and then treated with a solution of aldehyde 349
(prepared164 from 250mg, 570 µmol of tetraol 329) in tetrahydrofuran (5mL) was added via can-
nula. The reaction was warmed to −20 ◦C stirred for 18h and quenched with satd NH4Cl. The
reaction mixture was concentrated, diluted with ethyl acetate, separated, and the aqueous layer
was extracted further with ethyl acetate. The combined organic layers were washed with brine,
dried and concentrated. The resulting yellow oil was purified using flash chromatography (SiO2,
10–20% ethyl acetate in hexanes) to afford the bisimide as a colorless oil (327mg, 73%). [α]20D
+3.4 (c 0.89, CHCl3); Rf = 0.53 (25% EtOAc/hexanes); IR (film) 3065, 3074, 2945, 2894, 2868,
1767, 1736, 1696, 1642, 1642 cm−1; 1H NMR (400MHz, CDCl3) δ 7.42–7.32 (m, 3H), 7.14–7.11 (m,
2H), 7.02 (dd, J = 15.3, 3.6Hz, 1H), 6.81 (dd, J = 1.6, 1.6Hz, 1H), 5.01 (sept, J = 6.2Hz, 1H),
4.70–4.60 (m, 1H), 1.61 (dd, J = 8.2, 5.6Hz, 1H), 1.20 (d, J = 3.1Hz, 3H), 1.18 (d, J = 3.1Hz,
3H), 1.09–0.85 (m, 14H); 13C NMR (100MHz, CDCl3) ppm 170.3, 153.4, 138.1, 135.3, 129.0, 128.7,
128.7, 128.2, 128.2, 128.1, 128.1, 127.8, 80.9, 71.8, 65.9, 62.4, 52.7, 36.5, 21.6, 21.3, 17.6, 17.5, 17.5,
17.4, 16.9, 14.0, 12.6; HRMS (ESI): Exact mass calcd for C41H60N2NaO9Si2 [M+Na]
+ 803.3735,
found 803.3746. Anal calcd for C41H60N2O9Si2: C, 63.05; H, 7.75; N, 3.59; found C, 63.30; H, 7.60;
N, 3.57.
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Bis(triazoline) 351. To a solution of the bisimide 350 (400mg, 500µmol) and benzyl azide
(665mg, 5.00mmol) in acetonitrile (2.5mL) at −20 ◦C was added triflic acid (220 µL, 2.5mmol)
and the solution was stirred at −20 ◦C for 6 h. The reaction was quenched with triethylamine
(450µL 2.5mmol) and warmed to rt. The reaction mixture was poured into water and extracted
with ethyl acetate. The combined organic layers were washed with brine, dried and concentrated.
The brown residue was purified using flash chromatography at 0 ◦C (SiO2, 10–30% ethyl acetate
in hexanes) to afford the triazoline as a yellow oil (358mg, 68%). [α]20D 114.2 (c 10.10, CHCl3); Rf
= 0.38 (25% EtOAc/hexanes); IR (film) 3063, 3030, 2942, 2867, 1710 cm−1; 1H NMR (600MHz,
CDCl3) δ 7.38–7.24 (m, 6H), 7.20 (d, J = 7.6Hz, 2H), 7.11 (ddd, J = 6.8, 1.6, 1.6Hz, 2H), 6.08 (d,
J = 10.1Hz, 1H), 5.31 (d, J = 15.4Hz, 1H), 5.05 (septet, J = 6.3Hz, 1H), 4.54 (d, J = 15.5Hz,
1H), 4.31–4.25 (m, 1H), 3.89 (dd, J = 9.2, 1.0Hz, 1H), 1.27–1.22 (m, 4H), 1.18 (d, J = 6.2Hz,
3H), 1.12–0.81 (m, 14H); 13C NMR (150MHz, CDCl3) ppm 170.3, 153.4, 138.1, 135.3, 129.0, 128.7,
128.7, 128.2, 128.2, 128.1, 128.1, 127.8, 80.9, 71.8, 65.9, 62.4, 52.7, 36.5, 21.6, 21.3, 17.6, 17.5, 17.5,
17.4, 16.9, 14.0, 12.6; HRMS (ESI): Exact mass calcd for C55H74N8NaO9Si2 [M+Na]
+ 1069.5015,
found 1069.5051.
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Bis(oxazolidine dione) 346.To a solution of triazoline (12.00 g, 11.46µmol) in dichloromethane
(120mL) at −78 ◦C was added toluenesulfonic acid monohydrate (8.72 g, 45.8mmol) via syringe.
The solution was slowly warmed to rt, stirred for 1 h. To the reaction mixture was added solid
NaHCO3 (3.85 g, 45.8mmol) and stirring was continued for 1 h at rt. Celite (ca. (10 g) was added
and the reaction mixture was filtered through a pad of Celite, the filter cake was washed with
CH2Cl2 and the resulting solution was concentrated. The resultin green oil was purified using flash
chromatography (SiO2, 25% ethyl acetate in hexanes) to afford the bis(oxazolidine dione) as a
yellow oil (10.0 g, 96%). [α]20D 14.1 (c 0.92, CHCl3); Rf = 0.30 (25% EtOAc/hexanes); IR (film)
3029, 2945, 2867, 1817, 1746, 1598, 1502 cm−1; 1H NMR (400MHz, CDCl3) δ 7.50–7.17 (m, 10H),
5.11 (d, J = 3.8Hz, 1H), 4.40 (ddd, J = 7.4, 5.2, 5.2Hz, 1H), 3.96 (d, J = 13.0Hz, 1H), 3.85 (d,
J = 13.0Hz, 1H), 3.27 (dd, J = 4.6, 4.4Hz, 1H), 1.96 (dd, J = 7.0, 6.3Hz, 1H), 1.61 (brs, 1H),
1.07–1.00 (m, 14H); 13C NMR (100MHz, CDCl3) 170.7, 154.2, 139.4, 130.8, 129.3, 128.9, 128.5,
128.3, 127.3, 125.7, 79.7, 68.0, 64.3, 53.6, 17.6, 17.5, 17.4, 17.3, 13.6, 12.9 ppm; HRMS (ESI): Exact
mass calcd for C49H62N4NaO9Si2 [M+Na]
+ 929.4134, found 929.4128.
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Bis(ester) 352. To a suspension of bis(oxazolidine dione) (31mg, 34µmol) in anhydrous methanol
(500µL) was added titanium(IV) isopropoxide (31 µL, 100 µmol) and the suspension was stirred at
rt for 48h. The reaction mixture was poured into water and extracted with dichloromethane. The
combined organic layers were washed with brine, dried and concentrated. The residue was purified
using flash chromatography (SiO2, 0.5–1% methanol in chloroform) to afford the product as a clear
oil (18.2 g, 55%). [α]20D −13.9 (c 0.72, CHCl3); Rf = 0.12 (0.5% MeOH/CHCl3); IR (film) 3304,
3197, 3132, 3061, 3028, 2946, 2893, 2867, 1738, 1602, 1556 cm−1; 1H NMR (600MHz, CDCl3) δ
8.12 (brs, 1H) 7.37–7.16 (m, 9H), 6.99 (t, J = 7.4Hz, 1H), 5.44 (d, J = 4.6Hz, 1H), 4.14 (ddd,
J = 8.1, 5.2, 2.3Hz, 1H), 3.96 (d, J = 13.3Hz, 1H), 3.85 (d, J = 13.5Hz, 1H), 3.74 (s, 3H), 3.31
(dd, J = 4.6, 2.5Hz, 1H), 2.07 (dd, J = 6.8, 6.6Hz, 1H), 1.96 (br, 1H), 1.04–0.96 (m, 9H), 0.92–0.86
(m, 5H); 13C NMR (150MHz, CDCl3) ppm 170.3, 152.8, 138.9, 137.9, 128.8, 128.6, 128.4, 128.3,
128.1, 127.3, 123.2, 118.7, 70.8, 68.2, 61.3, 52.4, 51.2, 33.9, 17.4, 17.3, 17.3, 17.1, 13.2, 12.5; HRMS
(ESI): Exact mass calcd for C51H70N4NaO11Si2 [M+Na]
+ 993.4458, found 993.4620.
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Bis(amide) 355. To a suspension of bis(oxazolidine dione) (1.20 g, 1.30mmol) in anhydrous
methanol (50mL) was added a saturated solution of ammonia in methanol (5.0mL). The reaction
was warmed to rt and stirred for 18h. The solution was concentrated and purified using flash
chromatography (SiO2, 10–35% ethyl acetate in hexanes) to afford the product as a colorless oil
(97.7mg, 8%). [α]20D 16.1 (c 3.31, CHCl3); Rf = 0.30 (25% EtOAc/hexanes); IR (film) 3312, 3062,
2928, 2866, 1752, 1685, 1600, 1530 cm−1; 1H NMR (400MHz, CDCl3) δ 9.06 (s, 1H), 8.12 (s, 1H),
7.62 (d, J = 8.0Hz, 2H), 7.56 (d, J = 8.0Hz, 2H), 7.41–7.28 (m, 9H), 7.21–7.06 (m, 6H), 6.99 (dd,
J = 7.5, 7.3Hz, 1H), 6.76 (br, 1H), 4.95 (d, J = 15.0Hz, 1H), 4.84 (dd, J = 9.9, 9.7Hz, 1H), 4.76
(d, J = 14.6Hz, 1H), 4.64 (dd, J = 7.0, 2.4Hz, 1H), 4.54 (d, J = 5.4Hz, 1H), 4.17 (d, J = 14.6Hz,
1H), 4.14 (d, J = 10.9Hz, 1H), 3.95 (d, J = 15.1Hz, 1H), 3.85 (dd, J = 8.9, 2.2Hz, 1H), 3.75 (s,
3H), 3.52–3.43 (m, 3H), 1.39 (dd, J = 13.0, 12.9Hz, 1H), 1.29–0.99 (m, 23H), 0.97–0.78 (m, 5H),
0.22 (dd, J = 12.9, 12.4Hz, 1H); 13C NMR (100MHz, CDCl3) 171.0, 166.8, 160.1, 156.3, 137.4,
136.6, 136.3, 134.6, 130.0, 129.2, 129.0, 128.3, 128.2, 127.83, 127.78, 125.1, 124.4, 120.0, 119.6, 77.2,
73.6, 71.7, 65.9, 65.7, 64.7, 62.5, 55.0, 53.8, 46.3, 35.9, 29.7, 17.8, 17.7, 17.4, 17.29, 17.27, 17.25,
16.7, 14.2, 14.1, 13.8, 13.4, 12.9, 12.5, ppm; HRMS (ESI): Exact mass calcd for C50H67N4O10Si2
[M+H]+ 939.4396, found 939.4413.
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Bis(amide) 353. To a suspension of bis(oxazolidine dione) (120mg, 130 µmol) in anhydrous
methanol (10mL) was added a saturated solution of ammonia in methanol (1.0mL). The reaction
was warmed to rt and stirred for 18h. The solution was concentrated and purified using flash
chromatography (SiO2, 25–35% ethyl acetate in hexanes) to afford the product as a colorless oil
(81mg, 67%). [α]20D −79.7 (c 1.85, CHCl3); Rf = 0.25 (25% EtOAc/hexanes); IR (film) 3331, 3063,
2945, 2867, 1760, 1688, 1601 cm−1; 1H NMR (600MHz, CDCl3) δ 8.19 (s, 1H), 7.51 (d, J = 8.4Hz,
2H), 7.34 (d, J = 7.6Hz, 1H), 7.33 (d, J = 7.8Hz, 1H), 7.29–7.22 (m, 3H), 7.18–7.14 (m, 3H),
4.94 (d, J = 15.5Hz, 1H), 4.85 (d, J = 4.8Hz, 1H), 4.39–4.34 (m, 1H), 4.11 (d, J = 15.3Hz, 1H),
3.89 (d, J = 5.0Hz, 1H), 1.66 (dt, J = 14.6, 8.8Hz, 1H), 1.18–0.82 (m, 14H); 13C NMR (150MHz,
CDCl3) ppm 170.7, 154.2, 139.4, 130.8, 129.3, 128.9, 128.5, 128.3, 127.3, 125.7, 79.7, 68.0, 64.3,
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53.6, 34.4, 17.6, 17.5, 17.4, 17.3, 13.6, 12.9; HRMS (ESI): Exact mass calcd for C49H63N4O9Si2
[M+H]+ 907.4134, found 907.4100.
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Bis(imide) 359. To a solution of the amide (271mg, 299 µmol) in CH3CN (1.2mL) at 0 ◦C was
added Boc2O (655mg, 3.00mmol) followed by 4-DMAP (185mg, 1.50mmol) and the reaction was
stirred at rt for 20h. The reaction mixture was concentrated and purified using flash chromatogra-
phy (SiO2, 30–60% ethyl acetate in hexanes) to afford the product as a yellow oil (201mg, 61%).
[α]20D −49.2 (c 1.14, CHCl3); Rf = 0.45 (50% EtOAc/hexanes); IR (film) 3065, 3033, 2944, 2894,
2867, 1775, 1727 cm−1; 1H NMR (400MHz, CDCl3) δ 7.43–7.33 (m, 3H), 7.32–7.24 (m, 3H), 7.23–
7.17 (m, 2H), 6.96–6.89 (m, 2H), 5.69 (d, J = 2.9Hz, 1H), 5.05 (d, J = 15.1Hz, 1H), 4.57 (ddd, J
= 6.6, 1.5, 1.5Hz, 1H), 4.26 (d, J = 15.4Hz, 1H), 3.87 (dd, J = 3.3, 1.5Hz, 1H), 1.72 (dt, J = 13.6,
8.5Hz, 1H), 1.32 (s, 9H), 1.20–1.10 (m, 7H), 1.02–0.93 (m, 4H), 0.76 (d, J = 7.1Hz, 3H); 13C NMR
(100MHz, CDCl3) ppm 171.0, 157.7, 152.6, 137.4, 135.7, 129.1, 128.7, 128.3, 127.8, 127.6, 84.3,
73.4, 68.8, 61.9, 47.4, 31.2, 27.5, 17.6, 17.54, 17.47, 16.7, 13.3, 12.7; HRMS (ESI): Exact mass calcd
for C59H78N4NaO13Si2 [M+Na]
+ 1129.5002, found 1129.5039.
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Bis(carboxylic acid) 360. To a solution of the imide (200mg, 180 µmol) in THF–H2O (3:1
v/v, 3.6mL) at 0 ◦C was added LiOH (40mg), followed by H2O2 (30% in water, 400 µL), and the
reaction was stirred at rt for 15min. The reaction was cooled to 0 ◦C, quenched with solid Na2SO3
(1 g) and warmed to rt. Water (5mL) and ethyl acetate (5mL) were added and the solution was
vigorously stirred for 5min. The layers were separated and the aqueous layer was acidified to pH
5 with KHSO4(s). The aqueous layer was extracted with ethyl acetate and the combined organic
layers were dried and concentrated to afford the carboxylic acid as a colorless oil (129mg, 95%).
[α]20D 28.4 (c 0.37, CHCl3); Rf = 0.32 (10% H2O/MeCN); IR (film) 3512, 3032, 2946, 2868, 1756,
1497, 1444, 1363 cm−1; 1H NMR (400MHz, CDCl3) δ 7.36–7.21 (m, 3H), 7.12 (d, J = 7.8Hz, 2H),
5.00 (d, J = 15.7Hz, 1H), 4.84 (d, J = 4.0Hz, 1H), 4.70–4.0 (br s, 1H), 4.31 (dd, J = 8.1, 6.6Hz,
1H), 3.89 (d, J = 15.7Hz, 1H), 3.50 (d, J = 4.1Hz, 1H), 1.34 (dt, J = 15.0, 8.9Hz, 1H), 1.18–0.76
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(m, 14H); 13C NMR (100MHz, CD3OD) ppm 177.1, 161.1, 137.3, 130.9, 130.0, 129.6, 74.3, 65.2,
47.7, 31.7, 18.4, 18.3, 18.0, 17.3, 15.9, 14.1; HRMS (ESI): Exact mass calcd for C37H52N2NaO11Si2
[M+Na]+ 779.3007, found 779.2975.
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Bis(ester) 361. A solution of bis(carboxylic acid) (132mg, 175 µmol) in diethyl ether (2mL) was
treated with a solution of diazomethane198 in diethyl ether (25mL). The resulting solution was
stirred at rt for 18h and concentrated to afford the bis(ester) as a yellow oil (137mg, 99%). [α]20D
+27.7 (c 0.75, CHCl3); Rf = 0.23 (25% EtOAc/hexanes); IR (film) 2947, 2868, 1769, 1625 cm−1;
1H NMR (400MHz, CDCl3) δ 7.39–7.28 (m, 3H), 7.21–7.16 (m, 2H), 5.00 (d, J = 15.2Hz, 1H),
4.74 (d, J = 4.4Hz, 1H), 4.26 (ddd, J = 13.8, 8.4, 7.8Hz, 1H), 3.99 (d, J = 15.3Hz, 1H), 3.73 (s,
3H), 3.54 (dd, J = 4.8, 1.0Hz, 1H), 1.37 (dt, J = 14.1, 8.8Hz, 1H), 1.16–0.81 (m, 14H); 13C NMR
(100MHz, CDCl3) ppm 169.3, 156.9, 134.7, 128.9, 128.2, 127.6, 70.7, 65.7, 62.0, 52.9, 46.5, 34.5,
17.5, 17.3 (2C), 16.6, 14.0, 12.6; HRMS (ESI): Exact mass calcd for C39H56N2NaO11Si2 [M+Na]
+
807.3320, found 807.3301.
toluene, rt, 18 h
O OMeO2C
TIPDS
CO2Me
N
O O
N
BnBn OO
DIBAL
O OiBuO2C
TIPDS
CO2iBu
N
O O
N
BnBn OO
Bis(isobutyl ester) 425. To a solution of the bis(methyl ester) (14.1mg, 17.9µmol) in toluene
(300µL) was added DIBAL (1.0m in toluene, 36µL, 36µmol) and the solution was stirred at rt
for 18h. The reaction was quenched by the addition of aq satd Rochelle’s salt (1mL), the layers
were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic
layers were dried, concentrated and purified using flash chromatography (SiO2, 25% ethyl acetate
in hexanes) to afford the bis(isobutyl ester) as a yellow oil (5.1mg, 33%). [α]20D +30.0 (c 0.54,
CHCl3); Rf = 0.48 (25% EtOAc/hexanes); IR (film) 2960, 2868, 1772 cm−1; 1H NMR (600MHz,
CDCl3) δ 7.35–7.37 (m, 3H), 7.18 (d, J = 8.2Hz, 2H), 5.00 (J = 15.4Hz, 1H), 4.73 (d, J = 4.4Hz,
1H), 4.26 (ddd, J = 13.8, 8.4, 7.8Hz, 1H), 3.99 (d, J = 15.4Hz, 1H), 3.90 (dd, J = 10.6, 6.6Hz,
1H), 3.87 (dd, J = 10.6, 6.6Hz, 1H), 3.54 (d, J = 4.3Hz, 1H), 1.91–1.81 (m, 1H), 1.37 (dt, J =
13.8, 8.0Hz, 1H), 1.15–1.08 (m, 7H), 1.06 (d, J = 7.7Hz, 3H), 0.97 (d, J = 7.5Hz, 3H), 0.91–0.85
(m, 1H), 0.84 (d, J = 6.7Hz, 3H), 0.83 (d, J = 6.7Hz, 3H); 13C NMR (150MHz, CDCl3) ppm
169.0, 157.0, 134.8, 129.0, 128.2, 127.7, 72.1, 70.8, 65.9, 62.1, 46.6, 34.6, 27.6, 18.8 (2C), 17.6, 17.4,
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16.7, 14.0, 12.6; HRMS (ESI): Exact mass calcd for C45H68N2NaO11Si2 [M+Na]
+ 891.4259, found
891.4265.
MeOH, rt, 3 h
O O
TIPDS
N
O O
N
BnBn OO
O OMeO2C
TIPDS
CO2Me
N
O O
N
BnBn OO
NaBH4
HO OH
Bis(alcohol) 356. To a suspension of the bis(ester) (32.5mg, 41.3 µmol) in anhydrous methanol
(600µL) at 0 ◦C was added NaBH4 (4.7mg, 120 µmol. The reaction was warmed to rt, stirred for
30min and then quenched by addition of NH4Cl (200mg). The reaction mixture was concentrated,
diluted with water and extracted with ethyl acetate. The combined organic layers were dried,
concentrated and purified using flash chromatography (SiO2, 5% methanol in dichloromethane) to
afford the product as a colorless oil (27.7mg, 92%). [α]20D −20.4 (c 1.26, CHCl3); Rf = 0.20 (5%
MeOH/CH2Cl2); IR (film) 3417, 3089, 3064, 3032, 2944, 2894, 2867, 1752, 1738 cm−1; 1H NMR
(600MHz, CDCl3) δ 7.34–7.29 (m, 2H), 7.29–7.24 (m, 1H), 7.23–7.19 (m, 2H), 4.91 (d, J = 15.1Hz,
1H), 4.34 (dd, J = 8.9, 4.2Hz, 1H), 4.14 (ddd, J = 13.7, 7.9, 7.9Hz, 1H), 4.04 (d, J = 15.3Hz,
1H), 3.61 (d, J = 12.0Hz, 1H), 3.48 (d, J = 4.6Hz, 1H), 3.44 (d, J = 11.9Hz, 1H), 2.88 (br s,
1H), 1.25 (dt, J = 15.1, 8.7Hz, 1H), 1.14–0.99 (m, 10H), 0.95–0.91 (m, 3H), 0.87–0.81 (m, 1H);
13C NMR (150MHz, CDCl3) ppm 158.2, 135.3, 128.8, 128.8, 128.0, 127.9, 74.4, 66.0, 63.4, 60.4,
46.6, 33.9, 17.6, 17.4 (2C), 16.7, 14.1, 12.6; HRMS (ESI): Exact mass calcd for C37H56N2NaO9Si2
[M+Na]+ 751.3422, found 751.3451.
DMF, rt, 3 h
O O
TIPDS
N
O O
N
BnBn OO
TBSCl, ImH
HO OTBSO OTIPDS
N
O O
N
BnBn OO
HO OH
Alcohol 426. A solution of bis(alcohol) (24mg, 33µmol), TBSCl (4.0mg, 26µmol) and imidazole
(2.7mg, 17µmol) in DMF (600 µL) was stirred at rt until TLC analysis showed presence of bis(silyl
ether). To the reaction was added aq 5% LiCl (1mL) and the mixture was extracted with ethyl
acetate. The combined organic layers were dried, concentrated, and purified using flash chromatog-
raphy (SiO2, 37% ethyl acetate in hexanes) to afford the desired product as a colorless oil (8.9mg,
32%). [α]20D −25.5 (c 2.51, CHCl3); Rf = 0.30 (37% EtOAc/hexanes); IR (film) 3443, 3031, 2945,
2867, 1755 cm−1; 1H NMR (600MHz, CDCl3) δ 7.34–7.25 (m, 6H), 7.24–7.21 (m, 4H), 4.94 (d, J
= 15.3Hz, 1H), 4.91 (d, J = 15.2Hz, 1H), 4.42 (dd, J = 8.9, 4.6Hz, 1H), 4.19 (dd, J = 10.4,
2.4Hz, 1H), 4.15–4.05 (m, 4H), 4.03 (d, J = 15.3Hz, 1H), 3.68 (ddd, J = 12.1, 4.6, 4.6Hz, 1H),
3.58 (dd, J = 10.5, 3.1Hz, 1H), 3.50–3.43 (m, 3H), 2.34 (t, J = 5.8Hz, 1H), 1.26–0.81 (m, 30H),
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0.78 (s, 9H), −0.05 (s, 3H), −0.04 (s, 3H); 13C NMR (150MHz, CDCl3) ppm 158.0, 157.9, 135.7,
135.2, 128.8 (2C), 128.0 (2C), 127.9 (2C), 74.1, 67.5, 65.5, 63.7, 63.3, 60.6, 60.5, 46.8, 46.6, 33.7,
29.7, 25.7, 18.3, 17.6, 17.4 (2C), 16.8, 16.7, 14.1, 13.8, 12.6 (2C), -5.6 (2C); HRMS (ESI): Exact
mass calcd for C43H70N2NaO9Si3 [M+Na]
+ 865.4287, found 865.4275.
pyridine, 65–70 °C
O O
TIPDS
N
O O
N
BnBn OO
Ph3CCl
HO OCPh3
O O
TIPDS
N
O O
N
BnBn OO
HO OH
Alcohol 357. A solution of bis(alcohol) (276mg, 378µmol) and triphenylmethyl chloride (84.5mg,
300 µmol) in anhydrous pyridine (2.0mL) was stirred at 65 ◦C–70 ◦C for 8h. The reaction mixture
was poured into 1m HCl and ethyl acetate (20mL) was added. The layers were separated and
the organic layer was washed with 1m HCl. The combined aqueous layers were extracted with
ethyl acetate, and the organic layers were combined, dried and concentrated. The resulting oil
was purified using flash chromatography (SiO2, 25–100% ethyl acetate in hexanes) to afford the
desired product as a colorless oil (110mg, 30%) and unreacted substrate as a colorless oil (177mg,
64%). [α]20D −26.5 (c 1.50, CHCl3); Rf = 0.50 (50% EtOAc/hexanes); IR (film) 3424, 3062, 3030,
2928, 2866, 1753, 1492, 1443 cm−1; 1H NMR (400MHz, CDCl3) δ 7.39–7.22 (m, 15H), 7.22–7.10
(m, 10H), 4.97 (d, J = 15.3Hz, 1H), 4.92 (d, J = 15.4Hz, 1H), 4.38 (dd, J = 9.2, 4.7Hz, 1H),
4.26 (dd, J = 9.4, 4.8Hz, 1H), 4.19 (dd, J = 10.0, 3.4Hz, 1H), 4.05 (d, J = 15.1Hz, 1H), 4.04 (dd,
J = 9.2, 3.8Hz, 1H), 3.96 (d, J = 15.4Hz, 1H), 3.53–3.45 (m, 2H), 3.42 (d, J = 4.4Hz, 1H), 3.35
(ddd, J = 11.2, 5.5, 5.4Hz, 1H), 3.28 (d, J = 4.8Hz, 1H), 3.17 (dd, J = 9.2, 6.0Hz, 1H), 3.05 (dd,
J = 10.0, 4.0Hz, 1H), 1.51 (br s, 2H), 1.30–0.70 (m, 28H); 13C NMR (100MHz, CDCl3) ppm 157.9,
143.0, 135.4, 135.3, 128.9, 128.8, 128.5, 128.2, 127.8, 127.2, 87.2, 77.2, 73.8, 73.2, 66.9, 64.9, 63.9,
63.7, 61.2, 60.5, 46.8, 46.4, 34.0, 29.7, 25.8, 17.6, 17.5, 17.46, 17.41, 16.7, 14.2, 13.9, 12.7, 12.5;
HRMS (ESI): Exact mass calcd for C56H70N2NaO9Si2 [M+Na]
+ 993.4518, found 993.4495.
CH2Cl2, 0 °C, 1 h
C6F5OCHO
iPr2NEtHO NH2
CO2Me
HO N
CO2Me
CHO
HHCl
(S)-methyl 2-formamido-3-hydroxypropanoate (376). To a suspension of l-Ser hydrochlo-
ride (1.00 g, 6.43mmol) in CHCl3 (10mL) was added pentafluorophenyl formate (980µL, 7.72 µmol)
and Hünig’s base (1.12mL, 6.63mmol) via syringe. The solution was stirred for 1 h at 0 ◦C and
concentrated. The residue was purified using flash chromatography (SiO2, 50–95% ethyl acetate in
hexanes) to afford the desired product as a clear oil (854mg, 90%). [α]20D +38.1 (c 1.00, CHCl3);
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Rf = 0.25 (EtOAc); IR (film) 3300, 3031, 2857, 2823, 1748, 1718, 1683, 1669, 1653, 1617, 1558,
1539, 1521, 1516 cm−1; 1H NMR (400MHz, CDCl3) δ 8.27 (s, 1H), 6.57 (br s, 1H), 5.07 (ddd, J
= 7.6, 3.6, 3.0Hz, 1H), 4.00 (dd, J = 11.5, 2.9Hz, 1H), 3.92 (dd, J = 11.5, 3.4Hz, 1H), 3.83 (s,
3H), OH peak was not observed; 13C NMR (100MHz, CDCl3) ppm 168.8, 160.6, 53.2, 51.8, 44.8;
HRMS (ESI): Decomp.
THF, 0 °C to rt, 3 h
HN3, Ph3P, DEAD
HO N
CO2Me
N3
N
CO2Me
CHO
HH
CHO
(S)-methyl 3-azido-2-formamidopropanoate (374). To a solution of the alcohol (147mg,
1.00mmol) and triphenylphosphine (340mg, 1.20mmol) in THF at 0 ◦C was added HN3 (1.0m in
benzene, 2.0mL, 2.0mmol) via syringe. The reaction was stirred at 0 ◦C for 5min and DEAD
(200µL, 1.30mmol) was added dropwise via syringe. The reaction was stirred at 0 ◦C for 5min,
warmed to rt and stirred for 3h. The reaction was quenched with satd aq NaHCO3, the layers
were separated and the aqueous layer was extracted with ethyl acetate, dried and concentrated.
The resulting residue was purified using flash chromatography (40–70% ethyl acetate in hexanes)
to afford the desired product as a clear oil (107mg, 62%). [α]20D +95.7 (c 5.25, CHCl3); Rf = 0.15
(50% EtOAc/hexanes); IR (film) 3304, 3036, 2955, 2923, 2875, 2856, 2107, 1744, 1666, 1515 cm−1;
1H NMR (400MHz, CDCl3) δ 8.26 (s, 1H), 6.65 (br s, 1H), 4.83 (ddd, J = 7.6, 3.5, 3.4Hz, 1H),
3.82 (s, 3H), 3.79 (d, J = 3.8Hz, 2H); 13C NMR (100MHz, CDCl3) ppm 169.5, 160.8, 53.1, 52.1,
50.8; HRMS (ESI): Exact mass calcd for C5H9N4O3 [M+H]
+ 173.0669, found 173.0664.
DMF, 0 °C to rt, 4 h
TBSCl, ImH
HO N
CO2Me
CHO
H
TBSO N
CO2Me
CHO
H
S-(methyl 3-((tert-butyldimethylsilyl)oxy)-2-formamidopropanoate (427). To a solution
of the alcohol (200mg, 1.36mmol) in DMF (1mL) at 0 ◦C was added TBSCl (310mg, 2.0mmol)
and imidazole (140mg, 2.0mmol). The reaction was warmed to rt and stirred for 4h. The reaction
mixture was poured into water and extracted with ethyl acetate. The combined organic layers were
dried, concentrated and purified using flash chromatography (SiO2, 50% ethyl acetate in hexanes)
to afford the silyl ether as a colorless oil (222mg, 62%). [α]20D +47.1 (c 3.08, CHCl3); Rf = 0.35
(50% EtOAc/hexanes); IR (film) 3314, 3029, 2953, 2933, 2885, 2858, 1750, 1677, 1514, 1468 cm−1;
1H NMR (400MHz, CDCl3) δ 8.26 (s, 1H), 6.43 (br s, 1H), 4.75 (ddd, J = 8.4, 2.6, 2.6Hz, 1H),
4.08 (dd, J = 10.2, 2.6Hz, 1H), 3.84 (dd, J = 10.2, 2.9Hz, 1H), 3.76 (s, 3H), 0.85 (s. 9H), 0.02 (s,
3H), 0.02 (s, 3H); 13C NMR (100MHz, CDCl3) ppm 170.3, 160.6, 63.4, 52.8, 52.5, 25.6, 18.1, −5.6,
−5.7; HRMS (ESI): Exact mass calcd for C10H20O4N1Si [M–CH3]– 246.1156, found 246.1158.
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CH2Cl2, 3 h
–78 °C to –30 °C
TBSO NC
CO2Me
TBSO N
CO2Me
CHO
H triphosgene
NMM
S-methyl 3-((tert-butyldimethylsilyl)oxy)-2-isocyanopropanoate (428). To a solution of
the formamide (60.1mg, 230 µmol) in dichloromethane (1.0mL) at rt was addedN -methylmorpholine
(51.0 µL, 460 µmol) and the reaction was cooled to −78 ◦C. Triphosgene (24.0mg, 80.0 µmol) was
added in one portion and the reaction was slowly warmed to −30 ◦C and stirred for 3h. The reac-
tion was quenched with water (at −30 ◦C), warmed to rt, and extracted with dichloromethane. The
combined organic layers were dried, concentrated to ca. 2mL and purified using flash chromatog-
raphy (SiO2, 25% ethyl acetate in hexanes) to afford the isonitrile as a pale yellow oil (35.3mg,
63%). [α]20D +4.4 (c 1.72, CHCl3); Rf = 0.45 (25% EtOAc/hexanes); IR (film) 2955, 2887, 2859,
2150, 1763, 1467, 1439 cm−1; 1H NMR (400MHz, CDCl3) δ 4.34 (dd, J = 4.7, 4.6Hz, 1H), 4.01
(dd, J = 5.2, 4.1Hz, 2H), 3.82 (s, 3H), 0.89 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H); 13C NMR (100MHz,
CDCl3) ppm 165.5, 160.8, 63.7, 58.6, 53.3, 25.6, 18.1, −5.5, −5.6; HRMS (ESI): Exact mass calcd
for C10H18O3N1Si [M–CH3]
– 228.1050, found 228.1042.
CH2Cl2
0 °C to rt, 3 h
TMSCl, NMM
HO N
CO2Me
CHO
H
TMSO N
CO2Me
CHO
H
S-methyl 2-formamido-3-((trimethylsilyl)oxy)propanoate (429). To a solution of the alco-
hol (200mg, 1.36mmol) in dichloromethane (7mL) at 0 ◦C was added TMSCl (190 µL, 1.50mmol)
and N -methylmoropholine (222 µL, 2.02mmol). The reaction was warmed to rt and stirred for 3h.
The reaction mixture was concentrated and purified using flash chromatography (SiO2, 25% ethyl
acetate in hexanes) to afford the silyl ether as a colorless oil (219mg, 74%). [α]20D +33.3 (c 1.09,
CHCl3); Rf = 0.35 (25% EtOAc/hexanes); IR (film) 3277, 3028, 2955, 2890, 1753, 1669, 1523,
1440 cm−1; 1H NMR (400MHz, CDCl3) δ 8.24 (s, 1H), 6.48 (br s, 1H), 4.75 (ddd, J = 8.5, 2.8,
2.8Hz, 1H), 4.04 (dd, J = 10.4, 2.6Hz, 1H), 3.84 (dd, J = 10.4, 3.1Hz, 1H), 3.75 (s, 3H), 0.07 (s,
9H); 13C NMR (100MHz, CDCl3) ppm 170.3, 160.6, 62.7, 52.6, 52.5, −0.8; HRMS (ESI): Exact
mass calcd for C7H14O4N1Si [M–CH3]
– 204.0687, found 204.0694.
CH2Cl2, 3 h
–78 °C to –30 °C
TMSO NC
CO2Me
TMSO N
CO2Me
CHO
H triphosgene
NMM
S-methyl 2-isocyano-3-((trimethylsilyl)oxy)propanoate (430). To a solution of the for-
mamide (110mg, 500 µmol) in dichloromethane (2.5mL) at rt was added N -methylmorpholine
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(110µL, 1.00mmol) and the reaction was cooled to −78 ◦C. Triphosgene (57.0mg, 190 µmol) was
added in one portion and the reaction was slowly warmed to −30 ◦C and stirred for 3 h. The re-
action was quenched with water (at −30 ◦C), warmed to rt and extracted with ethyl acetate. The
combined organic layers were dried, concentrated to ca. 2mL and purified using flash chromatogra-
phy (SiO2, 25% ethyl acetate in hexanes) to afford the isonitrile as a pale yellow oil (68mg, 68%).
[α]20D +8.3 (c 0.93, CHCl3); Rf = 0.41 (25% EtOAc/hexanes); IR (film) 2958, 2887, 2151, 1762,
1439 cm−1; 1H NMR (400MHz, CDCl3) δ 4.34 (dd, J = 4.9, 4.6Hz, 1H), 3.98 (d, J = 4.6Hz, 2H),
3.83 (s, 3H), 0.14 (s, 9H); 13C NMR (100MHz, CDCl3) ppm 165.4, 160.9, 63.1, 58.6, 53.3, −0.6;
HRMS (ESI): Exact mass calcd for C7H12O3N1Si [M–CH3]
– 186.0581, found 186.0577.
CH2Cl2, 0 °C, 1 h
C6F5OCHO
iPr2NEtBocHN
NH2
CO2Me
BocHN
N
CO2Me
CHO
H
S-methyl 3-((tert-butoxycarbonyl)amino)-2-formamidopropanoate (380). To a solution
of the amine (500mg, 2.30mmol) in CH2Cl2 (3.6mL) was added pentafluorophenyl formate (600 µL,
2.76mmol) and Hünig’s base (400 µL, 2.30mmol) via syringe. The solution was stirred for 15min at
0 ◦C and concentrated. The residue was purified using flash chromatography (SiO2, 1–5% methanol
in dichloromethane) to afford the desired product as a colorless oil (503mg, 89%). [α]20D +13.0 (c
2.24, CHCl3); Rf = 0.35 (4% MeOH/CH2Cl2); IR (film) 3330, 2978, 1743, 1682, 1517, 1440 cm−1;
1H NMR (400MHz, CDCl3) δ 8.21 (s, 1H), 7.00 (br s, 1H), 5.03 (dd, J = 6.2, 5.8Hz, 1H), 4.67
(ddd, J = 6.1, 5.1, 5.0Hz, 1H), 3.76 (s, 3H), 3.56 (m, 2H), 1.41 (s, 9H); 13C NMR (100MHz,
CDCl3) ppm 170.3, 161.2, 156.7, 80.3, 52.8, 52.4, 42.0, 28.2; HRMS (ESI): Exact mass calcd for
C10H18O5N2Na [M+Na]
+ 269.1113, found 269.1113.
CH2Cl2, 3 h
–78 °C to –30 °C
BocHN NC
CO2Me
BocHN
N
CO2Me
CHO
H triphosgene
NMM
S-methyl 3-((tert-butoxycarbonyl)amino)-2-isocyanopropanoate (381). To a solution of
the formamide (203mg, 824 µmol) in dichloromethane (3.0mL) at rt was addedN -methylmorpholine
(180µL, 1.65mmol) and the reaction was cooled to −78 ◦C. Triphosgene (90.5mg, 305 µmol) was
added in one portion and the reaction was slowly warmed to −30 ◦C and stirred for 3 h. The re-
action was quenched with water (at −30 ◦C), warmed to rt and extracted with ethyl acetate. The
combined organic layers were dried, concentrated to ca. 2mL and purified using flash chromatogra-
phy (SiO2, 25% ethyl acetate in hexanes) to afford the isonitrile as a pale yellow oil (133mg, 71%).
[α]20D −7.3 (c 1.30, CHCl3); Rf = 0.51 (25% EtOAc/hexanes); IR (film) 3363, 2879, 2152, 1756,
185
1709, 1519, 1441 cm−1; 1H NMR (400MHz, CDCl3) δ 5.24 (br s, 1H), 4.45 (t, J = 5.4Hz, 1H),
3.78 (s, 3H), 3.68–3.59 (m, 1H), 3.56–3.46 (m, 1H), 1.39 (s, 9H); 13C NMR (100MHz, CDCl3) ppm
165.5, 161.0, 155.4, 80.3, 56.2, 53.4, 42.6, 28.1; HRMS (ESI): Exact mass calcd for C10H15O4N2Si
[M–H]– 227.1026, found 227.1028.
O O
TIPDS
N
O O
N
BnBn OO
OCPh3O
O PhO
H
N
OMeO
BocHN
1,2-DCE
80 °C, 3 h
Me3SnOH
O O
TIPDS
N
O O
N
BnBn OO
OCPh3O
O PhO
H
N
OHO
BocHN
Carboxylic acid 385. To a vial containing the methyl ester (50.2mg, 37.8µmol) in 1,2-DCE
(1mL) was added trimethyltin hydroxide (20.5mg, 113 µmol) and the resulting solution was stirred
at 70–80 ◦C for 4 h. The reaction mixture was cooled, diluted with dichloromethane and washed
with a 10% solution of KHSO4. The combined aqueous layers were extracted with ethyl acetate
and the combined organic layers were dried and concentrated. The resulting yellow oil was dis-
solved in anhydrous methanol and filtered. The methanol solution was concentrated and purified
using preparative HLPC (XBridgeTM Prep C18 5 µm ODBTM 19× 150 µm column) using the fol-
lowing program: 10mLmin−1 40min gradient from 40% buffer A (95% water, 5% acetonitrile,
5mm NH4OAc) and 60% buffer B (95% acetonitrile, 5% water, 5mm NH4OAc) to 100% buffer B
and then 40min buffer B; tr(minor diastereomer) = 36.0min, tr(major diastereomer) = 38.7min.
Removal of solvent gave the minor diastereomer as a colorless oil (8.4mg, 17%) and major diastere-
omer as a colorless oil (12.3mg, 25%). [α]20D −40.0 (c 1.23, CHCl3);
Major diastereomer: IR (film) 3391, 3062, 3032, 2944, 2867, 1741, 1698, 1601, 1525, 1496 cm−1;
1H NMR (600MHz, CDCl3) δ 8.07 (br d, J = 3.4Hz, 1H), 7.98 (d, J = 8.0Hz, 2H), 7.53 (dd,
J = 8.3, 7.0Hz, 1H), 7.37–7.30 (m, 7H), 7.28–7.19 (m, 12H), 7.16 (d, J = 7.5Hz, 2H), 7.13 (d,
J = 7.5Hz, 1H), 7.11 (d, J = 7.8Hz, 1H), 7.04 (br d, J = 7.0Hz, 1H), 6.99 (br dd, J = 7.5, 7.0Hz,
1H), 6.89 (br s, 2H), 5.28 (m, 2H), 5.01 (br s, 1H), 4.97 (d, J = 15.5Hz, 1H), 4.86 (d, J = 15.5Hz,
1H), 4.48 (br d, J = 4.1Hz, 1H), 4.29 (br d, J = 4.4Hz, 1H), 4.22 (d, J = 9.6Hz, 1H), 4.17 (d,
J = 15.3Hz, 1H), 3.98 (d, j = 9.8Hz, 1H), 3.90 (d, J = 15.3Hz, 1H), 3.67 (m, 1H), 3.62 (br s,
1H), 3.52 (m, 1H), 3.49 (br s, 1H), 3.33 (dd, J = 10.1, 4.7Hz, 1H), 2.97 (dd, J = 10.5, 3.5Hz, 1H),
1.34 (s, 9H), 1.28–1.20 (m, 2H), 1.11 (d, J = 7.2Hz, 3H), 1.08 (d, J = 7.3Hz, 3H), 1.07–0.96 (m,
11H), 0.95–0.85 (m, 6H), 0.80 (m, 1H), 0.75–0.66 (m, 4H), carboxylic acid OH was not observed;
13C NMR (150MHz, CDCl3) ppm 171.0, 166.8, 164.8, 158.8, 157.5, 157.3, 143.1, 135.4, 134.4, 133.8,
130.4, 128.7, 128.5, 128.3, 128.0, 127.9, 127.7, 127.6, 127.1, 87.1, 80.5, 73.6, 73.5, 73.2, 67.7, 65.3,
63.5, 60.8, 60.0, 55.0, 47.0, 46.2, 41.3, 33.0, 28.1, 28.0, 17.63, 17.58, 17.5, 17.39, 17.36, 16.7, 16.6,
14.2, 13.6, 12.5, 12.4; HRMS (ESI): Exact mass calcd for C72H88N4NaO15Si2 [M+Na]
+ 1327.5682,
found 1327.5653.
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i) iBuO2CCl, NMM
THF, –20 °C, 2 h
Amide 386. A solution of the carboxylic acid (8.4mg, 6.4µmol) in THF (300µL) was cooleld
to 0 ◦C and NMM (2.2 µL, 19µmol) was added via syringe. The reaction mixture was cooled to
−20 ◦C and iBuO2CCl (3.0 µL, 23µmol) was added via syringe. The reaction was stirred at −15 ◦C
for 2 h and then NH4OH (28–30%, 20µL) was added via syringe and the reaction was warmed to
rt and stirred for additional 6 h. The reaction was quenched with satd aq NH4Cl and the resulting
mixture was extracted with ethyl acetate. The combined organic layers were dried, concentrated,
and the residue was dissolved in anhydrous methanol. The methanol solution was concentrated
and purified using preparative HLPC (XBridgeTM Prep C18 5 µm ODBTM 19× 150 µm column)
using the following program: 10mLmin−1 40min gradient from 40% buffer A (95% water, 5%
acetonitrile, 5mm NH4OAc) and 60% buffer B (95% acetonitrile, 5% water, 5mm NH4OAc) to
100% buffer B and then 40min buffer B; tr = 59.7min. Removal of solvent gave the desired amide
as a colorless oil (5.0mg, 59%). [α]20D −49.2 (c 0.50, CHCl3); IR (film) 3338, 3061, 3032, 2945, 2867,
1746, 1681, 1520, 1445 cm−1; 1H NMR (600MHz, CDCl3) δ 10.11 (br a, 1H), 8.65 (d, J = 5.0Hz,
1H), 8.17 (d, J = 8.3Hz, 2H), 7.65 (ddd, J = 7.5, 1.2, 1.2Hz, 1H), 7.49 (d, J = 8.0Hz, 1H), 7.47
(d, J = 7.8Hz, 1H), 7.38–7.27 (m, 12H), 7.26–7.16 (m, 13H), 6.79 (br s, 1H), 5.77 (br s, 1H), 5.30
(br, 1H), 5.20 (dd, J = 6.2, 5.9Hz, 1H), 4.92 (d, J = 15.3Hz, 1H), 4.82 (d, J = 14.8Hz, 1H), 4.48
(m, 1H), 4.33 (br d, J = 4.6Hz, 1H), 4.27 (d, J = 12.0Hz, 1H), 4.18 (d, J = 15.3Hz, 1H), 4.10 (br
s, 1H), 4.09 (d, J = 15.0Hz, 1H), 3.99 (d, J = 11.5Hz, 1H), 3.70 (br s, 1H), 3.59 (m, 2H), 3.29
(dd, J = 9.9, 4.8Hz, 1H), 3.04 (dd, J = 10.5, 4.0Hz, 1H), 1.66 (dd, J = 12.8, 12.0Hz, 2H), 1.41 (s,
9H), 1.15 (d, J = 7.4Hz, 3H), 1.11 (d, J = 7.3Hz, 3H), 1.07 (d, J = 7.6Hz, 3H), 1.05–0.95 (m,
11H), 0.94 (m, 3H), 0.83 (m, 1H), 0.72 (br s, 4H); 13C NMR (150MHz, CDCl3) ppm 171.7, 166.0,
165.3, 158.4, 157.9, 157.2, 143.2, 135.6, 134.5, 134.0, 130.3, 128.8, 128.7, 128.7, 128.51, 128.48,
128.3, 128.2, 128.0, 127.9, 127.7, 127.1, 87.1, 80.5, 75.3, 74.1, 73.5, 67.8, 64.6, 63.7, 61.6, 60.9, 55.7,
47.1, 46.9, 42.3, 20.5, 17.62, 17.59, 17.47, 17.40, 17.36, 16.68, 16.66, 14.2, 13.6, 12.5; HRMS (ESI):
Exact mass calcd for C72H89N5NaO14Si2 [M+Na]
+ 1326.5842, found 1326.5819.
The same reaction performed on the second (major) diastereomer of the carboxylic acid (12.1mg,
9.2 µmol) using (3.0 µL, 27µmol) of NMM, (4µL, 30µmol) of iBuO2CCl and (30 µL) of NH4OH in
(300µL) of THF afforded the amide as a colorless oil (10.5mg, 86%) after HPLC. [α]20D −53.2 (c
10.5, CHCl3); 1H NMR (500MHz, CDCl3) δ 8.44 (d, J = 5.7Hz, 1H), 8.12 (d, J = 7.7Hz, 2H),
7.65 (dd, J = 7.5, 7.2Hz, 1H), 7.49 (dd, J = 7.8, 7.7 lbHz, 2H), 7.33 (d, J = 7.6Hz, 6H), 7.28–7.18
(m, 10H), 7.18–7.08 (m, 6H), 7.06 (dd, J = 8.6, 6.7Hz, 1H), 6.96 (dd, J = 7.6, 7.3Hz, 2H), 6.71
(br s, 1H), 5.48 (br s, 1H), 5.25 (br dd, J = 6.1, 5.9Hz, 1H), 4.96–4.86 (m, 3H), 4.45 (m, 1H),
4.28–4.19 (m, 2H), 4.14 (d, J = 0Hz, 1H), 3.99 (m, 1H), 3.95 (d, J = 14.9Hz, 1H), 3.63 (br d,
J = 3.9Hz, 1H), 3.60–3.46 (m, 3H), 3.29 (dd, J = 10.6, 4.8Hz, 1H), 3.00 (dd, J = 10.3, 3.9Hz,
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1H), 1.20 (s, 9H), 1.14–1.09 (m, 6H), 1.08–0.98 (m, 12H), 0.97–0.088 (m, 6H), 0.83 (m, 2H), 0.74
(s, 4H), downfield amide N−H was not observed; 13C NMR (125MHz, CDCl3) ppm 171.4, 166.8,
165.6, 158.1, 157.8, 157.0, 143.1, 135.4, 134.7, 134.0, 130.6, 128.7, 128.6, 128.5, 128.1, 128.0, 127.9,
127.74, 127.69, 127.2, 87.2, 80.2, 73.8, 73.5, 72.9, 67.8, 65.0, 63.7, 60.9, 60.1, 55.6, 47.1, 46.3, 42.5,
33.1, 28.0, 17.7, 17.6, 17.5, 17.43, 17.36, 17.34, 16.7, 14.3, 13.7, 12.6, 12.4;
THF, –78 °C
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Bis(carbamate) 391. To a suspension of lithium powder (6.6mg, 940µmol) in anhydrous THF
(1mL) was added naphthalene (0.8mg, 6.0µmol). The suspension was vigorously stirred at rt for
30min and then cooled to −78 ◦C and stirried for additional 30min until solution turned dark
brown. A solution of carbamate (30.0mg, 31.3µmol) in THF (500 µL) was added via cannula and
the reaction was stirred at −78 ◦C for 2 h. The reaction was quenched by slow addition of satd aq
NH4Cl and warmed to rt and diluted with ethyl acetate. The layers were separated and the aqueous
layer was extracted with ethyl acetate. The combined organic layers were dried, concentrated and
the resulting oil was purified using flash chromatography (SiO2, 30–50% ethyl acetate in hexanes)
to afford the title compound as colorless oil (19.7mg, 81%). [α]20D −23.0 (c 3.28, CHCl3); Rf = 0.27
(40% EtOAc/hexanes); IR (film) 3265, 3155, 2948, 2865, 1756 cm−1; 1H NMR (400MHz, CDCl3)
δ 5.96 (s, 1H), 4.39 (dd, J = 4.9, 4.1Hz, 1H), 3.99 (m, 1H), 3.80 (dd, J = 4.7, 4.0Hz, 1H), 3.75 (dd,
J = 11.1, 5.3Hz, 1H), 3.69 (dd, J = 11.0, 4.1Hz, 1H), 1.50 (dt, J = 13.9, 8.1Hz, 1H), 1.50–0.92 (m,
14H), 0.88 (s, 9H), 0.07 (s, 6H); 13C NMR (100MHz, CDCl3) 158.8, 68.7, 63.7, 58.9, 33.2, 25.7,
18.2, 17.5, 17.3, 17.2, 13.7, 12.8, -5.5 ppm; HRMS (ESI): Exact mass calcd for C35H72N2NaO9Si2
[M+Na]+ 799.4213, found 799.4201.
CH2Cl2, rt
O O
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Bis(carbamate) 392. To a solution of the carbamate (30.1mg, 38.7µmol) in DCM 200 µLat
0 ◦C was added Boc2O (84.5mg, 387 µmol), followed by DMAP (23.7mg, 194 µmol). The solution
was warmed to rt and stirred overnight. The reaction mixture was concentrated and the residue
was purified using flash chromatography (SiO2, 10–25% ethyl acetate in hexanes) to afford the
title compound as a colorless oil (42.3mg, 99%). [α]20D 13.4 (c 2.12, CHCl3); Rf = 0.77 (40%
EtOAc/hexanes); IR (film) 2933, 2865, 1800, 1720 cm−1; 1H NMR (400MHz, CDCl3) δ 4.57 (d,
188
J = 3.0Hz, 1H), 4.53 (dd, J = 8.6, 6.3Hz, 1H), 4.08 (d, J = 2.7Hz, 1H), 3.80 (dd, J = 11.2, 4.0Hz,
1H), 3.57 (dd, J = 11.2, 2.2Hz, 1H), 1.46 (s, 9H), 1.30 (dt, J = 13.0, 7.0Hz, 1H), 1.07–0.92 (m,
12H), 0.85 (s, 9H), 0.85–0.67 (m, 2H), 0.05 (s, 3H), 0.05 (s, 3H); 13C NMR (100MHz, CDCl3)
151.3, 149.9, 83.7, 81.0, 72.5, 65.9, 64.0, 61.2, 36.8, 18.0, 17.5, 17.2, 17.0, 13.7, 12.7, -5.5, -5.6 ppm;
HRMS (ESI): Exact mass calcd for C45H88N2NaO13Si2 [M+Na]
+ 999.5261, found 999.5229.
ii) TsCl, THF, –78 °C
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Bis(alcohol) 431. To a solution of the carbamate (52.0mg, 66.9µmol) in dimethylformamide
(300µL) at 0 ◦C was added sodium hydride (4.8mg, 200µmol). The solution was stirred for 30min
and then cooled to −78 ◦C. Tosyl chloride (37.1mg, 167 µmol) was added in one portion and
the reaction was warmed to rt. The reaction was quenched with water and extracted with ethyl
acetate. The combined organic layers were dried, concentrated, and the residue was purified using
flash chromatography (SiO2, 25% methanol in dichloromethane) to afford the bis(alcohol) as a
clear oil (4.2mg, 11%) [α]20D −36.2 (c 0.82, EtOH); Rf = 0.23 (10% MeOH/CH2Cl2); IR (film)
3336, 3288, 3271, 2941, 2927, 2866, 1739, 1658, 1461 cm−1; 1H NMR (600MHz, CD3OD) δ 4.63
(dd, J = 8.6, 4.4Hz, 1H), 4.60 (br s, 1H), 4.18–4.11 (m, 1H), 3.79–3.72 (m, 2H), 3.62 (dd, J =
12.1, 4.3Hz, 1H), 1.45 (ddd, J = 13.9, 8.1Hz, 1H), 1.19–1.00 (m, 14H), O−H resonances were not
observed; 13C NMR (150MHz, CD3OD) ppm 161.6, 78.6, 69.5, 64.2, 60.1, 36.6, 18.2, 17.93, 17.89,
17.7, 15.0, 14.2; HRMS (ESI): Exact mass calcd for C23H44N2NaO9Si2 [M+Na]
+ 571.2483, found
571.2498.
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–78 °C, 4 h
Sulfonamide 394. To a solution of the carbamate (15.5mg, 20.0 µmol) in tetrahydrofuran (200 µL)
at −78 ◦C was added n-butyllithium (2.5m in hexanes, 20µL, 50µmol) and the solution was stirred
for 30min. p-Toluenesulfonyl chloride (8.8mg, 43µmol) was added in one portion, the reaction
was stirred for 4 h at −78 ◦C, and then quenched with satd aq NH4Cl. The reaction mixture was
extracted with ethyl acetate, and the combined organic layers were dried and concentrated. The
yellow residue was purified using flash chromatography (SiO2, 10–25% ethyl acetate in hexanes)
to afford the product as a clear oil (19.8mg, 91%). [α]20D −24.4 (c 1.98, EtOH); Rf = 0.55 (50%
MeOH/CH2Cl2); IR (film) 3066, 3033, 2848, 2832, 2897, 2864, 1789, 1465 cm−1; 1H NMR (600MHz,
189
CD3OD) δ 7.96 (d, J = 8.3Hz, 2H), 7.33 (d, J = 8.1Hz, 2H), 4.68 (dd, J = 7.5, 4.3Hz, 1H), 4.53
(ddd, J = 14.0, 8.0, 8.0Hz, 1H), 4.19 (d, J = 2.9Hz, 1H), 3.56 (d, J = 4.6Hz, 2H), 2.44 (s, 3H),
1.35 (dt, J = 13.8, 8.0Hz, 1H), 1.17–1.08 (m, 6H), 1.00–0.97 (m, 3H), 0.94–0.90 (m, 3H), 0.84 (s,
9H), 0.81–0.75 (m, 2H), 0.03 (s, 3H), −0.05 (s, 3H); 13C NMR (150MHz, CDCl3) ppm 152.2, 145.6,
135.0, 129.8, 129.7, 128.5, 127.9, 74.0, 68.4, 63.9, 63.4, 37.1, 25.8, 21.7, 18.5, 17.5, 16.9, 13.7, 12.9,
−5.4, −5.6; HRMS (ESI): Exact mass calcd for C49H84N2NaO13S2Si4 [M+Na]+ 1107.4390, found
1107.4420.
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Diol 395. To a vial containing bis(N -tosyl carbamate) (9.5mg, 8.8 µmol) and Cs2CO3 (8.5mg,
26µmol) was added anhydrous methanol (200µL), and the reaction was stirred at ambient temper-
ature for 1 day. The reaction was quenched with satd aq NH4Cl and extracted with ethyl acetate.
The combined extracts were dried, concentrated, and purified using flash chromatography (SiO2,
25–75% ethyl acetate in hexanes) to afford the product as a colorless oil (4.6mg, 51%). [α]20D
20.2 (c 0.46, CHCl3); Rf = 0.25 (50% EtOAc/hexanes); IR (film) 3491, 3307, 3032, 2931, 2893,
2864, 1599 cm−1; 1H NMR (400MHz, CDCl3) δ 7.75 (d, J = 8.1Hz, 2H), 7.28 (d, J = 8.4Hz,
2H), 5.18 (d, J = 7.6Hz, 1H), 4.27 (ddd, J = 8.4, 5.5, 2.8Hz, 1H), 3.94 (dd, J = 7.6, 6.0Hz, 1H),
3.27–3.18 (m, 2H), 3.12 (dd, J = 10.3, 5.7Hz, 1H), 3.00 (d, J = 1.8Hz, 1H), 2.41 (s, 3H), 1.61 (dt,
J = 14.0, 8.3Hz, 1H), 1.14–0.78 (m, 21H), −0.02 (s, 3H), −0.05 (s, 3H) (N−H and O−H peaks
were not observed); 13C NMR (125MHz, CDCl3) ppm 143.2, 138.3, 129.6, 127.0, 72.1, 70.2, 63.9,
57.4, 37.3, 25.8, 25.7, 21.5, 18.2, 17.5, 17.42, 17.37, 17.2, 13.5, 12.5, −5.49, −5.51; HRMS (ESI):
Exact mass calcd for C47H88N2NaO11S2Si [M+Na]
+ 1055.4804, found 1055.4791.
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Bis(carbamate) 397. To a solution of the selenoester (9.9mg, 9.6 µmol) in toluene (100 µL)
at rt was added nBu3SnH (10.2 µL, 38.4 µmol) and the solution was heated to 100 ◦C. To a hot
reaction mixture was added AIBN (3.1mg, 19µmol) in one portion, and the reaction was stirred
at 100 ◦C for 20min. The reaction mixture was cooled to rt, concentrated, and purified using flash
chromatography (SiO2, 25–75% ethyl acetate in hexanes) to afford the product as a colorless oil
(5.1mg, 80%). [α]20D −11.7 (c 0.52, CHCl3); Rf = 0.2 (30% EtOAc/hexanes); IR (film) 2943,
190
2867, 1452 cm−1; 1H NMR (500MHz, CDCl3) δ 7.53–7.29 (m, 3H), 7.29–7.17 (m, 2H), 4.98 (d,
J = 15.5Hz, 1H), 4.35–4.11 (m, 3H), 4.02 (d, J = 15.3Hz, 1H), 3.63 (dd, J = 8.8, 4.9Hz, 1H),
1.54–0.76 (m, 15H); 13C NMR (125MHz, CDCl3) ppm 158.5, 135.5, 128.9, 128.1, 128.0, 66.2,
62.7, 58.2, 46.6, 34.1, 17.6, 17.45, 17.40, 16.8, 14.1, 12.7; HRMS (ESI): Exact mass calcd for
C35H52N2NaO7Si2 [M+Na]
+ 691.3211, found 691.3212.
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Methyl ester 398. To a solution of the bis(carboxylic acid) (570mg, 753 µmol) in methanol (5mL)
was added conc. H2SO4 (1.0 µL, 18µmol) and the reaction was heated to reflux and stirred for
6–8 h. The reaction mixture was cooled, concentrated, diluted with ethyl acetate, and washed with
water. The combined aqueous layers were extracted with ethyl acetate and the combined extracts
were dried and concentrated. The resulting yellow oil was dissolved in anhydrous methanol and
filtered. The methanol solution was concentrated and purified using preparative HLPC (XBridgeTM
Prep C18 5 µm ODBTM 19× 150 µm column) using the following program: 10mLmin−1, 23min
gradient from 77% buffer A (99.9% water, 0.1% TFA) and 23% buffer B (99.9% acetonitrile, 0.1%
TFA) to 100% buffer B and then 5min buffer B; tr(diacid) = 8.5min, tr(monoester) = 16.2min,
tr(diester) = 23.6min. Removal of solvent gave the desired product as a colorless oil (242mg, 41%)
together with the unreacted bis(carboxylic acid) (110mg, 19%) and bis(methyl ester) (90mg, 15%);
[α]20D −28.7 (c 2.01, CHCl3); Rf = 0.50 (20% MeOH/CH2Cl2); IR (film) 3488, 3030, 2947, 2868,
1766, 1439 cm−1; 1H NMR (400MHz, CDCl3) δ 7.37–7.22 (m, 5H), 7.22–7.10 (m, 5H), 6.90 (br
s, 1H), 4.92 (d, J = 14.8Hz, 1H), 4.80 (d, J = 15.4Hz, 1H), 4.66 (d, J = 3.9Hz, 1H), 4.57 (d,
J = 3.4Hz, 1H), 4.24 (d, J = 10.9Hz, 1H), 4.19 (d, J = 11.7Hz, 1H), 4.06 (d, J = 15.4Hz,
1H), 4.02 (d, J = 15.4Hz, 1H), 4.71 (d, J = 3.6Hz, 1H), 3.68 (s, 3H), 3.61 (d, J = 3.9Hz, 1H),
1.60 (dd, J = 13.0, 12.0Hz, 1H), 1.40 (dd, J = 12.6, 12.3Hz, 1H), 1.22–0.72 (m, 28H); 13C NMR
(150MHz, CDCl3) ppm 175.1, 169.5, 158.7, 157.3, 135.2, 134.9, 128.94, 128.89, 128.1, 127.9, 127.6,
127.4, 127.3, 72.9, 71.2, 67.1, 66.0, 63.5, 62.2, 53.0, 46.7, 46.5, 33.8, 20.9, 17.7, 17.6, 17.50, 17.45,
17.4, 17.3, 16.71, 16.68, 14.0, 13.9, 12.7, 12.5; HRMS (ESI): Exact mass calcd for C38H55N2O11Si2
[M+H]+ 771.3344, found 771.3376.
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DOWEX 50WX8
(50–100 mesh)
Butyl ester 399. To a flask containing bis(carboxylic acid) (1.514 g, 2.00mmol) and DOWEX
50WX8 (50–100 mesh, 4 g) was added toluene (36mL) and nBuO2CH (4mL). The mixture was
heated to 90 ◦C and vigorously stirred for 4 h. The resin was filtered and washed with acetonitrile
and ethanol. The resulting solution was concentrated and purified using flash chromatography
(SiO2, AcOH–MeOH–CH2Cl2, gradient 1:2:97 to 1:8:91 and then 1:20:79) to afford the bis(ester)
as a yellow oil (365mg, 21%) the mono ester as a yellow oil (933mg, 57%), and the bis(carboxylic
acid) as a yellow oil (257mg, 17%).
Monoester: [α]20D −33.6 (c 1.48, CHCl3); Rf = 0.50 (20% MeOH/CH2Cl2); IR (film) 3455, 3065,
3032, 2947, 2869, 1766, 1441 cm−1; 1H NMR (400MHz, CDCl3) δ 7.38–7.27 (m, 6H), 7.19 (d,
J = 7.3Hz, 2H), 7.17 (d, J = 7.1Hz, 2H), 4.98 (d, J = 15.5Hz, 2H), 4.81 (d, J = 4.5Hz,
1H), 4.64 (d, J = 4.4Hz, 1H), 4.30 (d, J = 10.5Hz, 1H), 4.21 (d, J = 1.1Hz, 1H), 4.13 (ddd,
J = 14.9, 10.8, 6.9Hz, 1H), 4.09 (ddd, J = 14.9, 10.8, 6.9Hz, 1H), 4.03 (d, J = 3.2Hz, 1H), 3.99
(d, J = 3.2Hz, 1H), 3.62 (d, J = 4.6Hz, 1H), 3.57 (d, J = 4.0Hz, 1H), 2.37 (br, 1H), 1.51 (dt,
J = 13.9, 6.8Hz, 2H), 1.40 (m, 2H), 1.25 (dt, J = 15.2, 7.8Hz, 2H), 1.17–0.79 (m, 31H); 13C NMR
(100MHz, CDCl3) ppm 170.7, 168.8, 157.5, 157.4, 134.7, 134.6, 129.0, 128.9, 128.2, 127.6, 71.2,
70.5, 66.9, 66.1, 65.5, 62.4, 62.1, 46.8, 46.6, 33.9, 30.3, 18.8, 17.51, 17.48, 17.38, 17.36, 17.33,
17.29, 16.6, 14.0, 13.8, 13.5, 12.6; HRMS (ESI): Exact mass calcd for C41H60N2NaO11Si2 [M+Na]
+
835.3633, found 835.3636.
Bis(ester): [α]20D −34.3 (c 3.73, CHCl3); Rf = 0.95 (5%MeOH/CH2Cl2); IR (film) 2930, 2868, 1771,
1496, 1461, 1422 cm−1; 1H NMR (400MHz, CDCl3) δ 7.37–7.26 (m, 3H), 7.17 (dd, J = 7.0, 1.2Hz,
2H), 5.00 (d, J = 15.1Hz, 1H), 4.71 (d, J = 4.5Hz, 1H), 4.25 (dd, J = 7.5, 6.2Hz, 1H), 4.13 (ddd,
J = 14.9, 10.8, 6.8Hz, 1H), 4.09 (ddd, J = 14.9, 10.8, 6.8Hz, 1H), 4.00 (d, J = 15.4Hz, 1H), 3.54
(d, J = 4.5Hz, 1H), 1.53 (m, 2H), 1.36 (dd, J = 8.3, 5.9Hz, 1H), 1.26 (m, 2H), 1.18–1.08 (m, 7H),
1.05 (d, J = 7.5Hz, 3H), 0.96 (d, J = 7.2Hz, 3H), 0.91–0.80 (m, 4H); 13C NMR (100MHz, CDCl3)
ppm 168.9, 157.2, 134.6, 129.0, 128.2, 127.6, 70.9, 66.1, 65.9, 62.1, 46.6, 34.3, 30.3, 18.8, 17.5, 17.3,
16.6, 14.0, 13.5, 12.6; HRMS (ESI): Exact mass calcd for C45H68N2NaO11Si2 [M+Na]
+ 891.4261,
found 891.4261.
O OMeO2C
TIPDS
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O O
N
BnBn OO
O OMeO2C
TIPDS
CO2H
N
O O
N
BnBn OO i) iBuO2CCl, NMM
THF, –10 °C, 30 min
ii) PhSeH, NMM
THF –10 °C to rt
Selenoester 432. To a solution of the carboxylic acid (10.2mg, 13.2 µmol) in dichloromethane
(200µL) was added N-methyl morpholine (4.5 µL, 40µmol) and the solution was cooled to −10 ◦C.
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To this solution was added isobutyl chloroformate (5.0 µL, 40µmol) and the reaction was stirred at
−10 ◦C for 30min. To the reaction mixture was then added N-methyl morpholine (4.5 µL, 40 µmol)
followed by benzeneselenol (3.0 µL, 26µmol), and the reaction was warmed to rt and stirred for 1h.
The reaction was quenched with satd aq NH4Cl, the layers were separated, and the aqueous layer
was extracted with dichloromethane. The combined organic layers were dried and concentrated,
and the resulting yellow oil was purified using flash chromatography (SiO2, 10–50% ethyl acetate in
hexanes) to afford the selenoester as a pale yellow oil (5.2mg, 44%). [α]20D −25.4 (c 0.35, CHCl3);
Rf = 0.2 (25% EtOAc/hexanes); IR (film) 3063, 3032, 2946, 2867, 1771, 1714 cm−1; 1H NMR
(400MHz, CDCl3) δ 7.45–7.30 (m, 11H), 7.27 (d, J = 6.8Hz, 2H), 7.18 (d, J = 6.8Hz, 2H), 5.08
(d, J = 15.5Hz, 1H), 5.01 (d, J = 15.5Hz, 1H), 4.79 (d, J = 4.6Hz, 1H), 4.72 (d, J = 4.1Hz,
1H), 4.28 (dd, J = 8.8, 2.8Hz, 1H), 4.25 (dd, J = 8.8, 2.8Hz, 1H), 4.00 (d, J = 15.5Hz, 1H), 3.95
(d, J = 15.5Hz, 1H), 3.68 (s, 3H), 3.52 (dd, J = 3.8, 0.9Hz, 1H), 3.46 (dd, J = 3.8, 0.9Hz, 1H),
1.39–1.29 (m, 2H), 1.18–1.05 (m, 20H) 1.02 (d, J = 7.6Hz, 3H), 1.00 (d, J = 7.8Hz, 3H), 0.93
(m, 2H); 13C NMR (150MHz, CDCl3) ppm 204.1, 169.3, 157.0, 156.4, 135.9, 134.6, 134.5, 129.5,
129.4, 129.1, 129.0, 128.4, 128.3, 127.8, 127.6, 124.2, 78.7, 70.5, 65.9, 65.0, 62.3, 62.0, 52.9, 46.7,
46.4, 35.2, 17.6, 17.42, 17.40, 17.37, 16.70, 16.67, 14.2, 14.1, 12.6; HRMS (ESI): Exact mass calcd
for C44H58N2NaO10Si2Se [M+Na]
+ 933.2693, found 933.2665.
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nBu3SnH, AIBN
toluene, 100 °C
Ester 433. To a solution of the selenoester (24.9mg, 27.4 µmol) in toluene (200 µL) at rt was added
nBu3SnH (15µL, 55µmol) and the solution was heated to 100 ◦C. To a hot reaction mixture was
added AIBN (4.4mg, 28µmol) in one portion, and the reaction was stirred for 20min at 100 ◦C. The
reaction mixture was cooled to rt, concentrated, and purified using flash chromatography (SiO2,
25–75% ethyl acetate in hexanes) to afford the product as a colorless oil (11.5mg, 58%). [α]20D
−15.0 (c 1.15, CHCl3); Rf = 0.2 (25% EtOAc/hexanes); IR (film) 3064, 3031, 2845, 2867, 1760,
1494, 1458, 1438, 1422 cm−1; 1H NMR (600MHz, CDCl3) δ 7.38–7.27 (m, 6H), 7.23 (d, J = 7.5Hz,
2H), 7.18 (d, J = 7.5Hz, 2H), 5.00 (d, J = 15.4Hz, 1H), 4.97 (d, J = 15.3Hz, 1H), 4.76 (d,
J = 4.5Hz, 1H), 4.27 (d, J = 10.9Hz, 1H), 4.23–4.13 (m, 3H), 4.02 (d, J = 15.1Hz, 1H), 3.97
(d, J = 15.4Hz, 1H), 3.73 (s, 3H), 3.63 (ddd, J = 9.7, 5.4, 1.1Hz, 1H), 3.49 (dd, J = 4.4, 0.7Hz,
1H), 1.42–1.36 (m, 1H), 1.18–1.03 (m, 21H), 0.99 (d, J = 7.6Hz, 3H), 0.97 (d, J = 7.6Hz, 3H),
0.90–0.82 (m, 2H); 13C NMR (150MHz, CDCl3) ppm 169.5, 158.5, 156.9, 135.5, 134.7, 129.0, 128.9,
128.3, 128.1, 128.0, 127.7, 70.6, 66.1, 65.5, 62.7, 62.1, 58.1, 53.0, 46.6, 46.5, 34.5, 17.59, 17.57, 17.42,
17.37, 16.8, 16.7, 14.10, 14.09, 12.7, 12.6; HRMS (ESI): Exact mass calcd for C37H54N2NaO9Si2
[M+Na]+ 749.3266, found 749.3267.
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BnBn OO 1) (COCl)2, cat. DMF
then PhSeH, NMM
THF, 0 °C, 15 min
2) nBu3SnH, AIBN
toluene, 100 °C, 7 min
Ester 402. To a solution of the carboxylic acid (812.1mg, 1.000mmol) in CH2Cl2 (5.00mL)
was added DMF (40µL, 50µmol), and the solution was cooled to 0 ◦C. Oxalyl chloride (430 µL,
5.00mmol) was added via syringe and the reaction was warmed to rt, stirred for 30min, and con-
centrated. In a separate flask, N-methyl morpholine (440 µL, 4.00mmol) was added via syringe,
followed by THF (5.00mL) and benzeneselenol (215 µL, 2.00mmol). The resulting yellow suspen-
sion was stirred at rt for 30min and cooled to 0 ◦C. A suspension of the acid chloride in THF (2mL)
was slowly added via cannula. The resulting yellow suspension was stirred at 0 ◦C for 15min and
then poured into a separatory funnel containing ethyl acetate (100mL). The resulting solution
was washed with satd aq NH4Cl, and the combined aqueous layers were extracted with ethyl ac-
etate. The combined organic layers were dried and concentrated, and the resulting yellow oil was
dried under vacuum over P2O5 for 6 h. To a flask containing crude selenoester was added toluene
(5.00mL) and nBu3SnH (810 µL, 3.00mmol) and the solution was heated to 100 ◦C. AIBN (330mg,
2.00mmol) was added in one portion, and the reaction was stirred at 100 ◦C for 10min (vigorous
gas evolution was observed after ca. 3min). The reaction was cooled to rt and concentrated, and
the residue was purified using flash chromatography (SiO2, 15–50% ethyl acetate in hexanes) to
afford the product as a pale yellow oil (515mg, 67%). [α]20D −25.4 (c 0.35, CHCl3); Rf = 0.2 (25%
EtOAc/hexanes); IR (film) 3063, 3032, 2946, 2867, 1771, 1714 cm−1; 1H NMR (400MHz, CDCl3)
δ 7.37–7.25 (m, 6H), 7.22 (d, J = 7.7Hz, 2H), 7.17 (d, J = 7.2Hz, 2H), 4.99 (d, J = 14.7Hz, 1H),
4.95 (d, J = 14.5Hz, 1H), 4.68 (d, J = 4.2Hz, 1H), 4.23 (d, J = 11.1Hz, 1H), 4.18 (m, 3H), 4.11 (d,
J = 6.7Hz, 1H), 4.09 (d, J = 7.0Hz, 1H), 4.01 (d, J = 15.0Hz, 1H), 3.99 (d, J = 15.3Hz, 1H), 3.61
(dd, J = 7.5, 7.5Hz, 1H), 3.51 (d, J = 4.4Hz, 1H), 1.53 (m, 2H), 1.37 (ddd, J = 14.4, 11.3, 1.8Hz,
1H), 1.31–1.21 (m, 2H), 1.19–1.00 (m, 21H), 1.00–0.91 (m, 6H), 0.90–0.79 (m, 5H); 13C NMR
(100MHz, CDCl3) ppm 169.0, 158.4, 156.9, 135.4, 134.7, 128.9, 128.8, 128.1, 128.0, 127.9, 127.5,
70.7, 66.0, 65.9, 65.7, 62.5, 62.0, 58.1, 46.5, 34.3, 30.2, 18.8, 17.48, 17.47, 17.33, 17.30, 17.27, 16.7,
16.6, 14.0, 13.9, 13.5, 12.6, 12.5; HRMS (ESI): Exact mass calcd for C40H60N2NaO9Si2 [M+Na]
+
791.3735, found 791.3710.
O O
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N
O O
N
HH OO
O O
TIPDS
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O O
N
BnBn OO 1. MOMCl, iPr2NEt
CH2Cl2, rt
2. Li0, NH3, –78 °C
MOMOHO
MOM ether 404. To a solution of the alcohol (490mg, 700µmol) in CH2Cl2 (1.7mL at 0 ◦C
was added DIPEA (905 µL, 7.00mmol) followed by MOMCl (563 µL, 7.00mmol). The reaction
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was stirred at 0 ◦C for 1h and then warmed to rt and stirred for additional 3 h. The reaction was
quenched with water and concentrated. The resulting mixture was poured into ether and washed
with satd aq NH4Cl. The combined aqueous layers were extracted with diethyl ether. The combined
organic layers were dried and concentrated to give the desired MOM ether (520mg, 99%) that was
used without further purification.
In a wide tall vial containing lithium (88mg, 11mmol), ammonia (ca. 1mL) was condensed at
−78 ◦C. The resulting deep blue solution was stirred at −78 ◦C for 1 h. A solution of the MOM
ether in THF (200 µL) was added dropwise via syringe and the reaction was stirred at −78 ◦C
for 30min. The reaction was quenched by addition of solid NH4Cl and the resulting slurry was
allowed to slowly warm to rt. Ethyl acetate (3mL) was added, and the pH of the aqueous layer
was adjusted with solid KHSO4 to pH 4. The aqueous layer was extracted with ethyl acetate,
and the combined organic extracts were dried and concentrated to give the desired product as a
colorless solid (301mg, 76%), which was used in the next step without further purification. [α]20D
−42.3 (c 1.01, CHCl3); Rf = 0.3 (5% MeOH/CH2Cl2); IR (film) 3280, 3150, 2943, 2867, 1740,
1465, 1412 cm−1; 1H NMR (400MHz, CDCl3) δ 6.57 (s, 1H), 6.51 (s, 1H), 4.64 (s, 2H), 4.54 (dd,
J = 9.6, 4.7Hz, 1H), 4.44 (dd, J = 9.1, 8.6Hz, 1H), 4.27 (dd, J = 8.8, 5.5Hz, 1H), 3.99 (m, 2H),
3.87 (ddd, J = 9.4, 5.0, 5.0Hz, 1H), 3.72 (m, 1H), 3.68 (dd, J = 4.2, 3.9Hz, 2H), 3.56 (s, 3H),
1.57 (ddd, J = 15.4, 11.2, 2.6Hz, 1H), 1.46 (ddd, J = 15.6, 11.0, 2.6Hz, 1H), 1.14–0.77 (m, 28H);
13C NMR (100MHz, CDCl3) ppm 159.9, 159.1, 96.7, 68.7, 68.6, 68.3, 66.5, 59.4, 57.1, 55.5, 34.7,
17.5, 17.3, 17.22, 17.18, 13.8, 13.7, 12.8, 12.7; HRMS (ESI): Exact mass calcd for C24H46N2NaO9Si2
[M+Na]+ 585.2640, found 585.2651.
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N
BnBn OO 1. NaBH4, MeOH, rt
2. (MeO)2CH, P2O5
3. Li0, NH3, –78 °C nni
4. nBuLi, THF, –78 °C
then TsCl
MOMO
MOM ether 405. To a solution of the ester (47.6mg, 65.5 µmol) in methanol (1mL) was added
NaBH4 (7.5mg, 200µmol). The reaction was stirred at rt for 30min, concentrated and diluted with
ethyl acetate. The solution was washed with satd aq NH4Cl, dried and concentrated. The residue
was dissolved in CHCl3 (1mL) and dimethoxymethane (60µL, 680 µmol) was added, followed by
P2O5 (280mg, 1.0mmol). The slurry was stirred at rt for 30min and then poured into ice-cold
satd aq Na2CO3. The resulting solution was extracted with diethyl ether and the combined organic
layers were dried and concentrated to give the product as a colorless oil that was used in the next
step without further purification.
In a vial, ammonia (ca. 1mL) was condensed at −78 ◦C and lithium (8mg, 1mmol) was added.
The resulting deep blue solution was stirred at −78 ◦C for 1h. A solution of the MOM ether in
THF (200 µL) was added dropwise via syringe and the reaction was stirred at −78 ◦C for 15min.
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The reaction was quenched by addition of solid NH4Cl and the resulting slurry was allowed to
slowly warm to rt. Ethyl acetate (3mL) was added, and the pH of the aqueous layer was adjusted
with 10% KHSO4 to pH 4. The aqueous layer was extracted with ethyl acetate, and the combined
organic extracts were dried and concentrated to give the desired product as a colorless solid (28.8mg,
78%), which was used in the next step without further purification.
To a vial containing the carbamate in THF (500 µL) was added nBuLi (2.5m in hexanes, 61µL,
150 µmol), and the solution was stirred at −78 ◦C for 30min. Tosyl chloride (23.4mg, 123 µmol)
was added in one portion, and the reaction was warmed to 0 ◦C and stirred for 6 h. The reaction
was quenched with satd aq NH4Cl and diluted with ethyl acetate. The layers were separated and
the aqueous layer was extracted with ethyl acetate. The combined organic layers were dried and
concentrated, and the resulting oil was purified using flash chromatography (SiO2, 25–50% ethyl
acetate in hexanes) to afford the product as a colorless oil (21.1mg, 50%). [α]20D 50.2 (c 2.11,
CHCl3); Rf = 0.2 (25% EtOAc/hexanes); IR (film) 2946, 2895, 2868, 1783, 1596, 1493, 1464 cm−1;
1H NMR (500MHz, CDCl3) δ 7.97 (d, J = 8.6Hz, 2H), 7.94 (d, J = 9.3Hz, 2H), 7.36 (d, J = 8.3Hz,
2H), 7.33 (d, J = 8.3Hz, 2H), 4.76 (d, J = 2.8Hz, 1H), 4.61 (dd, J = 11.0, 2.4Hz, 1H), 4.52 (dd,
J = 8.6, 2.8Hz, 1H), 4.34 (dd, J = 8.6, 2.4Hz, 1H), 4.28–4.18 (m, 3H), 4.16 (d, J = 3.0Hz, 1H),
3.62 (dd, J = 11.0, 2.4Hz, 1H), 3.40 (dd, J = 11.1, 2.3Hz, 1H), 3.11 (s, 3H), 2.45 (s, 3H), 2.44 (s,
3H), 1.41–1.24 (m, 2H), 1.17–0.99 (m, 24H), 0.97 (d, J = 7.2Hz, 3H), 0.93–0.81 (m, 2H); 13C NMR
(125MHz, CDCl3) ppm 152.7, 152.4, 145.8, 145.4, 134.9, 134.7, 129.8, 129.4, 128.7, 128.5, 96.1,
72.8, 68.3, 68.2, 67.7, 63.4, 63.2, 61.3, 55.4, 37.1, 21.70, 21.65, 17.6, 17.50, 17.47, 17.4, 17.0, 13.77,
13.75, 12.8, 12.7; HRMS (ESI): Exact mass calcd for C38H58N2NaO13Si2S2 [M+Na]
+ 893.2817,
found 893.2825.
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Alcohol 406. To a solution of the alcohol (45.3mg, 51.9 µmol) in dichloromethane (200µL) was
added trifluoroacetic acid (300 µL). The solution was stirred at rt for 12 h and then concentrated.
The residue was purified using flash chromatography (SiO2, 75% ethyl acetate in hexanes) to
afford the alcohol as a colorless oil (35.4mg, 82%). [α]20D +64.0 (c 1.71, CHCl3); Rf = 0.3 (75%
EtOAc/hexanes); IR (film) 3549, 3029, 2946, 2894, 2868, 1784, 1596, 1493, 1465 cm−1; 1H NMR
(500MHz, CDCl3) δ 7.95 (d, J = 8.2Hz, 2H), 7.92 (d, J = 8.2Hz, 2H), 7.35 (d, J = 8.2Hz,
2H), 7.32 (d, J = 8.2Hz, 2H), 4.73 (d, J = 3.0Hz, 1H), 4.60 (dd, J = 10.8, 3.0Hz, 1H), 4.53
(m, 2H), 4.32 (dd, J = 9.0, 2.9Hz, 1H), 4.23 (m, 2H), 3.71 (dd, J = 12.4, 3.5Hz, 1H), 3.49 (dd,
J = 12.2, 2.8Hz, 1H), 2.44 (s, 3H), 2.42 (s, 3H), 2.12 (br, 1H), 1.35 (m, 2H), 1.20–0.82 (m, 28H);
13C NMR (125MHz, CDCl3) ppm 152.8, 152.6, 145.9, 145.7, 134.6, 134.5, 129.8, 129.6, 128.5, 128.4,
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74.3, 68.2, 68.1, 63.3, 63.2, 63.1, 61.2, 37.2, 21.7, 17.50, 17.46, 17.0, 13.8, 12.79, 12.76; HRMS (ESI):
Exact mass calcd for C36H54N2NaO12Si2S2 [M+Na]
+ 849.2554, found 849.2515.
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CDCl3, rt, 1 h
ii) PhCO2H, –20 °C
NCBocHN
OMeO
O Ph
Methyl ester 408. To a flask containing the alcohol (50.2mg, 60.7 µmol) and Dess–Martin pe-
riodinane (27.0mg, 63.7 µmol) was added CDCl3 (3mL) at room temperature. The reaction was
stirred for 1 h and then benzoic acid (111mg, 911 µmol) was added in one portion. The reaction
was cooled to −78 ◦C and the solution of the isonitrile (20.8mg, 91.0 µmol) in CDCl3 (300 µL) was
added via syringe. The reaction was warmed slowly to −20 ◦C and stirred for 8 h. A portion of
the reaction mixture was analyzed by 1H NMR to determine diastereoselectivity of the reaction
(3.7:1 dr). The reaction mixture was warmed to room temperature, concentrated, and the residue
was dissolved in diethyl ether. The solution was washed with satd aq Na2S2O3 and then with satd
aq NaHCO3. The combined aqueous layers were extracted with ether, and the combined organic
layers were dried and concentrated. The residue was purified using flash chromatography (SiO2,
30–60% ethyl acetate in hexanes) to afford the desired product as a yellow oil (35.6mg, 50%).
IR (film) 3400, 3067, 2947, 2868, 1788, 1434, 1694, 1598, 1520, 1456 cm−1; 1H NMR (600MHz,
CDCl3) δ 8.09 (dd, J = 8.5, 1.5Hz, 1H), 8.07 (d, J = 7.6Hz, 1H), 8.00–7.96 (m, 2H), 7.80 (d,
J = 8.2Hz, 2H), 7.64 (ddd, J = 7.6, 1.3, 1.2Hz, 1H), 7.60 (ddd, J = 7.4, 1.3, 1.2Hz, 1H), 7.49–7.42
(m, 2H), 7.36 (d, J = 8.2Hz, 2H), 7.01 (d, J = 8.2Hz, 2H), 5.51 (d, J = 2.9Hz, 1H), 5.37 (br
s, 1H), 4.94 (t, J = 5.9Hz, 1H), 4.66 (dd, J = 11.5, 1.6Hz, 1H), 4.61 (d, J = 11.3Hz, 1H), 4.57
(dd, J = 7.9, 3.9Hz, 1H), 4.47 (m, 1H), 4.39 (d, J = 3.3Hz, 1H), 4.26–4.17 (m, 2H), 3.71 (s, 3H),
3.60–3.49 (m, 2H), 2.45 (s, 3H), 2.30 (s, 3H), 1.49 (ddd, J = 15.5, 2.3, 2.3Hz, 1H), 1.36–1.29 (m,
1H), 1.26 (s, 9H), 1.16–0.79 (m, 28H); 13C NMR (150MHz, CDCl3) ppm 170.4, 169.6, 165.9, 165.3,
157.1, 152.9, 151.5, 145.7, 145.7, 145.5, 134.6, 134.4, 134.2, 133.6, 130.6, 130.1, 129.9, 129.5, 128.6,
128.45, 128.42, 128.39, 127.6, 80.4, 73.4, 73.2, 68.1, 67.8, 62.8, 62.5, 61.1, 54.7, 52.7, 41.6, 37.0,
28.0, 21.72, 21.70, 17.6, 17.5, 17.4, 17.0, 16.9, 13.9, 13.8, 12.9, 12.8; HRMS (ESI): Exact mass calcd
for C53H74N4NaO18S2Si2 [M+Na]
+ 1197.3876, found 1197.3870.
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Carboxylic acid 409. To a vial containing the methyl ester (35.6mg, 30.0µmol) in 1,2-DCE
(500µL) was added trimethyltin hydroxide (27.1mg, 150 µmol) and the resulting solution was
stirred at 60–70 ◦C for 4h. The reaction mixture was cooled, diluted with dichloromethane and
washed with a 10% solution of aq KHSO4. The combined aqueous layers were extracted with
ethyl acetate, and the combined organic layers were dried and concentrated. The resulting yellow
oil was dissolved in anhydrous methanol and filtered. The methanol solution was concentrated
and purified using preparative HLPC (XBridgeTM Prep C18 5 µm ODBTM 19× 150 µm column)
using the following program: 10mLmin−1 40min gradient from 40% buffer A (95% water, 5%
acetonitrile, 5mm NH4OAc) and 60% buffer B (95% acetonitrile, 5% water, 5mm NH4OAc) to
100% buffer B; tr = 25.5min. Removal of solvent gave the product as a colorless oil (11.5mg,
32%). IR (film) 3398, 3067, 2946, 2868, 1788, 1733, 1691, 1598, 1522, 1461 cm−1; 1H NMR
(600MHz, CDCl3) δ 8.27 (br s, 1H), 8.04 (d, J = 8.1Hz, 2H), 7.95 (d, J = 8.0Hz, 2H), 7.80 (d,
J = 8.0Hz, 2H), 7.62 (dd, J = 7.6, 7.5Hz, 1H), 7.42 (t, J = 7.8Hz, 2H), 7.34 (d, J = 8.3Hz,
2H), 7.02 (d, J = 8.1Hz, 2H), 5.53 (br d,J = 2.5Hz, 1H), 5.34 (br s, 1H), 5.28 (br s, 1H), 4.61
(d, J = 12.0Hz, 1H), 4.58 (d, J = 11.8Hz, 1H), 4.55 (dd, J = 8.0, 3.8Hz, 1H), 4.43 (br s, 1H),
4.39 (br s, 1H), 4.26 (dd, J = 9.9, 4.5Hz, 1H), 4.20 (dd, J = 9.1, 8.3Hz, 1H), 3.62 (m, 1H), 3.47
(m, 1H), 2.44 (s, 3H), 2.30 (s, 3H), 1.48 (t, J = 12.6Hz, 1H), 1.31 (dd, J = 12.6, 11.8Hz, 1H),
1.22 (s, 9H), 1.13–0.69 (m, 28H) [carboxylic acid proton was not observed]; 13C NMR (150MHz,
CDCl3) ppm 171.5, 166.5, 165.2, 157.6, 153.0, 151.7, 145.8, 145.6, 134.5, 134.3, 134.2, 130.6, 129.8,
129.5, 128.6, 128.4, 127.5, 80.6, 73.3, 73.0, 68.1, 67.8, 62.75, 62.68, 61.0, 55.2, 41.6, 36.9, 28.0, 21.7,
21.7, 17.6, 17.51, 17.49, 17.4, 17.0, 16.9, 13.8, 13.7, 12.9, 12.7; HRMS (ESI): Exact mass calcd for
C52H72N4O18S2Si2 [M+Na]
+ 1183.3719, found 1183.3678.
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i) iBuO2CCl, NMM
THF, –20 °C, 2 h
Amide 410. A solution of the carboxylic acid (11.5mg, 10.0 µmol) in THF (300 µL) was cooled
to 0 ◦C and NMM (3.3 µL, 30µmol) was added via syringe. The reaction mixture was cooled to
−20 ◦C and iBuO2CCl (4.2 µL, 30µmol) was added via syringe. The reaction was stirred at −15 ◦C
for 2 h and then NH4OH (28–30%, 20µL) was added via syringe and the reaction was warmed to
rt and stirred for additional 6 h. The reaction was quenched with satd aq NH4Cl and the resulting
mixture was extracted with ethyl acetate. The combined organic layers were dried, concentrated,
and the residue was dissolved in anhydrous methanol. The methanol solution was concentrated
and purified using preparative HLPC (XBridgeTM Prep C18 5 µm ODBTM 19× 150 µm column)
using the following program: 10mLmin−1 30min gradient from 30% buffer A (95% water, 5%
198
acetonitrile, 5mm NH4OAc) and 70% buffer B (95% acetonitrile, 5% water, 5mm NH4OAc) to
100% buffer B; tr = 26.0min. Removal of the solvent gave the desired amide as a colorless oil
(5.6mg, 49%). IR (film) 3360, 3067, 2945, 2868, 1788, 1680, 1598, 1518 cm−1; 1H NMR (600MHz,
CDCl3) δ 8.45 (br d, J = 4.7Hz, 1H), 8.08 (d, J = 8.3Hz, 2H), 7.97 (d, J = 8.3Hz, 2H), 7.88 (d,
J = 7.5Hz, 2H), 7.64 (t, J = 7.5Hz, 1H), 7.46 (dd, J = 8.0, 7.5Hz, 2H), 7.36 (d, J = 8.0Hz, 2H),
7.13 (d, J = 8.3Hz, 2H), 6.63 (br s, 1H), 5.54 (br s, 1H), 5.29 (m, 2H), 5.24 (dd, J = 6.5, 6.3Hz,
1H), 4.60 (d, J = 11.8Hz, 1H), 4.56 (d, J = 12.0Hz, 1H), 4.52 (dd, J = 8.0, 3.8Hz, 1H), 4.47
(d, J = 3.3Hz, 1H), 4.42 (ddd, J = 8.5, 3.0, 3.0Hz, 1H), 4.24 (dd, J = 9.8, 4.0Hz, 1H), 4.20 (dd,
J = 9.0, 8.5Hz, 1H), 3.54 (ddd, J = 15.1, 6.0, 2.8Hz, 1H), 3.44 (ddd, J = 14.8, 6.3, 6.3Hz, 1H), 2.45
(s, 3H), 2.35 (s, 3H), 1.41 (dd, J = 13.0, 12.3Hz, 1H), 1.29 (ddd, J = 13.8, 2.3, 2.3Hz, 1H), 1.21 (s,
9H), 1.16–1.02 (m, 18H), 1.00 (s, 3H), 0.96 (d, J = 7.3Hz, 3H), 0.89 (d, J = 7.5Hz, 3H), 0.70 (m,
1H), 13C NMR (150MHz, CDCl3) ppm 171.3, 166.2, 166.0, 157.9, 152.8, 151.7, 145.8, 145.8, 134.6,
134.5, 134.4, 130.6, 129.9, 129.6, 128.7, 128.5, 128.4, 127.5, 80.5, 74.1, 73.1, 68.1, 67.9, 62.8, 62.7,
61.1, 55.6, 42.9, 37.0, 28.0, 21.74, 21.71, 17.6, 17.50, 17.49, 17.4, 17.0, 16.9, 13.9, 13.7, 13.0; HRMS
(ESI): Exact mass calcd for C52H73N5NaO17S2Si2 [M+Na]
+ 1182.3879, found 1182.3843.
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 The sample was submitted by Hubert Muchalski (research group of J. Johnston, 
Department of Chemistry & Vanderbilt Institute of Chemical Biology, Vanderbilt 
University).  A colorless plate (approximate dimensions 0.23  0.20  0.10 mm3) was 
placed onto the tip of a 0.1 mm diameter glass capillary and mounted on a Bruker APEX 
II Kappa Duo diffractometer equipped with an APEX II detector at 150(2) K. 
 
Data collection 
 The data collection was carried out using Mo Kradiation (graphite 
monochromator) with a frame time of 30 seconds and a detector distance of 5.00 cm. A 
collection strategy was calculated and complete data to a resolution of 0.77 Å with a 
redundancy of 4 were collected. Five major sections of frames were collected with 0.50º 
 and  scans. Data to a resolution of 0.82 Å were considered in the reduction. Final cell 
constants were calculated from the xyz centroids of 237 strong reflections from the actual 
data collection after integration (SAINT).
1
 The intensity data were corrected for 
absorption (SADABS).
2
 Please refer to Table 1 for additional crystal and refinement 
information. 
 
Structure solution and refinement 
 The polar space group P212121 was determined based on intensity statistics and 
systematic absences. The structure was solved using SIR-2004
3
 and refined with 
SHELXL-97.
4
 A direct-methods solution was calculated, which provided most non-
hydrogen atoms from the E-map. Full-matrix least squares / difference Fourier cycles 
were performed, which located the remaining non-hydrogen atoms. All non-hydrogen 
atoms were refined with anisotropic displacement parameters. The hydrogen atoms were 
placed in ideal positions and refined as riding atoms with relative isotropic displacement 
parameters with the exception of N and O bound hydrogen atoms. The final full matrix 
least squares refinement converged to R1 = 0.0335 and wR2 = 0.0621 (F
2
, all data). The 
remaining electron density is minuscule and located on bonds.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure description 
 The structure was found as proposed with two solvent molecules per formula 
unit. The absolute configuration was established by anomalous dispersion effects in the 
diffraction data; chiral centers have the following configuration:  C1, R; C3, R; 
C4, S; C12, R; C22, S; C30, R. Hydrogen bonding was observed and is 
listed in the tables. 
 
 
 
 
1
 SAINT, Bruker Analytical X-Ray Systems, Madison, WI, current version. 
2
 An empirical correction for absorption anisotropy. R. Blessing, Acta Cryst. A51, 33 - 
38 (1995). 
3
 Sir2004, A Program for Automatic Solution and Refinement of Crystal Structures.  
 M. C. Burla, R. Caliandro, M. Carnalli, B. Carrozzini, G. L. Cascarano, L. De Caro, C. 
Giacovazzo, G. Polidori, R. Sagna. Vers. 1.0 (2004).  
4
 A short history of SHELX. G. M. Sheldrick, Acta Cryst. A64, 112 - 122 (2008). 
 
 
 
 
 
 
 
Bulk material. 
 
Formula unit. 
 
Formula unit, hydrogen atoms and methanol solvent omitted for clarity. 
 
Hydrogen bonding 
 
Stereo view. 
 
Cell plot, view along a. 
 
Cell plot, view along b. 
 
Cell plot, view along c. 
Table 1.  Crystal data and structure refinement for 10108. 
Empirical formula  C53 H78 N4 O13 Si2 
Formula weight  1035.37 
Crystal color, shape, size  colorless plate, 0.23  0.20  0.10 mm3 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system, space group  Orthorhombic, P212121 
Unit cell dimensions a = 14.5176(13) Å = 90°. 
 b = 19.5896(18) Å = 90°. 
 c = 19.6398(17) Å  = 90°. 
Volume 5585.4(9) Å3 
Z 4 
Density (calculated) 1.231 Mg/m3 
Absorption coefficient 0.127 mm-1 
F(000) 2224 
 
Data collection 
Diffractometer APEX II Kappa Duo, Bruker 
Theta range for data collection 1.47 to 25.07°. 
Index ranges -17<=h<=17, -23<=k<=23, -23<=l<=22 
Reflections collected 43241 
Independent reflections 9901 [R(int) = 0.0788] 
Observed Reflections 7789 
Completeness to theta = 25.07° 99.9 %  
 
Solution and Refinement 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9874 and 0.9713 
Solution Direct methods 
Refinement method Full-matrix least-squares on F2 
Weighting scheme w = [ 2Fo2+AP2]-1, with  
 P = (Fo2+ 2 Fc2)/3, A = 0.0186  
Data / restraints / parameters 9901 / 173 / 679 
Goodness-of-fit on F2 0.902 
Final R indices [I>2sigma(I)] R1 = 0.0335, wR2 = 0.0590 
R indices (all data) R1 = 0.0491, wR2 = 0.0621 
Absolute structure parameter -0.02(7) 
Largest diff. peak and hole 0.184 and -0.152 e.Å-3 
_______________________________________________________ 
Goodness-of-fit = [[w(Fo
2
  Fc
2
)
2
]/Nobservns  Nparams)]
1/2
, all data. 
R1 = (|Fo|  |Fc|) /  |Fo|.       wR2 = [[w(Fo
2
  Fc
2
)
2
] /  [w(Fo
2
)
2
]]
1/2
. 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) 
for 10108.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________ 
Si1 -422(1) 2040(1) 8413(1) 22(1) 
Si2 -1297(1) 1083(1) 9528(1) 21(1) 
O1 570(1) 1633(1) 8423(1) 21(1) 
O2 -376(1) 596(1) 9580(1) 22(1) 
O3 -1100(1) 1703(1) 8987(1) 22(1) 
O4 -93(1) 47(1) 6941(1) 39(1) 
O5 168(1) -786(1) 7699(1) 50(1) 
O6 1879(1) -317(1) 7952(1) 31(1) 
O7 2881(1) -626(1) 7128(1) 43(1) 
O8 1547(1) 1726(1) 10922(1) 35(1) 
O9 2418(1) 1787(1) 9978(1) 43(1) 
O10 2596(1) 410(1) 9960(1) 32(1) 
O11 3302(1) -180(1) 10804(1) 34(1) 
N1 2157(1) 1115(1) 7789(1) 26(1) 
N2 2935(1) -1077(1) 8209(1) 30(1) 
N3 908(1) -273(1) 10211(1) 26(1) 
N4 3874(1) -135(1) 9716(1) 30(1) 
C1 661(1) 910(1) 8333(1) 20(1) 
C2 1074(1) 602(1) 8977(1) 21(1) 
C3 566(1) 804(1) 9623(1) 20(1) 
C4 1251(1) 804(1) 7690(1) 22(1) 
C5 2606(2) 1325(1) 7144(1) 34(1) 
C6 2225(2) 1959(1) 6810(1) 32(1) 
C7 1891(2) 1937(1) 6156(1) 41(1) 
C8 1536(2) 2521(2) 5852(1) 56(1) 
C9 1525(2) 3129(1) 6202(1) 59(1) 
C10 1863(2) 3158(1) 6851(1) 57(1) 
C11 2214(2) 2577(1) 7151(1) 45(1) 
C12 1346(2) 60(1) 7467(1) 27(1) 
C13 419(2) -290(1) 7400(1) 32(1) 
C14 -973(2) -251(1) 6781(1) 51(1) 
C15 2610(2) -680(1) 7703(1) 28(1) 
C16 3678(2) -1541(1) 8168(1) 33(1) 
C17 3834(2) -1935(1) 8744(1) 39(1) 
C18 4552(2) -2396(1) 8756(1) 55(1) 
C19 5107(2) -2474(1) 8205(1) 67(1) 
C20 4956(2) -2082(2) 7638(1) 69(1) 
C21 4238(2) -1614(1) 7611(1) 51(1) 
C22 961(1) 475(1) 10268(1) 23(1) 
C23 892(2) -626(1) 10874(1) 32(1) 
C24 -10(2) -591(1) 11251(1) 30(1) 
C25 -804(2) -835(1) 10962(1) 47(1) 
C26 -1628(2) -843(2) 11307(2) 66(1) 
C27 -1650(2) -601(2) 11958(2) 72(1) 
C28 -882(2) -337(2) 12254(1) 77(1) 
C29 -51(2) -336(1) 11902(1) 53(1) 
C30 1950(1) 692(1) 10436(1) 27(1) 
C31 2022(2) 1461(1) 10401(1) 31(1) 
C32 1550(2) 2466(1) 10969(1) 45(1) 
C33 3274(1) 6(1) 10219(1) 27(1) 
C34 4686(2) -529(1) 9761(1) 30(1) 
C35 5162(2) -633(1) 9152(1) 37(1) 
C36 5966(2) -1008(1) 9148(1) 49(1) 
C37 6304(2) -1279(1) 9743(2) 61(1) 
C38 5836(2) -1167(1) 10345(1) 62(1) 
C39 5027(2) -798(1) 10358(1) 46(1) 
C40 -975(2) 1938(1) 7557(1) 30(1) 
C41 -414(2) 2320(1) 7013(1) 43(1) 
C42 -1993(2) 2150(1) 7522(1) 44(1) 
C43 -100(1) 2932(1) 8621(1) 28(1) 
C44 616(2) 2969(1) 9187(1) 47(1) 
C45 -914(2) 3389(1) 8788(1) 45(1) 
C46 -2190(1) 481(1) 9210(1) 28(1) 
C47 -3145(2) 807(1) 9139(1) 43(1) 
C48 -1900(2) 139(1) 8543(1) 39(1) 
C49 -1647(2) 1482(1) 10351(1) 28(1) 
C50 -1922(2) 951(1) 10888(1) 48(1) 
C51 -942(2) 1974(1) 10640(1) 42(1) 
O1S 2030(1) -1177(1) 9493(1) 38(1) 
C1S 1403(2) -1714(1) 9420(2) 82(1) 
O2S 3710(1) 564(1) 8456(1) 38(1) 
C2S 4147(2) 1189(1) 8645(1) 58(1) 
________________________________________________________________________
________
Table 3.   Bond lengths [Å] and angles [°] for 10108. 
________________________________________________________________________ 
 Si1-O3 1.6354(13) Si1-O1 1.6467(14)
 Si1-C43 1.855(2) Si1-C40 1.8741(19)
 Si2-O3 1.6393(13) Si2-O2 1.6469(14)
 Si2-C46 1.861(2) Si2-C49 1.864(2)
 O1-C1 1.433(2) O2-C3 1.430(2)
 O4-C13 1.343(3) O4-C14 1.439(3)
 O5-C13 1.193(2) O6-C15 1.368(2)
 O6-C12 1.432(2) O7-C15 1.201(2)
 O8-C31 1.338(2) O8-C32 1.453(3)
 O9-C31 1.196(2) O10-C33 1.361(2)
 O10-C30 1.434(2) O11-C33 1.206(2)
 N1-C4 1.462(3) N1-C5 1.483(2)
 N1-H1N 0.865(16) N2-C15 1.346(2)
 N2-C16 1.414(3) N2-H2N 0.8800
 N3-C22 1.471(3) N3-C23 1.475(2)
 N3-H3N 0.848(17) N4-C33 1.347(2)
 N4-C34 1.412(3) N4-H4N 0.8800
 C1-C2 1.524(2) C1-C4 1.540(2)
 C1-H1 1.0000 C2-C3 1.520(2)
 C2-H2A 0.9900 C2-H2B 0.9900
 C3-C22 1.532(2) C3-H3 1.0000
 C4-C12 1.528(3) C4-H4 1.0000
 C5-C6 1.509(3) C5-H5A 0.9900
 C5-H5B 0.9900 C6-C7 1.374(3)
 C6-C11 1.383(3) C7-C8 1.390(3)
 C7-H7 0.9500 C8-C9 1.374(4)
 C8-H8 0.9500 C9-C10 1.367(4)
 C9-H9 0.9500 C10-C11 1.380(3)
 C10-H10 0.9500 C11-H11 0.9500
 C12-C13 1.516(3) C12-H12 1.0000
 C14-H14A 0.9800 C14-H14B 0.9800
 C14-H14C 0.9800 C16-C21 1.369(3)
 C16-C17 1.388(3) C17-C18 1.379(3)
 C17-H17 0.9500 C18-C19 1.359(3)
 C18-H18 0.9500 C19-C20 1.370(4)
 C19-H19 0.9500 C20-C21 1.390(3)
 C20-H20 0.9500 C21-H21 0.9500
 C22-C30 1.534(3) C22-H22 1.0000
 C23-C24 1.507(3) C23-H23A 0.9900
 C23-H23B 0.9900 C24-C25 1.371(3)
 C24-C29 1.373(3) C25-C26 1.376(4)
 C25-H25 0.9500 C26-C27 1.363(4)
 C26-H26 0.9500 C27-C28 1.359(4)
 C27-H27 0.9500 C28-C29 1.390(4)
 C28-H28 0.9500 C29-H29 0.9500
 C30-C31 1.511(3) C30-H30 1.0000
 C32-H32A 0.9800 C32-H32B 0.9800
 C32-H32C 0.9800 C34-C39 1.376(3)
 C34-C35 1.396(3) C35-C36 1.379(3)
 C35-H35 0.9500 C36-C37 1.375(3)
 C36-H36 0.9500 C37-C38 1.381(3)
 C37-H37 0.9500 C38-C39 1.380(3)
 C38-H38 0.9500 C39-H39 0.9500
 C40-C42 1.537(3) C40-C41 1.537(3)
 C40-H40 1.0000 C41-H41A 0.9800
 C41-H41B 0.9800 C41-H41C 0.9800
 C42-H42A 0.9800 C42-H42B 0.9800
 C42-H42C 0.9800 C43-C45 1.519(3)
 C43-C44 1.524(3) C43-H43 1.0000
 C44-H44A 0.9800 C44-H44B 0.9800
 C44-H44C 0.9800 C45-H45A 0.9800
 C45-H45B 0.9800 C45-H45C 0.9800
 C46-C48 1.530(3) C46-C47 1.534(3)
 C46-H46 1.0000 C47-H47A 0.9800
 C47-H47B 0.9800 C47-H47C 0.9800
 C48-H48A 0.9800 C48-H48B 0.9800
 C48-H48C 0.9800 C49-C51 1.518(3)
 C49-C50 1.535(3) C49-H49 1.0000
 C50-H50A 0.9800 C50-H50B 0.9800
 C50-H50C 0.9800 C51-H51A 0.9800
 C51-H51B 0.9800 C51-H51C 0.9800
 O1S-C1S 1.400(3) O1S-H1OS 0.95(2)
 C1S-H1SA 0.9800 C1S-H1SB 0.9800
 C1S-H1SC 0.9800 O2S-C2S 1.429(3)
 O2S-H2OS 0.84(3) C2S-H2SA 0.9800
 C2S-H2SB 0.9800 C2S-H2SC 0.9800
 O3-Si1-O1 108.82(7) O3-Si1-C43 112.34(8)
 O1-Si1-C43 103.49(8) O3-Si1-C40 108.55(8)
 O1-Si1-C40 109.44(8) C43-Si1-C40 113.99(9)
 O3-Si2-O2 109.16(7) O3-Si2-C46 111.91(8)
 O2-Si2-C46 102.64(8) O3-Si2-C49 107.40(8)
 O2-Si2-C49 114.27(8) C46-Si2-C49 111.51(9)
 C1-O1-Si1 123.96(12) C3-O2-Si2 127.94(11)
 Si1-O3-Si2 148.33(9) C13-O4-C14 116.02(18)
 C15-O6-C12 116.71(15) C31-O8-C32 115.75(18)
 C33-O10-C30 116.97(14) C4-N1-C5 113.46(16)
 C4-N1-H1N 111.8(12) C5-N1-H1N 107.1(11)
 C15-N2-C16 126.59(18) C15-N2-H2N 116.7
 C16-N2-H2N 116.7 C22-N3-C23 113.56(15)
 C22-N3-H3N 105.0(12) C23-N3-H3N 107.6(12)
 C33-N4-C34 127.28(18) C33-N4-H4N 116.4
 C34-N4-H4N 116.4 O1-C1-C2 109.06(14)
 O1-C1-C4 106.52(14) C2-C1-C4 114.10(15)
 O1-C1-H1 109.0 C2-C1-H1 109.0
 C4-C1-H1 109.0 C3-C2-C1 113.44(15)
 C3-C2-H2A 108.9 C1-C2-H2A 108.9
 C3-C2-H2B 108.9 C1-C2-H2B 108.9
 H2A-C2-H2B 107.7 O2-C3-C2 109.93(14)
 O2-C3-C22 106.59(14) C2-C3-C22 113.48(15)
 O2-C3-H3 108.9 C2-C3-H3 108.9
 C22-C3-H3 108.9 N1-C4-C12 110.73(17)
 N1-C4-C1 109.60(15) C12-C4-C1 114.43(16)
 N1-C4-H4 107.3 C12-C4-H4 107.3
 C1-C4-H4 107.3 N1-C5-C6 115.99(17)
 N1-C5-H5A 108.3 C6-C5-H5A 108.3
 N1-C5-H5B 108.3 C6-C5-H5B 108.3
 H5A-C5-H5B 107.4 C7-C6-C11 118.4(2)
 C7-C6-C5 120.6(2) C11-C6-C5 120.9(2)
 C6-C7-C8 120.4(2) C6-C7-H7 119.8
 C8-C7-H7 119.8 C9-C8-C7 120.2(2)
 C9-C8-H8 119.9 C7-C8-H8 119.9
 C10-C9-C8 119.9(3) C10-C9-H9 120.0
 C8-C9-H9 120.0 C9-C10-C11 119.7(3)
 C9-C10-H10 120.2 C11-C10-H10 120.2
 C10-C11-C6 121.4(2) C10-C11-H11 119.3
 C6-C11-H11 119.3 O6-C12-C13 107.69(17)
 O6-C12-C4 110.51(15) C13-C12-C4 112.05(17)
 O6-C12-H12 108.8 C13-C12-H12 108.8
 C4-C12-H12 108.8 O5-C13-O4 124.2(2)
 O5-C13-C12 126.7(2) O4-C13-C12 109.15(19)
 O4-C14-H14A 109.5 O4-C14-H14B 109.5
 H14A-C14-H14B 109.5 O4-C14-H14C 109.5
 H14A-C14-H14C 109.5 H14B-C14-H14C 109.5
 O7-C15-N2 129.1(2) O7-C15-O6 123.02(19)
 N2-C15-O6 107.92(17) C21-C16-C17 119.7(2)
 C21-C16-N2 124.4(2) C17-C16-N2 115.83(19)
 C18-C17-C16 120.1(2) C18-C17-H17 119.9
 C16-C17-H17 119.9 C19-C18-C17 120.5(2)
 C19-C18-H18 119.8 C17-C18-H18 119.8
 C18-C19-C20 119.4(2) C18-C19-H19 120.3
 C20-C19-H19 120.3 C19-C20-C21 121.3(2)
 C19-C20-H20 119.3 C21-C20-H20 119.3
 C16-C21-C20 118.9(2) C16-C21-H21 120.5
 C20-C21-H21 120.5 N3-C22-C3 109.71(15)
 N3-C22-C30 109.96(17) C3-C22-C30 114.26(16)
 N3-C22-H22 107.5 C3-C22-H22 107.5
 C30-C22-H22 107.5 N3-C23-C24 115.27(17)
 N3-C23-H23A 108.5 C24-C23-H23A 108.5
 N3-C23-H23B 108.5 C24-C23-H23B 108.5
 H23A-C23-H23B 107.5 C25-C24-C29 118.5(2)
 C25-C24-C23 120.71(19) C29-C24-C23 120.8(2)
 C24-C25-C26 122.0(2) C24-C25-H25 119.0
 C26-C25-H25 119.0 C27-C26-C25 118.6(3)
 C27-C26-H26 120.7 C25-C26-H26 120.7
 C28-C27-C26 120.9(3) C28-C27-H27 119.5
 C26-C27-H27 119.5 C27-C28-C29 120.0(3)
 C27-C28-H28 120.0 C29-C28-H28 120.0
 C24-C29-C28 119.9(3) C24-C29-H29 120.0
 C28-C29-H29 120.0 O10-C30-C31 108.00(17)
 O10-C30-C22 111.42(16) C31-C30-C22 109.35(17)
 O10-C30-H30 109.3 C31-C30-H30 109.3
 C22-C30-H30 109.3 O9-C31-O8 124.8(2)
 O9-C31-C30 126.7(2) O8-C31-C30 108.44(18)
 O8-C32-H32A 109.5 O8-C32-H32B 109.5
 H32A-C32-H32B 109.5 O8-C32-H32C 109.5
 H32A-C32-H32C 109.5 H32B-C32-H32C 109.5
 O11-C33-N4 128.0(2) O11-C33-O10 123.82(19)
 N4-C33-O10 108.21(17) C39-C34-C35 119.7(2)
 C39-C34-N4 124.25(19) C35-C34-N4 116.00(19)
 C36-C35-C34 120.1(2) C36-C35-H35 119.9
 C34-C35-H35 119.9 C37-C36-C35 120.2(2)
 C37-C36-H36 119.9 C35-C36-H36 119.9
 C36-C37-C38 119.4(3) C36-C37-H37 120.3
 C38-C37-H37 120.3 C39-C38-C37 121.2(3)
 C39-C38-H38 119.4 C37-C38-H38 119.4
 C34-C39-C38 119.4(2) C34-C39-H39 120.3
 C38-C39-H39 120.3 C42-C40-C41 110.27(18)
 C42-C40-Si1 114.99(14) C41-C40-Si1 110.13(15)
 C42-C40-H40 107.0 C41-C40-H40 107.0
 Si1-C40-H40 107.0 C40-C41-H41A 109.5
 C40-C41-H41B 109.5 H41A-C41-H41B 109.5
 C40-C41-H41C 109.5 H41A-C41-H41C 109.5
 H41B-C41-H41C 109.5 C40-C42-H42A 109.5
 C40-C42-H42B 109.5 H42A-C42-H42B 109.5
 C40-C42-H42C 109.5 H42A-C42-H42C 109.5
 H42B-C42-H42C 109.5 C45-C43-C44 110.23(17)
 C45-C43-Si1 113.99(15) C44-C43-Si1 112.25(15)
 C45-C43-H43 106.6 C44-C43-H43 106.6
 Si1-C43-H43 106.6 C43-C44-H44A 109.5
 C43-C44-H44B 109.5 H44A-C44-H44B 109.5
 C43-C44-H44C 109.5 H44A-C44-H44C 109.5
 H44B-C44-H44C 109.5 C43-C45-H45A 109.5
 C43-C45-H45B 109.5 H45A-C45-H45B 109.5
 C43-C45-H45C 109.5 H45A-C45-H45C 109.5
 H45B-C45-H45C 109.5 C48-C46-C47 110.69(18)
 C48-C46-Si2 111.99(14) C47-C46-Si2 113.35(15)
 C48-C46-H46 106.8 C47-C46-H46 106.8
 Si2-C46-H46 106.8 C46-C47-H47A 109.5
 C46-C47-H47B 109.5 H47A-C47-H47B 109.5
 C46-C47-H47C 109.5 H47A-C47-H47C 109.5
 H47B-C47-H47C 109.5 C46-C48-H48A 109.5
 C46-C48-H48B 109.5 H48A-C48-H48B 109.5
 C46-C48-H48C 109.5 H48A-C48-H48C 109.5
 H48B-C48-H48C 109.5 C51-C49-C50 110.34(18)
 C51-C49-Si2 114.00(14) C50-C49-Si2 112.52(15)
 C51-C49-H49 106.5 C50-C49-H49 106.5
 Si2-C49-H49 106.5 C49-C50-H50A 109.5
 C49-C50-H50B 109.5 H50A-C50-H50B 109.5
 C49-C50-H50C 109.5 H50A-C50-H50C 109.5
 H50B-C50-H50C 109.5 C49-C51-H51A 109.5
 C49-C51-H51B 109.5 H51A-C51-H51B 109.5
 C49-C51-H51C 109.5 H51A-C51-H51C 109.5
 H51B-C51-H51C 109.5 C1S-O1S-H1OS 109.5(15)
 O1S-C1S-H1SA 109.5 O1S-C1S-H1SB 109.5
 H1SA-C1S-H1SB 109.5 O1S-C1S-H1SC 109.5
 H1SA-C1S-H1SC 109.5 H1SB-C1S-H1SC 109.5
 C2S-O2S-H2OS 106.7(19) O2S-C2S-H2SA 109.5
 O2S-C2S-H2SB 109.5 H2SA-C2S-H2SB 109.5
 O2S-C2S-H2SC 109.5 H2SA-C2S-H2SC 109.5
 H2SB-C2S-H2SC 109.5  
________________________________________________________________________ 
Table 4.   Anisotropic displacement parameters (Å2x 103)for 10108.  The 
anisotropic 
displacement factor exponent takes the form: -2 2[ h2a*2U11 + ... + 2 h k a* b* 
U12 ] 
________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
________________________________________________________________________ 
Si1 20(1)  21(1) 23(1)  3(1) 2(1)  2(1) 
Si2 18(1)  22(1) 23(1)  2(1) 2(1)  1(1) 
O1 21(1)  20(1) 23(1)  1(1) 2(1)  2(1) 
O2 19(1)  22(1) 24(1)  3(1) 1(1)  1(1) 
O3 19(1)  21(1) 26(1)  2(1) 0(1)  2(1) 
O4 32(1)  45(1) 39(1)  -2(1) -8(1)  1(1) 
O5 57(1)  36(1) 58(1)  7(1) -7(1)  -9(1) 
O6 33(1)  36(1) 23(1)  2(1) 3(1)  17(1) 
O7 40(1)  65(1) 25(1)  3(1) 5(1)  22(1) 
O8 37(1)  32(1) 37(1)  -4(1) -1(1)  1(1) 
O9 40(1)  49(1) 40(1)  7(1) -1(1)  -13(1) 
O10 23(1)  52(1) 21(1)  2(1) 1(1)  12(1) 
O11 35(1)  44(1) 24(1)  5(1) -1(1)  10(1) 
N1 23(1)  32(1) 24(1)  0(1) 4(1)  2(1) 
N2 32(1)  31(1) 26(1)  1(1) 2(1)  11(1) 
N3 27(1)  26(1) 24(1)  5(1) -1(1)  2(1) 
N4 24(1)  42(1) 24(1)  2(1) 1(1)  5(1) 
C1 21(1)  22(1) 18(1)  1(1) 0(1)  3(1) 
C2 20(1)  26(1) 16(1)  2(1) 2(1)  5(1) 
C3 18(1)  23(1) 18(1)  1(1) 2(1)  0(1) 
C4 21(1)  28(1) 18(1)  4(1) 0(1)  3(1) 
C5 27(1)  42(2) 32(1)  8(1) 13(1)  2(1) 
C6 27(1)  31(1) 37(1)  5(1) 13(1)  -2(1) 
C7 45(2)  45(2) 33(1)  3(1) 9(1)  0(1) 
C8 65(2)  65(2) 39(1)  14(1) 6(1)  8(2) 
C9 64(2)  47(2) 67(2)  25(2) 20(2)  9(2) 
C10 70(2)  31(2) 70(2)  2(1) 19(2)  -7(1) 
C11 49(2)  41(2) 46(1)  -3(1) 7(1)  -6(1) 
C12 27(1)  34(1) 20(1)  1(1) -1(1)  12(1) 
C13 38(2)  31(1) 27(1)  -9(1) 0(1)  6(1) 
C14 38(2)  60(2) 55(2)  -14(1) -10(1)  0(1) 
C15 25(1)  30(1) 28(1)  -6(1) 2(1)  6(1) 
C16 30(1)  30(1) 38(1)  -8(1) -3(1)  6(1) 
C17 36(2)  35(1) 47(1)  7(1) 2(1)  7(1) 
C18 53(2)  47(2) 67(2)  19(1) 2(2)  18(2) 
C19 70(2)  62(2) 68(2)  4(2) 4(2)  44(2) 
C20 62(2)  91(2) 54(2)  0(2) 16(2)  42(2) 
C21 47(2)  69(2) 36(1)  1(1) 5(1)  27(2) 
C22 23(1)  31(1) 17(1)  2(1) 4(1)  5(1) 
C23 33(1)  39(1) 26(1)  11(1) 0(1)  7(1) 
C24 30(1)  29(1) 32(1)  12(1) 4(1)  4(1) 
C25 40(2)  44(2) 57(2)  1(1) 5(1)  -6(1) 
C26 38(2)  65(2) 95(2)  17(2) 5(2)  -11(2) 
C27 52(2)  90(3) 74(2)  39(2) 32(2)  22(2) 
C28 74(2)  118(3) 38(2)  12(2) 18(2)  28(2) 
C29 50(2)  77(2) 31(1)  6(1) 2(1)  13(2) 
C30 24(1)  39(1) 18(1)  1(1) 1(1)  4(1) 
C31 23(1)  42(1) 27(1)  0(1) -8(1)  -2(1) 
C32 49(2)  33(2) 52(2)  -7(1) -11(1)  -3(1) 
C33 22(1)  29(1) 30(1)  -2(1) -5(1)  -1(1) 
C34 24(1)  25(1) 42(1)  1(1) 3(1)  1(1) 
C35 33(2)  34(1) 44(1)  -3(1) 8(1)  -2(1) 
C36 41(2)  42(2) 65(2)  -1(1) 20(1)  3(1) 
C37 42(2)  51(2) 91(2)  12(2) 19(2)  18(2) 
C38 39(2)  75(2) 71(2)  24(2) 9(1)  24(2) 
C39 32(2)  53(2) 51(2)  9(1) 7(1)  12(1) 
C40 33(1)  30(1) 27(1)  2(1) -1(1)  4(1) 
C41 51(2)  49(2) 30(1)  10(1) -1(1)  3(1) 
C42 38(2)  54(2) 39(1)  1(1) -12(1)  1(1) 
C43 28(1)  24(1) 32(1)  2(1) 5(1)  0(1) 
C44 57(2)  36(2) 48(1)  1(1) -13(1)  -5(1) 
C45 44(2)  31(1) 61(2)  -6(1) 10(1)  3(1) 
C46 21(1)  26(1) 37(1)  4(1) 1(1)  -2(1) 
C47 24(1)  38(2) 66(2)  -8(1) -6(1)  -3(1) 
C48 34(2)  37(1) 47(1)  -9(1) -5(1)  -5(1) 
C49 30(1)  28(1) 28(1)  4(1) 5(1)  7(1) 
C50 56(2)  51(2) 35(1)  9(1) 20(1)  0(1) 
C51 49(2)  45(2) 31(1)  -10(1) 0(1)  2(1) 
O1S 38(1)  38(1) 39(1)  -3(1) 6(1)  2(1) 
C1S 71(2)  69(2) 107(2)  -53(2) 25(2)  -27(2) 
O2S 33(1)  43(1) 39(1)  5(1) -2(1)  1(1) 
C2S 48(2)  60(2) 67(2)  6(2) -12(1)  -14(2) 
_______________________________________________________________________
Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(Å2x 103) for 10108. 
________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________ 
 
H1N 2128(12) 1473(8) 8046(8) 5(5) 
H2N 2656 -1043 8606 55(8) 
H3N 399(13) -351(9) 10015(8) 8(5) 
H4N 3745 37 9313 36(6) 
H1 37 708 8256 24 
H2A 1068 98 8936 25 
H2B 1725 748 9016 25 
H3 591 1312 9673 24 
H4 942 1056 7311 27 
H5A 2557 943 6816 41 
H5B 3269 1400 7235 41 
H7 1903 1519 5910 49 
H8 1300 2500 5401 67 
H9 1283 3527 5993 71 
H10 1856 3578 7095 68 
H11 2453 2601 7601 55 
H12 1666 46 7017 32 
H14A -1281 25 6433 76 
H14B -1354 -265 7193 76 
H14C -883 -716 6609 76 
H17 3446 -1887 9130 47 
H18 4659 -2662 9153 66 
H19 5596 -2796 8212 80 
H20 5351 -2131 7255 83 
H21 4137 -1348 7213 61 
H22 561 615 10658 28 
H23A 1378 -426 11167 39 
H23B 1050 -1112 10800 39 
H25 -784 -1003 10508 56 
H26 -2170 -1015 11097 79 
H27 -2210 -616 12208 87 
H28 -913 -153 12701 92 
H29 488 -160 12112 63 
H30 2110 536 10906 33 
H32A 1248 2606 11393 67 
H32B 1218 2659 10580 67 
H32C 2187 2632 10967 67 
H35 4932 -445 8740 45 
H36 6286 -1080 8733 59 
H37 6855 -1540 9741 74 
H38 6075 -1349 10758 74 
H39 4708 -729 10775 55 
H40 -947 1442 7440 35 
H41A -656 2211 6561 64 
H41B 233 2181 7041 64 
H41C -462 2813 7092 64 
H42A -2229 2069 7062 65 
H42B -2049 2636 7633 65 
H42C -2350 1881 7849 65 
H43 196 3126 8204 34 
H44A 741 3449 9297 71 
H44B 1186 2749 9035 71 
H44C 382 2735 9593 71 
H45A -696 3855 8872 68 
H45B -1227 3217 9195 68 
H45C -1345 3391 8404 68 
H46 -2247 110 9557 33 
H47A -3591 459 8996 64 
H47B -3122 1171 8798 64 
H47C -3334 999 9579 64 
H48A -2382 -180 8397 59 
H48B -1323 -111 8612 59 
H48C -1811 488 8191 59 
H49 -2213 1756 10253 34 
H50A -2145 1184 11297 71 
H50B -1385 671 11005 71 
H50C -2411 658 10706 71 
H51A -1193 2192 11049 62 
H51B -797 2324 10300 62 
H51C -380 1724 10759 62 
H1OS 1738(17) -805(13) 9719(12) 65(9) 
H1SA 828 -1541 9224 123 
H1SB 1278 -1917 9866 123 
H1SC 1664 -2062 9117 123 
H2OS 3200(20) 669(14) 8273(13) 78(11) 
H2SA 3728 1458 8930 87 
H2SB 4303 1449 8234 87 
H2SC 4711 1090 8901 87 
________________________________________________________________________
Table 6.  Torsion angles [°] for 10108. 
________________________________________________________________________ 
 O3-Si1-O1-C1 56.00(14) C43-Si1-O1-C1 175.65(13)
 C40-Si1-O1-C1 -62.48(14) O3-Si2-O2-C3 43.27(15)
 C46-Si2-O2-C3 162.13(14) C49-Si2-O2-C3 -76.98(15)
 O1-Si1-O3-Si2 -10.59(19) C43-Si1-O3-Si2 -124.58(16)
 C40-Si1-O3-Si2 108.44(17) O2-Si2-O3-Si1 8.00(19)
 C46-Si2-O3-Si1 -104.91(17) C49-Si2-O3-Si1 132.39(16)
 Si1-O1-C1-C2 -117.61(15) Si1-O1-C1-C4 118.81(14)
 O1-C1-C2-C3 51.9(2) C4-C1-C2-C3 170.89(16)
 Si2-O2-C3-C2 -112.55(15) Si2-O2-C3-C22 124.07(14)
 C1-C2-C3-O2 58.7(2) C1-C2-C3-C22 177.99(16)
 C5-N1-C4-C12 79.2(2) C5-N1-C4-C1 -153.65(16)
 O1-C1-C4-N1 60.83(19) C2-C1-C4-N1 -59.6(2)
 O1-C1-C4-C12 -174.11(15) C2-C1-C4-C12 65.5(2)
 C4-N1-C5-C6 74.6(2) N1-C5-C6-C7 -122.1(2)
 N1-C5-C6-C11 58.6(3) C11-C6-C7-C8 -1.1(3)
 C5-C6-C7-C8 179.6(2) C6-C7-C8-C9 0.7(4)
 C7-C8-C9-C10 -0.1(4) C8-C9-C10-C11 0.0(4)
 C9-C10-C11-C6 -0.5(4) C7-C6-C11-C10 1.1(4)
 C5-C6-C11-C10 -179.7(2) C15-O6-C12-C13 109.67(19)
 C15-O6-C12-C4 -127.65(18) N1-C4-C12-O6 56.6(2)
 C1-C4-C12-O6 -67.9(2) N1-C4-C12-C13 176.68(15)
 C1-C4-C12-C13 52.2(2) C14-O4-C13-O5 -4.1(3)
 C14-O4-C13-C12 175.64(17) O6-C12-C13-O5 0.6(3)
 C4-C12-C13-O5 -121.1(2) O6-C12-C13-O4 -179.15(15)
 C4-C12-C13-O4 59.1(2) C16-N2-C15-O7 -1.4(4)
 C16-N2-C15-O6 178.96(18) C12-O6-C15-O7 9.5(3)
 C12-O6-C15-N2 -170.85(17) C15-N2-C16-C21 6.0(4)
 C15-N2-C16-C17 -174.7(2) C21-C16-C17-C18 0.3(4)
 N2-C16-C17-C18 -179.1(2) C16-C17-C18-C19 -0.6(4)
 C17-C18-C19-C20 0.9(5) C18-C19-C20-C21 -1.0(5)
 C17-C16-C21-C20 -0.3(4) N2-C16-C21-C20 179.0(2)
 C19-C20-C21-C16 0.6(5) C23-N3-C22-C3 -155.73(17)
 C23-N3-C22-C30 77.8(2) O2-C3-C22-N3 61.19(19)
 C2-C3-C22-N3 -60.0(2) O2-C3-C22-C30 -174.80(15)
 C2-C3-C22-C30 64.1(2) C22-N3-C23-C24 75.5(2)
 N3-C23-C24-C25 58.3(3) N3-C23-C24-C29 -124.0(2)
 C29-C24-C25-C26 -1.3(4) C23-C24-C25-C26 176.5(2)
 C24-C25-C26-C27 0.0(4) C25-C26-C27-C28 1.9(5)
 C26-C27-C28-C29 -2.5(5) C25-C24-C29-C28 0.7(4)
 C23-C24-C29-C28 -177.0(2) C27-C28-C29-C24 1.2(4)
 C33-O10-C30-C31 118.72(18) C33-O10-C30-C22 -121.16(18)
 N3-C22-C30-O10 53.2(2) C3-C22-C30-O10 -70.6(2)
 N3-C22-C30-C31 172.56(15) C3-C22-C30-C31 48.7(2)
 C32-O8-C31-O9 -1.6(3) C32-O8-C31-C30 179.48(17)
 O10-C30-C31-O9 11.9(3) C22-C30-C31-O9 -109.5(2)
 O10-C30-C31-O8 -169.13(15) C22-C30-C31-O8 69.5(2)
 C34-N4-C33-O11 -0.9(4) C34-N4-C33-O10 178.94(18)
 C30-O10-C33-O11 7.7(3) C30-O10-C33-N4 -172.09(16)
 C33-N4-C34-C39 -4.7(3) C33-N4-C34-C35 176.3(2)
 C39-C34-C35-C36 0.5(3) N4-C34-C35-C36 179.7(2)
 C34-C35-C36-C37 -0.3(4) C35-C36-C37-C38 -0.5(4)
 C36-C37-C38-C39 1.0(4) C35-C34-C39-C38 -0.1(4)
 N4-C34-C39-C38 -179.1(2) C37-C38-C39-C34 -0.7(4)
 O3-Si1-C40-C42 48.18(18) O1-Si1-C40-C42 166.82(15)
 C43-Si1-C40-C42 -77.85(18) O3-Si1-C40-C41 173.49(14)
 O1-Si1-C40-C41 -67.87(16) C43-Si1-C40-C41 47.46(18)
 O3-Si1-C43-C45 -50.90(17) O1-Si1-C43-C45 -168.10(15)
 C40-Si1-C43-C45 73.12(17) O3-Si1-C43-C44 75.33(16)
 O1-Si1-C43-C44 -41.88(16) C40-Si1-C43-C44 -160.65(15)
 O3-Si2-C46-C48 60.90(16) O2-Si2-C46-C48 -56.02(16)
 C49-Si2-C46-C48 -178.78(14) O3-Si2-C46-C47 -65.21(17)
 O2-Si2-C46-C47 177.88(15) C49-Si2-C46-C47 55.12(18)
 O3-Si2-C49-C51 -57.61(17) O2-Si2-C49-C51 63.62(17)
 C46-Si2-C49-C51 179.44(15) O3-Si2-C49-C50 175.77(15)
 O2-Si2-C49-C50 -63.00(18) C46-Si2-C49-C50 52.83(19) 
________________________________________________________________________ 
 
Table 7.  Hydrogen bonds for 10108 [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________ 
 N2-H2N...O1S 0.88 1.98 2.850(2) 168.2 
 N3-H3N...O2 0.848(17) 2.330(17) 2.811(2) 116.4(14) 
 N4-H4N...O2S 0.88 1.97 2.837(2) 166.4 
 O1S-H1OS...N3 0.95(2) 1.86(3) 2.788(2) 163(2) 
 O2S-H2OS...N1 0.84(3) 2.00(3) 2.824(2) 167(3) 
________________________________________________________________________ 
checkCIF/PLATON report (basic structural check)
No syntax errors found.                               CIF dictionary
Please wait while processing ....                     Interpreting this report
Datablock: 10108
Bond precision: C-C = 0.0033 A Wavelength=0.71073
Cell: a=14.5176(13) b=19.5896(18) c=19.6398(17)
alpha=90 beta=90 gamma=90
Temperature:150 K
Calculated Reported
Volume 5585.4(9) 5585.4(9)
Space group P 21 21 21 P2(1)2(1)2(
Hall group P 2ac 2ab ?
Moiety formula C51 H70 N4 O11 Si2, 2(C H4 O) C51 H70 N4 O11 Si2, 2 (C H4 O)
Sum formula C53 H78 N4 O13 Si2 C53 H78 N4 O13 Si2
Mr 1035.37 1035.37
Dx,g cm-3 1.231 1.231
Z 4 4
Mu (mm-1) 0.127 0.127
F000 2224.0 2224.0
F000' 2225.68
h,k,lmax 17,23,23 17,23,23
Nref 5470[ 9904] 9901
Tmin,Tmax 0.971,0.987 0.971,0.987
Tmin' 0.971
Correction method= MULTI-SCAN
Data completeness= 1.81/1.00 Theta(max)= 25.070
R(reflections)= 0.0335( 7789) wR2(reflections)= 0.0621( 9901)
S = 0.902 Npar= 679
The following ALERTS were generated. Each ALERT has the format
       test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.
Alert level A
PLAT222_ALERT_3_A Large Non-Solvent    H    Uiso(max)/Uso(min) ...      10.00 Ratio
Alert level C
PLAT220_ALERT_2_C Large Non-Solvent    C     Ueq(max)/Ueq(min) ...       3.92 Ratio
PLAT230_ALERT_2_C Hirshfeld Test Diff for    O11    --  C33     ..       5.49 su   
PLAT245_ALERT_2_C U(iso) H1N     Smaller than U(eq) N1      by ...       0.02 AngSq
PLAT245_ALERT_2_C U(iso) H3N     Smaller than U(eq) N3      by ...       0.02 AngSq
PLAT790_ALERT_4_C Centre of Gravity not Within Unit Cell: Resd.  #          2      
              C H4 O                                                           
Alert level G
REFLT03_ALERT_4_G Please check that the estimate of the number of Friedel pairs is
            correct. If it is not, please give the correct count in the
            _publ_section_exptl_refinement section of the submitted CIF.
           From the CIF: _diffrn_reflns_theta_max           25.07
           From the CIF: _reflns_number_total               9901
           Count of symmetry unique reflns         5470
           Completeness (_total/calc)            181.01%
           TEST3: Check Friedels for noncentro structure
           Estimate of Friedel pairs measured      4431
           Fraction of Friedel pairs measured     0.810
           Are heavy atom types Z>Si present        yes
PLAT860_ALERT_3_G Note: Number of Least-Squares Restraints .......        173      
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          8      
PLAT791_ALERT_4_G Note: The Model has Chirality at C1     (Verify)          R      
PLAT791_ALERT_4_G Note: The Model has Chirality at C3     (Verify)          R      
PLAT791_ALERT_4_G Note: The Model has Chirality at C4     (Verify)          S      
PLAT791_ALERT_4_G Note: The Model has Chirality at C12    (Verify)          R      
PLAT791_ALERT_4_G Note: The Model has Chirality at C22    (Verify)          S      
PLAT791_ALERT_4_G Note: The Model has Chirality at C30    (Verify)          R      
   1 ALERT level A = In general: serious problem
   0 ALERT level B = Potentially serious problem
   5 ALERT level C = Check and explain
   9 ALERT level G = General alerts; check
   0 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
   4 ALERT type 2 Indicator that the structure model may be wrong or deficient
   2 ALERT type 3 Indicator that the structure quality may be low
   9 ALERT type 4 Improvement, methodology, query or suggestion
   0 ALERT type 5 Informative message, check
Publication of your CIF in IUCr journals
A basic structural check has been run on your CIF. These basic checks will be run on all CIFs submitted for publication in
IUCr journals (Acta Crystallographica, Journal of Applied Crystallography, Journal of Synchrotron Radiation); however,
if you intend to submit to Acta Crystallographica Section C or E, you should make sure that full publication checks are run
on the final version of your CIF prior to submission.
Publication of your CIF in other journals
Please refer to the Notes for Authors of the relevant journal for any special instructions relating to CIF submission.
PLATON version of 22/10/2010; check.def file version of 11/10/2010
Datablock 10108 - ellipsoid plot
Download CIF editor (publCIF) from the IUCr
Download CIF editor (enCIFer) from the CCDC
Test a new CIF entry
APPENDIX C
Spectral data and characterization.
225
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
3.20
0.98
0.99
2.04
0.99
1.00
15.51
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 4
00
.1
30
00
89
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
1 
   
   
 4
00
.1
32
00
07
 M
Hz
PL
1W
   
   
  1
8.
35
86
95
98
 W
PL
1 
   
   
   
   
  −
2.
50
 d
B
P1
   
   
   
   
   
 1
1.
38
 u
se
c
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 1
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
25
.6
1 
us
ec
D
W
   
   
   
   
   
96
.0
00
 u
se
c
R
G
   
   
   
   
   
   
 3
2
A
Q 
   
   
   
  3
.1
45
77
79
 s
ec
FI
D
R
ES
   
   
   
0.
15
89
46
 H
z
SW
H 
   
   
   
  5
20
8.
33
3 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
   
16
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 P
AB
BO
 B
B−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
  8
.4
1
D
at
e_
   
   
   
 2
00
91
21
7
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
1
N
A
M
E 
   
 E
tO
2C
 a
nt
i o
xa
zo
lid
in
e 
di
on
e
Et
O
2C
N
Ph
2H
C
O
N OO
Ph
H
Figure C.1. 1H NMR (CDCl3) of 75
226
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Figure C.2. 13C NMR (CDCl3) of 75
227
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Figure C.3. 1H NMR (CDCl3) of 76
228
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Figure C.4. 13C NMR (CDCl3) of 76
229
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Figure C.5. 1H NMR (CDCl3) of 78
230
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Figure C.9. 1H NMR (CDCl3) of 82
234
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Figure C.10. 13C NMR (CDCl3) of 82
235
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Figure C.11. 1H NMR (CDCl3) of 83
236
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Figure C.12. 13C NMR (CDCl3) of 83
237
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Figure C.13. 1H NMR (CDCl3) of 85
238
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Figure C.14. 13C NMR (CDCl3) of 85
239
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Figure C.15. 1H NMR (CDCl3) of 86
240
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Figure C.16. 13C NMR (CDCl3) of 86
241
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Figure C.17. 1H NMR (CDCl3) of 87
242
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Figure C.18. 13C NMR (CDCl3) of 87
243
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Figure C.19. 1H NMR (CDCl3) of 88
244
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Figure C.20. 13C NMR (CDCl3) of 88
245
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Figure C.21. 1H NMR (CDCl3) of 131
246
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Figure C.26. 13C NMR (CDCl3) of 133
251
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Figure C.27. 1H NMR (CDCl3) of 134
252
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Figure C.28. 13C NMR (CDCl3) of 134
253
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Figure C.29. 1H NMR (CDCl3) of 138
254
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Figure C.30. 13C NMR (CDCl3) of 138
255
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Figure C.31. 1H NMR (CDCl3) of 139
256
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Figure C.32. 13C NMR (CDCl3) of 139
257
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Figure C.33. 1H NMR (CDCl3) of 140
258
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Figure C.34. 13C NMR (CDCl3) of 140
259
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Figure C.35. 1H NMR (CDCl3) of 141
260
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Figure C.36. 13C NMR (CDCl3) of 141
261
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Figure C.37. 1H NMR (CDCl3) of 162
262
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Figure C.38. 13C NMR (CDCl3) of 162
263
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Figure C.39. 1H NMR (CDCl3) of 415
264
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Figure C.40. 13C NMR (CDCl3) of 415
265
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Figure C.41. 1H NMR (CDCl3) of 416
266
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Figure C.42. 13C NMR (CDCl3) of 416
267
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Figure C.43. 1H NMR (CDCl3) of 417
268
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Figure C.44. 13C NMR (CDCl3) of 417
269
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Figure C.45. 1H NMR (CDCl3) of 418
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Figure C.55. 1H NMR (CDCl3) of 203
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Figure C.56. 13C NMR (CDCl3) of 203
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Figure C.57. 1H NMR (CDCl3) of 204
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Figure C.58. 13C NMR (CDCl3) of 204
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Figure C.59. 1H NMR (CDCl3) of 215
284
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Figure C.60. 13C NMR (CDCl3) of 215
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Figure C.61. 1H NMR (CDCl3) of 216
286
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Figure C.62. 13C NMR (CDCl3) of 216
287
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Figure C.63. 1H NMR (CDCl3) of 217
288
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Figure C.64. 13C NMR (CDCl3) of 217
289
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Figure C.65. 1H NMR (CDCl3) of 218
290
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Figure C.67. 1H NMR (CDCl3) of 219
292
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Figure C.68. 13C NMR (CDCl3) of 219
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Figure C.69. 1H NMR (DMSO−d6) of 223
294
21
0
20
0
19
0
18
0
17
0
16
0
15
0
14
0
13
0
12
0
11
0
10
0
90
80
70
60
50
40
30
20
10
0
pp
m
PC
   
   
   
   
   
  1
.4
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  1
.5
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 1
00
.6
12
64
70
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
2 
   
   
 4
00
.1
32
00
07
 M
Hz
PL
13
   
   
   
   
  1
9.
84
 d
B
PL
12
   
   
   
   
  1
7.
31
 d
B
PL
2 
   
   
   
   
  −
4.
10
 d
B
PC
PD
2 
   
   
   
  1
00
.0
0 
us
ec
N
UC
2 
   
   
   
   
   
 1
H
CP
DP
RG
2 
   
   
  w
al
tz
16
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f2
 =
==
==
==
=
SF
O
1 
   
   
 1
00
.6
22
83
03
 M
Hz
PL
1 
   
   
   
   
  −
1.
82
 d
B
P1
   
   
   
   
   
 1
4.
90
 u
se
c
N
UC
1 
   
   
   
   
   
13
C
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
EL
TA
   
   
  1
.3
99
99
99
8 
se
c
d1
1 
   
   
   
0.
03
00
00
00
 s
ec
D
1 
   
   
   
 1
.5
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.2
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
19
.8
00
 u
se
c
R
G
   
   
   
   
   
 1
63
84
A
Q 
   
   
   
  0
.6
48
87
62
 s
ec
FI
D
R
ES
   
   
   
0.
77
06
46
 H
z
SW
H 
   
   
   
 2
52
52
.5
25
 H
z
D
S 
   
   
   
   
   
   
 8
N
S 
   
   
   
   
   
  8
88
SO
LV
EN
T 
   
   
   
  D
M
SO
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
 z
gp
g3
0
PR
O
BH
D 
  5
 m
m
 P
AB
BI
 1
H/
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
1.
38
D
at
e_
   
   
   
 2
00
90
60
7
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
2
N
A
M
E 
   
 p
Cl
−N
H−
NH
Ph
−n
o−
Bo
c
Cl
N
H
O
Ph
O
H
N
O
Figure C.70. 13C NMR (DMSO−d6) of 223
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Figure C.71. 1H NMR (CDCl3) of 236
296
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Figure C.72. 13C NMR (CDCl3) of 236
297
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Figure C.73. 1H NMR (CDCl3) of 420
298
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Figure C.74. 13C NMR (CDCl3) of 420
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Figure C.75. 1H NMR (CDCl3) of 230a
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Figure C.76. 13C NMR (CDCl3) of 230a
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Figure C.77. 1H NMR (CDCl3) of 230b
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Figure C.78. 13C NMR (CDCl3) of 230b
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Figure C.79. 1H NMR (CDCl3) of 232
304
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Figure C.80. 13C NMR (CDCl3) of 232
305
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Figure C.81. 1H NMR (CDCl3) of 421
306
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Figure C.82. 13C NMR (CDCl3) of 421
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Figure C.83. 1H NMR (CDCl3) of 236
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Figure C.84. 13C NMR (CDCl3) of 236
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Figure C.85. 1H NMR (CDCl3) of 237
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Figure C.86. 13C NMR (CDCl3) of 237
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Figure C.87. 1H NMR (CDCl3) of 238
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Figure C.88. 13C NMR (CDCl3) of 238
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Figure C.89. 1H NMR (CDCl3) of 240
314
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Figure C.90. 13C NMR (CDCl3) of 240
315
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Figure C.91. 1H NMR (CDCl3) of 242
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Figure C.92. 13C NMR (CDCl3) of 242
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Figure C.93. 1H NMR (CDCl3) of 319
318
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Figure C.94. 13C NMR (CDCl3) of 319
319
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Figure C.95. 1H NMR (CDCl3) of 322
320
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Figure C.96. 13C NMR (CDCl3) of 322
321
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Figure C.97. 1H NMR (CDCl3) of 312
322
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Figure C.98. 13C NMR (CDCl3) of 312
323
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Figure C.99. 1H NMR (CDCl3) of 422
324
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Figure C.100. 13C NMR (CDCl3) of 422
325
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Figure C.101. 1H NMR (CDCl3) of 423
326
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Figure C.102. 13C NMR (CDCl3) of 423
327
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Figure C.103. 1H NMR (CDCl3) of 328
328
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Figure C.104. 13C NMR (CDCl3) of 328
329
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Figure C.105. 1H NMR (CDCl3) of 331
330
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Figure C.106. 13C NMR (CDCl3) of 331
331
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Figure C.107. 1H NMR (CDCl3) of 335
332
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Figure C.108. 13C NMR (CDCl3) of 335
333
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Figure C.109. 1H NMR (CDCl3) of 336
334
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Figure C.110. 13C NMR (CDCl3) of 336
335
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Figure C.111. 1H NMR (CDCl3) of 337
336
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Figure C.112. 13C NMR (CDCl3) of 337
337
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Figure C.113. 1H NMR (CDCl3) of 338
338
21
0
20
0
19
0
18
0
17
0
16
0
15
0
14
0
13
0
12
0
11
0
10
0
90
80
70
60
50
40
30
20
10
0
pp
m
PC
   
   
   
   
   
  1
.4
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  1
.5
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 1
00
.6
12
77
75
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
2 
   
   
 4
00
.1
32
00
07
 M
Hz
PL
13
   
   
   
   
  1
7.
81
 d
B
PL
12
   
   
   
   
  1
7.
81
 d
B
PL
2 
   
   
   
   
 1
20
.0
0 
dB
PC
PD
2 
   
   
   
  1
00
.0
0 
us
ec
N
UC
2 
   
   
   
   
   
 1
H
CP
DP
RG
2 
   
   
  w
al
tz
16
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f2
 =
==
==
==
=
SF
O
1 
   
   
 1
00
.6
22
83
03
 M
Hz
PL
1 
   
   
   
   
  −
1.
80
 d
B
P1
   
   
   
   
   
 1
5.
50
 u
se
c
N
UC
1 
   
   
   
   
   
13
C
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
EL
TA
   
   
  1
.3
99
99
99
8 
se
c
d1
1 
   
   
   
0.
03
00
00
00
 s
ec
D
1 
   
   
   
 1
.5
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
19
.8
00
 u
se
c
R
G
   
   
   
   
   
 1
63
84
A
Q 
   
   
   
  0
.6
48
87
62
 s
ec
FI
D
R
ES
   
   
   
0.
77
06
46
 H
z
SW
H 
   
   
   
 2
52
52
.5
25
 H
z
D
S 
   
   
   
   
   
   
 8
N
S 
   
   
   
   
   
  5
12
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
 z
gp
g3
0
PR
O
BH
D 
  5
 m
m
 P
AB
BI
 1
H/
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
4.
02
D
at
e_
   
   
   
 2
01
00
71
7
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
2
N
A
M
E 
   
 d
tb
s−
im
id
e−
ip
r
O
Si
O
t B
u
t B
u
N
N
O
O
Bn
CO
2i
Pr
CO
2i
Pr
Bn
Figure C.114. 13C NMR (CDCl3) of 338
339
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Figure C.116. 13C NMR (CDCl3) of 339
341
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Figure C.117. 1H NMR (CDCl3) of 340
342
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Figure C.118. 13C NMR (CDCl3) of 340
343
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Figure C.119. 1H NMR (CDCl3) of 341
344
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Figure C.120. 13C NMR (CDCl3) of 341
345
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Figure C.121. 1H NMR (CDCl3) of 342
346
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Figure C.122. 13C NMR (CDCl3) of 342
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Figure C.123. 1H NMR (CDCl3) of 343
348
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Figure C.124. 13C NMR (CDCl3) of 343
349
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Figure C.125. 1H NMR (CDCl3) of 316
350
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Figure C.126. 13C NMR (CDCl3) of 316
351
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Figure C.127. 1H NMR (CDCl3) of 344
352
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Figure C.128. 13C NMR (CDCl3) of 344
353
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Figure C.129. 1H NMR (CDCl3) of 345
354
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Figure C.130. 13C NMR (CDCl3) of 345
355
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Figure C.131. 1H NMR (CDCl3) of 424
356
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Figure C.132. 13C NMR (CDCl3) of 424
357
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Figure C.133. 1H NMR (CDCl3) of 347
358
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Figure C.134. 13C NMR (CDCl3) of 347
359
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
16.56
6.57
1.20
1.08
1.16
1.00
1.16
2.14
3.32
G
B 
   
   
   
   
   
  0
.1
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
2
W
D
W
   
   
   
   
   
QS
IN
E
SF
   
   
   
 4
00
.1
30
00
00
 M
Hz
M
C2
   
   
   
   
   
   
QF
SI
   
   
   
   
   
  1
02
4
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 4
00
.1
30
00
97
 M
Hz
SI
   
   
   
   
   
 3
27
68
Fn
M
O
DE
   
 E
ch
o−
An
tie
ch
o
SW
   
   
   
   
   
13
.0
17
 p
pm
FI
D
R
ES
   
   
  1
0.
17
25
06
 H
z
SF
O
1 
   
   
   
  4
00
.1
32
 M
Hz
TD
   
   
   
   
   
   
51
2
N
D
0 
   
   
   
   
   
   
2
SF
O
1 
   
   
 4
00
.1
31
88
57
 M
Hz
PL
1 
   
   
   
   
  −
3.
50
 d
B
P1
   
   
   
   
   
  8
.6
0 
us
ec
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 2
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
96
.0
00
 u
se
c
R
G
   
   
   
   
   
   
12
8
A
Q 
   
   
   
  3
.1
45
87
40
 s
ec
FI
D
R
ES
   
   
   
0.
15
89
46
 H
z
SW
H 
   
   
   
  5
20
8.
33
3 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
   
16
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 P
AB
BI
 1
H/
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
  0
.2
1
D
at
e_
   
   
   
 2
01
01
01
5
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
  1
N
A
M
E 
   
 0
8−
tip
ds
−i
m
id
e−
ip
r−
ph
O S
i O
SiO
i P
r i P
r
i P
ri P
r
N
N
O
O
Ph
i P
rO
2C
CO
2i
Pr
Ph
Figure C.135. 1H NMR (CDCl3) of 350
360
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Figure C.136. 13C NMR (CDCl3) of 350
361
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Figure C.137. 1H NMR (CDCl3) of 351
362
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Figure C.138. 13C NMR (CDCl3) of 351
363
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Figure C.139. 1H NMR (CDCl3) of 346
364
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Figure C.140. 13C NMR (CDCl3) of 346
365
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Figure C.141. 1H NMR (CDCl3) of 352
366
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Figure C.142. 13C NMR (CDCl3) of 352
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Figure C.143. 1H NMR (CDCl3) of 355
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Figure C.144. 13C NMR (CDCl3) of 355
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Figure C.145. 1H NMR (CDCl3) of 353
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Figure C.146. 13C NMR (CDCl3) of 353
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Figure C.147. 1H NMR (CDCl3) of 359
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Figure C.148. 13C NMR (CDCl3) of 359
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Figure C.149. 1H NMR (CDCl3) of 360
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Figure C.150. 13C NMR (MeOD) of 360
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Figure C.151. 1H NMR (CDCl3) of 361
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Figure C.152. 13C NMR (CDCl3) of 361
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Figure C.153. 1H NMR (CDCl3) of 361
378
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Figure C.154. 13C NMR (CDCl3) of 361
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Figure C.155. 1H NMR (CDCl3) of 356
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Figure C.156. 13C NMR (CDCl3) of 356
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Figure C.157. 1H NMR (CDCl3) of 427
382
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Figure C.158. 13C NMR (CDCl3) of 427
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Figure C.159. 1H NMR (CDCl3) of 357
384
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Figure C.160. 13C NMR (CDCl3) of 357
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Figure C.161. 1H NMR (CDCl3) of 376
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Figure C.162. 13C NMR (CDCl3) of 376
387
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Figure C.163. 1H NMR (CDCl3) of 374
388
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Figure C.164. 13C NMR (CDCl3) of 374
389
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Figure C.165. 1H NMR (CDCl3) of 380
390
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Figure C.166. 13C NMR (CDCl3) of 380
391
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Figure C.167. 1H NMR (CDCl3) of 381
392
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Figure C.168. 13C NMR (CDCl3) of 381
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Figure C.169. 1H NMR (CDCl3) of 385
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Figure C.170. 13C NMR (CDCl3) of 385
395
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
4.11
1.67
3.48
11.13
3.27
3.06
3.21
9.31
1.97
1.06
1.05
2.05
1.04
1.16
1.95
1.06
1.10
1.03
1.04
1.49
1.06
1.04
1.00
1.10
1.07
13.75
12.68
1.04
1.08
1.10
2.00
1.01
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 6
00
.1
30
00
00
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
1 
   
   
 6
00
.1
33
00
06
 M
Hz
PL
1W
   
   
   
6.
35
60
70
52
 W
PL
1 
   
   
   
   
   
3.
80
 d
B
P1
   
   
   
   
   
  8
.9
0 
us
ec
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 1
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
33
.7
3 
us
ec
D
W
   
   
   
   
   
59
.4
00
 u
se
c
R
G
   
   
   
   
   
   
  4
A
Q 
   
   
   
  1
.9
46
46
92
 s
ec
FI
D
R
ES
   
   
   
0.
25
68
82
 H
z
SW
H 
   
   
   
  8
41
7.
50
9 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
  1
28
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
  8
.1
9
D
at
e_
   
   
   
 2
01
11
11
9
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
1
N
A
M
E 
   
   
   
   
5−
18
8a
O
O
TI
PD
S
N
O
O
N
Bn
Bn
O
O
O
CP
h 3
O
O
Ph
O
H N N
H
2
O
Bo
cH
N
Figure C.171. 1H NMR (CDCl3) of 386a
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Figure C.172. 13C NMR (CDCl3) of 386a
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Figure C.173. 1H NMR (CDCl3) of 386b
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Figure C.174. 13C NMR (CDCl3) of 386b
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Figure C.175. 1H NMR (CDCl3) of 391
400
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Figure C.176. 13C NMR (CDCl3) of 391
401
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Figure C.177. 1H NMR (CDCl3) of 392
402
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Figure C.178. 13C NMR (CDCl3) of 392
403
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Figure C.179. 1H NMR (CDCl3) of 431
404
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Figure C.180. 13C NMR (CDCl3) of 431
405
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
2.94
2.96
2.87
9.17
3.34
3.47
6.63
1.31
3.37
2.05
1.00
1.00
1.12
2.51
2.35
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 6
00
.1
30
01
00
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
1 
   
   
 6
00
.1
33
00
06
 M
Hz
PL
1W
   
   
   
6.
35
60
70
52
 W
PL
1 
   
   
   
   
   
3.
80
 d
B
P1
   
   
   
   
   
  8
.5
0 
us
ec
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 1
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 3
00
.0
 K
D
E 
   
   
   
   
   
33
.8
1 
us
ec
D
W
   
   
   
   
   
59
.4
00
 u
se
c
R
G
   
   
   
   
   
   
  8
A
Q 
   
   
   
  1
.9
46
46
92
 s
ec
FI
D
R
ES
   
   
   
0.
25
68
82
 H
z
SW
H 
   
   
   
  8
41
7.
50
9 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
   
16
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
4.
13
D
at
e_
   
   
   
 2
01
20
20
4
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
1
N
A
M
E 
   
   
   
   
 5
−2
20
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
TB
SO
O
TB
S
Figure C.181. 1H NMR (CDCl3) of 394
406
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Figure C.182. 13C NMR (CDCl3) of 394
407
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Figure C.183. 1H NMR (CDCl3) of 394
408
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Figure C.184. 13C NMR (CDCl3) of 394
409
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Figure C.186. 13C NMR (CDCl3) of 394
411
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Figure C.187. 1H NMR (CDCl3) of 398
412
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Figure C.190. 13C NMR (CDCl3) of 399
415
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Figure C.191. 1H NMR (CDCl3) of 432
416
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Figure C.192. 13C NMR (CDCl3) of 432
417
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Figure C.193. 1H NMR (CDCl3) of 433
418
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Figure C.194. 13C NMR (CDCl3) of 433
419
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Figure C.195. 1H NMR (CDCl3) of 402
420
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Figure C.196. 13C NMR (CDCl3) of 402
421
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Figure C.197. 1H NMR (CDCl3) of 404
422
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Figure C.198. 13C NMR (CDCl3) of 404
423
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Figure C.199. 1H NMR (CDCl3) of 405
424
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Figure C.200. 13C NMR (CDCl3) of 405
425
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Figure C.201. 1H NMR (CDCl3) of 406
426
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Figure C.202. 13C NMR (CDCl3) of 406
427
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Figure C.203. 1H NMR (CDCl3) of 408
428
21
0
20
0
19
0
18
0
17
0
16
0
15
0
14
0
13
0
12
0
11
0
10
0
90
80
70
60
50
40
30
20
10
0
pp
m
PC
   
   
   
   
   
  1
.4
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  1
.5
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 1
50
.9
02
81
23
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
2 
   
   
 6
00
.1
33
00
10
 M
Hz
PL
13
W
   
   
  0
.0
55
35
90
6 
W
PL
12
W
   
   
  0
.0
56
64
85
4 
W
PL
2W
   
   
   
6.
35
60
70
52
 W
PL
13
   
   
   
   
  2
4.
40
 d
B
PL
12
   
   
   
   
  2
4.
30
 d
B
PL
2 
   
   
   
   
   
3.
80
 d
B
PC
PD
2 
   
   
   
   
90
.0
0 
us
ec
N
UC
2 
   
   
   
   
   
 1
H
CP
DP
RG
2 
   
   
  w
al
tz
16
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f2
 =
==
==
==
=
SF
O
1 
   
   
 1
50
.9
19
40
80
 M
Hz
PL
1W
   
   
 1
78
.9
23
84
33
8 
W
PL
1 
   
   
   
   
  −
3.
00
 d
B
P1
   
   
   
   
   
  5
.0
0 
us
ec
N
UC
1 
   
   
   
   
   
13
C
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
11
   
   
   
 0
.0
30
00
00
0 
se
c
D
1 
   
   
   
 2
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
13
.8
00
 u
se
c
R
G
   
   
   
   
   
  1
82
0
A
Q 
   
   
   
  0
.4
50
37
16
 s
ec
FI
D
R
ES
   
   
   
1.
11
03
18
 H
z
SW
H 
   
   
   
 3
62
31
.8
83
 H
z
D
S 
   
   
   
   
   
   
 8
N
S 
   
   
   
   
   
 8
19
2
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
26
32
PU
LP
RO
G
   
   
   
   
zg
pg
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
1.
18
D
at
e_
   
   
   
 2
01
20
52
7
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
15
2
N
A
M
E 
   
   
   
  5
−2
75
−2
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
O
O
H N
Bo
cH
N
O
M
eO
O
Ph
Figure C.204. 13C NMR (CDCl3) of 408
429
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
35.59
8.99
1.84
1.45
2.98
3.00
1.08
1.11
1.42
1.20
1.23
1.23
1.18
1.10
1.17
1.08
1.10
1.00
1.99
2.11
1.99
0.99
2.00
2.44
1.70
0.74
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 6
00
.1
30
01
01
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
1 
   
   
 6
00
.1
33
00
06
 M
Hz
PL
1W
   
   
   
6.
35
60
70
52
 W
PL
1 
   
   
   
   
   
3.
80
 d
B
P1
   
   
   
   
   
  9
.0
0 
us
ec
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 1
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
90
.0
 K
D
E 
   
   
   
   
   
33
.7
1 
us
ec
D
W
   
   
   
   
   
59
.4
00
 u
se
c
R
G
   
   
   
   
   
   
  4
A
Q 
   
   
   
  1
.9
46
46
92
 s
ec
FI
D
R
ES
   
   
   
0.
25
68
82
 H
z
SW
H 
   
   
   
  8
41
7.
50
9 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
   
64
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
5.
16
D
at
e_
   
   
   
 2
01
20
51
3
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
1
N
A
M
E 
   
   
   
5−
27
6h
pl
c
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
O
O
H N
Bo
cH
N
O
H
O
O
Ph
Figure C.205. 1H NMR (CDCl3) of 409
430
21
0
20
0
19
0
18
0
17
0
16
0
15
0
14
0
13
0
12
0
11
0
10
0
90
80
70
60
50
40
30
20
10
0
pp
m
PC
   
   
   
   
   
  1
.4
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  1
.5
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 1
50
.9
02
81
60
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
2 
   
   
 6
00
.1
33
00
10
 M
Hz
PL
13
W
   
   
  0
.0
55
35
90
6 
W
PL
12
W
   
   
  0
.0
56
64
85
4 
W
PL
2W
   
   
   
6.
35
60
70
52
 W
PL
13
   
   
   
   
  2
4.
40
 d
B
PL
12
   
   
   
   
  2
4.
30
 d
B
PL
2 
   
   
   
   
   
3.
80
 d
B
PC
PD
2 
   
   
   
   
90
.0
0 
us
ec
N
UC
2 
   
   
   
   
   
 1
H
CP
DP
RG
2 
   
   
  w
al
tz
16
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f2
 =
==
==
==
=
SF
O
1 
   
   
 1
50
.9
19
40
80
 M
Hz
PL
1W
   
   
 1
78
.9
23
84
33
8 
W
PL
1 
   
   
   
   
  −
3.
00
 d
B
P1
   
   
   
   
   
  5
.0
0 
us
ec
N
UC
1 
   
   
   
   
   
13
C
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
11
   
   
   
 0
.0
30
00
00
0 
se
c
D
1 
   
   
   
 2
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
90
.0
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
13
.8
00
 u
se
c
R
G
   
   
   
   
   
  1
82
0
A
Q 
   
   
   
  0
.4
50
37
16
 s
ec
FI
D
R
ES
   
   
   
1.
11
03
18
 H
z
SW
H 
   
   
   
 3
62
31
.8
83
 H
z
D
S 
   
   
   
   
   
   
 8
N
S 
   
   
   
   
   
 8
19
2
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
26
32
PU
LP
RO
G
   
   
   
   
zg
pg
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
5.
18
D
at
e_
   
   
   
 2
01
20
51
3
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
2
N
A
M
E 
   
   
   
5−
27
6h
pl
c
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
O
O
H N
Bo
cH
N
O
H
O
O
Ph
Figure C.206. 13C NMR (CDCl3) of 409
431
9.
0
8.
5
8.
0
7.
5
7.
0
6.
5
6.
0
5.
5
5.
0
4.
5
4.
0
3.
5
3.
0
2.
5
2.
0
1.
5
1.
0
0.
5
0.
0
pp
m
1.60
3.95
4.44
4.88
22.01
9.00
2.47
1.29
3.36
4.10
1.33
1.07
1.26
0.99
1.05
1.07
1.08
1.05
1.19
1.18
2.05
1.89
1.08
2.14
2.37
2.14
1.20
2.12
2.33
2.00
0.96
PC
   
   
   
   
   
  1
.0
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  0
.3
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 6
00
.1
30
00
98
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
1 
   
   
 6
00
.1
33
00
06
 M
Hz
PL
1W
   
   
   
6.
35
60
70
52
 W
PL
1 
   
   
   
   
   
3.
80
 d
B
P1
   
   
   
   
   
  8
.5
0 
us
ec
N
UC
1 
   
   
   
   
   
 1
H
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
1 
   
   
   
 1
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
33
.8
1 
us
ec
D
W
   
   
   
   
   
59
.4
00
 u
se
c
R
G
   
   
   
   
   
   
  4
A
Q 
   
   
   
  1
.9
46
46
92
 s
ec
FI
D
R
ES
   
   
   
0.
25
68
82
 H
z
SW
H 
   
   
   
  8
41
7.
50
9 
Hz
D
S 
   
   
   
   
   
   
 0
N
S 
   
   
   
   
   
   
64
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
27
68
PU
LP
RO
G
   
   
   
   
zg
30
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
7.
04
D
at
e_
   
   
   
 2
01
20
60
1
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
1
N
A
M
E 
   
   
   
   
 5
−2
77
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
O
O
Ph
O
H N N
H
2
O
Bo
cH
N
Figure C.207. 1H NMR (CDCl3) of 410
432
21
0
20
0
19
0
18
0
17
0
16
0
15
0
14
0
13
0
12
0
11
0
10
0
90
80
70
60
50
40
30
20
10
0
pp
m
PC
   
   
   
   
   
  1
.4
0
G
B 
   
   
   
   
   
   
 0
LB
   
   
   
   
   
  1
.5
0 
Hz
SS
B 
   
   
   
   
   
   
0
W
D
W
   
   
   
   
   
   
EM
SF
   
   
   
 1
50
.9
02
81
17
 M
Hz
SI
   
   
   
   
   
 3
27
68
SF
O
2 
   
   
 6
00
.1
33
00
10
 M
Hz
PL
13
W
   
   
  0
.0
55
35
90
6 
W
PL
12
W
   
   
  0
.0
56
64
85
4 
W
PL
2W
   
   
   
6.
35
60
70
52
 W
PL
13
   
   
   
   
  2
4.
40
 d
B
PL
12
   
   
   
   
  2
4.
30
 d
B
PL
2 
   
   
   
   
   
3.
80
 d
B
PC
PD
2 
   
   
   
   
90
.0
0 
us
ec
N
UC
2 
   
   
   
   
   
 1
H
CP
DP
RG
2 
   
   
  w
al
tz
16
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f2
 =
==
==
==
=
SF
O
1 
   
   
 1
50
.9
19
40
80
 M
Hz
PL
1W
   
   
 1
78
.9
23
84
33
8 
W
PL
1 
   
   
   
   
  −
3.
00
 d
B
P1
   
   
   
   
   
  5
.0
0 
us
ec
N
UC
1 
   
   
   
   
   
13
C
=
=
=
=
=
=
=
=
 C
HA
NN
EL
 f1
 =
==
==
==
=
TD
0 
   
   
   
   
   
   
1
D
11
   
   
   
 0
.0
30
00
00
0 
se
c
D
1 
   
   
   
 2
.0
00
00
00
0 
se
c
TE
   
   
   
   
   
 2
98
.0
 K
D
E 
   
   
   
   
   
 6
.0
0 
us
ec
D
W
   
   
   
   
   
13
.8
00
 u
se
c
R
G
   
   
   
   
   
  1
82
0
A
Q 
   
   
   
  0
.4
50
37
16
 s
ec
FI
D
R
ES
   
   
   
1.
11
03
18
 H
z
SW
H 
   
   
   
 3
62
31
.8
83
 H
z
D
S 
   
   
   
   
   
   
 8
N
S 
   
   
   
   
   
 8
19
2
SO
LV
EN
T 
   
   
   
 C
DC
l3
TD
   
   
   
   
   
 3
26
32
PU
LP
RO
G
   
   
   
   
zg
pg
PR
O
BH
D 
  5
 m
m
 C
PT
CI
 1
H−
IN
ST
RU
M
   
   
   
  s
pe
ct
Ti
m
e 
   
   
   
   
 1
7.
14
D
at
e_
   
   
   
 2
01
20
60
1
PR
O
CN
O
   
   
   
   
   
 1
EX
PN
O
   
   
   
   
   
10
2
N
A
M
E 
   
   
   
   
 5
−2
77
O
O
TI
PD
S
N
O
O
N
Ts
Ts
O
O
O
O
Ph
O
H N N
H
2
O
Bo
cH
N
Figure C.208. 13C NMR (CDCl3) of 410
433
References
[1] Curtius, T. Ber. Dtsch. Chem. Ges. 1883, 16, 2230–2231.
[2] Kano, T.; Hashimoto, T.; Maruoka, K. J. Am. Chem. Soc. 2006, 128, 2174–2175.
[3] Li, W.; Wang, J.; Hu, X.; Shen, K.; Wang, W.; Chu, Y.; Lin, L.; Liu, X.; Feng, X. J. Am.
Chem. Soc. 2010, 132, 8532–8533.
[4] Davies, H. M. L.; Bois, J. D.; Yu, J.-Q. Chem. Soc. Rev. 2011, 40, 1855–1856.
[5] Davies, H. M. L.; Manning, J. R. Nature 2008, 451, 417–424.
[6] Davies, H. M. L.; Morton, D. Chem. Soc. Rev. 2011, 40, 1857–1869, and references therein.
[7] Davies, H. M.; Yang, J.; Nikolai, J. J. Organomet. Chem. 2005, 690, 6111–6124.
[8] Huang, H.; Wang, Y.; Chen, Z.; Hu, W. Adv. Synth. Catal. 2005, 347, 531–534.
[9] Roy, M.-N.; Lindsay, V. N. G.; Charette, A. B. In Stereoselective Synthesis 1: Stereoselective
Reactions of Carbon–Carbon Double Bonds; Vries, J. G. D., Ed.; Georg Thieme Verlag KG:
Stuttgart, 2011; Chapter 1.14 Cyclopropanation, pp 731–819.
[10] Mazet, C.; Koehler, V.; Pfaltz, A. Angew. Chem. Int. Ed. 2005, 44, 4888–4891.
[11] Austin, W. F.; Zhang, Y.; Danheiser, R. L. Org. Lett. 2005, 7, 3905–3908.
[12] Regitz, M.; Maas, G. Diazo compounds: properties and synthesis; Academic Press, Inc.:
Orlando, FL, 1986.
[13] Patai, S. The Chemistry of diazonium and diazo groups; J. Wiley, 1978.
[14] Doyle, M. P.; McKervey, M. A.; Ye, T. Modern catalytic methods for organic synthesis with
diazo compounds : from cyclopropanes to ylides; Wiley: New York; Chichester, 1998.
[15] Maas, G. Angew. Chem. Int. Ed. 2009, 48, 8186–8195.
[16] Regitz, M. Angew. Chem. Int. Ed. Eng. 1967, 6, 733–749.
[17] Regitz, M.; Bartz, W. Chem. Ber. 1970, 103, 1477–1485.
[18] Koskinen, A. M. P.; Munoz, L. J. Chem. Soc. Chem. Commun. 1990, 652–653.
[19] Davies, H. M. L.; Cantrell, J.; William, R.; Romines, R., Karen; Baum, J. S. Org. Synth.
1992, 70, 93.
[20] Hazen, G. G.; Weinstock, L. M.; Connell, R.; Bollinger, F. W. Synth. Commun. 1981, 11,
947–956.
[21] Baum, J. S.; Shook, D. A.; Davies, H. M. L.; Smith, H. D. Synth. Commun. 1987, 17,
1709–1716.
434
[22] Kitamura, M.; Tashiro, N.; Miyagawa, S.; Okauchi, T. Synthesis 2011, 2011, 1037–1044.
[23] Doyle, M. P.; Dorow, R. L.; Terpstra, J. W.; Rodenhouse, R. A. J. Org. Chem. 1985, 50,
1663–1666.
[24] Danheiser, R. L.; Miller, R. F.; Brisbois, R. G.; Park, S. Z. J. Org. Chem. 1990, 55, 1959–
1964.
[25] Arnold, B.; Regitz, M. Angew. Chem. Int. Ed. Eng. 1979, 18, 320–320.
[26] Forster, M. O. J. Chem. Soc., Trans. 1915, 107, 260–267.
[27] Corey, E.; Myers, A. G. Tetrahedron Lett. 1984, 25, 3559–3562.
[28] House, H. O.; Blankley, C. J. J. Org. Chem. 1968, 33, 53–60.
[29] Toma, T.; Shimokawa, J.; Fukuyama, T. Org. Lett. 2007, 9, 3195–3197.
[30] Creary, X.; Butchko, M. A. J. Org. Chem. 2001, 67, 112–118.
[31] Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. Org. Lett. 2001, 3, 2785–2788.
[32] Aggarwal, V. K.; Alonso, E.; Hynd, G.; Lydon, K. M.; Palmer, M. J.; Porcelloni, M.; Stud-
ley, J. R. Angew. Chem. Int. Ed. 2001, 40, 1430–1433.
[33] Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. J. Org. Chem. 2003, 68, 5381–5383.
[34] Aggarwal, V. K.; Alonso, E.; Bae, I.; Hynd, G.; Lydon, K. M.; Palmer, M. J.; Patel, M.;
Porcelloni, M.; Richardson, J.; Stenson, R. A.; Studley, J. R.; Vasse, J.-L.; Winn, C. L. J.
Am. Chem. Soc. 2003, 125, 10926–10940.
[35] Fulton, J. R.; Aggarwal, V. K.; Vicente, J. d. Eur. J. Org. Chem. 2005, 2005, 1479–1492.
[36] Arndt, F. Org. Synth. 1935, 15, 3.
[37] Proctor, L. D.; Warr, A. J. Org. Process Res. Dev. 2002, 6, 884–892.
[38] Sweeney, J. Eur. J. Org. Chem. 2009, 4911–4919.
[39] Sweeney, J. B. Chem. Soc. Rev. 2002, 31, 247–258.
[40] Gabriel, S. Dtsch. Chem. Ges. 1888, 21, 1049.
[41] Muchalski, H.; Johnston, J. N. In Stereoselective Synthesis 1: Stereoselective Reactions of
Carbon–Carbon Double Bonds; Vries, J. G. D., Ed.; Georg Thieme Verlag KG: Stuttgart,
2011; Chapter 1.4 Aziridination, pp 155–185.
[42] Muller, P.; Fruit, C. Chem. Rev. 2003, 103, 2905–2920.
[43] Hubert, A. J.; Feron, A.; Warin, R.; Teyssie, P. Tetrahedron Lett. 1976, 17, 1317–1318.
[44] Bartnik, R.; Mloston, G. Synthesis 1983, 924–925.
[45] Bartnik, R.; Mloston, G. Tetrahedron 1984, 40, 2569–2576.
435
[46] Rasmussen, K. G.; Jorgensen, K. A. J. Chem. Soc. Chem. Commun. 1995, 1401–1402.
[47] Hansen, K. B.; Finney, N. S.; Jacobsen, E. N. Angew. Chem. Int. Ed. Eng. 1995, 34, 676–678.
[48] Casarrubios, L.; Perez, J. A.; Brookhart, M.; Templeton, J. L. J. Org. Chem. 1996, 61,
8358–8359.
[49] Rasmussen, K. G.; Jorgensen, K. A. J. Chem. Soc., Perkin Trans. 1 1997, 1287–1292.
[50] Rasmussen, K. G.; Hazell, R. G.; Jorgensen, K. A. Chem. Commun. 1997, 1103–1104.
[51] Rasmussen, K. G.; Juhl, K.; Hazell, R. G.; Jorgensen, K. A. J. Chem. Soc., Perkin Trans. 2
1998, 1347–1350.
[52] Juhl, K.; Hazell, R. G.; Jorgensen, K. A. J. Chem. Soc., Perkin Trans. 1 1999, 2293–2297.
[53] Antilla, J. C.; Wulff, W. D. J. Am. Chem. Soc. 1999, 121, 5099–5100.
[54] Antilla, J. C.; Wulff, W. D. Angew. Chem. Int. Ed. 2000, 39, 4518–4521.
[55] Patwardhan, A. P.; Pulgam, V. R.; Zhang, Y.; Wulff, W. D. Angew. Chem. Int. Ed. 2005,
44, 6169–6172.
[56] Zhang, Y.; Desai, A.; Lu, Z.; Hu, G.; Ding, Z.; Wulff, W. D. Chem.–Eur. J. 2008, 14,
3785–3803.
[57] Zhang, Y.; Lu, Z.; Wulff, W. D. Synlett 2009, 2715–2739.
[58] Hu, G.; Huang, L.; Huang, R. H.; Wulff, W. D. J. Am. Chem. Soc. 2009, 131, 15615–15617.
[59] Williams, A. L.; Johnston, J. N. J. Am. Chem. Soc. 2004, 126, 1612–1613.
[60] Uraguchi, D.; Sorimachi, K.; Terada, M. J. Am. Chem. Soc. 2005, 127, 9360–9361.
[61] Hashimoto, T.; Maruoka, K. J. Am. Chem. Soc. 2007, 129, 10054–10055.
[62] Zhang, H.; Wen, X.; Gan, L.; Peng, Y. Org. Lett. 2012, 14, 2126–2129.
[63] Akiyama, T.; Suzuki, T.; Mori, K. Org. Lett. 2009, 11, 2445–2447.
[64] Hashimoto, T.; Uchiyama, N.; Maruoka, K. J. Am. Chem. Soc. 2008, 130, 14380–14381.
[65] Zeng, X.; Zeng, X.; Xu, Z.; Lu, M.; Zhong, G. Org. Lett. 2009, 11, 3036–3039.
[66] Desai, A. A.; Wulff, W. D. J. Am. Chem. Soc. 2010, 132, 13100–13103.
[67] Hashimoto, T.; Nakatsu, H.; Watanabe, S.; Maruoka, K. Org. Lett. 2010, 12, 1668–1671,
PMID: 20232814.
[68] Hashimoto, T.; Nakatsu, H.; Yamamoto, K.; Maruoka, K. J. Am. Chem. Soc. 2011, 133,
9730–9733.
[69] Huang, L.; Wulff, W. D. J. Am. Chem. Soc. 2011, 133, 8892–8895.
436
[70] Troyer, T. L. Brønsted acid promoted additions of diazoalkanes to imines: the interplay of
mechanism and stereochemical outcome as a tool to discover and develop a new syn-glycolate
Mannich reaction. Ph.D. thesis, Vanderbilt University, 2008.
[71] Troyer, T. L.; Muchalski, H.; Hong, K. B.; Johnston, J. N. Org. Lett. 2011, 13, 1790–1792.
[72] Mahoney, J. M.; Smith, C. R.; Johnston, J. N. J. Am. Chem. Soc. 2005, 127, 1354–1355.
[73] Hong, K. B. Brønsted acid-promoted olefin functionalization (anti-aminohydro-xylation) and
progress toward (+)-zwittermicin A. Ph.D. thesis, Vanderbilt University, 2010.
[74] Hong, K. B.; Donahue, M. G.; Johnston, J. N. J. Am. Chem. Soc. 2008, 130, 2323–2328.
[75] Chandra, A.; Viswanathan, R.; Johnston, J. N. Org. Lett. 2007, 9, 5027–5029.
[76] Wilt, J. C.; Pink, M.; Johnston, J. N. Chem. Commun. 2008, 4177–4179.
[77] Guenard, D.; Gueritte-Voegelein, F.; Potier, P. Acc. Chem. Res. 1993, 26, 160–167.
[78] Okino, T.; Matsuda, H.; Murakami, M.; Yamaguchi, K. Tetrahedron Lett. 1993, 34, 501–504.
[79] Matsuura, F.; Hamada, Y.; Shioiri, T. Tetrahedron 1994, 50, 11303–11314.
[80] Salimbeni, A.; Paleari, F.; Poma, D.; Criscuoli, M.; Scolastico, C. Eur. J. Med. Chem. 1996,
31, 827–832.
[81] Umezawa, H.; Aoyagi, T.; Suda, H.; Hamada, M.; Takeuchi, T. J. Antibiot. 1976, 29, 97.
[82] Nishizawa, R.; Saino, T.; Takita, T.; Suda, H.; Aoyagi, T.; Umezawa, H. J. Med. Chem.
1977, 20, 510–515.
[83] Zhu, J.; Ma, D. Angew. Chem. Int. Ed. 2003, 42, 5348–5351.
[84] Kunze, B.; Bohlendorf, B.; Reichenbach, H.; Hofle, G. J. Antibiot. 2008, 61, 18–26.
[85] Sharpless, K. B.; Patrick, D. W.; Truesdale, L. K.; Biller, S. A. J. Am. Chem. Soc. 1975, 97,
2305–2307.
[86] Li, G.; Chang, H.-T.; Sharpless, K. B. Angew. Chem. Int. Ed. Eng. 1996, 35, 451–454.
[87] Christie, S. D. R.; Warrington, A. D. Synthesis 2008, 1325–1341.
[88] Donohoe, T. J.; Chughtai, M. J.; Klauber, D. J.; Griffin, D.; Campbell, A. D. J. Am. Chem.
Soc. 2006, 128, 2514–2515.
[89] Alexanian, E. J.; Lee, C.; Sorensen, E. J. J. Am. Chem. Soc. 2005, 127, 7690–7691.
[90] Liu, G.; Stahl, S. S. J. Am. Chem. Soc. 2006, 128, 7179–7181.
[91] Michaelis, D. J.; Shaffer, C. J.; Yoon, T. P. J. Am. Chem. Soc. 2007, 129, 1866–1867.
[92] Michaelis, D. J.; Ischay, M. A.; Yoon, T. P. J. Am. Chem. Soc. 2008, 130, 6610–6615.
[93] Williamson, K. S.; Yoon, T. P. J. Am. Chem. Soc. 2010, 132, 4570–4571, PMID: 20232850.
437
[94] Cochran, B. M.; Michael, F. E. Org. Lett. 2008, 10, 5039–5042.
[95] Hart, D. J.; Ha, D. C. Chem. Rev. 1989, 89, 1447–1465.
[96] Kobayashi, S.; Mori, Y.; Fossey, J. S.; Salter, M. M. Chem. Rev. 2011, 111, 2626–2704.
[97] Kobayashi, S.; Ishitani, H.; Ueno, M. J. Am. Chem. Soc. 1998, 120, 431–432.
[98] Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. Angew. Chem. Int. Ed. 2004, 43, 1566–1568.
[99] List, B.; Pojarliev, P.; Biller, W. T.; Martin, H. J. J. Am. Chem. Soc. 2002, 124, 827–833.
[100] Cordova, A.; Notz, W.; Zhong, G.; Betancort, J. M.; Barbas, C. F. J. Am. Chem. Soc. 2002,
124, 1842–1843.
[101] Trost, B. M.; Terrell, L. R. J. Am. Chem. Soc. 2003, 125, 338–339.
[102] Trost, B. M.; Jaratjaroonphong, J.; Reutrakul, V. J. Am. Chem. Soc. 2006, 128, 2778–2779.
[103] Harada, S.; Handa, S.; Matsunaga, S.; Shibasaki, M. Angew. Chem. Int. Ed. 2005, 44, 4365–
4368.
[104] Matsunaga, S.; Yoshida, T.; Morimoto, H.; Kumagai, N.; Shibasaki, M. J. Am. Chem. Soc.
2004, 126, 8777–8785.
[105] Sugita, M.; Yamaguchi, A.; Yamagiwa, N.; Handa, S.; Matsunaga, S.; Shibasaki, M. Org.
Lett. 2005, 7, 5339–5342.
[106] Yamaguchi, A.; Matsunaga, S.; Shibasaki, M. Tetrahedron Lett. 2006, 47, 3985–3989.
[107] Martin, S. F.; Lopez, O. D. Tetrahedron Lett. 1999, 40, 8949–8953.
[108] Carswell, E. L.; Snapper, M. L.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2006, 45, 7230–7233.
[109] Wieland, L. C.; Vieira, E. M.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2009,
131, 570–576.
[110] Mandai, H.; Mandai, K.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2008, 130,
17961–17969.
[111] Muchalski, H.; Doody, A. B.; Troyer, T. L.; Johnston, J. N. Organic Syntheses 2011, 88,
212–223.
[112] Evans, D. A.; Britton, T. C.; Ellman, J. A. Tetrahedron Lett. 1987, 28, 6141 – 6144.
[113] Ihmels, H.; Maggini, M.; Prato, M.; Scorrano, G. Tetrahedron Letters 1991, 32, 6215–6218.
[114] Jencks, W. P.; Carriuolo, J. J. Am. Chem. Soc. 1960, 82, 675–681.
[115] Jencks, W. P.; Carriuolo, J. J. Am. Chem. Soc. 1960, 82, 1778–1786.
[116] Nugent, B. M.; Yoder, R. A.; Johnston, J. N. J Am Chem Soc 2004, 126, 3418–3419.
438
[117] Davis, T. A.; Wilt, J. C.; Johnston, J. N. J. Am. Chem. Soc. 2010, 132, 2880–2882, PMID:
20151644.
[118] Davis, T. A.; Danneman, M. W.; Johnston, J. N. Chem. Commun. 2012, 48, 5578–5580.
[119] Myers, E. L.; Butts, C. P.; Aggarwal, V. K. Chem. Commun. 2006, 4434–4436.
[120] Sibi, M. P.; Cook, G. R. In Lewis Acids in Organic Synthesis; Yamamoto, H., Ed.; Wiley-
VCH: Weinheim, 2000; Vol. 2; Chapter 12, pp 543–544.
[121] Doyle, M. P. Chem. Rev. 1986, 86, 919–939.
[122] Desimoni, G.; Faita, G.; Jorgensen, K. A. Chem. Rev. 2006, 106, 3561–3651.
[123] Koskinen, A. Asymmetric Synthesis of Natural Products; Wiley, 1993.
[124] Mckee, B. H.; Gilheany, D. G.; Sharpless, K. B. Org. Synth. 1992, 70, 47.
[125] Wang, Z. M.; Sharpless, K. B. J. Org. Chem. 1994, 59, 8302–8303.
[126] Chang, H.-T.; Sharpless, K. B. J Org Chem 1996, 61, 6456–6457.
[127] Denmark, S. E.; Nakajima, N.; Nicaise, O. J. C.; Faucher, A.-M.; Edwards, J. P. J. Org.
Chem. 1995, 60, 4884–4892.
[128] Evans, D. A.; Peterson, G. S.; Johnson, J. S.; Barnes, D. M.; Campos, K. R.; Woerpel, K. A.
J. Org. Chem. 1998, 63, 4541–4544.
[129] Desimoni, G.; Faita, G.; Mella, M. Tetrahedron 1996, 52, 13649–13654.
[130] Handelsman, J.; Raffel, S.; Mester, E. H.; Wunderlich, L.; Grau, C. R. Appl. Environ. Mi-
crobiol. 1990, 56, 713–718.
[131] Handelsman, J.; Nesmith, W. C.; Raffel, S. J. Curr. Microbiol. 1991, 22, 317–319.
[132] Smith, K. P. Plant Disease 1993, 77, 139.
[133] Phipps, P. Biological and Cultural Tests for Plant Disease 1992, 7, 60.
[134] He, H.; Silo-Suh, L. A.; Handelsman, J.; Clardy, J. Tetrahedron Lett. 1994, 35, 2499–2502.
[135] Silo-Suh, L. A.; Lethbridge, B. J.; Raffel, S. J.; He, H.; Clardy, J.; Handelsman, J. Appl.
Environ. Microbiol 1994, 60, 2023–2030.
[136] Silo-Suh, L. A.; Stabb, E. V.; Raffel, S. J.; Handelsman, J. Curr. Microbiol. 1998, 37, 6–11.
[137] Broderick, N. A.; Goodman, R. M.; Raffa, K. F.; Handelsman, J. Environ. Etnomol. 2000,
29, 101–107.
[138] Thomson, J. A. J. Nutr. 2002, 132, 3441S–3442S.
[139] Rogers, E. W.; Molinski, T. F. Org. Lett. 2007, 9, 437–440.
[140] Rogers, E. W.; Dalisay, D.; Molinski, T. Angew. Chem. Int. Ed. 2008, 47, 8086–8089.
439
[141] Rogers, E. W.; Molinski, T. F. J. Org. Chem. 2009, 74, 7660–7664.
[142] Hoffmann, R. W.; Kahrs, B. C.; Schiffer, J.; Fleischhauer, J. J. Chem. Soc., Perkin Trans. 1
1996, 2407–2414.
[143] Sasaki, M.; Tanino, K.; Hirai, A.; Miyashita, M. Org. Lett. 2003, 5, 1789–1791.
[144] Emmert, E. A. B.; Klimowicz, A. K.; Thomas, M. G.; Handelsman, J. Appl. Environ. Micro-
biol. 2004, 70, 104–113.
[145] Kevany, B. M.; Rasko, D. A.; Thomas, M. G. Appl. Environ. Microbiol. 2009, 75, 1144–1155.
[146] Müller, I.; Weinig, S.; Steinmetz, H.; Kunze, B.; Veluthoor, S.; Mahmud, T.; Müller, R.
ChemBioChem 2006, 7, 1197–1205.
[147] Poss, C. S.; Schreiber, S. L. Acc. Chem. Res. 1994, 27, 9–17.
[148] Magnuson, S. R. Tetrahedron 1995, 51, 2167–2213.
[149] Holland, J. M.; Lewis, M.; Nelson, A. The Journal of Organic Chemistry 2003, 68, 747–753.
[150] Inoue, M.; Sato, T.; Hirama, M. Journal of the American Chemical Society 2003, 125, 10772–
10773.
[151] Roe, S. J.; Stockman, R. A. Chem. Commun. 2008, 3432–3434.
[152] Hudlicky, T.; Reed, J. W. Chem. Soc. Rev. 2009, 38, 3117–3132.
[153] Cortijos, A. M.; Snape, T. J. Tetrahedron: Asymmetry 2008, 19, 1761–1763.
[154] Candy, M.; Audran, G.; Bienayme, H.; Bressy, C.; Pons, J.-M. J. Org. Chem. 2010, 75,
1354–1359, PMID: 20128625.
[155] Lubineau, A.; Bouchain, G. Tetrahedron Lett. 1997, 38, 8031–8032.
[156] Zhang, Y.; Arpin, C. C.; Cullen, A. J.; Mitton-Fry, M. J.; Sammakia, T. J. Org. Chem. 2011,
76, 7641–7653.
[157] Kireev, A. S.; Manpadi, M.; Kornienko, A. J. Org. Chem. 2006, 71, 2630–2640.
[158] Cailleau, T.; Cooke, J. W. B.; Davies, S. G.; Ling, K. B.; Naylor, A.; Nicholson, R. L.;
Price, P. D.; Roberts, P. M.; Russell, A. J.; Smith, A. D.; Thomson, J. E. Org. Biomol.
Chem. 2007, 5, 3922–3931.
[159] Rychnovsky, S.; Griesgraber, G.; Powers, J. Org. Synth. 2004, Coll. Vol. 10, 276–280.
[160] Whitehead, A.; McReynolds, M. D.; Moore, J. D.; Hanson, P. R. Org. Lett. 2005, 7, 3375–
3378.
[161] Guan, Y.; Wu, J.; Sun, L.; Dai, W.-M. J. Org. Chem. 2007, 72, 4953–4960.
[162] Nicolaou, K. C.; Adsool, V. A.; Hale, C. R. H. Org. Lett. 2010, 12, 1552–1555.
[163] Pappo, R.; Allen, D. S., Jr.; Lemieux, R. U.; Johnson, W. S. J. Org. Chem. 1956, 21, 478–479.
440
[164] Zhong, Y.-L.; Shing, T. K. M. J. Org. Chem. 1997, 62, 2622–2624.
[165] Markiewicz, W. T. J. Chem. Res. (S) 1979, 24.
[166] Ziegler, T.; Dettmann, R.; Bien, F.; Jurisch, C. Trends in Organic Chemistry 1997, 6, 91–100.
[167] Kocienski, P. Protecting groups, 3rd ed.; Thieme: Stuttgart; New York, 2004.
[168] Wuts, P. Greene’s protective groups in organic synthesis., 4th ed.; Wiley-Interscience: Hobo-
ken N.J., 2007.
[169] Evans, D. A.; Carter, P. H.; Dinsmore, C. J.; Barrow, J. C.; Katz, J. L.; Kung, D. W.
Tetrahedron Lett. 1997, 38, 4535–4538.
[170] Carter, P. H. Total Synthesis of the Bryostatins. Ph.D. thesis, Harvard University, 1998.
[171] Tojo, G. Oxidation of alcohols to aldehydes and ketones : a guide to current common practice;
Springer: New York, 2006.
[172] Meyer, S. D.; Schreiber, S. L. J. Org. Chem. 1994, 59, 7549–7552.
[173] Rao, S. L. N. Biochemistry 1975, 14, 5218–5221.
[174] Kurtz, A. C. J. Biol. Chem. 1938, 122, 477–484.
[175] Kurtz, A. C. J. Biol. Chem. 1949, 180, 1253–1267.
[176] Kjaer, A.; Larsen, P. O. Acta Chem. Scand. 1959, 13, 1565–1574.
[177] Anders, K. r.; Vesterager, E. Acta Chem. Scand. 1960, 14, 961–964.
[178] Rogers, E. W. Zwittermicin A: Determination of its Complete Configuration and Total Syn-
thesis of its Enantiomer. Ph.D. thesis, University of California, San Diego, 2008.
[179] De Luca, L.; Giacomelli, G.; Porcheddu, A.; Salaris, M. Synlett 2004, 2570–2572.
[180] Kim, J.; Jang, D. Synlett 2010, 2093–2096.
[181] Kotha, S.; Behera, M.; Khedkar, P. Tetrahedron Lett. 2004, 45, 7589–7590.
[182] Lei, M.; Ma, L.; Hu, L. Tetrahedron Lett. 2010, 51, 4186–4188.
[183] Zhu, J.; Wu, X.; Danishefsky, S. J. Tetrahedron Lett. 2009, 50, 577–579.
[184] Muramatsu, I.; Murakami, M.; Yoneda, T.; Hagitani, A. Bull. Chem. Soc. Jpn. 1965, 38,
244–246.
[185] Kisfaludy, L.; Ötvös, L., Jr. Synthesis 1987, 1987, 510–510.
[186] Egbertson, M. S.; Homnick, C. F.; Hartman, G. D. Synth. Commun. 1993, 23, 703–709.
[187] Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. Angew. Chem. Int. Ed.
2005, 44, 1378–1382.
441
[188] Ogawa, H.; Chihara, T.; Taya, K. J. Am. Chem. Soc. 1985, 107, 1365–1369.
[189] Ogawa, H.; Hiraga, N.; Chihara, T.; Teratani, S.; Taya, K. Bull. Chem. Soc. Jpn. 1988, 61,
2383–2386.
[190] Ogawa, H.; Ichimura, Y.; Teratani, T. C. S.; Taya, K. Bull. Chem. Soc. Jpn. 1986, 59,
2481–2483.
[191] de la Zerda, J.; Barak, G.; Sasson, Y. Tetrahedron 1989, 45, 1533–1536.
[192] Klibanov, A. M. Acc. Chem. Res. 1990, 23, 114–120.
[193] Saitoh, M.; Fujisaki, S.; Ishii, Y.; Nishiguchi, T. Tetrahedron Letters 1996, 37, 6733–6736.
[194] Nishiguchi, T.; Ishii, Y.; Fujisaki, S. J. Chem. Soc., Perkin Trans. 1 1999, 3023–3027.
[195] Inokuchi, T.; Matsumoto, S.; Nishiyama, T.; Torii, S. The Journal of Organic Chemistry
1990, 55, 462–466.
[196] Andreana, P. R.; Liu, C. C.; Schreiber, S. L. Org. Lett. 2004, 6, 4231–4233.
[197] Denney, D. B.; Goldstein, B. J. Org. Chem. 1956, 21, 479–479.
[198] Arndt, F. Org. Synth. 1943, Coll. Vol. 2, 165.
442
